{"custom_id": "drug1_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"MK-677\" (also known as \"mk-677\"), here are the article headings along with their IDs:\n896: MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism\n898: LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report\n901: Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats\n907: Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group\n909: Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man\n912: Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women\n915: Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial\n918: Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males\n921: The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms\n924: Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677\n927: Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a)\n930: Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure\n934: Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults\n936: Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects\n938: Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men\n941: Determination of a novel growth hormone secretagogue (MK-677) in human plasma at picogram levels by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug2_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"RAD-140\" (also known as \"rad-140\"), here are the article headings along with their IDs:\n893: RAD-140 Drug-Induced Liver Injury\n894: Drug-Induced Liver Injury Associated With Alpha Bolic (RAD-140) and Alpha Elite (RAD-140 and LGD-4033)\n895: Comparison of the three SARMs RAD-140, GLPG0492 and GSK-2881078 in two different in vitro bioassays, and in an in silico androgen receptor binding assay\n897: Acute Myocarditis From the Use of Selective Androgen Receptor Modulator (SARM) RAD-140 (Testolone)\n900: Severe liver injury following use of RAD-140, a selective androgen receptor modulator, for body building\n903: Myopericarditis Following Use of Selective Androgen Receptor Modifier \"RAD-140\"\n905: Selective androgen receptor modulator abuse-induced heart failure: catastrophic effects of RAD-140 (Testolone)\n908: RAD140 (Testolone) negatively impacts skeletal muscle adaptation, frailty status and mortality risk in female mice\n911: Metabolic studies of selective androgen receptor modulators RAD140 and S-23 in horses\n914: Label-free proteomics for discovering biomarker candidates of RAD140 administration to castrated horses\n917: A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer\n920: Human In Vivo Metabolism and Elimination Behavior of Micro-Dosed Selective Androgen Receptor Modulator RAD140 for Doping Control Purposes\n923: Comparison of in vitro approaches for predicting the metabolism of the selective androgen receptor modulator RAD140\n925: Idiosyncratic drug-induced liver injury related to use of novel selective androgen receptor modulator RAD140 (Testalone): a case report\n929: Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140\n932: Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats\n935: Expanding sports drug testing assays: mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105\n939: Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug3_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"GW-501516\" (also known as \"gw-501516\"), here are the article headings along with their IDs:\n899: GW-501516 GlaxoSmithKline/Ligand\n902: PPARdelta activator GW-501516 has no acute effect on glucose transport in skeletal muscle\n904: Synthesis, biological evaluation and molecular modeling of GW 501516 analogues\n906: Synthesis, molecular modeling studies and biological evaluation of fluorine substituted analogs of GW 501516\n910: Synthesis and dual PPARalpha/delta agonist effects of 1,4-disubstituted 1,2,3-triazole analogues of GW 501516\n913: Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination\n916: Testing for GW501516 (cardarine) in human hair using LC/MS-MS and confirmation by LC/HRMS\n919: PPAR\u03b4 Agonist GW501516 Suppresses the TGF-\u03b2-Induced Profibrotic Response of Human Bronchial Fibroblasts from Asthmatic Patients\n922: GW501516-Mediated Targeting of Tetraspanin 15 Regulates ADAM10-Dependent N-Cadherin Cleavage in Invasive Bladder Cancer Cells\n926: Metabolic modulators of the exercise response: doping control analysis of an agonist of the peroxisome proliferator-activated receptor \u03b4 (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR)\n928: PPAR\u03b4 Modulation by GW501516: An Unsuccessful Exercise Mimetic\n931: Selective PPAR\u03b4 Agonist GW501516 Protects Against LPS-Induced Macrophage Inflammation and Acute Liver Failure in Mice via Suppressing Inflammatory Mediators\n933: Response to \"PPAR\u03b4 Modulation by GW501516: An Unsuccessful Exercise Mimetic\"\n937: Early controlled release of peroxisome proliferator-activated receptor \u03b2/\u03b4 agonist GW501516 improves diabetic wound healing through redox modulation of wound microenvironment\n940: PPAR\u03b2/\u03b4 agonist GW501516 inhibits TNF\u03b1-induced repression of adiponectin and insulin receptor in 3T3-L1 adipocytes\n942: Comprehensive characterization of the peroxisome proliferator activated receptor-\u03b4 agonist GW501516 for horse doping control analysis\n943: [Effects of GW501516 on the proliferation of pulmonary artery smooth muscle cells induced by hypoxia and its mechanisms]\n944: Highly selective peroxisome proliferator-activated receptor \u03b4 (PPAR\u03b4) modulator demonstrates improved safety profile compared to GW501516\n945: Synthesis of the PPARbeta/delta-selective agonist GW501516 and C4-thiazole-substituted analogs\n946: A metabolomic study of the PPAR\u03b4 agonist GW501516 for enhancing running endurance in Kunming mice\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug4_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"HCG\" (also known as \"hcg\"), here are the article headings along with their IDs:\n947: Hyperglycosylated hCG\n948: hCG - related molecules and their measurement\n950: Hyperglycosylated hCG: a Unique Human Implantation and Invasion Factor\n951: [Influence of hCG glycosylation on its functions in female reproduction]\n953: hCG, the wonder of today's science\n956: A rational diagnostic approach to the \"phantom hCG\" and other clinical scenarios in which a patient is thought to be pregnant but is not\n957: Total hCG tests\n960: Familial HCG syndrome\n964: Pituitary as a Source of HCG: Residual Levels After Bilateral Testicular Tumor Removal\n966: Hyperglycosylated hCG activates LH/hCG-receptor with lower activity than hCG\n968: What we know about low-level hCG: definition, classification and management\n969: Recurrent miscarriage and hCG supplementation: a review and metaanalysis\n971: Clinical use of HCG and hCG beta determinations\n974: Hyperglycosylated hCG: a variant with separate biological functions to regular hCG\n976: The suitability of human chorionic gonadotropin (hCG)-based birth-control vaccines\n978: The role of hCG in regulation of the thyroid gland in normal and abnormal pregnancy\n980: [Persistent low hCG levels beyond pregnancy: report of two cases and review of the literature]\n982: On the role of human chorionic gonadotropin (hCG) in the embryo-endometrial microenvironment: implications for differentiation and implantation\n985: Persistently elevated serum concentrations of human chorionic gonadotropin (hCG)\n987: Hyperglycosylated hCG and pregnancy failures\n989: The classification, functions and clinical use of different isoforms of HCG\n992: Diagnostic value of a single \u03b2-hCG test in predicting reproductive outcomes in women undergoing cleavage embryo transfer: a retrospective analysis from a single center\n993: HCG variants, the growth factors which drive human malignancies\n996: Hyperglycosylated hCG is a marker of early human trophoblast invasion\n997: USA hCG reference service, 10-year report\n999: Retrospective evaluation of 99th percentile hCG results to adjust clinical decision points\n1000: Proportion hyperglycosylated hCG: a new test for discriminating gestational trophoblastic diseases\n1003: Effect of GnRH and hCG injection on the reproductive performance and serum progesterone concentration of ewes during spring season\n1005: Hyperglycosylated HCG expression in pregnancy: cellular origin and clinical applications\n1007: Use of the rat model to study hCG/LH effects on uterine blood flow\n1009: Performance of qualitative urinary hCG assays\n1011: Case Report: The first familial hCG syndrome in a Chinese family\n1013: hCG production by mucinous adenocarcinoma of the ovary in a reproductive aged woman\n1015: Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases\n1017: Hyperglycosylated hCG (invasive trophoblast antigen, ITA) a key antigen for early pregnancy detection\n1019: Establishing reference intervals for hCG in postmenopausal women\n1021: hCG treatment on day of mating improves embryo viability and fertility in ewe lambs\n1023: Does hCG or hCG\u03b2 play a role in cancer cell biology?\n1025: Effects of hCG on reduced numbers of hCG receptors in the prefrontal cortex and cerebellum of rat models of Alzheimer's disease\n1027: Combined analysis of clinical features, human chorionic gonadotropin (hCG) value, and hCG ratios for early prediction of postmolar gestational trophoblastic neoplasia\n1029: The application of single beta-human chorionic gonadotropin (\u03b2-hCG) level measurement in women undergoing single blastocyst transfer\n1031: Detection of hCG in trophoblastic disease. The USA hCG reference service experience\n1033: Pregnancy testing with hCG--future prospects\n1036: Phantom hCG and phantom choriocarcinoma\n1038: A 43-year-old woman with unexplained elevation of hCG\n1041: Effect of additional human chorionic gonadotrophin (hCG) on follicular growth and ovulation in gonadotrophin-treated gilts\n1044: Discriminatory hCG zone: its use in the sonographic evaluation for ectopic pregnancy\n1047: beta-HCG/LH receptor (beta-HCG/LH-R) expression in eutopic endometrium and endometriotic implants: evidence for beta-HCG sensitivity of endometriosis\n1050: Clinical Pregnancy and Incidence of Ovarian Hyperstimulation Syndrome in High Ovarian Responders Receiving Different Doses of hCG Supplementation in a GnRH-Agonist Trigger Protocol\n1053: Analytical sensitivity of four commonly used hCG point of care devices\n1056: Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans\n1058: Hyperglycosylated-hCG (h-hCG) and Down syndrome screening in the first and second trimesters of pregnancy\n1061: The quagmire of hCG and hCG testing in gynecologic oncology\n1065: [Mechanism of regulation of synthesis and secretion of human chorionic gonadotropin (hCG) during pregnancy]\n1068: BRCA1 regulation on \u03b2-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer\n1070: Direct DNA binding by BRCA1 on \u03b2-hCG promoter and its clinical implications\n1073: The need for a quantitative urine hCG assay\n1076: A Case of Pseudoelevation of Serum HCG Caused by Rheumatoid Factor\n1079: [Studies on the thyrotropic activity of hCG and its derivatives]\n1082: Human chorionic gonadotropin (hCG) in the secretome of cultured embryos: hyperglycosylated hCG and hCG-free beta subunit are potential markers for infertility management and treatment\n1085: Review: hCGs: different sources of production, different glycoforms and functions\n1087: [The human chorionic gonadotropin (hCG) receptor: a new class within the family of GTP protein coupled receptors. Epitope mapping of receptor-bound agonistic and antagonistic forms of hCG]\n1091: [Relationship between serum hCG and urinary hCG in cases of pregnancy, abortion, and hydatidiform mole]\n1094: Hyperglycosylated hCG, a potential alternative to hCG in Down syndrome screening\n1096: Total hCG versus free beta-hCG combined with alpha-fetoprotein for Down syndrome screening in Taiwan\n1099: Human chorionic gonadotropin (hCG) plasma levels at oocyte retrieval and IVF outcomes\n1103: The interplay of human chorionic gonadotropin (hCG) with basic fibroblast growth factor and adipokines on angiogenesis in vitro\n1106: Dual trigger of triptorelin and HCG optimizes clinical outcome for high ovarian responder in GnRH-antagonist protocols\n1108: The use of free beta-hCG in antenatal screening for Down's syndrome\n1112: Predicting gestational trophoblastic neoplasia (GTN): is urine hCG the answer?\n1115: Choriocarcinoma-like human chorionic gonadotrophin (HCG) and HCG bioactivity during the first trimester of pregnancy\n1117: Quantitative urine hCG and urine pregnancy test in gestational trophoblastic disease patients with low hCG titer\n1120: [HCG in serum and peritoneal fluid in suspected ectopic pregnancy]\n1122: Pretranslational regulation of ectopic hCG alpha production in ChaGo lung cancer cells by sodium butyrate\n1126: Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia\n1129: Hyperthyroidism induced by paraneoplastic human chorionic gonadotropin (hCG) production from testicular tumours: a retrospective clinical and histopathological study\n1132: Physiological studies of human chorionic gonadotropin (hCG), alpha hCG, and beta hCG as measured by specific monoclonal immunoradiometric assays\n1136: The effect of hCG treatment on Day 12 post-mating on ovarian function and reproductive performance of ewes and ewe lambs\n1140: Separation of nicked human chorionic gonadotropin (hCG), intact hCG, and hCG beta fragment from standard reference preparations and raw urine samples\n1143: Comparative Effects of Different Dosages of hCG on Follicular Development in Postpartum Dairy Cows With Cystic Ovarian Follicles\n1146: Urine free beta-hCG and total estriol for Down syndrome screening during the second trimester in an Asian population\n1149: Role of HCG and inhibin in breast-cancer (review)\n1152: First trimester biochemical screening for Down syndrome: free beta hCG versus intact hCG\n1153: Immunohistochemical interaction on antisera to HCG and its subunits with chorionic tissue of early gestation\n1158: False-negative results in point-of-care qualitative human chorionic gonadotropin (hCG) devices due to excess hCGbeta core fragment\n1160: The role of trophoblast differentiation in the control of the hCG and hPL genes\n1164: Urine reference intervals for human chorionic gonadotropin (hCG) isoforms by immunoextraction-tandem mass spectrometry to detect hCG use\n1167: Rat as model for studying behavior effects of hCG\n1171: A Subovulatory Dose of Human Chorionic Gonadotropin (hCG) May Sustain Terminal Follicle Development and Reproductive Efficiency during Anestrus in Sheep\n1174: CSF and serum hCG in patients without gestational and neoplastic hCG-secretion\n1178: Temporal relationship between hCG induced desensitization of LH/hCG responsive adenylyl cyclase and downregulation of LH/hCG receptors in the rat testis\n1181: Effect of an antiestrogen on the testicular response to acute and chronic administration of hCG in normal and hypogonadotropic hypogonadic men: tamoxifen and testicular response to hCG\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug5_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"BPC-157\" (also known as \"bpc-157\"), here are the article headings along with their IDs:\n949: Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing\n952: BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing\n955: The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration\n959: Pentadecapeptide BPC 157 and the central nervous system\n962: Stable Gastric Pentadecapeptide BPC 157 and Wound Healing\n965: Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle\n967: Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function\n970: BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection\n972: Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain\n973: Stable Gastric Pentadecapeptide BPC 157-Possible Novel Therapy of Glaucoma and Other Ocular Conditions\n975: Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy\n977: BPC 157 and blood vessels\n979: Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation\n981: The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity\n983: Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future\n984: Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways\n986: Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications\n988: BPC 157 as Potential Treatment for COVID-19\n990: Stable gastric pentadecapeptide BPC 157-NO-system relation\n991: Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review\n994: Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing\n995: Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome\n998: Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract\n1001: BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling \"Negative-Like\" Symptoms of Schizophrenia\n1002: Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study\n1004: The anti-nociceptive effect of BPC-157 on the incisional pain model in rats\n1006: Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?\n1008: Pentadecapeptide BPC 157 as Therapy for Inferior Caval Vein Embolization: Recovery of Sodium Laurate-Post-Embolization Syndrome in Rats\n1010: Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma\n1012: Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157\n1014: BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment\n1016: Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro\n1018: Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats\n1020: Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia\n1022: BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats\n1024: Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion\n1026: BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias\n1028: Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats\n1030: Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats\n1032: Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157\n1035: Stomach perforation-induced general occlusion/occlusion-like syndrome and stable gastric pentadecapeptide BPC 157 therapy effect\n1039: Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats\n1043: Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats\n1045: Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response\n1048: The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats\n1051: BPC 157's effect on healing\n1055: Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation\n1059: Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats\n1062: Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway\n1064: Pentadecapeptide BPC 157 shortens duration of tetracaine- and oxybuprocaine-induced corneal anesthesia in rats\n1067: Stable gastric pentadecapeptide BPC 157 and bupivacaine\n1071: Corrigendum: Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats\n1074: Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal\n1077: BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats\n1080: Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats\n1084: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts\n1088: Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator\n1090: Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula\n1092: Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy\n1097: Antiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy\n1100: Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS\n1102: Stable gastric pentadecapeptide BPC 157 heals rectovaginal fistula in rats\n1105: BPC 157 antagonized the general anaesthetic potency of thiopental and reduced prolongation of anaesthesia induced by L-NAME/thiopental combination\n1109: Pentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine\n1111: Perforating corneal injury in rat and pentadecapeptide BPC 157\n1114: Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin\n1118: Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress\n1123: Fourier Transform Infrared Spectroscopy Reveals Molecular Changes in Blood Vessels of Rats Treated with Pentadecapeptide BPC 157\n1125: Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights\n1128: Over-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157\n1131: Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157\n1134: Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy\n1135: Innate Vascular Failure by Application of Neuroleptics, Amphetamine, and Domperidone Rapidly Induced Severe Occlusion/Occlusion-like Syndromes in Rats and Stable Gastric Pentadecapeptide BPC 157 as Therapy\n1138: Complex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats\n1141: Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances\n1144: Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions\n1147: Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats\n1151: Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint\n1154: In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro\n1157: BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients low sphincters pressure\n1161: Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats\n1162: Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157\n1166: Therapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats\n1169: Hypermagnesemia disturbances in rats, NO-related: pentadecapeptide BPC 157 abrogates, L-NAME and L-arginine worsen\n1172: Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME\n1175: Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat\n1177: Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H\n1180: Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice\n1182: Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities\n1184: Pentadecapeptide BPC 157 and anaphylactoid reaction in rats and mice after intravenous dextran and white egg administration\n1185: Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension\n1187: Robert's Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157\n1188: Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat\n1191: Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth\n1193: Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system\n1195: Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats\n1197: Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats\n1199: The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks\n1201: Physiological and Immunological Status of Adult Honeybees (Apis mellifera) Fed Sugar Syrup Supplemented with Pentadecapeptide BPC 157\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug6_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"bacteriostaticwater\" (also known as \"bacteriostaticwater\"), here are the article headings along with their IDs:\n954: Critical Aspects of pH Measurement for Bacteriostatic Water for Injection\n958: Neurotoxicity of bacteriostatic water\n961: Stability of aminophylline in bacteriostatic water for injection stored in plastic syringes at two temperatures\n963: Stability of lorazepam diluted in bacteriostatic water for injection at two temperatures\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug7_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Clomiphene\" (also known as \"clomiphene\"), here are the article headings along with their IDs:\n1034: Clomiphene Citrate for the Treatment of Hypogonadism\n1037: Clomiphene\n1040: Clomiphene\n1042: Clomiphene and migraine\n1046: Clomiphene citrate in the twenty-first century\n1049: Clomiphene citrate therapy for male infertility\n1052: Clomiphene misuse and risk of severe cardiovascular events\n1054: Testing for clomiphene in keratinous matrices (hair and nail)\n1057: Clomiphene Citrate Shows Effective and Sustained Antimicrobial Activity againstMycobacterium abscessus\n1060: Development, pharmacology and clinical experience with clomiphene citrate\n1063: Clomiphene citrate: the case for a monoisomeric preparation\n1066: Clomiphene-induced psychosis\n1069: Clomiphene for ovulation\n1072: Clomiphene for ovulation\n1075: Comparative effectiveness of 9 ovulation-induction therapies in patients with clomiphene citrate-resistant polycystic ovary syndrome: a network meta-analysis\n1078: Depletion of clomiphene residues in eggs and muscle after oral administration to laying hens\n1081: Clomiphene-induced neurological dysfunction\n1083: Clomiphene\n1086: Clomiphene citrate and ovulation induction\n1089: [Pro clomiphene]\n1093: A rare case of clomiphene-induced leukocytoclastic vasculitis\n1095: Clinical experience with clomiphene\n1098: The agonistic-antagonistic properties of clomiphene: a review\n1101: [Clomiphene]\n1104: Induction of ovulation with clomiphene citrate\n1107: Is ultrasound monitoring of the ovaries during ovulation induction by clomiphene citrate essential? A systematic review\n1110: Corifollitropin alpha, clomiphene citrate and dydrogesterone without daily gonadotrophin: a new option of a friendly protocol for high-responder oocyte donors\n1113: Clomiphene in pubertal-adolescent gynecomastia\n1116: [Clomiphene stimulation of ovulation]\n1119: Clomiphene therapy\n1121: Assessing human urinary clomiphene metabolites after consumption of eggs from clomiphene-treated laying hens using chromatographic-mass spectrometric approaches\n1124: Low-dosage clomiphene reduces premature ovulation rates and increases transfer rates in natural-cycle IVF\n1127: Clomiphene citrate and enclomiphene for the treatment of hypogonadal androgen deficiency\n1130: Future use of clomiphene in ovarian stimulation. Psychic effects of clomiphene citrate\n1133: Pharmacokinetics of intravenous clomiphene isomers\n1137: Sex ratio and clomiphene treatment\n1139: [Clomiphene citrate]\n1142: [Clomiphene-exposed pregnancies--analysis of 39 information requests including 25 cases with known outcome]\n1145: Quantification of clomiphene metabolite isomers in human plasma by rapid-resolution liquid chromatography-electrospray ionization-tandem mass spectrometry\n1148: Clomiphene citrate treatment in oligozoospermia: comparison between two regimens of low-dose treatment\n1150: [Clomiphene and cyclofenil]\n1155: Use of clomiphene citrate in infertile women: a committee opinion\n1156: Further clinical experience with clomiphene citrate\n1159: Anencephaly and clomiphene-induced pregnancy\n1163: [Clomiphene resistant PCO syndrome: IVF treatment as an alternative in failed gonadotropin treatment]\n1165: Anovulation treated with clomiphene\n1168: Visual disturbance secondary to clomiphene citrate\n1170: Induction of ovulation with clomiphene citrate\n1173: Acupuncture and clomiphene for Chinese women with polycystic ovary syndrome (PCOSAct): statistical analysis approach with the revision and explanation\n1176: Clomiphene citrate or gonadotrophins for induction of ovulation?\n1179: Clomiphene as an anticonvulsant drug: A case report\n1183: [Use of clomiphene for treating sterility]\n1186: Update on the safety and efficacy of clomiphene citrate as a therapeutic agent\n1189: Clomiphene citrate 'stair-step' protocol vs. traditional protocol in patients with polycystic ovary syndrome: a randomized controlled trial\n1190: Clomiphene citrate does not modify the exaggerated thyrotrophin response to thyrotrophin-releasing hormone occurring in primary testicular failure\n1192: Single-dose pharmacokinetics of clomiphene citrate in normal volunteers\n1194: Use of clomiphene citrate in women\n1196: Clomiphene citrate as a possible cause of psychosis\n1198: [Experiences with clomiphene]\n1200: [Experiences with clomiphene]\n1202: Clinical trial of clomiphene in advanced breast cancer\n1203: Mass spectrometric identification and characterization of new clomiphene metabolites in human urine by liquid chromatography-quadrupole time-of-flight tandem mass spectrometry\n1204: Residual effect of clomiphene citrate?\n1205: Ovulation induction with low doses of clomiphene citrate\n1206: Ovulation induction with clomiphene and the rise in heterotopic pregnancies. A report of two cases\n1207: Outcome of pregnancy after clomiphene therapy\n1208: Pregnancy outcome following frozen embryo transfer after artificial cycle or treatment by clomiphene citrate\n1209: Monitoring plasma concentrations to individualize treatment with clomiphene citrate\n1210: Cost-effectiveness of treatment strategies in women with PCOS who do not conceive after six cycles of clomiphene citrate\n1211: [Recent data on the artificial induction of ovulation. II. Clomiphene]\n1212: [Recent data on the treatment of unexplained infertility with clomiphene citrate, intrauterine insemination, and in vitro fertilization]\n1213: Effects of cis- and trans-clomiphene in the induction of sexual behavior\n1214: Interest of hair tests and supplement tests to discriminate a tail end of a doping regimen from a supplement contamination in case of challenging an anti-doping rule violation. VII. Case example with clomiphene\n1215: Ovulation and pregnancy rates with clomiphene citrate\n1216: A comparison of the effects on follicular development between clomiphene citrate, its two separate isomers and spontaneous cycles\n1217: An association between clomiphene citrate and ectopic pregnancy: a preliminary report\n1218: Letter: Congenital anomalies and clomiphene\n1219: Testicular germ cell tumors after clomiphene therapy for subfertility\n1220: Clomiphene therapy and its potential role in rheumatic symptoms: comment on the article by A. and E. Ben-Chetrit\n1221: Clomiphene citrate utilization in the Netherlands 1998-2007\n1222: Clomiphene citrate induction of ovulation\n1223: Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites\n1224: [Clomiphene in the treatment of amenorrheas]\n1225: Blockade of ovulation by clomiphene citrate and its reversal by human chorionic gonadotropin or prostaglandin F2 alpha in rats\n1227: Fluoro-clomiphene and its synthetic precursors: synthesis and receptor binding\n1228: Dose-response relationship between dose of clomiphene citrate and incidence of ovulation\n1230: Progestin-primed ovarian stimulation with or without clomiphene citrate supplementation in normal ovulatory women undergoing in vitro fertilization/intracytoplasmic sperm injection: A prospective randomized controlled trial\n1232: [Clomiphene in ovulatory pathology]\n1234: [Clomiphene (MRL-41) in gynecology]\n1236: Natural versus clomiphene citrate cycles for in vitro fertilization?\n1238: Determination by liquid chromatography-mass spectrometry of clomiphene isomers in the plasma of patients undergoing treatment for the induction of ovulation\n1239: Pulmonary embolism during clomiphene therapy for infertility in a male: a case report\n1242: [Clomiphene, nidation and fetus survival]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug8_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Tamoxifen\" (also known as \"tamoxifen\"), here are the article headings along with their IDs:\n1226: Tamoxifen in men: a review of adverse events\n1229: Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics\n1231: Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications\n1233: Tamoxifen\n1235: Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis\n1237: [Tamoxifen, a high-potential molecule to treat all centronuclear myopathies]\n1240: Tamoxifen-induced acute mania: A case report\n1241: Tamoxifen to raloxifene and beyond\n1243: Tamoxifen in the treatment of breast cancer\n1244: Tamoxifen: catalyst for the change to targeted therapy\n1245: The tamoxifen controversy\n1247: Tamoxifen resistance in breast cancer\n1249: Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use\n1251: Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer\n1252: Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives\n1253: [Research Progress in the Role of Tamoxifen in Nervous System and Cognitive Function]\n1255: Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects\n1258: Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer\n1259: [Tamoxifen and breast cancer]\n1262: Tamoxifen as adjuvant therapy in breast cancer. Current status\n1264: Tamoxifen's impact on the management of breast cancer: the oncologist's perspective\n1265: [Atrophic tamoxifen maculopathy]\n1268: Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance\n1269: Tamoxifen, screening and new oestrogen receptor modulators\n1271: Tamoxifen metabolism and its effect on endocrine treatment of breast cancer\n1274: Tamoxifen's role in chemoprevention of breast cancer: an update\n1276: Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy\n1277: Acquired tamoxifen resistance in human breast cancer--potential mechanisms and clinical implications\n1279: Personalized tamoxifen: what is the best way forward?\n1281: Tamoxifen maculopathy: The importance of screening and long follow-up\n1283: [Tamoxifen in the treatment of breast cancer]\n1284: Tamoxifen therapy\n1287: Tamoxifen flare\n1289: Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team\n1291: 50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?\n1293: Clinical efficacy of tamoxifen\n1294: [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects]\n1296: Serine synthesis influences tamoxifen response in ER+ human breast carcinoma\n1298: [Tamoxifen treatment and pulmunary embolism: a case report and literature review]\n1300: Gastric intestinal metaplasia and tamoxifen: can we reverse the inevitable?\n1302: [Tamoxifen-induced toxic maculopathy at low cumulative dose : The value of multimodal imaging]\n1304: Tamoxifen: 25-year perspective\n1306: Tamoxifen and hypercalcemia\n1307: Controversies regarding tamoxifen and uterine carcinoma\n1308: Tamoxifen: how boldly to go where no women have gone before\n1309: Tamoxifen metabolites treatment promotes ER\u03b1+ transition to triple negative phenotype in vitro, effects of LDL in chemoresistance\n1310: Tamoxifen in the prevention of breast cancer. Are the risks likely to outweigh the benefits?\n1311: Tamoxifen and the gynaecologist\n1312: [Tamoxifen and cardiovascular risk]\n1313: Tamoxifen inhibits mitochondrial membrane damage caused by disulfiram\n1314: Low dose TamOxifen and LifestylE changes for bReast cANcer prevention (TOLERANT study): Study protocol of a randomized phase II biomarker trial in women at increased risk for breast cancer\n1315: Delineating the molecular mechanisms of tamoxifen's oncolytic actions in estrogen receptor-negative cancers\n1316: Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism\n1317: Prolonged tamoxifen-enriched diet is associated with cardiomyopathy and nutritional frailty in mice\n1318: [Isolated superior ophthalmic vein thrombosis due to tamoxifen]\n1319: [Tamoxifen in male infertility. Analysis of a questionable therapy]\n1320: Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug\n1321: Tamoxifen for retroperitoneal fibrosis\n1322: Interaction of tamoxifen's impact on overall net mortality and quality of life\n1323: Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients\n1324: The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation\n1325: A realistic clinical perspective of tamoxifen and endometrial carcinogenesis\n1326: Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial\n1327: Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer\n1328: Calculating tamoxifen's benefits\n1329: Vaginal tamoxifen for treatment of vulvar and vaginal atrophy: Pharmacokinetics and local tolerance in a rabbit model over 28 days\n1330: Investigating the molecular mechanisms of Tamoxifen on the EMT pathway among patients with breast cancer\n1332: A risk-benefit assessment of tamoxifen therapy\n1333: Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors\n1336: Variation in human gut microbiota impacts tamoxifen pharmacokinetics\n1339: Effects of tamoxifen and glutamate and glutamine levels in brain regions in repeated sleep deprivation-induced mania model in mice\n1340: Single-Cell Screening of Tamoxifen Abundance and Effect Using Mass Spectrometry and Raman-Spectroscopy\n1341: Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility\n1342: Developmental malformations resulting from high-dose maternal tamoxifen exposure in the mouse\n1344: CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine\n1346: Interaction of neutral and protonated Tamoxifen with the DPPC lipid bilayer using molecular dynamics simulation\n1348: Comprehensive understanding of multiple actions of anticancer drug tamoxifen in isolated mitochondria\n1350: An electrochemical outlook on tamoxifen biotransformation: current and future prospects\n1352: [Tamoxifen: a surprising prescription in a bodybuilder]\n1354: Potential role of tamoxifen in prevention of breast cancer\n1355: Tamoxifen modulates cell migration and expression of angiogenesis-related genes in human endometrial endothelial cells\n1357: Persistent Metabolic Effects of Tamoxifen: Considerations for an Experimental Tool and Clinical Breast Cancer Treatment\n1359: [Uterine sarcoma associated with tamoxifen use after breast cancer: Review of the pathogenesis]\n1361: [Antidepressants and tamoxifen: an unrecognized interaction]\n1363: Low concentrations of 17\u03b2-estradiol exacerbate tamoxifen resistance in breast cancer treatment through membrane estrogen receptor-mediated signaling pathways\n1365: Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen?\n1366: How long should adjuvant tamoxifen be continued?\n1368: Reduction in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Chronic Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interaction\n1370: Dissimilar action of tamoxifen and 4-hydroxytamoxifen on phosphatidylcholine model membranes\n1372: Interaction of tamoxifen and noise-induced damage to the cochlea\n1374: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer\n1375: Leishmania is not prone to develop resistance to tamoxifen\n1377: The Breast Cancer Prevention Trial: evaluating tamoxifen's efficacy in preventing breast cancer\n1379: Tamoxifen and liver cancer\n1382: Tamoxifen's trials and tribulations\n1383: Tamoxifen's clinical applications: old and new\n1385: Tamoxifen-like metallocifens target the thioredoxin system determining mitochondrial impairment leading to apoptosis in Jurkat cells\n1387: Tamoxifen in the treatment and chemoprevention of breast cancer\n1389: Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer\n1391: [Endometrial cancers arising in polyps associated with tamoxifen use]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug9_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Tesofensine\" (also known as \"tesofensine\"), here are the article headings along with their IDs:\n1246: Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons\n1248: Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity\n1250: Tesofensine and weight loss\n1254: Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat\n1256: Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat\n1257: Tesofensine and weight loss\n1260: Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study\n1261: Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial\n1263: Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial\n1266: Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats\n1267: Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users\n1270: Under-reporting of adverse effects of tesofensine\n1272: The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant\n1273: Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease\n1275: Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach\n1278: Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET\n1280: A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam\n1282: Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13\n1285: Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats\n1286: [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication]\n1288: The effect of tesofensine on appetite sensations\n1290: Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine\n1292: Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine\n1295: Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease\n1297: Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease\n1299: The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug11_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"YK-11\" (also known as \"yk-11\"), here are the article headings along with their IDs:\n1301: Equine metabolism of the selective androgen receptor modulator YK-11 in urine and plasma following oral administration\n1303: Mass spectrometric characterization of the selective androgen receptor modulator (SARM) YK-11 for doping control purposes\n1305: Detection of selective androgen receptor modulator YK-11 in a doping control sample\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug12_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Andarine\" (also known as \"andarine\"), here are the article headings along with their IDs:\n1331: In vitro anti-carcinogenic effect of andarine as a selective androgen receptor modulator on MIA-PaCa-2 cells by decreased proliferation and cell-cycle arrest at G0/G1 phase\n1334: Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (S-4) for routine doping control purposes\n1335: Detection of the selective androgen receptor modulator S-4 (Andarine) in a doping control sample\n1337: Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product\n1338: Detection of the selective androgen receptor modulator andarine (S-4) in a routine equine blood doping control sample\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug14_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Melanotanii\" (also known as \"melanotanii\"), here are the article headings along with their IDs:\n1343: CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists\n1345: Melanoma associated with the use of melanotan-II\n1347: Melanotan-II reverses memory impairment induced by a short-term HF diet\n1349: 5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II\n1351: Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food\n1353: Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism\n1356: The unregulated use of melanotan-II is of public health interest to Australian dermatologists\n1358: Effect of Melanotan-II on Brain Fos Immunoreactivity and Oxytocin Neuronal Activity and Secretion in Rats\n1360: Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide\n1362: Co-treatment with melanotan-II, a potent melanocortin, does not protect against cisplatin ototoxicity\n1364: The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat\n1367: High-performance liquid chromatographic assay for the alpha-melanotropin[4,10] fragment analogue (Melanotan-II) in rat plasma\n1369: Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study\n1371: A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats\n1373: The use of telemetry technology to test the proerectile effect of melanotan-II (MT-II) in conscious rats\n1376: Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice\n1378: The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat\n1380: Reduced anorexigenic efficacy of leptin, but not of the melanocortin receptor agonist melanotan-II, predicts diet-induced obesity in rats\n1381: Melanotan-II: Investigation of the inducer and facilitator effects on penile erection in anaesthetized rat\n1384: 5-HT(2C) receptor activation is a common mechanism on proerectile effects of apomorphine, oxytocin and melanotan-II in rats\n1386: Inhibitory Effect of the Melanocortin Receptor Agonist Melanotan-II (MTII) on Feeding Depends on Dietary Fat Content and not Obesity in Rats on Free-Choice Diets\n1388: The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice\n1390: A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotan-II. Plasma and brain tissue concentrations following administration in mice\n1392: The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes in the male rat\n1393: Effects of ghrelin, corticotrophin-releasing hormone, and melanotan-II on food intake in rats with paraventricular nucleus lesions\n1394: Determination of melanotan-II in rat plasma by liquid chromatography/tandem mass spectrometry: determination of pharmacokinetic parameters in rat following intravenous administration\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug15_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Anastrozole\" (also known as \"anastrozole\"), here are the article headings along with their IDs:\n1395: Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial\n1396: Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial\n1397: Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial\n1398: Anastrozole-Associated Lichenoid Eruption\n1399: Anastrozole-related dermatitis with mainly unilateral distribution\n1400: Anastrozole Regulates Fatty Acid Synthase in Breast Cancer\n1401: Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials\n1402: The Effect of Anastrozole on the Lipid Profile: Systematic Review and Meta-analysis of Randomized Controlled Trials\n1403: Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial\n1404: Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial\n1405: Efficacy and safety of letrozole or anastrozole in the treatment of male infertility with low testosterone-estradiol ratio: A meta-analysis and systematic review\n1406: Anastrozole and related glucuronic acid conjugate are electrophilic species\n1407: Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial\n1408: Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study\n1409: Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?\n1410: Anastrozole: Repurposed drug could prevent thousands of breast cancer cases\n1411: Anastrozole: a new addition to the armamentarium against advanced breast cancer\n1412: Anastrozole in the management of breast cancer\n1413: Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial\n1414: Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer\n1415: In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review\n1416: Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8\n1417: Anastrozole and levonorgrestrel-releasing intrauterine device in the treatment of endometriosis: a randomized clinical trial\n1418: Anastrozole-mediated modulation of mitochondrial activity by inhibition of mitochondrial permeability transition pore opening: an initial perspective\n1419: Fulvestrant plus anastrozole for metastatic breast cancer\n1420: Anastrozole--a new generation in aromatase inhibition: clinical pharmacology\n1421: Combination Vistusertib and Anastrozole Shows Benefit in Endometrial Cancer\n1422: Association of Crystalline Retinopathy With Anastrozole\n1423: Anastrozole may aid breast cancer prevention\n1424: Anastrozole versus progestins/tamoxifen\n1425: The effect of anastrozole therapy on final height and sex hormone levels in pubertal boys receiving growth hormone therapy\n1426: Anastrozole for the prevention of breast cancer in high-risk postmenopausal women: cost-effectiveness analysis in the UK and the USA\n1427: Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor \u03b1\n1428: A novel anastrozole intravaginal ring for endometriosis: Pharmacokinetic characteristics and mucosal irritation\n1429: Combined Anastrozole and Antiplatelet Therapy Treatment Differentially Promotes Breast Cancer Cell Survival\n1430: Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management\n1431: Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients\n1432: Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2\n1433: Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer\n1434: Anastrozole as a therapeutic option for gynecomastia in a person receiving antiretroviral therapy: Case report\n1435: Effects of psoralen on the pharmacokinetics of anastrozole in rats\n1436: Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report\n1437: Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer\n1438: Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer\n1439: Gynaecomastia: the anastrozole paradox\n1440: Testosterone and luteinizing hormone predict semen parameter improvement in infertile men treated with anastrozole\n1441: Anastrozole is a dose-specific superovulator and favors implantation in rats: a prospective study\n1442: Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy\n1443: Aromatase inhibitor anastrozole modifies cellular functions in gingival fibroblasts and endothelial cells: possible periodontal complications of aromatase inhibitor treatment\n1444: Anastrozole-induced liver injury after a prolonged latency: a very rare complication of a commonly prescribed medication\n1445: Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation\n1446: Anastrozole-induced subacute cutaneous lupus erythematosus\n1447: Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability\n1448: Modelling the procoagulatory effect of Anastrozole relative to ER\u03b1 and ER\u03b2 expression in breast cancer cells\n1450: Effects ofCYP3A4andCYP2C9genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226\n1452: Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer\n1454: Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole\n1456: First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis\n1458: Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail\n1460: Vitreo-retinal traction and anastrozole use\n1462: Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer\n1463: Evaluation of Pharmacokinetics and Safety With Bioequivalence of Anastrozole in Healthy Chinese Volunteers: Bioequivalence Study Findings\n1465: Anastrozole. An effective, second-line hormonal treatment for advanced breast cancer\n1467: Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure\n1469: Trajectories of neuropsychological symptom burden in postmenopausal women prescribed anastrozole for early-stage breast cancer\n1471: Amalgamation of quercetin with anastrozole and capecitabine: A novel combination to treat breast and colon cancers - Anin vitrostudy\n1475: Parahydrogen in Reversible Exchange Induces Long-Lived15N Hyperpolarization of Anticancer Drugs Anastrozole and Letrozole\n1478: Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer\n1483: Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)\n1486: Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)\n1488: Aromatase inhibitor (anastrozole) affects growth of endometrioma cells in culture\n1490: Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Male Volunteers: A Randomized, Single-Dose, Two-Period, Two-Sequence Crossover Study\n1492: Anastrozole: brain draining or sparing?\n1495: The effects of anastrozole on the proliferation of FM3A cells\n1499: Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action\n1501: Effects of anastrozole on Ki-67 antigen expression in the vaginal epithelium of female rats in persistent estrus\n1504: Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation\n1507: Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results\n1510: Anastrozole: carpal tunnel syndrome. Possibly a hormonal mechanism\n1513: Segmental Erythema Multiforme: An Unusual Drug Reaction to Anastrozole\n1516: Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer\n1519: Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group\n1522: Exploring Radioiodinated Anastrozole and Epirubicin as AKT1-Targeted Radiopharmaceuticals in Breast Cancer: In Silico Analysis and Potential Therapeutic Effect with Functional Nuclear Imagining Implications\n1525: An experience of the intervention effect of individualized on the rehabilitation exercise on bone and joint pain symptoms caused by anastrozole\n1528: Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women?\n1531: Anastrozole for ductal carcinoma in situ\n1535: Optic Neuritis as a Consequence of Long-Term Medical Treatment Using Anastrozole: A Case Report\n1539: Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro\n1542: Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial\n1544: Prevention: targeted therapy-anastrozole prevents breast cancer\n1547: Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903\n1550: Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis\n1554: Anastrozole monotherapy further improves near-adult height after the initial combined treatment with leuprorelin and anastrozole in early-maturing girls with compromised growth prediction: results from the second phase of the GAIL study\n1557: Rapid and Sensitive Liquid Chromatographic Method for Determination of Anastrozole in Different Polymer-Lipid Hybrid Nanoparticles\n1560: Simultaneous Method Development and Validation of Anastrozole Along with Piperine: Degradation Studies and Degradants Characterization Using LC-QTOF-ESI-MS Along with In-silico ADMET Predictions\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug18_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Glutathione\" (also known as \"glutathione\"), here are the article headings along with their IDs:\n1449: Glutathione: overview of its protective roles, measurement, and biosynthesis\n1451: Glutathione: subcellular distribution and membrane transport1\n1453: Unraveling the Potential Role of Glutathione in Multiple Forms of Cell Death in Cancer Therapy\n1455: An Update on Glutathione's Biosynthesis, Metabolism, Functions, and Medicinal Purposes\n1457: The Glutathione Conundrum: Stoichiometric Disconnect between Its Formation and Oxidative Stress\n1459: Glutathione: a marker and antioxidant for aging\n1461: Glutathione and glutathione delivery compounds\n1464: Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy\n1466: Glutathione, altruistic metabolite in fungi\n1468: Implications of glutathione-S transferase P1 in MAPK signaling as a CRAF chaperone: In memory of Dr. Irving Listowsky\n1470: Glutathione in defense and signaling: lessons from a small thiol\n1473: Glutathione and glutathione analogues; therapeutic potentials\n1476: Glutathione metabolism and its role in hepatotoxicity\n1477: Glutathione--nutritional and pharmacological viewpoints: part II\n1480: Role of glutathione metabolism and glutathione-related antioxidant defense systems in hypertension\n1482: Coordination chemistry of glutathione\n1484: Glutathione, reduced (GSH). Monograph\n1489: Glutathione therapy: from prodrugs to genes\n1493: Bioactivation of hexachlorobutadiene by glutathione conjugation\n1497: Analysis of endogenous glutathione-adducts and their metabolites\n1498: Biosynthesis and metabolism of glutathione in plants\n1503: Glutathione-associated regulation of plant growth and stress responses\n1506: Historical aspects of glutathione and cancer chemotherapy\n1508: Glutathione Pulse Therapy: Promote Spatiotemporal Delivery of Reduction-Sensitive Nanoparticles at the \"Cellular Level\" and Synergize PD-1 Blockade Therapy\n1512: Elevation of mouse kidney thiol content following administration of glutathione\n1515: [Glutathione and glutathione assays]\n1517: Regulation of hepatic glutathione synthesis: current concepts and controversies\n1520: [Glutathione metabolism]\n1523: An overview on glutathione in Saccharomyces versus non-conventional yeasts\n1527: Oxidative Stress and Low Glutathione in Common Ear, Nose, and Throat Conditions: A Systematic Review\n1530: Glutathione: a radical treatment for cystic fibrosis lung disease?\n1532: The role of glutathione in intestinal dysfunction\n1536: Guarding against cellular glutathione deficiency\n1538: Design and synthesis of glutathione analogues\n1541: Glutathione-nutritional and pharmacologic viewpoints: Part IV\n1545: Dietary modulation of the glutathione detoxification pathway and the potential for altered xenobiotic metabolism\n1548: Glutathione monoethyl ester prevents TDP-43 pathology in motor neuronal NSC-34 cells\n1551: 4-Hydroxybenzyl-substituted glutathione derivatives from Gastrodia elata\n1553: Glutathione conjugates of misonidazole\n1556: [Plasmatic glutathione levels and their relationships with clinical and therapeutic features in patients with schizophrenia]\n1559: Regulation of hepatic glutathione metabolism and its role in hepatotoxicity\n1562: Heritability of the aged glutathione phenotype is dependent on tissue of origin\n1563: Glutathione reductase activity with an oxidized methylated glutathione analog\n1564: Chromatographic and mass spectrometric analysis of glutathione in biological samples\n1566: Methods for measuring glutathione concentration and rate of synthesis\n1568: The role of glutathione in the transport and catabolism of nitric oxide\n1570: Mitochondrial glutathione content determines the rate of liver regeneration after partial hepatectomy in eu- and hypothyroid rats\n1572: The chemistry of the S-nitrosoglutathione/glutathione system\n1575: Elucidation of Plasma-induced Chemical Modifications on Glutathione and Glutathione Disulphide\n1577: Analytical methods to investigate glutathione and related compounds in biological and pathological processes\n1579: [Biochemistry of thiol groups: the role of glutathione]\n1581: Comparison of inhibitory effects between acetaminophen-glutathione conjugate and reduced glutathione in human glutathione reductase\n1584: Glutathione transferase omega 1 catalyzes the reduction of S-(phenacyl)glutathiones to acetophenones\n1586: Label-free detection of glutathione and glutathione disulfide in biological fluid by using an alpha-hederin nanopore\n1587: Multiple roles of glutathione in the central nervous system\n1588: Glutathione synthesis in normal liver and in Yoshida AH-130 hepatoma\n1589: Glutathione--nutritional and pharmacological viewpoints: Part III\n1590: Glutathione-nutritional and pharmacologic viewpoints: part I\n1591: Glutathione--nutritional and pharmacologic viewpoints: Part V\n1592: Influence of glutathione fructosylation on its properties\n1593: Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine\n1594: Glutathione monoethyl ester: high-performance liquid chromatographic analysis and direct preparation of the free base form\n1595: A high-throughput glutathione trapping assay with combined high sensitivity and specificity in high-resolution mass spectrometry by applying product ion extraction and data-dependent neutral loss\n1597: Stereoselective formation of bromobenzene glutathione conjugates\n1599: A Hg(II)-mediated \"signal-on\" electrochemical glutathione sensor\n1601: Glutathione disulfide variability in normal human blood\n1603: Glutathione, S-substituted glutathiones, and leukotriene C4 as substrates for peptidylglycine alpha-amidating monooxygenase\n1605: Stereoisomers of glutathione: preparation and enzymatic reactivities\n1607: Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA)\n1609: Rapid spectrophotometric differentiation between glutathione-dependent and glutathione-independent gentisate and homogentisate pathways\n1610: Esterification of reduced glutathione\n1611: [Sulfhydryl-glutathione and anesthesia]\n1612: Production of glutathione sulfonamide and dehydroglutathione from GSH by myeloperoxidase-derived oxidants and detection using a novel LC-MS/MS method\n1613: Rapid Method for the Quantification of Reduced and Oxidized Glutathione in Human Plasma and Saliva\n1614: Single-molecule transformation and analysis of glutathione oxidized and reduced in nanopore\n1615: Glutathione prevents ethanol induced gastric mucosal damage and depletion of sulfhydryl compounds in humans\n1616: Interaction of a glutathione S-conjugate with glutathione reductase. Kinetic and X-ray crystallographic studies\n1617: Engineering the Redox-Driven Channel for Precisely Regulating Nanoconfined Glutathione Identification and Transport\n1619: Cysteine and glutathione metabolism in organ-cultured rat corneas\n1622: The effects of 3 weeks of oral glutathione supplementation on whole body insulin sensitivity in obese males with and without type 2 diabetes: a randomized trial\n1623: The thiol compounds glutathione and homoglutathione differentially affect cell development in alfalfa (Medicago sativa L.)\n1625: Glutathione as a primary osmotic driving force in hepatic bile formation\n1628: Studies on the fate of the glutathione and cysteine conjugates of acetaminophen in mice\n1630: Glutathione conjugates of 2- or 6-substituted 5,8-dimethoxy-1,4-naphthoquinone derivatives: formation and structure\n1632: Glucose-derived Amadori compounds of glutathione\n1634: Glutathione transport across hepatocyte plasma membranes. Analysis using isolated rat-liver sinusoidal-membrane vesicles\n1636: Copper-glutathione complexes under physiological conditions: structures in solution different from the solid state coordination\n1639: Radioprotection by glutathione ester: transport of glutathione ester into human lymphoid cells and fibroblasts\n1641: Rapid Quantification of Oxidized and Reduced Forms of Glutathione Using Ortho -phthalaldehyde in Cultured Mammalian Cells In Vitro\n1642: Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity\n1645: p-aminophenol nephrotoxicity: biosynthesis of toxic glutathione conjugates\n1646: Super-assembled periodic mesoporous organosilica membranes with hierarchical channels for efficient glutathione sensing\n1648: Overview of glutathione function and metabolism\n1650: Structure of a glutathione conjugate bound to the active site of aldose reductase\n1652: Transport of glutathione at blood-brain barrier of the rat: inhibition by glutathione analogs and age-dependence\n1654: Reactivity of glutathione adducts of 4-(dimethylamino)phenol. Formation of a highly reactive cyclization product\n1655: Exogenous glutathione increases endurance to muscle effort in mice\n1657: Measurement of glutathione redox state in cytosol and secretory pathway of cultured cells\n1659: Glutathione disulfide (GSSG) efflux from cells and tissues\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug19_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Tesamorelin\" (also known as \"tesamorelin\"), here are the article headings along with their IDs:\n1472: Tesamorelin\n1474: Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy\n1479: Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy\n1481: Tesamorelin improves fat quality independent of changes in fat quantity\n1485: Tesamorelin, a human growth hormone releasing factor analogue\n1487: Tesamorelin\n1491: Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD\n1494: Tesamorelin update\n1496: Clinical Review Report: Tesamorelin (Egrifta) [Internet]\n1500: Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach\n1502: Pharmacoeconomic Review Report: Tesamorelin (Egrifta) [Internet]\n1505: Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial\n1509: Spotlight on tesamorelin in HIV-associated lipodystrophy\n1511: Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial\n1514: Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors\n1518: Tesamorelin, liver fat, and NAFLD in the setting of HIV\n1521: Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects\n1524: CADTH Canadian Drug Expert Committee Final Recommendation: Tesamorelin: (Egrifta \u2014 Theratechnologies Inc.) [Internet]\n1526: Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor\n1529: Tesamorelin: A hope for ART-induced lipodystrophy\n1533: Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data\n1534: Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV\n1537: The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV\n1540: Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction\n1543: The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH\n1546: Neuroendocrinology: Tesamorelin can improve cognitive function\n1549: Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial\n1552: Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers\n1555: Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue\n1558: Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension\n1561: Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects\n1565: Effects of Tesamorelin on Neurocognitive Impairment in Abdominally Obese Persons with HIV\n1567: Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat\n1569: Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin\n1571: Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation\n1573: Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy\n1574: Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy\n1576: FDA approves tesamorelin for HIV-related lipodystrophy\n1578: Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial\n1580: Side effects and complications. Tesamorelin--results from Phase III\n1582: Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation\n1583: The next generation of human growth hormone. How Serostim and tesamorelin measure up\n1585: Side effects and complications. Clinical trials of tesamorelin in Canada\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug20_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"S-23\" (also known as \"s-23\"), here are the article headings along with their IDs:\n1596: In vitro characterization of S-23 metabolites produced by human liver microsomes, and subsequent application to urine after a controlled oral administration\n1598: Sequence of the 16 S-23 s spacer region in two ribosomal RNA operons of Escherichia coli\n1600: Detection of the selective androgen receptor modulator S-23 and its metabolites in equine urine and plasma following oral administration\n1602: Characterization of in vitro generated metabolites of the selective androgen receptor modulators S-22 and S-23 and in vivo comparison to post-administration canine urine specimens\n1604: Euglena gracilis chloroplast ribosomal RNA transcription units. II. Nucleotide sequence homology between the 16 S--23 S ribosomal RNA spacer and the 16 S ribosomal RNA leader regions\n1606: Isolated keratinized gingiva incision in alveolar cleft bone grafts improves qualitative outcomes: a single surgeon's 23 year experience\n1608: Survivorship of Periprosthetic Joint Infection in Unicompartmental Knee Arthroplasty: A Single Healthcare System's 23-Year Experience\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug21_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Raloxifene\" (also known as \"raloxifene\"), here are the article headings along with their IDs:\n1618: Raloxifene\n1620: Raloxifene as a treatment option for viral infections\n1621: Raloxifene\n1624: Raloxifene as Treatment for Various Types of Brain Injuries and Neurodegenerative Diseases: A Good Start\n1626: Raloxifene has favorable effects on the lipid profile in women explaining its beneficial effect on cardiovascular risk: A meta-analysis of randomized controlled trials\n1627: Estradiol and raloxifene as adjunctive treatment for women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials\n1629: Raloxifene hydrochloride\n1631: The effects of raloxifene on endothelial function and Inflammation in Postmenopausal women: A Meta-analysis of randomized controlled trials\n1633: Raloxifene: a review of its use in postmenopausal osteoporosis\n1635: Raloxifene: cardiovascular considerations\n1637: Raloxifene and its role in breast cancer prevention\n1638: Raloxifene administration enhances retention in an orthodontic relapse model\n1640: A Raloxifene Withdrawal Response: Translational Research, Definitions, and Clinical Applications\n1643: [Raloxifene - an unexploited possibility of prevention and treatment of postmenopausal osteoporosis]\n1644: Raloxifene is a Female-specific Proteostasis Therapeutic in the Spinal Cord\n1647: Raloxifene in breast cancer prevention\n1649: Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines\n1651: Raloxifene for older women: a review of the literature\n1653: Long-term raloxifene for postmenopausal osteoporosis\n1656: Raloxifene use in clinical practice: efficacy and safety\n1658: Review on raloxifene: profile of a selective estrogen receptor modulator\n1660: Cardiovascular effects of raloxifene hydrochloride\n1661: Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications\n1662: Raloxifene prevents intracellular invasion of pathogenic bacteria through modulation of cell metabolic pathways\n1663: Novel anti-Acanthamoebic properties of raloxifene sulfonate/sulfamate derivatives\n1664: Age-and Region-Dependent Disposition of Raloxifene in Rats\n1665: Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis\n1666: [Raloxifene]\n1667: Raloxifene: a review of its use in the prevention of invasive breast cancer\n1668: Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants\n1670: The use of raloxifene in osteoporosis treatment\n1671: The effect of raloxifene supplementation on blood pressure and Apo-lipoproteins in postmenopausal women: A systematic review and meta-analysis\n1673: Raloxifene for prevention of osteoporotic fractures\n1675: Raloxifene, a cannabinoid type-2 receptor inverse agonist, mitigates visual deficits and pathology and modulates microglia after ocular blast\n1677: The NSABP Study of Tamoxifen and Raloxifene (STAR) trial\n1679: Raloxifene: a new choice for treating and preventing osteoporosis\n1682: [Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy]\n1683: Review of raloxifene and its clinical applications in osteoporosis\n1685: Synthesis of raloxifene-like quinoxaline derivatives by intramolecular electrophilic cyclization with disulfides\n1687: Combined Raloxifene and Letrozole for Breast Cancer Patients\n1689: Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects\n1691: Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator\n1693: [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient]\n1695: [Raloxifene: a selective modulator of estrogen receptors]\n1698: Raloxifene prevents stress granule dissolution, impairs translational control and promotes cell death during hypoxia in glioblastoma cells\n1700: Raloxifene attenuates oxidative stress and preserves mitochondrial function in astrocytic cells upon glucose deprivation\n1702: Raloxifene-encapsulated hyaluronic acid-decorated chitosan nanoparticles selectively induce apoptosis in lung cancer cells\n1705: Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action\n1706: Formulation and Characterization of Raloxifene Nanostructured Lipid Carriers for Permeability and Uptake Enhancement Applications\n1708: Raloxifene\n1710: Raloxifene potentiates the effect of fluoxetine against maximal electroshock induced seizures in mice\n1712: Mandibular Osteonecrosis Associated With Raloxifene\n1713: The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women\n1716: Raloxifene temporarily reduces arterial stiffness\n1718: Raloxifene for women with Alzheimer disease: A randomized controlled pilot trial\n1721: Benefit-risk assessment of raloxifene in postmenopausal osteoporosis\n1725: Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer\n1728: Identification of raloxifene as a novel \u03b1-glucosidase inhibitor using a systematic drug repurposing approach in combination with cross molecular docking-based virtual screening and experimental verification\n1731: Raloxifene improves the ovariectomy-induced impairment in endothelium-dependent vasodilation\n1734: Chitosan-Raloxifene nanoparticle containing doxorubicin as a new double-effect targeting vehicle for breast cancer therapy\n1738: The Interplay of Raloxifene and Sonochemical Bio-Oss in Early Maxillary Sinus Bone Regeneration: A Histological and Immunohistochemical Analysis in Rabbits\n1739: Raloxifene to prevent postmenopausal osteoporosis\n1742: Raloxifene reduces skeletal fractures in an animal model of osteogenesis imperfecta\n1746: Raloxifene trial in postmenopausal woman with treatment-resistant schizophrenia\n1749: Pulmonary delivery alters the disposition of raloxifene in rats\n1753: A STARring role for raloxifene?\n1756: The potential renoprotective effect of Raloxifene in renal ischemia-reperfusion injury in a male rat model\n1759: Efficacy of Raloxifene as Add-on Therapy on Disease Activity of Postmenopausal Women with Rheumatoid Arthritis: A Double-blind, Randomized, Placebo-controlled Clinical Trial\n1762: Binding of raloxifene to human complement fragment 5a (hC5a): a perspective on cytokine storm and COVID19\n1765: Immersion in Raloxifene does not significantly improve bone toughness or screw pull-out strength in multiple in vitro models\n1768: Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene\n1771: Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation\n1774: How does raloxifene reduce fracture risk?\n1775: Hypocalcemia induced by raloxifene\n1779: Raloxifene: another selective estrogen modulator\n1781: [Results of international clinical trials with raloxifene]\n1785: Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial\n1788: Raloxifene effects upon the neuronal system controlling sexual receptivity in female rats\n1791: Combined Thermoneutral Housing and Raloxifene Treatment Improves Trabecular Bone Microarchitecture and Strength in Growing Female Mice\n1794: Folic acid-conjugated raloxifene hydrochloride carbon nanotube for targeting breast cancer cells\n1796: Raloxifene and risk for stroke based on the framingham stroke risk score\n1800: Structural features underlying raloxifene's biophysical interaction with bone matrix\n1804: Raloxifene: handle with care\n1806: Raloxifene remains an option\n1808: Risk-benefit profiles of raloxifene for women\n1811: An update on raloxifene\n1814: Raloxifene and cardiovascular disease\n1817: Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial\n1821: Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8 and UGT1A9\n1824: Effect of Raloxifene on all-cause mortality\n1827: Novel hydroxyapatite biomaterial covalently linked to raloxifene\n1830: Raloxifene, arterial function and Ockham's razor\n1833: Comparative Pharmacokinetic Profiles of a Novel Low-Dose Micronized Formulation of Raloxifene 45 mg (AD-101) and the Conventional Raloxifene 60 mg in Healthy Subjects\n1836: Re: Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance\n1840: Raloxifene covalently bonded to titanium implants by interfacing with (3-aminopropyl)-triethoxysilane affects osteoblast-like cell gene expression\n1843: Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial\n1847: Design, synthesis, and biological evaluation of new raloxifene analogues of improved antagonist activity and endometrial safety\n1849: Bioavailability Enhancement of BCS Class II Raloxifene Hydrochloride by Inclusion Complex and Solid Dispersion Techniques\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug22_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Phenibut\" (also known as \"phenibut\"), here are the article headings along with their IDs:\n1669: Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug\n1672: Phenibut: A drug with one too many \"buts\"\n1674: Phenibut: Review and Pharmacologic Approaches to Treating Withdrawal\n1676: Phenibut (\u03b2-Phenyl-\u03b3-Aminobutyric Acid): an Easily Obtainable \"Dietary Supplement\" With Propensities for Physical Dependence and Addiction\n1678: Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review\n1680: A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal\n1681: A Systematic Review of Phenibut Withdrawals\n1684: Quantity of phenibut in dietary supplements before and after FDA warnings\n1686: Phenibut Dependence and Withdrawal\n1688: Phenibut withdrawal management in a neonate\n1690: Phenibut toxicosis in a dog\n1692: Acute phenibut withdrawal: A comprehensive literature review and illustrative case report\n1694: Phenibut overdose\n1696: Phenibut dependence\n1697: Safety and Tolerability of the Anxiolytic and Nootropic Drug Phenibut: A Systematic Review of Clinical Trials and Case Reports\n1699: Phenibut, a GABAB Agonist, Detected in a Fatality\n1701: F-phenibut (\u03b2-(4-Fluorophenyl)-GABA), a potent GABABreceptor agonist, activates an outward-rectifying K+current and suppresses the generation of action potentials in mouse cerebellar Purkinje cells\n1703: Chronic Phenibut Use: Symptoms, Severe Withdrawal, and Recovery\n1704: Phenibut Use in a Patient Prescribed Gabapentinoids\n1707: Toxidrome of an Easily Obtainable Nootropic: A Case Report of Phenibut Intoxication and Withdrawal Delirium\n1709: [Phenibut: harmless dietary supplement or dangerous drug?]\n1711: Phenibut Addiction in a Patient with Substance Use Disorder\n1714: Seizure Occurring During Baclofen Monotherapy for Phenibut Withdrawal\n1715: R-phenibut binds to the \u03b12-\u03b4 subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects\n1717: Management of Phenibut Use Disorder and Withdrawal in a Geriatric Patient\n1719: Phenibut (\u03b2-Phenyl-\u03b3-Aminobutyric Acid) Psychosis\n1722: Phenibut and Bromazolam Use Disorders Requiring Hospitalization for Medically Supervised Withdrawal\n1723: Phenibut exposures and clinical effects reported to a regional poison center\n1726: Phenibut: A Novel Nootropic With Abuse Potential\n1729: Acute Psychosis Associated with Phenibut Ingestion\n1732: Mitochondrial-Protective Effects of R-Phenibut after Experimental Traumatic Brain Injury\n1735: Severe phenibut poisoning: An adolescent case cluster\n1737: A case of phenibut withdrawal and treatment with baclofen\n1740: Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity\n1743: Plasma concentrations of phenibut and mitragynine in a single patient\n1745: Reasons for use and experiences of using phenibut, a mixed methods analysis of online reports\n1748: Phenibut (\u03b2-Phenyl-\u03b3-aminobutyric Acid) Dependence and Management of Withdrawal: Emerging Nootropics of Abuse\n1752: The neuroprotective effects of R-phenibut after focal cerebral ischemia\n1755: Experimental Substantiation of the Use of Phenibut Combinations with Salicylic, Nicotinic, and Glutamic Acids in Cerebral Ischemia\n1758: Comparative pharmacological activity of optical isomers of phenibut\n1761: Phenibut screening and quantification with liquid chromatography-tandem mass spectrometry and its application to driving cases\n1764: A Case of Phenibut Directed Detoxification Leading to Toxicity During the COVID-19 Pandemic\n1767: An Unusual Presentation of an Uncommon Drug: A Case Report on Phenibut Overdose\n1770: Acute behavioural disturbance associated with phenibut purchased via an internet supplier\n1773: A Case of Phenibut Withdrawal Management and Detoxification Using Baclofen in the Outpatient Setting\n1777: A Withdrawal Syndrome After a Switch of Phenibut to Another \u03b3-Aminobutyric Acid Agonist\n1778: Phenibutan\u2014an Illegal Food Supplement With Psychotropic Effects and Health Risks\n1783: Purchasing \"Nootropics\" Online: Identification and Quantification of Ingredients in Phenibut-Containing Products\n1784: Notes from the Field: Phenibut Exposures Reported to Poison Centers - United States, 2009-2019\n1787: Effects of Phenibut and Citrocard on Non-Competitive and Competitive Behavior during Provoked Aggression in Animals\n1790: Psychomotor Agitation Non-responsive to Treatment: A Case Report of Phenibut Withdrawal Syndrome\n1792: Quantitative analysis of phenibut in rat brain tissue extracts by liquid chromatography-tandem mass spectrometry\n1795: Phenibut, the appearance of another potentially dangerous product in the United States\n1798: Back Pedaling on Baclofen: Highlighting Concerns Surrounding Baclofen use in Phenibut Withdrawal\n1801: [Phenibut potentiation of the therapeutic action of antiparkinson agents]\n1802: Effects of the GABA receptor agonist phenibut on behavior and respiration in rabbits in emotionally negative situations\n1805: Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank\n1809: Effect of Phenibut and Glufimet, a Novel Glutamic Acid Derivative, on Respiration of Heart and Brain Mitochondria from Animals Exposed to Stress against the Background of Inducible NO-Synthase Blockade\n1813: Analytically confirmed recreational use of Phenibut (\u03b2-phenyl-\u03b3-aminobutyric acid) bought over the internet\n1816: Dissociative Intoxication and Prolonged Withdrawal Associated With Phenibut: A Case Report\n1819: Backpedaling on Baclofen: Highlighting Concerns Surrounding Baclofen Use in Phenibut Withdrawal: Letter to the Editor Response\n1822: Case Report of Physiologic Phenibut Dependence Treated With a Phenobarbital Taper in a Patient Being Treated With Buprenorphine\n1825: Detoxification of a Patient With Comorbid Dependence on Phenibut and Benzodiazepines by Tapering With Baclofen: Case Report\n1828: [Effect of phenibut on the respiratory arrest caused by serotonin]\n1831: Challenges in GC-MS analysis: Case studies on phenibut and ethylphenidate\n1835: Optical isomers of phenibut inhibit [H(3)]-Gabapentin binding in vitro and show activity in animal models of chronic pain\n1838: [Bioequivalence of anvifen and phenibut]\n1842: Telescoped Continuous Flow Synthesis of Optically Active \u03b3-Nitrobutyric Acids as Key Intermediates of Baclofen, Phenibut, and Fluorophenibut\n1844: Inhibition of the Expression of Inducible NO Synthase by Neuroactive Amino Acid Derivatives Phenibut and Glufimet In Vitro and Ex Vivo\n1846: Comparative study of immunocorrective activity of phenibut and its organic salts in experimental immunodeficiency\n1850: Withdrawal symptoms after Internet purchase of phenibut (\u03b2-phenyl-\u03b3-aminobutyric acid HCl)\n1852: [Gravidaprotective action of phenibut in experimental pre-eclampsia]\n1855: [Influence of GABA agonist phenibut on the neuronal activity and interaction in hippocampus and neocortex in emotionally negative situations]\n1858: [Psychotropic effect of phenibut salts and their compositions with organic acids]\n1860: [Effect of GABA receptor agonist phenibut on behavior and respiration of rabbits in the negative emotional situation]\n1861: [Use of phenibut in France: report of two cases]\n1863: [Effect of phenibut on interhemispheric transmission in the rat brain]\n1865: [Role of the GABAergic system in the mechanism of the stress-regulating action of phenibut]\n1867: [Peculiarities of nootropic effect of phenibut]\n1869: [Comparative study of immunomodulating properties of phenibut and gammoxin]\n1871: NEUROPROTECTIVE ACTION OF PHENIBUT AND NEUROGLUTAM IN EXPERIMENTAL CEREBRAL ISCHEMIA ON THE BACKGROUND OF ALTERED IMMUNOREACTIVITY\n1873: [Effect of phenibut and its composition with nicotinic acid on hemostasis in rats with brain ischemia]\n1874: [NO-DEPENDENT MECHANISM OF THE CARDIOPROTECTIVE ACTION OF PHENIBUT ON STRESS-INDUCED VIOLATION OF CONTRACTILE FUNCTION OF THE HEART]\n1876: [Effect of the GABA derivative phenibut on learning]\n1879: [Effect of phenibut on the content of monoamines, their metabolites, and neurotransmitter amino acids in rat brain structures]\n1880: [Effect of phenibut, obsidan and their combination on the human functional state in hyperthermia]\n1882: [Phenibut yielded withdrawal symptoms and psychosis. Drugs for cosmonauts--now marketed as dietary supplements online]\n1884: [Effects of phenibut on parameters of cerebral hemodynamics in swimmers with dysadaptation syndrome and various types of systemic hemodynamics]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug23_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Telmisartan\" (also known as \"telmisartan\"), here are the article headings along with their IDs:\n1720: Effects of telmisartan on metabolic syndrome components: a comprehensive review\n1724: Treatment of proteinuria in dogs with telmisartan: A retrospective study\n1727: Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia\n1730: [Telmisartan in the treatment of hypertensive patients]\n1733: Telmisartan: the ACE of ARBs?\n1736: Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm\n1741: Telmisartan Alleviates Alzheimer's Disease-Related Neuropathologies and Cognitive Impairments\n1744: Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial\n1747: Telmisartan (and/or nitrosamine) - induced occult melanoma: first reported case in world literature\n1750: Telmisartan: just an antihypertensive agent? A literature review\n1751: Telmisartan inhibits microglia-induced neurotoxic A1 astrocyte conversion via PPAR\u03b3-mediated NF-\u03baB/p65 degradation\n1754: Telmisartan-induced sprue-like enteropathy: a case report\n1757: Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial\n1760: Telmisartan and Walking Performance in Peripheral Artery Disease\n1763: Telmisartan prevents high-fat diet-induced neurovascular impairments and reduces anxiety-like behavior\n1766: Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials\n1769: Telmisartan anti-cancer activities mechanism through targeting N-cadherin by mimicking ADH-1 function\n1772: Telmisartan-Induced Myotoxicity in Patients with Essential Hypertension\n1776: Telmisartan is the most effective ARB to increase adiponectin via PPAR\u03b1 in adipocytes\n1780: Telmisartan Reduces Axon Degeneration in Mice With Experimental Glaucoma\n1782: Are the effects of telmisartan more marked in hypertensive patients?\n1786: Telmisartan ameliorates LPS-induced pneumonia in rats through regulation of the PPAR\u03b3/NF-\u03baB pathway\n1789: Telmisartan loading thermosensitive hydrogel repairs gut epithelial barrier for alleviating inflammatory bowel disease\n1793: Telmisartan Protects Auditory Hair Cells from Gentamicin-Induced Toxicity in vitro\n1797: Effect of telmisartan on an experimental model of periodontitis in mice\n1799: Micardis/HCT (telmisartan/hydrochlorothiazide)\n1803: An insight into the role of telmisartan as PPAR-\u03b3/\u03b1 dual activator in the management of nonalcoholic fatty liver disease\n1807: Telmisartan cardioprotects from the ischaemic/hypoxic damage through a miR-1-dependent pathway\n1810: Telmisartan 80 mg/hydrochlorothiazide 25 mg single-pill combination in the treatment of hypertension\n1812: Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats\n1815: Antihypertensive effect of telmisartan versus perindopril in hypertensive patients\n1818: MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells\n1820: Telmisartan attenuates human glioblastoma cells proliferation and oncogenicity by inducing the lipid oxidation\n1823: Telmisartan Protects Against Aluminum-Induced Alzheimer-like Pathological Changes in Rats\n1826: Telmisartan Improves Insulin Resistance: A Meta-Analysis\n1829: Telmisartan Protects Mitochondrial Function, Gait, and Neuronal Apoptosis by Activating the Akt/GSK3\u03b2/PGC1\u03b1 Pathway in an MPTP-Induced Mouse Model of Parkinson's Disease\n1832: Telmisartan Exacerbates Cisplatin-Induced Nephrotoxicity in a Mouse Model\n1834: Telmisartan improves myocardial remodeling by inhibiting leptin autocrine activity and activating PPAR\u03b3\n1837: Telmisartan ameliorates A\u03b2 oligomer-induced inflammation via PPAR\u03b3/PTEN pathway in BV2 microglial cells\n1839: Telmisartan: a multifaceted antihypertension drug\n1841: Clinical pharmacology of telmisartan:\n1845: Telmisartan attenuates obesity-induced insulin resistance via suppression of AMPK mediated ER stress\n1848: Telmisartan induces a specific gut microbiota signature which may mediate its antiobesity effect\n1851: Telmisartan Nanosuspension for Inhaled Therapy of COVID-19 Lung Disease and Other Respiratory Infections\n1853: Improving effects of telmisartan on spermatogenic disorder induced by fractionated low-dose irradiation in mice\n1854: Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease: The TELEX Randomized Clinical Trial\n1856: Telmisartan Is a Promising Agent for Managing Neuropathic Pain and Delaying Opioid Analgesic Tolerance in Rats\n1857: Telmisartan attenuates hydrogen peroxide-induced apoptosis in differentiated PC12 cells\n1859: Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats\n1862: Telmisartan Plus Amlodipine as the Preferred Initial Combination in Newly Diagnosed Indian Patients with Hypertension: An Expert Consensus Statements\n1864: Telmisartan induces browning of fully differentiated white adipocytes via M2 macrophage polarization\n1866: A new Febuxostat-Telmisartan Drug-Drug Cocrystal for Gout-Hypertension Combination Therapy\n1868: Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19\n1870: Telmisartan prevents development of obesity and normalizes hypothalamic lipid droplets\n1872: Telmisartan Restricts Chikungunya Virus InfectionIn VitroandIn Vivothrough the AT1/PPAR-\u03b3/MAPKs Pathways\n1875: Telmisartan Mitigates High-Glucose-Induced Injury in Renal Glomerular Endothelial Cells (rGECs) and Albuminuria in Diabetes Mice\n1877: Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan\n1878: Telmisartan Influences the Antiproliferative Activity of Linoleic Acid in Human Colon Cancer Cells\n1881: Telmisartan as an add-on treatment for dogs with refractory idiopathic epilepsy: a nonrandomized, uncontrolled, open-label clinical trial\n1883: Telmisartan neuroprotective effects in 3-nitropropionic acid Huntington's disease model in rats: Cross talk between PPAR-\u03b3 and PI3K/Akt/GSK-3\u03b2 pathway\n1885: Immunomodulation of Telmisartan-Loaded PCL/PVP Scaffolds on Macrophages Promotes Endogenous Bone Regeneration\n1886: Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial\n1887: Telmisartan ameliorates nephropathy and restores the hippo pathway in rats with metabolic syndrome\n1888: Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study\n1889: Electrospun orally disintegrating film formulation of telmisartan\n1890: Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction\n1891: Telmisartan/hydrochlorothiazide-induced nevus-associated cutaneous melanoma: first report in the medical literature\n1892: Telmisartan and captopril ameliorate pregabalin-induced heart failure in rats\n1893: Telmisartan Attenuates Uric Acid-Induced Epithelial-Mesenchymal Transition in Renal Tubular Cells\n1894: Three-Year Cardiovascular Outcomes of Telmisartan in Patients With Hypertension: An Electronic Health Record-Based Cohort Study\n1895: Telmisartan-Loaded Lactosylated Chitosan Nanoparticles as a Liver Specific Delivery System: Synthesis, Optimization and Targeting Efficiency\n1896: Intraperitoneal Administration of Telmisartan Prevents Postsurgical Adhesion Band Formation\n1897: Single-dose pharmacokinetics of telmisartan oral solution and effect of feeding in dogs\n1898: Triple Therapy with Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-analysis\n1899: The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics\n1900: Pre-clinical and clinical experience of telmisartan in cardiac remodelling\n1901: Telmisartan Exerts Cytotoxicity in Scirrhous Gastric Cancer Cells by Inducing G0/G1Cell Cycle Arrest\n1903: Telmisartan-Induced Cytotoxicity via G2/M Phase Arrest in Renal Cell Carcinoma Cell Lines\n1905: The telmisartan programme of research tO show Telmisartan End-organ proteCTION (PROTECTION) programme\n1907: Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients\n1909: Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19\n1911: Telmisartan Inhibits the NLRP3 Inflammasome by Activating the PI3K Pathway in Neural Stem Cells Injured by Oxygen-Glucose Deprivation\n1913: Telmisartan mitigates lipopolysaccharide (LPS)-induced production of mucin 5AC (MUC5AC) through increasing suppressor of cytokine signaling 1 (SOCS1)\n1915: A Novel Hybrid of Telmisartan and Borneol Ameliorates Neuroinflammation and White Matter Injury in Ischemic Stroke Through ATF3/CH25H Axis\n1917: Telmisartan Inhibits Nitric Oxide Production and Vessel Relaxation via Protein Phosphatase 2A-mediated Endothelial NO Synthase-Ser1179Dephosphorylation\n1919: Telmisartan attenuates diabetic nephropathy by mitigating oxidative stress and inflammation, and upregulating Nrf2/HO-1 signaling in diabetic rats\n1920: A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients\n1921: Telmisartan: An angiotensin receptor blocker regulates osteoclastogenesis via inhibition of the ERK triggering in osteoporotic male rats\n1922: [Sartans in the treatment of arterial hypertension: focus on telmisartan and azilsartan. A review]\n1923: Telmisartan attenuates kidney apoptosis and autophagy-related protein expression levels in an intermittent hypoxia mouse model\n1924: Telmisartan use in rats with preexisting osteoporotics bone disorders increases bone microarchitecture alterations via PPAR\u03b3\n1925: [Telmisartan chronotherapy and its influence on the indicators of the daily profile blood pressure]\n1926: Telmisartan Plus S-Amlodipine Single-Pill Combination Therapy is Safe and Effective in Patients with Hypertension from Large-Scale Nationwide Surveillance Data in Korea (NOVEL) Study\n1927: Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial\n1928: Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer\n1929: Evaluation of novobiocin and telmisartan for anti-CHIKV activity\n1930: Effect of Telmisartan on Arsenic-Induced (Sub-chronic) Perturbations in Redox Homeostasis, Pro-inflammatory Cascade and Aortic Dysfunction in Wistar Rats\n1931: Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target-mediated drug disposition and OATP1B3-mediated hepatic uptake in a physiologically based model\n1932: Telmisartan Protects a Microglia Cell Line from LPS Injury Beyond AT1 Receptor Blockade or PPAR\u03b3 Activation\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug24_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"CJC-1295\" (also known as \"cjc-1295\"), here are the article headings along with their IDs:\n1902: Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults\n1904: A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS\n1906: Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions\n1908: An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma\n1910: Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation\n1912: Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse\n1914: Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog\n1916: Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog\n1918: Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug25_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Bromantane\" (also known as \"bromantane\"), here are the article headings along with their IDs:\n1933: Toxic effect of single treatment with bromantane on neurological status of experimental animals\n1934: [Effect of bromantane on the rat neurologic status in two month course]\n1935: [The characteristics of the neuropsychotropic activity of bromantane in laboratory animals]\n1936: [Study of heat-protective effects of bromantane at various levels of overheating]\n1937: [A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]\n1938: [An acute toxicity study of bromantane]\n1939: [Effects of bromantane and sidnocarb on long-term operant conditioning and its vegetative correlates in rats]\n1940: [The neuro- and psychophysiological effects of bromantane]\n1941: [The effect of bromantane on the erythro- and leukocytic profile of the peripheral blood in rats]\n1942: [Correlated interconnection between pharmacokinetic and dynamic development of the pharmacologic effects of bromantane]\n1943: [The effect of bromantane on the physical work capacity of laboratory animals]\n1944: [The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain]\n1945: [The effect of bromantane, a new immunostimulant with psychostimulating action, on release and metabolism of dopamine in the dorsal striatum of freely moving rats: a microdialysis study]\n1946: [The effect of bromantane on the behavior of inbred mouse strains with different phenotypes of emotional stress reaction]\n1947: [Comparative analysis of effects of adapromine, midantan, and bromantane on the bioelectric activity of the rat brain]\n1948: [Analysis of pharmacological properties of bromantane]\n1949: [Complex evaluation of the effect of bromantane on animal behavior]\n1950: [The effect of bromantane on the cardiovascular and sympathetic-adrenal systems in animals]\n1951: [The effect of the actoprotector preparation bromantane on the postnatal development of rat pups]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug27_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Sermorelin\" (also known as \"sermorelin\"), here are the article headings along with their IDs:\n1952: Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?\n1953: A potentially effective drug for patients with recurrent glioma: sermorelin\n1954: Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug28_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Human\" (also known as \"hmg\"), here are the article headings along with their IDs:\n1955: HMG chromosomal proteins in development and disease\n1956: HMG domain proteins: architectural elements in the assembly of nucleoprotein structures\n1957: The HMG-box: a versatile protein domain occurring in a wide variety of DNA-binding proteins\n1958: HMG CoA reductase inhibitors\n1959: Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management\n1960: The HMG I proteins: dynamic roles in gene activation, development, and tumorigenesis\n1961: The HMG-14/-17 chromosomal protein family: architectural elements that enhance transcription from chromatin templates\n1962: The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases\n1963: Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy\n1964: Comparative tolerability of the HMG-CoA reductase inhibitors\n1965: The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients\n1966: HMG-I/Y in human breast cancer cell lines\n1967: HMG-like protein in barley and corn nuclei\n1968: HMG-I/Y, a new c-Myc target gene and potential oncogene\n1969: Binding and interplay of HMG proteins on chromatin: lessons from live cell imaging\n1970: HMG-D and histone H1 interplay during chromatin assembly and early embryogenesis\n1971: The molecular action and regulation of the testis-determining factors, SRY (sex-determining region on the Y chromosome) and SOX9 [SRY-related high-mobility group (HMG) box 9]\n1972: HMG-D is an architecture-specific protein that preferentially binds to DNA containing the dinucleotide TG\n1973: Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US Predicted High-Responder Patients: A Cost-Comparison Analysis\n1974: HMG-like chromosomal proteins in Trypanosoma cruzi\n1975: The HMG-1 box protein family: classification and functional relationships\n1976: HMG improves IVF outcome in patients with high basal FSH/LH ratio: a preliminary study\n1977: Modified hMG stimulated: an effective option in endometrial preparation for frozen-thawed embryo transfer in patients with normal menstrual cycles\n1979: HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors\n1981: Pregnancy And Neonatal Outcomes Of hMG Stimulation With Or Without Letrozole In Endometrial Preparation For Frozen-Thawed Embryo Transfer In Ovulatory Women: A Large Retrospective Cohort Study\n1986: Antibodies to HMG proteins in patients with drug-induced autoimmunity\n1987: Cost effectiveness of HMG-CoA reductase inhibitors in the management of coronary artery disease: the problem of under-treatment\n1990: The crystal structure of Capicua HMG-box domain complexed with the ETV5-DNA and its implications for Capicua-mediated cancers\n1991: HMG-17 is an early marker of inductive interactions in the developing mouse kidney\n1992: HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre\n1994: Chromatin-associated HMG-17 is a major regulator of homeodomain transcription factor activity modulated by Wnt/beta-catenin signaling\n1996: Insertion Mutation in HMG-CoA Lyase Increases the Production Yield of MPA throughAgrobacterium tumefaciens-Mediated Transformation\n1998: Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen\n2000: A retropseudogene for non-histone chromosomal protein HMG-1\n2003: Sequential clomiphene citrate/hMG versus hMG for ovulation induction in clomiphene citrate-resistant women\n2005: Ancestry and diversity of the HMG box superfamily\n2007: Biochemical properties of Caenorhabditis elegans HMG-5, a regulator of mitochondrial DNA\n2009: High mobility group protein, HMG-1, contains insignificant glycosyl modification\n2012: TOX defines a conserved subfamily of HMG-box proteins\n2014: Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study\n2016: HMG-1 enhances HMG-I/Y binding to an A/T-rich enhancer element from the pea plastocyanin gene\n2019: Targeted delivery of Chil3/Chil4 siRNA to alveolar macrophages using ternary complexes composed of HMG and oligoarginine micelles\n2020: Activation of HMG-CoA reductase by microsomal phosphatase\n2022: Comparing three superovulation protocols in dromedary camels: FSH, eCG-FSH and hMG\n2024: PU.1-mediated transcription is enhanced by HMG-I(Y)-dependent structural mechanisms\n2026: A unique HMG-box domain of mouse Maelstrom binds structured RNA but not double stranded DNA\n2028: A network of HMG-box transcription factors regulates sexual cycle in the fungus Podospora anserina\n2030: Dislocation of HMG-CoA reductase and Insig-1, two polytopic endoplasmic reticulum proteins, en route to proteasomal degradation\n2032: Chromosomal proteins HMG-14 and HMG-17 are synthesized throughout the S-phase in Burkitt's lymphoma\n2035: High mobility group protein-1 (HMG-1) is a unique activator of p53\n2037: Antibodies against chromosomal HMG proteins stain the cytoplasm of mammalian cells\n2039: A small region in HMG I(Y) is critical for cooperation with NF-kappaB on DNA\n2041: Interaction of HMG 14 and 17 with actively transcribed genes\n2043: Diversification pattern of the HMG and SOX family members during evolution\n2045: On the presence of the chromosomal proteins HMG I and HMG Y in rat organs\n2046: Fine structure and activity of discrete RAG-HMG complexes on V(D)J recombination signals\n2048: Structural and functional characterization of HMG-COA reductase from Artemisia annua\n2050: Neither HMG-14a nor HMG-17 gene function is required for growth of chicken DT40 cells or maintenance of DNaseI-hypersensitive sites\n2052: Production of HMG-3 by limited trypsin digestion of purified high-mobility-group nonhistone chromatin proteins\n2054: Expression of HMG-CoA reductase in human coronary atherosclerotic plaques and relationship to plaque destabilisation\n2057: Dynamic relocation of chromosomal protein HMG-17 in the nucleus is dependent on transcriptional activity\n2060: Modulation of HMG-N2 binding to chromatin by butyrate-induced acetylation in human colon adenocarcinoma cells\n2063: Physical studies of the nonhistone chromosomal proteins HMG-U and HMG-2\n2066: A cost per live birth comparison of HMG and rFSH randomized trials\n2069: Cumulative Live Birth Rates Following Stimulation With Corifollitropin Alfa Compared With hp-hMG in a GnRH Antagonist Protocol in Poor Ovarian Responders\n2071: A modified hMG-GnRH method for the induction of ovulation in infertile women with severe hypogonadotropic amenorrhea\n2075: Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer\n2078: The footprint of chromosomal proteins HMG-14 and HMG-17 on chromatin subunits\n2082: Recombinant FSH versus HP-HMG for controled ovarian stimulation in intracitoplasmic sperm injection cycles\n2085: Method for complete separation of the high mobility group (HMG) proteins HMG I and HMG Y from HMG 14 and HMG 17 and a procedure for purification of HMG I and HMG Y\n2087: Persistence of chromosomal proteins HMG-14/-17 in myotubes following differentiation-dependent reduction of HMG mRNA\n2090: Kinetic analysis of high-mobility-group proteins HMG-1 and HMG-I/Y binding to cholesterol-tagged DNA on a supported lipid monolayer\n2093: Phylogenetic relationships of HMG box DNA-binding domains\n2095: Replication-dependent and independent regulation of HMG expression during the cell cycle and conjugation in Tetrahymena\n2098: Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis\n2102: HMG protein family members stimulate human immunodeficiency virus type 1 and avian sarcoma virus concerted DNA integration in vitro\n2104: Effect of HMG protein 17 on the thermal stability of control and acetylated HeLa oligonucleosomes\n2109: Deciphering the role of the AT-rich interaction domain and the HMG-box domain of ARID-HMG proteins of Arabidopsis thaliana\n2111: Comparison of FSH and hMG on ovarian stimulation outcome with a GnRH antagonist protocol in younger and advanced reproductive age women\n2113: Incorporation of chromosomal proteins HMG-14/HMG-17 into nascent nucleosomes induces an extended chromatin conformation and enhances the utilization of active transcription complexes\n2116: Dual function of Ixr1 in transcriptional regulation and recognition of cisplatin-DNA adducts is caused by differential binding through its two HMG-boxes\n2118: Binding of HMG-I(Y) elicits structural changes in a silencer of the human beta-globin gene\n2121: Degradation of HMG-CoA reductase in vitro. Cleavage in the membrane domain by a membrane-bound cysteine protease\n2125: High mobility group (HMG-box) genes in the honeybee fungal pathogen Ascosphaera apis\n2128: Human menopausal gonadotropin versus highly purified-hMG in controlled ovarian hyperstimulation for in-vitro fertilisation: does purity improve outcome?\n2131: Assessment of the transcriptional activation potential of the HMG chromosomal proteins\n2134: Expression of mRNAs encoding mammalian chromosomal proteins HMG-I and HMG-Y during cellular proliferation\n2136: The plant-specific family of DNA-binding proteins containing three HMG-box domains interacts with mitotic and meiotic chromosomes\n2139: Competition between HMG-I(Y), HMG-1 and histone H1 on four-way junction DNA\n2142: ADP-ribosylation of HMG proteins and its modulation by different effectors in the liver of aging rats\n2144: Generic human menopausal gonadotropin (hMG) in place of more costly follicle-stimulating hormone (FSH) for routine ovulation induction\n2147: The oncogenic properties of the HMG-I gene family\n2148: Characterization of cDNA sequences corresponding to three distinct HMG-1 mRNA species in line CHO Chinese hamster cells and cell cycle expression of the HMG-1 gene\n2149: HMGA proteins as modulators of chromatin structure during transcriptional activation\n2151: Nonhistone chromatin proteins HMG-14 and HMG-17 bind preferentially to single-stranded DNA\n2152: Histone H1 and HMG 14/17 are deposited nonrandomly in the nucleus\n2154: A novel downstream positive regulatory element mediating transcription of the human high mobility group (HMG) I-C gene\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug29_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Liothyronine\" (also known as \"liothyronine\"), here are the article headings along with their IDs:\n1978: Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document\n1980: Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism\n1982: Role of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism\n1984: Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism\n1988: Liothyronine Use Beyond Replacement Therapy, with Caution\n1989: Designing a combined liothyronine (LT3), L- thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 - the importance of patient selection, choice of LT3 and trial design\n1993: Liothyronine prescribing in England: costs versus need\n1995: Combination Levothyroxine + Liothyronine Treatment in Pregnancy\n1997: Randomized double-blind placebo-controlled trial on levothyroxine and liothyronine combination therapy in totally thyroidectomized subjects: the LEVOLIO study\n1999: Liothyronine cost and prescriptions in England\n2001: Liothyronine for hypothyroidism: a candidate for disinvestment or in need of further research? A value of information analysis\n2002: Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement\n2004: Liothyronine use in primary hypothyroidism - current concepts\n2006: REVIEW: Treatment of hypothyroidism with combinations of levothyroxine plus liothyronine\n2008: Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR\n2010: Liothyronine Use in Hypothyroidism and its Effects on Cancer and Mortality\n2011: Liothyronine and levothyroxine prescribing in England: A comprehensive survey and evaluation\n2013: Liothyronine (LT3) prescribing in England: Are cost constraints inhibiting guideline implementation?\n2015: Trends in costs and prescribing for liothyronine and levothyroxine in England and wales 2011-2020\n2017: Liothyronine could block the programmed death-ligand 1 (PDL1) activity: an e-Pharmacophore modeling and virtual screening study\n2018: Liothyronine with levodopa in parkinsonism\n2021: Acute Effects of Liothyronine Administration on Cardiovascular System and Energy Metabolism in Healthy Volunteers\n2023: A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS\n2025: Liothyronine use in a 17 year observational population-based study - the tears study\n2027: Effect of Liothyronine Treatment on Quality of Life in Female Hypothyroid Patients With Residual Symptoms on Levothyroxine Therapy: A Randomized Crossover Study\n2029: Liothyronine and levothyroxine in Armour thyroid\n2031: Extended Absorption of Liothyronine from Poly-Zinc-Liothyronine: Results from a Phase 1, Double-Blind, Randomized, and Controlled Study in Humans\n2033: Liothyronine treatment of adult cretin with psychosis\n2034: Effect of Liothyronine Treatment on Dermal Temperature and Activation of Brown Adipose Tissue in Female Hypothyroid Patients: A Randomized Crossover Study\n2036: Preliminary Results of a Double-Blind Randomized Controlled Trial Evaluating the Cardiometabolic Effects of Levothyroxine and Liothyronine Compared to Levothyroxine with Placebo in Athyreotic Low-Risk Thyroid Cancer Patients\n2038: Combined therapy with levothyroxine and liothyronine for hypothyroidism\n2040: Liothyronine therapy in female infertility\n2042: Daily Administration of Short-Acting Liothyronine Is Associated with Significant Triiodothyronine Excursions and Fails to Alter Thyroid-Responsive Parameters\n2044: Response to Letter to the Editor From Bonnema et al: \"Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine + Liothyronine in Hypothyroidism\"\n2047: Use of Combination of Oral Levothyroxine and Liothyronine in Severe Hypothyroidism With Massive Pericardial Effusion\n2049: Use of liothyronine without levothyroxine in the treatment of mild consumptive hypothyroidism caused by hepatic hemangiomas\n2051: Use of liothyronine (L-T3) as an augmentation therapy for depression during pregnancy\n2053: Heart Failure and Stroke Risks in Users of Liothyronine With or Without Levothyroxine Compared with Levothyroxine Alone: A Propensity Score-Matched Analysis\n2055: Key data from the 2022 European Thyroid Association congress: Treatment of primary hypothyroidism: Levothyroxine alone or a combination of levothyroxine and liothyronine?\n2058: Sodium liothyronine in metabolic insufficiency syndrome and associated disorders; preliminary report\n2061: Letter to the Editor From S.J. Bonnema et al: \"Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism\"\n2064: Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial\n2067: Metal Coordinated Poly-Zinc-Liothyronine Provides Stable Circulating Triiodothyronine Levels in Hypothyroid Rats\n2070: Therapeutic effects of oral liothyronine on aluminum phosphide poisoning as an adjuvant therapy: A clinical trial\n2073: Liothyronine (L-triiodothyronine) as a substitute for desiccated thyroid\n2076: The uses of thyroxine and liothyronine\n2077: Successful treatment of myxedema coma with a combination of levothyroxine and liothyronine\n2080: Impurity profiling of liothyronine sodium by means of reversed phase HPLC, high resolution mass spectrometry, on-line H/D exchange and UV/Vis absorption\n2084: Liothyronine treatment in psychotic and nonpsychotic children under 6 years\n2088: Liothyronine as a replacement for thyroid therapy\n2091: Sexual function and depressive symptoms in young men with hypothyroidism receiving levothyroxine/liothyronine combination therapy\n2094: Treatment of chronic schizophrenics with liothyronine (L-triiodothyronine)\n2097: Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study\n2100: Liothyronine in the management of obesity\n2103: L-thyroxine plus liothyronine in hypothyroidism\n2105: Sexual function and depressive symptoms in young women with hypothyroidism receiving levothyroxine/liothyronine combination therapy: a pilot study\n2107: Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism\n2110: Substitution of liothyronine at a 1:5 ratio for a portion of levothyroxine: effect on fatigue, symptoms of depression, and working memory versus treatment with levothyroxine alone\n2114: LIOTHYRONINE SUPPRESSION OF PROTEIN-BOUND IODINE: A TEST FOR HYPERTHYROIDISM IN PREGNANCY\n2117: Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial\n2120: Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone\n2123: Male subfertility: treatment with liothyronine (cytomel)\n2126: THE RELATIVE POTENCIES OF THYROXINE AND LIOTHYRONINE BY ORAL AND SUBCUTANEOUS ADMINISTRATION IN THE RAT\n2129: Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine\n2132: Persistent hyperthyrotropinemia in congenital hypothyroidism: successful combination treatment with levothyroxine and liothyronine\n2135: The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients\n2138: Is combined therapy with levothyroxine and liothyronine effective in patients with primary hypothyroidism?\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug30_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Dihexa\" (also known as \"dihexa\"), here are the article headings along with their IDs:\n1983: AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway\n1985: Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug31_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Nebivolol\" (also known as \"nebivolol\"), here are the article headings along with their IDs:\n2056: Clinical pharmacokinetics of nebivolol: a systematic review\n2059: Therapeutic Properties of Highly Selective \u03b2-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease\n2062: Nebivolol/Valsartan: A Novel Antihypertensive Fixed-Dose Combination Tablet\n2065: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)\n2068: Nebivolol in the treatment of arterial hypertension\n2072: Nebivolol/valsartan combination for the treatment of hypertension: a review\n2074: Nebivolol/valsartan: Fixed-dose combination for treatment of hypertension\n2079: Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis\n2081: Does nebivolol have renoprotective action in patients with chronic kidney disease conditions? An integrative review\n2083: Nebivolol: a review\n2086: Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension\n2089: Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker\n2092: A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension\n2096: Nebivolol: a review of its clinical and pharmacological characteristics\n2099: A Review of Nebivolol Pharmacology and Clinical Evidence\n2101: Nebivolol Sensitizes BT-474 Breast Cancer Cells to FGFR Inhibitors\n2106: Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide\n2108: Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data\n2112: Association of rhabdomyolysis with nebivolol\n2115: Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design\n2119: Ameliorative effect of nebivolol in doxorubicin-induced cardiotoxicity\n2122: Nebivolol Improves Obesity-Induced Vascular Remodeling by Suppressing NLRP3 Activation\n2124: Nebivolol, an antihypertensive agent, has new application in inhibiting melanoma\n2127: Nebivolol Alleviates Vascular Endothelial Insulin Resistance by Inhibiting Endoplasmic Reticulum Stress\n2130: Effect of nebivolol monotherapy or combination therapy on blood pressure levels in patients with hypertension: an updated systematic review and multilevel meta-analysis of 91 randomized controlled trials\n2133: Nebivolol: a review of its use in the management of hypertension and chronic heart failure\n2137: Nebivolol protects erectile functions compared to Metoprolol in hypertensive men with atherogenic, venogenic, psychogenic erectile dysfunction: A prospective, randomized, cross-over, clinical trial\n2140: Nebivolol (Bystolic) for hypertension\n2141: Effect of nebivolol on erectile function: a systematic review and meta-analysis of randomized controlled trials\n2143: Nebivolol alleviates liver damage caused by methotrexate via AKT1/Hif1\u03b1/eNOS signaling\n2145: Nebivolol: more than a highly selective Beta blocker\n2146: Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage\n2150: Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol\n2153: Can nebivolol be helpful in Beh\u00e7et's disease?\n2155: Role of nebivolol in the control and management of central aortic blood pressure in hypertensive patients\n2156: Nebivolol elicits a neuroprotective effect in the cuprizone model of multiple sclerosis in mice: emphasis on M1/M2 polarization and inhibition of NLRP3 inflammasome activation\n2157: Nebivolol and incident cardiovascular events in hypertensive patients compared with nonvasodilatory beta blockers\n2158: A review of the safety and efficacy of nebivolol in the mildly hypertensive patient\n2159: Nebivolol Ameliorates Cisplatin-Induced Nephrotoxicity in Rats\n2160: Nebivolol in the treatment of chronic heart failure\n2161: Nebivolol in chronic heart failure: current evidence and future perspectives\n2162: Fixed-dose combination therapy of nebivolol and valsartan for the treatment of hypertension\n2163: Nebivolol to attenuate the effects of hyper-homocysteinaemia in rats\n2164: Nebivolol Prevents Up-Regulation of Nox2/NADPH Oxidase and Lipoperoxidation in the Early Stages of Ethanol-Induced Cardiac Toxicity\n2165: Nebivolol in older adults with heart failure: reduced rates for seniors?\n2166: Recent advances in the treatment of renal diseases with nebivolol: A literature review\n2167: Nebivolol Induced Hyperkalemia: Case Report\n2168: Nebivolol Increases Nitric Oxide Synthase via \u03b23Adrenergic Receptor in Endothelial Cells Following Exposure to Plasma from Preeclamptic Patients\n2169: Therapeutic Effects of Combination of Nebivolol and Donepezil: Targeting Multifactorial Mechanisms in ALS\n2170: Protective effect of nebivolol on rat ovary exposed to deltamethrin toxicity\n2171: Nebivolol/Valsartan (Byvalson) for Hypertension\n2172: Nebivolol prevents indomethacin-induced gastric ulcer in rats\n2173: Early nebivolol treatment is beneficial in myocardial infarction in rats partly through \u03b23-adrenoceptor remodelling\n2174: Nebivolol hydrochloride and its impurities induce pseudo-allergic reactions via mast cell activation\n2175: Antihypertrophic Effects of Nebivolol on Neonatal Cardiomyocyte Hypertrophy Models\n2176: Nebivolol reduces short-term blood pressure variability more potently than irbesartan in patients with intradialytic hypertension\n2177: Nebivolol protects against cyclophosphamide-induced nephrotoxicity through modulation of oxidative stress, inflammation, and apoptosis\n2178: Nebivolol: a new third-generation beta-blocker agent: implications for Clinical Nurse Specialist Practice\n2179: Nebivolol ameliorates sepsis-evoked kidney dysfunction by targeting oxidative stress and TGF-\u03b2/Smad/p53 pathway\n2180: Nebivolol attenuates the anticonvulsant action of carbamazepine and phenobarbital against the maximal electroshock-induced seizures in mice\n2181: Nebivolol is more effective than atenolol for blood pressure variability attenuation and target organ damage prevention in L-NAME hypertensive rats\n2182: Stereochemical comparison of nebivolol with other beta-blockers\n2184: Nebivolol has a beneficial effect in monocrotaline-induced pulmonary hypertension\n2186: Nebivolol Might Be Beneficial in the Prevention and Treatment of Diabetic Neuropathy\n2187: Nebivolol protects the liver against lipopolysaccharide-induced oxidative stress, inflammation, and endoplasmic reticulum-related apoptosis through Chop and Bip/GRP78 signaling\n2189: Antihypertensive Efficacy Of Nebivolol And Low Dose Spironolactone In Patients With Resistant Hypertension\n2191: [Nebivolol: the first vasodilatory beta-blocker with a beta3-adrenergic agonist activity]\n2193: Nebivolol-Loaded Microsponge Gel for Healing of Diabetic Wound\n2197: Nebivolol prevents redox imbalance and attenuates bladder dysfunction induced by cyclophosphamide in mice\n2200: Nebivolol stimulates mitochondrial biogenesis in 3T3-L1 adipocytes\n2203: Comparative beneficial effects of nebivolol and nebivolol/valsartan combination against mitochondrial dysfunction in angiotensin II-induced pathology in H9c2 cardiomyoblasts\n2206: Extemporaneous combination therapy with nebivolol/zofenopril in hypertensive patients: usage in Italy\n2208: Nebivolol Acts as a S-Nitrosoglutathione Reductase Inhibitor: A New Mechanism of Action\n2212: Nebivolol Ameliorates Hepatic Ischemia/Reperfusion Injury on Liver But Not on Distant Organs\n2214: Nebivolol prevents vascular oxidative stress and hypertension in rats chronically treated with ethanol\n2216: Nebivolol ameliorates asymmetric dimethylarginine-induced vascular response in rat aorta via \u03b23 adrenoceptor-mediated mechanism\n2219: Nebivolol combined with tetrahydrobiopterin affects diastolic function in spontaneously hypertensive rats via the nitric oxide/cyclic guanosine monophosphate signalling pathway\n2222: Synthesis of desfluorinated nebivolol isomers\n2225: The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol\n2229: Effect of nebivolol on altered skeletal and cardiac muscles induced by dyslipidemia in rats: impact on oxidative and inflammatory machineries\n2231: Arterial stiffness, hypertension, and rational use of nebivolol\n2233: Protective Effect of Nebivolol against Oxidative Stress Induced by Aristolochic Acids in Endothelial Cells\n2238: Nebivolol in oral subacute treatment prevents cardiac post-ischemic dysfunction in rats, but hyperthyroidism reduces this protection: mechanisms involved\n2240: Signalling transduction pathways implicated in Nebivolol-induced NO production in endothelial cells\n2244: Nebivolol has protective effect against endothelial and ileal dysfunction due to I/R\n2247: Nebivolol Effects on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients\n2251: Effect of nebivolol on fracture healing: An experimental rat model\n2254: Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension\n2257: Nebivolol efficacy and safety in patients with stage I-II hypertension\n2260: Protective effects of nebivolol on ovarian ischemia-reperfusion injury in rat\n2264: Nebivolol, a \u03b2-blocker abrogates streptozotocin-induced behavioral, biochemical, and neurophysiological deficit by attenuating oxidative-nitrosative stress: a possible target for the prevention of diabetic neuropathy\n2267: Nebivolol, a \u03b21-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis\n2270: Nebivolol prevents ethanol-induced reactive oxygen species generation and lipoperoxidation in the rat kidney by regulating NADPH oxidase activation and expression\n2273: Nebivolol ameliorated kidney damage in Zucker diabetic fatty rats by regulation of oxidative stress/NO pathway: Comparison with captopril\n2276: Nebivolol suppresses cardiac ryanodine receptor-mediated spontaneous Ca2+ release and catecholaminergic polymorphic ventricular tachycardia\n2279: The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol\n2282: Nebivolol, But Not Metoprolol, Treatment Improves Endothelial Fibrinolytic Capacity in Adults With Elevated Blood Pressure\n2285: Chronic Nebivolol Treatment Suppresses Endothelin-1-Mediated Vasoconstrictor Tone in Adults With Elevated Blood Pressure\n2288: Effect of nebivolol beneficial on lipid profile and glycemic control in comparison with Atenolol in patients with type 2 DM with concomitant hypertension\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug32_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Piracetam\" (also known as \"piracetam\"), here are the article headings along with their IDs:\n2183: Presence of Piracetam in Cognitive Enhancement Dietary Supplements\n2185: Cognitive effects of piracetam in adults with memory impairment: A systematic review and meta-analysis\n2188: Piracetam and other structurally related nootropics\n2190: Piracetam in acute stroke: a systematic review\n2192: Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders\n2194: Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders\n2198: Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles\n2201: Docosahexaenoic Acid Plus Piracetam Versus Piracetam Alone for Treatment of Breath-Holding Spells in Children: A Randomized Clinical Trial\n2204: A systematic review and meta-analysis of the efficacy of piracetam and piracetam-like compounds in experimental stroke\n2207: Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs\n2210: Effect of organic acids on the solid-state polymorphic phase transformation of piracetam\n2213: Effect of Piracetam and Iron Treatment on Heart Rate Variability in Patients With Breath-Holding Spell\n2217: Action of piracetam in childbirth\n2220: Isolation of two Ochrobactrum sp. strains capable of degrading the nootropic drug-Piracetam\n2223: Determination of piracetam in rat plasma by LC-MS/MS and its application to pharmacokinetics\n2226: Piracetam: physiological disposition and mechanism of action\n2228: Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis\n2232: Separation of piracetam derivatives on polysaccharide-based chiral stationary phases\n2235: [Pharmacokinetics of piracetam during delivery]\n2236: Development of a simple chromatographic method for the determination of piracetam in human plasma and its pharmacokinetic evaluation\n2239: The effect of piracetam on volunteers in a low-pressure tank\n2242: Investigation of polymorphic transitions of piracetam induced during wet granulation\n2243: [Therapeutic effect and mechanism of piracetam for the treatment of spinal cord injury in rats through MAPK pathway]\n2246: Effects of piracetam on learned helplessness in rats\n2250: [Effect of piracetam on nystagmus]\n2252: Letter: Piracetam and pyrithioxine\n2256: Determination of piracetam in serum by gas chromatography\n2259: Chromatographic separation of piracetam and its metabolite in a mixture of microsomal preparations, followed by an MS/MS analysis\n2262: Piracetam: toxicity and reproduction studies\n2265: Thermodynamic characterization of three polymorphic forms of piracetam\n2268: Optimized and validated flow-injection spectrophotometric analysis of topiramate, piracetam and levetiracetam in pharmaceutical formulations\n2272: New validated method for piracetam HPLC determination in human plasma\n2274: Piracetam: a novel therapy for autism?\n2277: Stability hierarchy between Piracetam forms I, II, and III from experimental pressure-temperature diagrams and topological inferences\n2280: Determination of piracetam in human plasma and urine by liquid chromatography\n2283: Liquid-chromatographic quantification of piracetam\n2286: [Clinical use of piracetam in chronic alcoholism and its complications predelirium and delirium]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug33_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Pramipexole\" (also known as \"pramipexole\"), here are the article headings along with their IDs:\n2195: Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease\n2196: Classics in Chemical Neuroscience: Pramipexole\n2199: Pramipexole for the Treatment of Depression: Efficacy and Mechanisms\n2202: [Pramipexole in bipolar depression: a literature review and clinical recommendations]\n2205: Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis\n2209: Pramipexole associated dystonia\n2211: Efficacy of pramipexole on quality of life in patients with Parkinson's disease: a systematic review and meta-analysis\n2215: Pramipexole modulates fronto-subthalamic pathway in sequential working memory\n2218: Pramipexole extended release in Parkinson's disease\n2221: Pramipexole for the treatment of early Parkinson's disease\n2224: Mirapex: pramipexole dihydrochloride tablets\n2227: P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease\n2230: Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease\n2234: Treatment of Pramipexole-Induced Problematic Sexual Behaviors\n2237: Pramipexole Inhibits MPP+-Induced Neurotoxicity by miR-494-3p/BDNF\n2241: Add-on pramipexole for anhedonic depression: study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden\n2245: Pramipexole for levodopa-induced complications in Parkinson's disease\n2248: Pramipexole alleviates traumatic brain injury in rats through inhibiting necroptosis\n2249: Pramipexole Protects Against Traumatic Brain Injury-Induced Blood-Brain Barrier (BBB) Dysfunction\n2253: Pramipexole-induced oedema: the importance of renal dopamine\n2255: Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease\n2258: Role of pramipexole in the management of Parkinson's disease\n2261: Pramipexole treatment attenuates mechanical hypersensitivity in male rats experiencing chronic inflammatory pain\n2263: Comparison of pramipexole and levodopa/benserazide combination therapy versus levodopa/benserazide monotherapy in the treatment of Parkinson's disease: a systematic review and meta-analysis\n2266: Pramipexole. A review of its use in the management of early and advanced Parkinson's disease\n2269: Intrathecal pramipexole and selegiline for sensory and motor block in rats\n2271: Pramipexole improves depression-like behavior in diabetes mellitus with depression rats by inhibiting NLRP3 inflammasome-mediated neuroinflammation and preventing impaired neuroplasticity\n2275: Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis\n2278: The complex molecular pharmacology of the dopamine D2receptor: Implications for pramipexole, ropinirole, and rotigotine\n2281: Pramipexole protects against diabetic neuropathy: Effect on oxidative stress, TLR4/IRAK-1/TRAF-6/NF-\u03baB and downstream inflammatory mediators\n2284: Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson's disease\n2287: Pramipexole in the treatment of advanced Parkinson's disease\n2289: Pramipexole and tolcapone alleviate thermal and mechanical nociception in naive rats\n2290: Pramipexole and Electroconvulsive Therapy in Treatment-Resistant Depression\n2291: Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease\n2292: The benefits of pramipexole selection in the treatment of Parkinson's disease\n2293: Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson's disease\n2294: Efficacy of Pramipexole for the Treatment of Primary Restless Leg Syndrome: A Systematic Review and Meta-analysis of Randomized Clinical Trials\n2295: Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke\n2296: Pramipexole attenuates 6-OHDA-induced Parkinson's disease by mediating the Nurr1/NF-\u03baB pathway\n2297: Pramipexole Enhances Reward Learning by Preserving Value Estimates\n2298: The Efficacy and Safety of Piribedil Relative to Pramipexole for the Treatment of Early Parkinson Disease: A Systematic Literature Review and Network Meta-Analysis\n2299: Pramipexole inhibits formalin-induce acute and long-lasting mechanical hypersensitivity via NF-kB pathway in rats\n2300: Impulse control disorders in Parkinson's disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis\n2301: High-degree atrioventricular heart block induced by pramipexole\n2302: The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting\n2303: Effectiveness of exercise and pramipexole in the treatment of restless leg syndrome: Implications on the dopaminergic system and PTPRD\n2304: Pre-clinical studies of pramipexole: clinical relevance\n2305: Pramipexole to Improve Cognition in Bipolar Disorder: A Randomized Controlled Trial\n2306: Pramipexole for the treatment of restless legs syndrome\n2307: Pramipexole nanocrystals for transdermal permeation: Characterization and its enhancement micro-mechanism\n2308: [Pramipexole and Parkinson's disease, an update]\n2309: Pramipexole attenuates neuronal injury in Parkinson's disease by targeting miR-96 to activate BNIP3-mediated mitophagy\n2310: A review of pramipexole and its clinical utility in Parkinson's disease\n2311: Three paradoxes related to the mode of action of pramipexole: The path from D2/D3 dopamine receptor stimulation to modification of dopamine-modulated functions\n2312: Pramipexole and somnolence\n2313: Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis\n2314: Pramipexole has a neuroprotective effect in spinal cord injury and upregulates D2 receptor expression in the injured spinal cord tissue in rats\n2315: Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease\n2316: Pramipexole Reduces zif-268 mRNA Expression in Brain Structures involved in the Generation of Harmaline-Induced Tremor\n2317: Add-On Pramipexole for the Treatment of Schizophrenia and Schizoaffective Disorder: A Randomized Controlled Trial\n2318: Pramipexole alters thermoregulation in restless legs syndrome\n2319: Pramipexole as an Augmentation Strategy to Electroconvulsive Therapy in the Treatment of Bipolar Depression Complicated With Parkinsonism: A Case Report\n2320: Schizophrenia With Decompensation on Clozapine With Pramipexole\n2322: Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis\n2323: Treating activated regulatory T cells with pramipexole protects human dopaminergic neurons from 6-OHDA-induced degeneration\n2324: Pramipexole restores behavioral inhibition in highly impulsive rats through a paradoxical modulation of frontostriatal networks\n2325: Effect of Pramipexole on Inflammatory Response in Central Nervous System of Parkinson's Disease Rat Model\n2326: Introduction: pramipexole: a novel dopamine agonist for the treatment of Parkinson's disease\n2328: Pramipexole in Treatment Resistant-Depression, Possible Role of Inflammatory Cytokines\n2332: Delusional infestation caused by pramipexole\n2334: Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease\n2335: Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial\n2337: Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial\n2339: Pramipexole modulates the neural network of reward anticipation\n2341: Pramipexole-associated fixed limb dystonia in Parkinson's disease\n2343: Zishen pingchan granules combined with pramipexole in the improvement of depressive symptoms in Parkinson's disease: a prospective, multicenter, randomized, double-blind, controlled clinical study\n2345: Pramipexole and Selegiline Combination Therapy in a Case of Treatment-Resistant Depression\n2347: Pramipexole reduces inflammation in the experimental animal models of inflammation\n2349: Renal tubular secretion of pramipexole\n2351: Pramipexole reverses Parkinson's disease-related motivational deficits in rats\n2353: Pramipexole reduces parkinsonian tremor induced by pilocarpine infusion in the rat striatum\n2355: Effects of pramipexole on the acquisition of responding with opioid-conditioned reinforcement in the rat\n2357: Pramipexole reduces phosphorylation of \u03b1-synuclein at serine-129\n2358: Pramipexole decreases allodynia and hyperalgesia via NF-\u03baB in astrocytes in rats with Parkinson's disease\n2361: Photo-degradation products of pramipexole\n2363: Pramipexole in patients with early Parkinson's disease\n2365: Pramipexole in peritoneal dialysis patients with restless legs syndrome (RLS): a protocol for a multicentre double-blind randomised controlled trial\n2367: Pramipexole-treated Parkinson's disease during pregnancy\n2369: Pramipexole Augmentation of Buprenorphine Improves Pain and Depression in Opioid Use Disorder: A Case Report\n2371: Pramipexole-induced psychosis in Parkinson's disease\n2374: Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study\n2375: Effects of Pramipexole Combined with Nerve Growth Factor on Cognitive Impairment and Urinary AD7c-NTP Expression in Patients with Parkinson's Disease\n2377: Effects of pramipexole on beta-amyloid1-42memory deficits and evaluation of oxidative stress and mitochondrial function markers in the hippocampus of Wistar rat\n2379: Dopamine receptor D3 agonist (Pramipexole) reduces morphine-induced cardiac fibrosis\n2381: The anterior caudate nucleus supports impulsive choices triggered by pramipexole\n2383: Formulation and characterization of pramipexole containing buccal films for using in Parkinson's disease\n2387: Pramipexole effects on startle gating in rats and normal men\n2388: The role of pramipexole in the treatment of patients with depression and Parkinson's disease: A meta-analysis of randomized controlled trials\n2391: Reorienting of pramipexole as a promising therapy for acute pancreatitis in a rat model by suppressing TLR4\\NF-\u03baB p65\\NLRP3 inflammasome signaling\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug34_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Semax\" (also known as \"semax\"), here are the article headings along with their IDs:\n2327: Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats\n2329: Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models\n2330: Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia\n2331: Effects of Semax on the Default Mode Network of the Brain\n2333: Semax prevents learning and memory inhibition by heavy metals\n2336: Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion\n2338: Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain\n2340: Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats\n2342: The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis\n2344: Functional Connectomic Approach to Studying Selank and Semax Effects\n2346: [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]\n2348: Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus\n2350: Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome\n2352: Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties\n2354: Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents\n2356: Heptapeptide semax attenuates the effects of chronic unpredictable stress in rats\n2359: Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats\n2360: Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism\n2362: Experimental Substantiation of Application of Semax as a Modulator of Immune Reaction on the Model of \"Social\" Stress\n2364: Composition of Colon Microbiota in Rats Treated with ACTH(4-7)-PGP Peptide (Semax) under Conditions of Restraint Stress\n2366: [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]\n2368: [The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain]\n2370: [Opposite Semax influence on conditioning and functional disturbances of avoidance responses in rats]\n2372: Therapeutic possibility of \"Semax\" for depression\n2373: Effect of Semax peptide on survival of cultured rat pheochromocytoma cells during oxidative stress\n2376: Modulation of GABA- and Glycine-Activated Ionic Currents with Semax in Isolated Cerebral Neurons\n2378: [Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration]\n2380: Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity\n2382: Effects of behaviorally active ACTH (4-10) analogue - Semax on rat basal forebrain cholinergic neurons\n2385: Semax prevents functional impairments of avoidance response in rats\n2389: Therapy of peptic ulcer with semax peptide\n2393: Semax corrects brain dysfunction caused by prenatal introduction of valproic acid\n2395: Effects of Semax on dopaminergic and serotoninergic systems of the brain\n2397: The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system\n2398: The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study\n2399: Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action\n2402: Morphofunctional State of the Large Intestine in Rats under Conditions of Restraint Stress and Administration of Peptide ACTH(4-7)-PGP (Semax)\n2404: Possible mechanism underlying the effect of Semax on the formation of indomethacin-induced ulcers in rats\n2406: [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]\n2408: Correction of long-lasting negative effects of neonatal isolation in white rats using semax\n2409: Glyprolines and semax prevent stress-induced microcirculatory disturbances in the mesentery\n2411: [Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application]\n2413: [Nootropic and analgesic effects of Semax following different routes of administration]\n2415: Effects of semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity\n2417: [The effect of semax and its C-end peptide PGP on Vegfa gene expression in the rat brain during incomplete global ischemia]\n2419: Influence of ACTG4-7-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress\n2421: Study of proteolysis of Semax analogues with different N-terminal amino acids by carboxypeptidases\n2423: Trophic effects of nootropic peptide preparations cerebrolysin and semax on cultured rat pheochromocytoma\n2425: [Semax and some glyproline peptides accelerate the healing of acetic ulcers in rats]\n2427: Stability of Semax acetyl to proteolysis in various biological media\n2429: [Neonatal Semax and saline injections induce open-field behavior changes in mice of different genotypes]\n2431: [Use of semax at a follow-up of patients with posthypoxic encephalopathy]\n2432: Effects of semax against the background of dopaminergic receptor blockade with haloperidol\n2434: The action of the peptide drug Semax on the currents of AMPA receptors of rat cerebellar Purkinje cells\n2436: Effect of Semax on homeostasis of gastric mucosa in albino rats\n2438: [Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone]\n2442: Changes in Sympathetic Innervation of the Heart in Rats with Experimental Myocardial Infarction. Effect of Semax\n2444: Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10\n2446: Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex\n2448: Semax attenuates the influence of neonatal maternal deprivation on the behavior of adolescent white rats\n2450: [The effect of semax and its C-end peptide PGP on expression of the neurotrophins and their receptors in the rat brain during incomplete global ischemia]\n2452: [A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study)]\n2454: The use of phospholipid nanoparticles for increasing Semax resistance in various proteolytic biological media\n2457: [Chronotropic activity of semax]\n2460: [Study of the analgesic effect of the semax preparation]\n2463: [Influence of Semax on the emotional state of white rats in the norm and against the background of cholecystokinin-tetrapeptide action]\n2467: [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency]\n2470: Effect of Semax on changes in pain sensitivity and behavior of animals induced by forced swimming\n2471: [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]\n2474: [Effects of neonatal fluvoxamine administration to white rats and their correction by semax treatment]\n2476: [Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease]\n2481: Effects of Semax on Ca2+ responses of human neutrophils\n2483: Semax increases erythrocyte deformability in the shearing blood stream in intact rats and rats with cerebral ischemia\n2485: Effects of Semax, a peptide ACTH4-10 analogue, on the respiratory burst in human neutrophils\n2488: Degradation of ACTH/MSH(4-10) and its synthetic analog semax by rat serum enzymes: an inhibitor study\n2491: Neonatal administration of ACTH4-10 and its analog Semax to young laboratory mice modulates the number of catecholaminergic neurons in adult animal diencephalon\n2494: [EFFECT OF PEPTIDE SEMAX ON SYNAPTIC ACTIVITY AND SHORT-TERM PLASTICITY OF GLUTAMATERGIC SYNAPSES OF CO-CULTURED DORSAL ROOT GANGLION AND DORSAL HORN NEURONS]\n2497: [An experimental substantiation for using the \"Semax\" neuroprotector in the treatment of optic-nerve diseases]\n2500: [Antihypoxic and antiamnesic effects of mexidol and semax]\n2503: [The binding of Semax, ACTH 4-10 heptapeptide, to plasma membranes of the rat forebrain basal nuclei and its biodegradation]\n2506: Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog\n2509: Secretory activity of mast cell during stress: effect of prolyl-glycyl-proline and Semax\n2511: [Proteolysis of semax analogues with different N-terminal amino acids by aminopeptidases]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug35_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"9-methyl-\u03b2-carboline\" (also known as \"9-methyl-\u03b2-carboline\"), here are the article headings along with their IDs:\n2321: Mechanisms of DNA damage by photoexcited 9-methyl-\u03b2-carbolines\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug36_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Selank\" (also known as \"selank\"), here are the article headings along with their IDs:\n2384: Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats\n2386: Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission\n2390: Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress\n2392: Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats\n2394: The Influence of Selank on the Level of Cytokines Under the Conditions of \"Social\" Stress\n2396: GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells\n2400: Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Behavioral Sensitization in DBA/2 Mice\n2401: Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons\n2403: Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress\n2405: Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity\n2407: Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats\n2410: [Optimization of the treatment of anxiety disorders with selank]\n2412: The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action\n2414: State of Colon Microbiota in Rats during Chronic Restraint Stress and Selank Treatment\n2416: Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank\n2418: Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank\n2420: Selank and its metabolites maintain homeostasis in the gastric mucosa\n2422: The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats\n2424: Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny\n2426: [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]\n2428: [Changes in expression of the genes for chemokines, cytokines, and their receptors in response to selank and its fragments]\n2430: Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation\n2433: Naloxone-blocked depriming effect of anxiolytic selank on apomorphine-induced behavioral manifestations of hyperfunction of dopamine system\n2435: The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity\n2437: The influence of Selank on the parameters of the hemostasis system, lipid profile, and blood sugar level in the course of experimental metabolic syndrome\n2439: [Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study]\n2440: [Selank-induced normalizing effects on the integrative brain activity and biogenic amine level disorders due to antenatal hypoxia]\n2441: [Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA]\n2443: [Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice]\n2445: Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress\n2447: [COMPARISON OF PHARMACOLOGICAL EFFECTS OF HEPTAPEPTIDE SELANK AFTER INTRANASAL AND INTRAPERITONEAL ADMINISTRATION TO BALB/c AND C57BL/6 MICE]\n2449: Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia\n2451: Seasonal effects of Selank on the behavior of hibernating animals\n2453: [Effect of new synthetic anxiolytic selank on gastric wall blood flow and mesenteryc lymphatic vessels contractility in anesthetized rats]\n2455: [Experimental optimization of learning and memory processes by selank]\n2459: [Effect of selank on the main carboxypeptidases in the rat nervous tissue]\n2462: [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]\n2465: [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]\n2468: [The role of opioid system in peculiarities of anti-anxiety effect of peptide anxiolytic selank]\n2472: [Antiviral activity of immunomodulator Selank in experimental influenza infection]\n2475: [Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank]\n2478: Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions\n2480: [Optimizing action of synthetic peptide Selank on active avoidance conditioning test in rats]\n2484: [Selank and short peptides of Taftsin derivatives in regulation of adaptive behavior of animals in stress]\n2487: Antiviral properties of structural fragments of the peptide Selank\n2490: [Compensatory and antiamnestic effects of heptapeptide Selank in monkeys]\n2493: Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo\n2496: [Compensatory effect of selank on the mnestic functions disturbed by neurotoxic damage of the noradrenergic system of the rat brain]\n2499: [Experimental hemorrhagic stroke: the study of neuropeptides (MIF, selank) in the intraperitoneal injection]\n2501: Transcriptomic response of rat hippocampus and spleen cells to single and chronic administration of the peptide selank\n2505: [Effects of the new peptide anxiolytic drug selank on the cardiovascular system functioning and respiration in cats]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug37_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Noopept\" (also known as \"noopept\"), here are the article headings along with their IDs:\n2456: Cognitive Enhancer Noopept Activates Transcription Factor HIF-1\n2458: Effects of noopept on ocular, pancreatic and renal histopathology in streptozotocin induced prepubertal diabetic rats\n2461: Drug with Neuroprotective Properties Noopept Does Not Stimulate Cell Proliferation\n2464: Effects of noopept on cognitive functions and pubertal process in rats with diabetes\n2466: Noopept Attenuates Diabetes-Mediated Neuropathic Pain and Oxidative Hippocampal Neurotoxicity via Inhibition of TRPV1 Channel in Rats\n2469: Noopept; a nootropic dipeptide, modulates persistent inflammation by effecting spinal microglia dependent Brain Derived Neurotropic Factor (BDNF) and pro-BDNF expression throughout apoptotic process\n2473: Neuroprotective Dipeptide Noopept Prevents DNA Damage in Mice with Modeled Prediabetes\n2477: [The original novel nootropic and neuroprotective agent noopept]\n2479: Noopept stimulates the expression of NGF and BDNF in rat hippocampus\n2482: Noopept normalizes parameters of the incretin system in rats with experimental diabetes\n2486: Molecular Mechanism Underlying the Action of Substituted Pro-Gly Dipeptide Noopept\n2489: Efficiency of noopept in streptozotocin-induced diabetes in rats\n2492: [Noopept in the treatment of mild cognitive impairment in patients with stroke]\n2495: Intranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats\n2498: Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves \u03b17AChRs on interneurons in hippocampal slices from rat\n2502: Immunopharmacological properties of noopept\n2504: [Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats]\n2507: Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by beta-amyloid25-35 injection into Meynert basal nuclei of rats)\n2508: Effect of Noopept on Dynamics of Intracellular Calcium in Neurons of Cultured Rat Hippocampal Slices\n2510: Dipeptide Piracetam Analogue Noopept Improves Viability of Hippocampal HT-22 Neurons in the Glutamate Toxicity Model\n2512: Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation\n2513: Nootropic dipeptide noopept enhances inhibitory synaptic transmission in the hippocampus\n2514: Noopept reduces the postischemic functional and metabolic disorders in the brain of rats with different sensitivity to hypoxia\n2515: Retraction notice to \"Noopept; a nootropic dipeptide, modulates persistent inflammation by effecting spinal microglia dependent Brain Derived Neurotropic Factor (BDNF) and pro-BDNF expression throughout apoptotic process\" [Heliyon (2021) e06219]\n2516: Comparative activity of proline-containing dipeptide noopept and inhibitor of dipeptidyl peptidase-4 sitagliptin in a rat model of developing diabetes\n2517: Original nootropic drug noopept prevents memory deficit in rats with muscarinic and nicotinic receptor blockade\n2518: Dipeptide preparation Noopept prevents scopolamine-induced deficit of spatial memory in BALB/c mice\n2519: Physicochemical and structural analysis of N-phenylacetyl-L-prolylglycine ethyl ester (Noopept) - An active pharmaceutical ingredient with nootropic activity\n2520: The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model\n2521: QbD-driven development of dissolving microneedle patch loaded with ultradeformable liposomes encapsulated Noopept: Exploring a patient friendly, once-daily option to manage dementia\n2522: Effect of noopept and afobazole on the development of neurosis of learned helplessness in rats\n2523: [Noopept improves the spatial memory and stimulates prefibrillar beta-amyloid(25-35) antibody production in mice]\n2524: Neuroprotective and nootropic drug noopept rescues \u03b1-synuclein amyloid cytotoxicity\n2525: [An experimental study of the anti-inflammatory action of noopept and its effect on the level of cytokines]\n2526: Novel nootropic dipeptide Noopept increases inhibitory synaptic transmission in CA1 pyramidal cells\n2527: [Neuroprotective activity of the proline-containing dipeptide noopept on the model of brain ischemia induced by the middle cerebral artery occlusion]\n2528: [The influence of self-massage combined with drug Noopept on the professional performance of teachers older]\n2529: Early postnatal effects of noopept and piracetam on declarative and procedural memory of adult male and female rats\n2530: Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin\n2531: [Behavior of mice from different strains: modifications produced by noopept]\n2532: [Effects of noopept and cortexin on the behavior of matured rats treated with corticoliberin or 70-kDa heat shock proteins in early ontogeny]\n2533: [The original nootropic and neuroprotective drug noopept potentiates the anticonvulsant activity of valproate in mice]\n2534: [Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment of posttraumatic and vascular origin]\n2535: [The using of noopept in treatment of neurasthenia]\n2536: [Effect of the novel dipeptide nootropic agent noopept and its metabolite cyclo-L-prolylglycine on the transcallosal evoked potential in the rat brain]\n2537: Impairment of learning and memory after photothrombosis of the prefrontal cortex in rat brain: effects of Noopept\n2538: [Genotype-dependent mice behavior in cognitive tasks. Effect of noopept]\n2539: Genotype-dependent characteristics of behavior in mice in cognitive tests. The effects of Noopept\n2540: [Interspecies differences of noopept pharmacokinetics]\n2541: [On the mechanism of noopept action: decrease in activity of stress-induced kinases and increase in expression of neutrophines]\n2542: Cyclopropyl glycine and proline-containing preparation noopept evoke two types of membrane potential responses in synaptoneurosomes\n2543: [The dynamics of behavioral and neuroreceptor effects after acute and long-term noopept administration in C57BL/6 and BALB/c mice]\n2544: [Anti-inflammatory properties of noopept (dipeptide nootropic agent GVS-111)]\n2545: [Effect of the novel nootropic and neuroprotective dipeptide noopept on the streptozotocin-induced model of sporadic Alzheimer disease in rats]\n2548: [Preclinical study of noopept toxicity]\n2550: [Efficacy of noopept in discirculatory encephalopathy]\n2552: [Prevention of neuro- and cardiotoxic side effects of tuberculosis chemotherapy with noopept]\n2553: [A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin]\n2556: [Comparative study of the long-term behavioral effects of noopept and piracetam in adult male rats and female rats in postnatal period]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug38_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"nicotinamideadeninedinucleotide\" (also known as \"nicotinamideadeninedinucleotide\"), here are the article headings along with their IDs:\n2546: Bioavailability of reduced nicotinamide-adenine-dinucleotide (NADH) in the central nervous system of the anaesthetized rat measured by laser-induced fluorescence spectroscopy\n2547: Cross-tolerance between nitric oxide synthase inhibition and atypical antipsychotics modify nicotinamide-adenine-dinucleotide phosphate-diaphorase activity in mouse lateral striatum\n2549: [BIOSYNTHESIS OF 3-ACETYLPYRIDINE-ADENINEDINUCLEOTIDEPHOSPHATE (3-APADP) FROM NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NADP)]\n2551: X-ray small-angle scattering of yeast glyceraldehyde-3-phosphate dehydrogenase as a function of saturation with nicotinamide-adenine-dinucleotide\n2554: [Binding of nicotinamide adenine dinucleotide to glutamate dehydrogenase]\n2555: Preparation and properties of reduced -nicotinamide-adenine-dinucleotide\n2557: X-ray small-angle scattering of yeast glyceraldehyde-3-phosphate dehydrogenase as a function of saturation with nicotinamide-adenine-dinucleotide\n2558: PHOSPHOLIPID--PROTEIN INTERACTION AS A DETERMINANT FOR THE SUBSTRATE SPECIFICITY OF MITOCHONDRIAL NICOTINAMIDE--ADENINE-DINUCLEOTIDE (PHOSPHATE) TRANSHYDROGENASE\n2559: INFLUENCE OF IRON ON OXIDATION OF REDUCED NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE IN RAT-LIVER MICROSOMES\n2562: A new method for preparation of nicotinamide-adenine-dinucleotide phosphate from Saccharomyces cerevisiae\n2563: Significance of streptozotocin induced nicotinamide-adenine-dinucleotide (NAD) degradation in mouse pancreatic islets\n2565: [STUDIES ON LEUKOCYTE METABOLISM. NICOTINAMIDE-ADENINE-DINUCLEOTIDE (NAD) CONTENT OF NORMAL AND LEUKEMIC LEUKOCYTES IN MAN. II]\n2567: [The formation of nicotinamide-adenine-dinucleotide from tryptophan after whole-body irradiation]\n2569: [Oxidation of reduced nicotinamide-adeninedinucleotide in Pseudomonas aeruginosa adaptation to hexane]\n2571: [The effect of thyroxine on the concentration of acetylation coenzyme and nicotinamide-adenine-dinucleotide in the liver of albino rats of various ages]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug40_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"MOTS-c\" (also known as \"mots-c\"), here are the article headings along with their IDs:\n2560: MOTS-c Functionally Prevents Metabolic Disorders\n2561: Role of MOTS-c in the regulation of bone metabolism\n2564: MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation\n2566: MOTS-c reduces myostatin and muscle atrophy signaling\n2568: MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus\n2570: Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases\n2572: MOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria\n2573: MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases\n2574: The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance\n2575: The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus\n2576: Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging\n2577: Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection\n2578: The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression\n2579: The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress\n2580: MOTS-c promotes muscle differentiation in vitro\n2581: MOTS-c repairs myocardial damage by inhibiting the CCN1/ERK1/2/EGR1 pathway in diabetic rats\n2582: MOTS-c Peptide Attenuated Diabetic Cardiomyopathy in STZ-Induced Type 1 Diabetic Mouse Model\n2583: Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c)\n2584: MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism\n2585: MOTS-c and aerobic exercise induce cardiac physiological adaptation via NRG1/ErbB4/CEBP\u03b2 modification in rats\n2586: Circulating levels of MOTS-c in patients with breast cancer treated with metformin\n2587: Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination\n2588: MOTS-c: an equal opportunity insulin sensitizer\n2589: The Mitochondrial-Derived Peptide MOTS-c Alleviates Radiation Pneumonitis via an Nrf2-Dependent Mechanism\n2590: MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis\n2591: Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes\n2592: MOTS-c regulates pancreatic alpha and beta cell functions in vitro\n2593: The mitochondrial-derived peptide MOTS-c suppresses ferroptosis and alleviates acute lung injury induced by myocardial ischemia reperfusion via PPAR\u03b3 signaling pathway\n2596: MOTS-c and Exercise Restore Cardiac Function by Activating of NRG1-ErbB Signaling in Diabetic Rats\n2598: MOTS-c modulates skeletal muscle function by directly binding and activating CK2\n2599: MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction\n2601: MOTS-c as a predictor of coronary lesions and complexity in patients with stable coronary artery disease\n2602: The role of MOTS-c-mediated antioxidant defense in aerobic exercise alleviating diabetic myocardial injury\n2603: Serum MOTS-c levels remain unchanged in patients with preeclampsia\n2604: Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration\n2605: Mitofusion is required for MOTS-c induced GLUT4 translocation\n2606: MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose\n2607: Effects of intracerebroventricular MOTS-c infusion on thyroid hormones and uncoupling proteins\n2608: Orally administered MOTS-c analogue ameliorates dextran sulfate sodium-induced colitis by inhibiting inflammation and apoptosis\n2609: The MOTS-c K14Q polymorphism in the mtDNA is associated with muscle fiber composition and muscular performance\n2610: The Mitochondrial-Derived Peptide (MOTS-c) Interacted with Nrf2 to Defend the Antioxidant System to Protect Dopaminergic Neurons Against Rotenone Exposure\n2612: MOTS-c interacts synergistically with exercise intervention to regulate PGC-1\u03b1 expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway\n2615: MOTS-c inhibits Osteolysis in the Mouse Calvaria by affecting osteocyte-osteoclast crosstalk and inhibiting inflammation\n2617: MOTS-c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice\n2619: Serum MOTS-C Levels are Decreased in Obese Children and Associated with Vascular Endothelial Function\n2621: The mitochondrial-derived peptide MOTS-c promotes homeostasis in aged human placenta-derived mesenchymal stem cells in vitro\n2623: Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72 to membrane\n2625: MOTS-c Serum Concentration Positively Correlates with Lower-Body Muscle Strength and Is Not Related to Maximal Oxygen Uptake-A Preliminary Study\n2627: Mitochondrial derived peptide MOTS-c prevents the development of heart failure under pressure overload conditions in mice\n2629: MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis\n2631: MOTS-c accelerates bone fracture healing by stimulating osteogenesis of bone marrow mesenchymal stem cells via positively regulating FOXF1 to activate the TGF-\u03b2 pathway\n2633: MOTS-c regulates the ROS/TXNIP/NLRP3 pathway to alleviate diabetic cardiomyopathy\n2635: Changes in MOTS-c Level in the Blood of Pregnant Women with Metabolic Disorders\n2637: Adropin and MOTS-c as new peptides: Do levels change in neurodegenerative diseases and ischemic stroke?\n2638: MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-\u03b2/SMAD signaling pathway\n2641: The protective effect of the mitochondrial-derived peptide MOTS-c on LPS-induced septic cardiomyopathy\n2643: Central MOTS-c infusion affects reproductive hormones in obese and non-obese rats\n2645: Protective effect of MOTS-c on acute lung injury induced by lipopolysaccharide in mice\n2647: The mitochondrial signaling peptide MOTS-c improves myocardial performance during exercise training in rats\n2649: Mitochondrial-Derived Peptide MOTS-c Ameliorates Spared Nerve Injury-Induced Neuropathic Pain in Mice by Inhibiting Microglia Activation and Neuronal Oxidative Damage in the Spinal Cordviathe AMPK Pathway\n2651: Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes\n2653: Mitochondrial-Derived Peptide MOTS-c Increases Adipose Thermogenic Activation to Promote Cold Adaptation\n2655: Exogenous humanin and MOTS-c function as protective agents against gentamicin-induced hair cell damage\n2656: Effects of MOTS-c on the mitochondrial function of cells harboring 3243 A to G mutant mitochondrial DNA\n2658: Nuclear transcriptional regulation by mitochondrial-encoded MOTS-c\n2662: The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity\n2666: Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals\n2669: A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c\n2671: [Effects of exercise intervention on mitochondrial-derived peptide MOTS-c in the germ cells of obese men]\n2674: The relationship of circulating MOTS-c level with liver fibrosis and metabolic components in patients with metabolic dysfunction-associated fatty liver disease\n2677: Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes\n2680: Evaluation of Serum Humanin and MOTS-c Peptide Levels in Patients with COVID-19 and Healthy Subjects\n2683: The Mitochondrial-Derived Peptide MOTS-c Attenuates Oxidative Stress Injury and the Inflammatory Response of H9c2 Cells Through the Nrf2/ARE and NF-\u03baB Pathways\n2687: MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-\u03b2/Smad pathway\n2689: MOTS-c attenuates endothelial dysfunction via suppressing the MAPK/NF-\u03baB pathway\n2693: Neuroprotective Mechanism of MOTS-c in TBI Mice: Insights from Integrated Transcriptomic and Metabolomic Analyses\n2694: Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction\n2697: Expression Patterns of MOTS-c in Adrenal Tumors: Results from a Preliminary Study\n2701: Evaluation of Coronary Flow Level with Mots-C in Patients with STEMI Undergoing Primary PCI\n2704: MOTS-c accelerates bone fracture healing by stimulating osteogenesis of bone marrow mesenchymal stem cells via positively regulating FOXF1 to activate the TGF-\u03b2 pathway\n2705: Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects\n2709: Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation\n2712: Relationship between the mitochondria-derived peptide MOTS-c and insulin resistance in obstructive sleep apnea\n2715: Comparison of Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Levels in Patients With Multiple Sclerosis and Healthy Controls\n2718: The DNA-dependent protein kinase catalytic subunit exacerbates endotoxemia-induced myocardial microvascular injury by disrupting the MOTS-c/JNK pathway and inducing profilin-mediated lamellipodia degradation\n2721: The intraperitoneal administration of MOTS-c produces antinociceptive and anti-inflammatory effects through the activation of AMPK pathway in the mouse formalin test\n2724: MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA\n2727: Mitochondrial-Derived Peptide MOTS-c Attenuates Vascular Calcification and Secondary Myocardial Remodeling via Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway\n2729: Circulating levels of mitochondrial oxidative stress-related peptides MOTS-c and Romo1 in stable COPD: A cross-sectional study\n2732: Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance\n2733: Could MOTS-C Levels in Children with Type 1 Diabetes Mellitus Be an \u0130ndicator for Early Diabetic Kidney Disease?\n2737: The Effect of Chronic Endurance Exercise on Serum Levels of MOTS-c and Humanin in Professional Athletes\n2739: Pyrroloquinoline Quinone Alleviates Mitochondria Damage in Radiation-Induced Lung Injury in a MOTS-c-Dependent Manner\n2742: Effect of Humanin and MOTS-c on ameliorating reproductive damage induced by prepubertal cyclophosphamide chemotherapy in male mice\n2744: MOTS-c Impact on Muscle Cell Differentiation and Metabolism Across Fiber Types\n2746: The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study\n2750: Peripheral Administration of a Cell-Penetrating MOTS-c Analogue Enhances Memory and Attenuates A\u03b21-42- or LPS-Induced Memory Impairment through Inhibiting Neuroinflammation\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug41_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"deltasleep-inducingpeptide\" (also known as \"deltasleep-inducingpeptide\"), here are the article headings along with their IDs:\n2594: The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep\n2595: Aminopeptidase in human CSF which degrades delta-sleep inducing peptide (DSIP)\n2597: Synthesis of the tripeptide L-Trp-L-Ser-L-Glu. Comparison of its biological activity with that of the delta-sleep-inducing-peptide (DSIP)\n2600: [Interhemispheric interaction in the rabbit after administration of delta-sleep-inducing-peptide]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug42_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Letrozole\" (also known as \"letrozole\"), here are the article headings along with their IDs:\n2611: Letrozole for Female Infertility\n2613: Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer\n2614: Letrozole: Pharmacology, toxicity and potential therapeutic effects\n2616: Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up\n2618: Letrozole Compared With Clomiphene Citrate for Polycystic Ovarian Syndrome: A Systematic Review and Meta-analysis\n2620: Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial\n2622: Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized controlled trial\n2624: Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial\n2626: Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study\n2628: Comparing efficacy and safety of stair step protocols for clomiphene citrate and letrozole in ovulation induction for women with polycystic ovary syndrome (PCOS): a randomized controlled clinical trial\n2630: A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study\n2632: Efficacy of letrozole for the treatment of tubal ectopic pregnancy: A meta-analysis\n2634: Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis\n2636: Letrozole in the management of advanced ovarian cancer: an old drug as a new targeted therapy\n2639: Co-treatment with letrozole during ovarian stimulation for IVF/ICSI: a systematic review and meta-analysis\n2640: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population\n2642: Efficacy and Safety of Letrozole in the Management of Constitutional Delay in Growth and Puberty: A Systematic Review and Meta-analysis\n2644: The efficacy of letrozole supplementation for medical abortion: a meta-analysis of randomized controlled trials\n2646: Letrozole versus clomiphene citrate in polycystic ovary syndrome: a meta-analysis of randomized controlled trials\n2648: Is combined letrozole and clomiphene superior to either as monotherapy: a systemic review and meta-analysis based on clinical trials\n2650: Does letrozole treatment have favorable effects on the lipid profile? A systematic review and meta-analysis of randomized clinical trials\n2652: Effects of using letrozole in combination with the GnRH antagonist protocol for patients with poor ovarian response: A meta-analysis\n2654: The Effectiveness of Letrozole Alone or in Combination with Methotrexate in the Management of Ectopic Pregnancy, A Systematic Review and Meta-Analysis\n2657: The Effect of Letrozole Combined with Dydrogesterone for Endometriosis in China: A Meta-Analysis\n2660: Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis\n2664: Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma\n2668: Risk of foetal harm with letrozole use in fertility treatment: a systematic review and meta-analysis\n2672: Letrozole and Unexplained Infertility: A Contemporary Meta-analysis\n2675: Letrozole treatment alters hippocampal gene expression in common marmosets (Callithrix jacchus)\n2679: Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review\n2681: Letrozole-induced inflammatory arthritis and tendinopathy in pediatric rheumatology setting\n2685: Diacerein ameliorates letrozole-induced polycystic ovarian syndrome in rats\n2688: Clomiphene citrate plus letrozole versus clomiphene citrate alone for ovulation induction in infertile women with ovulatory dysfunction: a randomized controlled trial\n2691: A case of letrozole induced mania\n2696: Low-dose letrozole - an effective option for women with symptomatic adenomyosis awaiting IVF: a pilot randomized controlled trial\n2699: Letrozole increases preantral follicle growth and decreases estradiol production without impairing follicle survival\n2703: Letrozole versus clomiphene in polycystic ovary syndrome-more than one way to crack an egg\n2706: Effectiveness and safety of aspirin combined with letrozole in the treatment of polycystic ovary syndrome: a systematic review and meta-analysis\n2708: Letrozole induced a polycystic ovary syndrome model in zebrafish by interfering with the hypothalamic-pituitary-gonadal axis\n2711: The pharmacokinetics of letrozole and its effect on gonadotropins in anestrous ewes\n2714: Comparison of clomiphene and letrozole for superovulation in patients with unexplained infertility undergoing intrauterine insemination: A systematic review and meta-analysis\n2716: Letrozole in fertility treatment\n2719: Letrozole More Effective Than Clomiphene for Infertility Treatment Among Individuals With Polycystic Ovary Syndrome\n2723: Letrozole Supplementation and the Increased Risk of Elevated Progesterone Levels on Trigger Day\n2726: Letrozole co-treatment in an antagonist protocol for overweight women undergoing IVF treatment: a retrospective study\n2730: Letrozole use in vitrified single-blastocyst transfer cycles is associated with lower risk of large for gestational age infants in patients with polycystic ovary syndrome\n2735: Aromatase inhibitor letrozole: a novel treatment for ectopic pregnancy\n2738: Letrozole- a controversial drug for OHSS prevention?\n2741: The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer\n2745: Depletion of gut microbiota influents glucose metabolism and hyperandrogenism traits of mice with PCOS induced by letrozole\n2748: PEGylated Protamine Letrozole Nanoparticles: A Promising Strategy to Combat Human Breast Cancer via MCF-7 Cell Lines\n2753: Impact of letrozole-associated controlled ovarian hyperstimulation on ART outcomes and endocrinological parameters\n2755: Letrozole cotreatment improves the follicular output rate in high-body-mass-index women with polycystic ovary syndrome undergoing IVF treatment\n2757: Effect of letrozole on follicular fluid steroids concentrations in cancer patients undergoing oocyte cryopreservation\n2759: Acquisition of Letrozole Resistance Through Activation of the p38/MAPK Signaling Cascade\n2761: Use of letrozole to augment height outcome in pubertal boys: a retrospective chart review\n2763: Letrozole supplementation during controlled ovarian stimulation in expected high responders: a pilot randomized controlled study\n2765: Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF: a multicentre, randomized, double-blinded placebo-controlled trial\n2767: Letrozole cotreatment progestin-primed ovarian stimulation in women undergoing controlled ovarian stimulation for in vitro fertilization\n2769: Long-Term Treatment With Letrozole in a Boy With Familial Male-Limited Precocious Puberty\n2771: The effect of letrozole overlapped with gonadotropin on IVF outcomes in women with DOR or aged over 40 years old with repeated cycles\n2773: The Efficacy of Letrozole Co-Treatment in an Antagonist Protocol for Women with Polycystic Ovary Syndrome Undergoing IVF: A Retrospective Study\n2775: Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer\n2777: Letrozole Versus Clomiphene Citrate and Natural Cycle: Endometrial Receptivity During Implantation Window in Women With Polycystic Ovary Syndrome\n2780: Letrozole Rat Model Mimics Human Polycystic Ovarian Syndrome and Changes in Insulin Signal Pathways\n2782: Complexity of intermittent letrozole adjuvant therapy\n2784: Letrozole delays acquisition of water maze task in female BALB/c mice: Possible involvement of anxiety\n2787: Can letrozole be repurposed for the treatment of visceral leishmaniasis?\n2789: Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen measurement\n2791: Development of a letrozole-based synchronization protocol for fixed-time artificial insemination in beef cattle\n2794: Effect of Letrozole Administration as a Selective Aromatase Inhibitor on Male Rat's Reproductive Performance\n2796: Assessing ovarian stimulation with letrozole and levonorgestrel intrauterine system after combined fertility-sparing approach for atypical endometrial lesions: a retrospective case-control study\n2798: Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5\n2801: Letrozole combined with rhGH treatment increases the adult height of short pubertal boys\n2803: Reply: Impact of letrozole-associated controlled ovarian hyperstimulation on ART outcomes and endocrinological parameters\n2805: Letrozole: a new treatment for delayed puberty in boys?\n2807: Effectiveness of letrozole in pituitary downregulated normogonadotrophic young women with an initial poor response\n2809: Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors\n2811: Effect of misoprostol with and without letrozole on the induction of abortion for women with first-trimester missed abortion\n2813: Adding Letrozole to Growth Hormone and Gonadotropin-Releasing Hormone Analog Increases Height in Girls With Short Stature: A Hospital Record-Based Retrospective Study\n2815: Cocktail treatment by GnRH-antagonist, letrozole, and mifepristone for the prevention of ovarian hyperstimulation syndrome: a prospective randomized trial\n2817: Ferrozoles: Ferrocenyl derivatives of letrozole with dual effects as potent aromatase inhibitors and cytostatic agents\n2820: Characterization of letrozole in human hair using LC-MS/MS and confirmation by LC-HRMS: Application to a doping case\n2824: Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer\n2827: Letrozole Effect on Final Height of Patients with Constitutional Delay of Growth and Puberty\n2831: Off-label use of letrozole in Chinese short pubertal boys: Effectiveness, safety, and exposure-response analysis\n2833: The impact of letrozole on oocyte quality in assisted reproductive technology (ART); a randomized double-blind clinical trial\n2836: Impact of letrozole co-treatment in an antagonist protocol for IVF/ICSI: a retrospective study\n2838: Comparative study of DHEA and letrozole induced polycystic ovary syndrome in post-pubertal rats\n2842: Interaction of letrozole and its degradation products with aromatase: chemometric assessment of kinetics and structure-based binding validation\n2846: Comparing the effectiveness of letrozole versus methotrexate for treatment of ectopic pregnancy: A randomized controlled trial\n2848: Therapeutic potential of icariin in rats with letrozole and high-fat diet-induced polycystic ovary syndrome\n2851: Protective efficacy of dark chocolate in letrozole-induced ovary toxicity model rats: hormonal, biochemical, and histopathological investigation\n2854: Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial\n2858: Why is letrozole concentration not associated with arthralgia in patients with breast cancer?\n2860: Live birth after letrozole as an adjunct to follicle-stimulating hormone versus follicle-stimulating hormone alone for ovarian stimulation in in vitro fertilisation cycles-study protocol for a randomised controlled trial\n2863: [Efficacy of letrozole in treatment of male adolescents with idiopathic short stature]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug43_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"L-carnitine\" (also known as \"l-carnitine\"), here are the article headings along with their IDs:\n2659: L-carnitine--metabolic functions and meaning in humans life\n2661: L-Carnitine and Acetyl-L-carnitine Roles and Neuroprotection in Developing Brain\n2663: L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management\n2665: Effect of Acute and Chronic Oral l-Carnitine Supplementation on Exercise Performance Based on the Exercise Intensity: A Systematic Review\n2667: Biological roles of l-carnitine in oocyte and early embryo development\n2670: Physiology of L-carnitine in plants in light of the knowledge in animals and microorganisms\n2673: L-Carnitine and intestinal inflammation\n2676: Role of L-carnitine in female infertility\n2678: Biomedical role of L-carnitine in several organ systems, cellular tissues, and COVID-19\n2682: Pharmacokinetics of L-carnitine\n2684: Effect of l-Carnitine Supplementation on Osteoarthritis: A Systematic Review\n2686: L-carnitine promotes liver regeneration after hepatectomy by enhancing lipid metabolism\n2690: L-carnitine and Acetyl-L Carnitine: A Possibility for Treating Alterations Induced by Obesity in the Central Nervous System\n2692: L-carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders\n2695: L-Carnitine\n2698: L-carnitine rescue for neonatal intractable mitochondrial cardiomyopathy\n2700: Inflammation and L-carnitine therapy in hemodialysis patients: a review\n2702: Propionyl-L-carnitine\n2707: l-Carnitine relieves cachexia-related skeletal muscle fibrosis by inducing deltex E3 ubiquitin ligase 3L to negatively regulate the Runx2/COL1A1 axis\n2710: L-Carnitine and Potential Protective Effects Against Ischemia-Reperfusion Injury in Noncardiac Organs: From Experimental Data to Potential Clinical Applications\n2713: L-Carnitine improves follicular survival and function in ovarian grafts in the mouse\n2717: L-carnitine for acute valproic acid overdose: a systematic review of published cases\n2720: Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials\n2722: L-carnitine in dialysis patients\n2725: Effects of asparaginases and L-carnitine on Western-diet-induced hepatosteatosis in mice\n2728: Using l-Carnitine as a Pharmacologic Probe of the Interpatient and Metabolic Variability of Sepsis\n2731: L-carnitine and peritoneal dialysis\n2734: Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review\n2736: L-carnitine\n2740: L-carnitine for anemia in hemodialysis patients: a last resort\n2743: L-Carnitine is a modulator of the glucocorticoid receptor alpha\n2747: L-Carnitine metabolism, protein turnover and energy expenditure in supplemented and exercised Labrador Retrievers\n2749: L-carnitine enhances developmental potential of bovine oocytes matured under high lipid concentrations in vitro\n2751: L-carnitine supplementation in the therapy of canine dilated cardiomyopathy\n2752: Production of L-carnitine-enriched edible filamentous fungal biomass through submerged cultivation\n2754: Potential nephroprotective effects of l-carnitine against drug-induced nephropathy: a review of literature\n2756: L-Carnitine moiety assay: an up-to-date reappraisal covering the commonest methods for various applications\n2758: Synthesis of L-carnitine by microorganisms and isolated enzymes\n2760: The aging eye and the role of L-carnitine and its derivatives\n2762: Potential utility of l-carnitine for preventing liver tumors derived from metabolic dysfunction-associated steatohepatitis\n2764: A systematic review about prophylactic L-carnitine administration in parenteral nutrition of extremely preterm infants\n2766: Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism\n2768: L-carnitine suppresses transient receptor potential vanilloid type 1 activity and myofibroblast transdifferentiation in human corneal keratocytes\n2770: l-Carnitine pretreatment ameliorates heat stress-induced acute kidney injury by restoring mitochondrial function of tubular cells\n2772: Metabolic functions of L-carnitine and its effects as feed additive in horses. A review\n2774: Propionyl l-carnitine: intermittent claudication and peripheral arterial disease\n2776: Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass\n2778: L-Carnitine supplementation reduces biomarkers of inflammatory and oxidative stress in patients with coronary artery disease: a randomised controlled trial\n2779: L-carnitine supplementation in humans. The effects on physical performance\n2781: Hepatocyte-Derived L-Carnitine Restricts Hepatitis B Surface Antigen Loss Through an Immunosuppressive Effect on Germinal Center-Related Immune Cells\n2783: L-carnitine in dialysed patients: the choice of dosage regimen\n2785: L-carnitine as essential methylated compound in animal metabolism. An overview\n2786: L-carnitine and its possible role in red cell and platelet storage\n2788: Adding L-carnitine to antagonist ovarian stimulation doesn't improve the outcomes of IVF/ ICSI cycle in patients with polycystic ovarian syndrome: a double-blind randomized clinical trial\n2790: [Effect and safety of L-carnitine in the treatment of idiopathic oligoasthenozoospermia: a systemic review]\n2792: What is the value of L-carnitine level determination for carnitine supplementation in hemodialysis patients?\n2793: Monograph. L-carnitine\n2795: Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders\n2797: L-carnitine supplementation in culture media improves the pregnancy rate of in vitro produced embryos with sexed semen from Bos taurus indicus cows\n2799: Effects of L-carnitine on thyroid hormone metabolism and on physical exercise tolerance\n2800: Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism\n2802: [L-carnitine: metabolism, functions and value in pathology]\n2804: Effect of chronic L-carnitine supplementation on carnitine levels, oxidative stress and apoptotic markers in peripheral organs of adult Wistar rats\n2806: [The biological function of L-carnitine and its content in the particular food examples]\n2808: L-carnitine for methylmalonicaciduria\n2810: L-carnitine enhances extracellular matrix synthesis in human primary chondrocytes\n2812: l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism\n2814: Transport and function of L-carnitine and L-propionylcarnitine: relevance to some cardiomyopathies and cardiac ischemia\n2816: [L-carnitine: properties and perspectives for use in sports practice]\n2819: Efficacy of L-carnitine supplementation for improving lean body mass and physical function in patients on hemodialysis: a randomized controlled trial\n2822: Neuroprotective effect of mildronate and L-carnitine on the cognitive parameters of aged mice and mice with LPS-induced inflammation\n2826: L-carnitine supplementation: influence upon physiological function\n2829: Protective effect of L-carnitine on apoptosis, DNA fragmentation, membrane integrity and Lipid peroxidation of spermatozoa in the asthenoteratospermic men\n2834: Dietary L-carnitine supplementation modifies blood parameters of mid-lactating dairy cows during standardized lipopolysaccharide-induced inflammation\n2837: Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis\n2839: L-carnitine and its derivatives: exciting experimental and clinical data are accumulating in the treatment of ocular disorders\n2843: Problems with the effectiveness of L-carnitine and paraffin oil in acute aluminum phosphide poisoning\n2845: L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study\n2850: Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine\n2853: L-Carnitine in dialysis, more than a commercial affair\n2856: Assessment of the Preventive Effect of L-carnitine on Post-statin Muscle Damage in a Zebrafish Model\n2861: L-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits\n2864: Protective effect of L-carnitine on myocardium after PCI in patients with acute ST segment elevation myocardial infarction\n2866: [L-carnitine and lipid lowering]\n2868: L-carnitine, inflammation and hypertension\n2869: L-carnitine improves glucose disposal in type 2 diabetic patients\n2871: Liver Lipidomics Analysis Revealed the Novel Ameliorative Mechanisms of L-Carnitine on High-Fat Diet-Induced NAFLD Mice\n2873: Supplementation of l-carnitine during in vitro maturation improves embryo development from less competent bovine oocytes\n2876: L-carnitine therapy in isovaleric acidemia\n2878: Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis\n2881: A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication\n2882: The propionyl-L-carnitine hypothesis: an alternative approach to treating heart failure\n2884: The effects of L-carnitine supplementation on performance during interval swimming\n2887: Oleoyl-L-carnitine inhibits glycine transport by GlyT2\n2889: [Vitamine-like substances L-carnitine and acetyl-L-carnitine: from biochemical studies to medicine]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug44_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"GHRP-6\" (also known as \"ghrp-6\"), here are the article headings along with their IDs:\n2818: Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency\n2821: [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle\n2823: Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms\n2825: Regulation of growth hormone secretion by the growth hormone releasing hexapeptide (GHRP-6)\n2828: Detection of GHRP-2 and GHRP-6 in urine samples from athletes\n2830: GHRP-6 induces CREB phosphorylation and growth hormone secretion via a protein kinase Csigma-dependent pathway in GH3 cells\n2832: GHRP-6 mimics ghrelin-induced stimulation of food intake and suppression of locomotor activity in goldfish\n2835: Ghrelin antagonist D-Lys3-GHRP-6 counteract ghrelin effects in bovine cumulus-oocytes complexes matured in vitro\n2840: GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP\n2841: D-Lys-3-GHRP-6 impairs memory consolidation and downregulates the hippocampal serotonin HT1A, HT7 receptors and glutamate GluA1 subunit of AMPA receptors\n2844: Small molecule mimetics of GHRP-6\n2847: Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment\n2849: The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men\n2852: Growth hormone response to GHRH, GHRP-6 and GHRH + GHRP-6 in patients with polycystic ovary syndrome\n2855: Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis\n2857: GHRP-6-induced changes in electrical activity of single cells in the arcuate, ventromedial and periventricular nucleus neurones [correction of nuclei] of a hypothalamic slice preparation in vitro\n2859: Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers\n2862: Limited short-term effects on human prostate cancer xenograft growth and epidermal growth factor receptor gene expression by the ghrelin receptor antagonist [D-Lys3]-GHRP-6\n2865: Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin\n2867: Protective effect of GHRP-6 and estrogen supplementation against some cardiometabolic risk factors in ovariectomized rats\n2870: GH responses to GHRH and GHRP-6 in Streptozotocin (STZ)-diabetic rats\n2872: Inhibition of ghrelin activity by the receptor antagonist [D-Lys3]-GHRP-6 enhances hepatic fatty acid oxidation and gluconeogenesis in a growing pig model\n2874: Evaluation of pituitary GH reserve with GHRP-6\n2875: Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6)\n2877: Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH\n2879: Atheroprotective and atheroregressive potential of azapeptide derivatives of GHRP-6 as selective CD36 ligands in apolipoprotein E-deficient mice\n2880: Insulin and growth hormone-releasing peptide-6 (GHRP-6) have differential beneficial effects on cell turnover in the pituitary, hypothalamus and cerebellum of streptozotocin (STZ)-induced diabetic rats\n2883: The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular adenosine 3',5'-monophosphate (cAMP) levels and GH secretion in ovine and rat somatotrophs\n2885: Comparison of the gastroprokinetic effects of ghrelin, GHRP-6 and motilin in rats in vivo and in vitro\n2886: Development and validation of a bioanalytical LC-MS method for the quantification of GHRP-6 in human plasma\n2888: Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature\n2890: Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure\n2891: Mechanism of action of hexarelin and GHRP-6: analysis of the involvement of GHRH and somatostatin in the rat\n2892: Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood\n2893: GHRP-6 induces a biphasic calcium response in rat pituitary somatotrophs\n2894: GHRP-6 in heifer and cow adenohypophisial cells separated by elutriation\n2895: Effect of GHRP-6 and GHRH on GH secretion in rats following chronic glucocorticoid treatment\n2896: d-Lys-GHRP-6 does not modify the endocrine response to acylated ghrelin or hexarelin in humans\n2897: Long-term treatment with the ghrelin receptor antagonist [d-Lys3]-GHRP-6 does not improve glucose homeostasis in nonobese diabetic MKR mice\n2898: Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy\n2899: GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal\n2900: D-Lys(3)-GHRP-6 antagonizes the effect of unacylated but not of acylated ghrelin on the growth of HECa10 murine endothelial cells\n2901: Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection\n2902: Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy\n2903: Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level\n2904: Gastric mucosal damage in water immersion stress: mechanism and prevention with GHRP-6\n2905: Partial restoration of GH responsiveness to ghrelin in Cushing's disease after 6 months of ketoconazole treatment: comparison with GHRP-6 and GHRH\n2906: The contractile effect of the ghrelin receptor antagonist, D-Lys3-GHRP-6, in rat fundic strips is mediated through 5-HT receptors\n2907: Growth hormone releasing hexapeptide (GHRP-6) activates the inositol (1,4,5)-trisphosphate/diacylglycerol pathway in rat anterior pituitary cells\n2908: Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action\n2909: Inhibition of Ghrelin Activity by Receptor Antagonist [d-Lys-3] GHRP-6 Attenuates Alcohol-Induced Hepatic Steatosis by Regulating Hepatic Lipid Metabolism\n2910: Structure-activity relationships of GHRP-6 azapeptide ligands of the CD36 scavenger receptor by solid-phase submonomer azapeptide synthesis\n2911: Growth hormone releasing peptides: a comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells\n2912: Local injection of d-lys-3-GHRP-6 in the rat amygdala, dentate gyrus or ventral tegmental area impairs memory consolidation\n2913: Impact of [d-Lys(3)]-GHRP-6 and feeding status on hypothalamic ghrelin-induced stress activation\n2914: Prokinetic effects of a ghrelin receptor agonist GHRP-6 in diabetic mice\n2915: Characterization of the binding of MSH-B, HB-228, GHRP-6 and 153N-6 to the human melanocortin receptor subtypes\n2916: The GHS-R blocker D-[Lys3] GHRP-6 serves as CCR5 chemokine receptor antagonist\n2917: Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells\n2918: Ghrelin and GHRP-6 enhance electrical and secretory activity in GC somatotropes\n2919: Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH\n2921: Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man\n2923: Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism\n2925: Pituitary enlargement due to primary hypothyroidism: growth hormone response to GHRH, GHRP-6 and GHRH plus GHRP-6\n2927: Regulation of His-dTrp-Ala-Trp-dPhe-Lys-NH2 (GHRP-6)-induced GH secretion in the rat\n2928: Identification of ghrelin receptor blocker, D-[Lys3] GHRP-6 as a CXCR4 receptor antagonist\n2929: Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome\n2930: Diagnosis of growth hormone deficiency in adults by testing with GHRP-6 alone or in combination with GHRH: comparison with the insulin tolerance test\n2931: Hypothalamic expression of NPY mRNA, vasopressin mRNA and CRF mRNA in response to food restriction and central administration of the orexigenic peptide GHRP-6\n2932: Evaluation of the reproducibility of the GHRH plus GHRP-6 test of growth hormone reserve in adults\n2933: Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6\n2934: The Peptidic GHS-R antagonist [D-Lys(3)]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity\n2935: Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome\n2936: Changes in Locomotor Activity Observed During Acute Nicotine Withdrawal Can Be Attenuated by Ghrelin and GHRP-6 in Rats\n2937: Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism\n2938: The effectiveness of arginine + GHRH test compared with GHRH + GHRP-6 test in diagnosing growth hormone deficiency in adults\n2939: Potassium Current Is Not Affected by Long-Term Exposure to Ghrelin or GHRP-6 in Somatotropes GC Cells\n2940: Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration\n2942: Growth Hormone (GH) but not IGF-I-Secretion is Stimulated in Aged Rats by Chronic Hexarelin and GHRP-6 administration\n2943: Growth hormone-releasing hexapeptide (GHRP-6) increases intracellular calcium concentrations in cultured cells from human pituitary adenomas of different types\n2945: Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp\n2947: Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity\n2949: Hexarelin, a novel GHRP-6 analog, stimulates growth hormone (GH) release in a GH-secreting rat cell line (GH1) insensitive to GH-releasing hormone\n2950: Regulation of Pit-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug46_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Follistatin-344\" (also known as \"follistatin-344\"), here are the article headings along with their IDs:\n2920: Detection of black market follistatin 344\n2922: Detection of black market follistatin 344\n2924: Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series\n2926: The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug47_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"NSI-189\" (also known as \"nsi-189\"), here are the article headings along with their IDs:\n2941: The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects\n2944: NSI-189 phosphate, a novel neurogenic compound, selectively benefits moderately depressed patients: A post-hoc analysis of a phase 2 study of major depressive disorder\n2946: NSI-189, a small molecule with neurogenic properties, exerts behavioral, and neurostructural benefits in stroke rats\n2948: Enhancement of synaptic plasticity and reversal of impairments in motor and cognitive functions in a mouse model of Angelman Syndrome by a small neurogenic molecule, NSI-189\n2951: Enhancement of Mitochondrial Function by the Neurogenic Molecule NSI-189 Accompanies Reversal of Peripheral Neuropathy and Memory Impairment in a Rat Model of Type 2 Diabetes\n2952: A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder\n2953: Amelioration of Both Central and Peripheral Neuropathy in Mouse Models of Type 1 and Type 2 Diabetes by the Neurogenic Molecule NSI-189\n2954: Remediation of Radiation-Induced Cognitive Dysfunction through Oral Administration of the Neuroprotective Compound NSI-189\n2955: A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients\n2956: A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug49_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Oxiracetam\" (also known as \"oxiracetam\"), here are the article headings along with their IDs:\n2957: Oxiracetam alleviates anti-inflammatory activity and ameliorates cognitive impairment in the early phase of traumatic brain injury\n2959: [Oxiracetam]\n2961: Co-administration of Nanowired Oxiracetam and Neprilysin with Monoclonal Antibodies to Amyloid Beta Peptide and p-Tau Thwarted Exacerbation of Brain Pathology in Concussive Head Injury at Hot Environment\n2963: Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial\n2965: Oxiracetam and Zinc Ameliorates Autism-Like Symptoms in Propionic Acid Model of Rats\n2967: Oxiracetam or fastigial nucleus stimulation reduces cognitive injury at high altitude\n2969: Nanodelivery of oxiracetam enhances memory, functional recovery and induces neuroprotection following concussive head injury\n2971: S-oxiracetam Facilitates Cognitive Restoration after Ischemic Stroke by Activating \u03b17nAChR and the PI3K-Mediated Pathway\n2975: Oxiracetam Mediates Neuroprotection Through the Regulation of Microglia Under Hypoxia-Ischemia Neonatal Brain Injury in Mice\n2977: Effect of l-oxiracetam and oxiracetam on memory and cognitive impairment in mild-to-moderate traumatic brain injury patients: Study protocol for a randomized controlled trial\n2980: Oxiracetam Offers Neuroprotection by Reducing Amyloid \u03b2-Induced Microglial Activation and Inflammation in Alzheimer's Disease\n2983: S-oxiracetam ameliorates ischemic stroke induced neuronal apoptosis through up-regulating \u03b17 nAChR and PI3K / Akt / GSK3\u03b2 signal pathway in rats\n2986: Oxiracetam can improve cognitive impairment after chronic cerebral hypoperfusion in rats\n2989: Oxiracetam prevents the MK-801 induced amnesia for the elevated plus-maze in mice\n2992: Pharmacokinetic comparisons of S-oxiracetam and R-oxiracetam in beagle dogs\n2995: Oxiracetam in dementia: a double-blind, placebo-controlled study\n2999: Pharmacokinetic Properties of S-oxiracetam After Single and Multiple Intravenous Infusions in Healthy Volunteers\n3002: Oxiracetam ameliorates cognitive deficits in vascular dementia rats by regulating the expression of neuronal apoptosis/autophagy-related genes associated with the activation of the Akt/mTOR signaling pathway\n3005: Effect of Butylphthalide combined with Oxiracetam on cognitive function, Intellectual recovery and serum inflammatory factors in patients with cognitive impairment after cerebral infarction\n3006: Combined bone marrow stromal cells and oxiracetam treatments ameliorates acute cerebral ischemia/reperfusion injury through TRPC6\n3009: Effects of oxiracetam on neurotransmitter release from rat hippocampus slices and synaptosomes\n3011: Safety, tolerability, and pharmacokinetics of oral (S)-oxiracetam in Chinese healthy volunteers: A randomized, double-blind, controlled phase I study\n3013: Enantioselective HPLC determination of oxiracetam enantiomers and application to a pharmacokinetic study in beagle dogs\n3015: Oxiracetam prevents haloperidol-induced passive avoidance impairment in mice\n3016: Development and validation of a chiral UPLC-MS/MS method for quantifying S-Oxiracetam and R-Oxiracetam in human plasma, urine and feces: Application to a phase-I clinical pharmacokinetic study\n3017: Bone marrow stromal cells combined with oxiracetam influences the expression of B-cell lymphoma 2 in rats with ischemic stroke\n3019: (S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates the Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats\n3020: S-oxiracetam protect against ischemic stroke via alleviating blood brain barrier dysfunction in rats\n3021: Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia\n3022: Oxiracetam prevents electroshock-induced decrease in brain acetylcholine and amnesia\n3023: Nerve growth factor in combination with Oxiracetam in the treatment of Hypertensive Cerebral Hemorrhage\n3024: Using HPLC to analyze (S)-oxiracetam and four related substances in the bulk drug of (S)-oxiracetam\n3025: Comparative toxicity and toxicokinetic studies of oxiracetam and (S)-oxiracetam in dogs\n3026: Effects of oxiracetam combined with ginkgo biloba extract in the treatment of acute intracerebral hemorrhage: A clinical study\n3027: Effect of oxiracetam on cerebrovascular impairment in rats\n3028: Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose\n3029: Oxiracetam prevented the scopolamine but not the diazepam induced memory deficits in mice\n3030: Oxiracetam prevents the hippocampal cholinergic hypofunction induced by the NMDA receptor blocker AP7\n3031: Effects of edaravone combined with Oxiracetam on neuronal apoptosis in rats with cerebral infarction through targeting SIRT1/NF-\u03baB inflammatory pathway\n3032: [Biochemical studies of oxiracetam (CT-848) on cholinergic neurons]\n3033: Clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment\n3034: Oxiracetam antagonizes the disruptive effects of scopolamine on memory in the radial maze\n3035: Oxiracetam and D-pyroglutamic acid antagonize a disruption of passive avoidance behaviour induced by the N-methyl-D-aspartate receptor antagonist 2-amino-5-phosphonovalerate\n3036: Oxiracetam in the treatment of multi-infarct dementia\n3037: Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine\n3038: Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study\n3039: Enhancement of hippocampally-mediated learning and protein kinase C activity by oxiracetam in learning-impaired DBA/2 mice\n3040: Efficacy and association of hyperbaric oxygen therapy combined with butylphthalide and oxiracetam with serum levels of inflammatory markers in vascular cognitive impairment after acute ischemic stroke\n3041: Treatment trial of oxiracetam in Alzheimer's disease\n3042: Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjects\n3043: Effect of oxiracetam and piracetam on central cholinergic mechanisms and active-avoidance acquisition\n3044: Pilot study to determine the interaction of oxiracetam with antiepileptic drugs\n3045: The effects of oxiracetam (CT-848) on local cerebral glucose utilization after focal cerebral ischemia in rats\n3046: Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree\n3047: Comparative pharmacokinetic studies of racemic oxiracetam and its pure enantiomers after oral administration in rats by a stereoselective HPLC method\n3049: Activity of oxiracetam in patients with organic brain syndrome: a neuropsychological study\n3051: Oxiracetam increases the release of endogenous glutamate from depolarized rat hippocampal slices\n3052: Oxiracetam pre- but not post-treatment prevented social recognition deficits produced with trimethyltin in rats\n3054: Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers\n3056: Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly\n3058: Effects of oxiracetam-nicotine combinations on active and passive avoidance learning in mice\n3059: Oxiracetam prevents mecamylamine-induced impairment of active, but not passive, avoidance learning in mice\n3061: Double-blind, placebo-controlled, clinical, psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life\n3064: The effects of ascorbic acid and oxiracetam on scopolamine-induced amnesia in a habituation test in aged mice\n3067: Absorption and disposition of 14C-labelled oxiracetam in rat, dog and man\n3070: Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia\n3073: Effects of acute doses of oxiracetam in the scopolamine model of human amnesia\n3076: Rapid quantitative analysis of oxiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry\n3078: Neuropsychological results of long-term therapy with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia in comparison with a control group\n3080: CNS pharmacology and clinical therapeutic effects of oxiracetam\n3083: Organic brain syndrome treated with oxiracetam. A double-blind randomized controlled trial\n3085: Effects of oxiracetam, physostigmine, and their combination on active and passive avoidance learning in mice\n3090: Relationships between arousal and cognition-enhancing effects of oxiracetam\n3093: Simultaneous determination of oxiracetam and its degraded substance in rat plasma by HPLC-MS/MS and its application to pharmacokinetic study after a single high-dose intravenous administration\n3096: Brain entry and direct central pharmacological effects of the nootropic drug oxiracetam. Oxiracetam: brain entry and pharmacological effects\n3099: Double-blind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsy\n3103: Effect of oxiracetam on cognition and brain cholinergic mechanisms\n3105: Pre- and postprandial pyridostigmine and oxiracetam effects on growth hormone secretion in anorexia nervosa\n3109: Facilitating effect of oxiracetam and piracetam on acquisition of discrete two-way shuttle avoidance in normal mice\n3113: Effects of oxiracetam on learning and memory in animals: comparison with piracetam\n3117: Rapid quantitative analysis of oxiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry\n3118: The GABAB receptor antagonist CGP 36,742 and the nootropic oxiracetam facilitate the formation of long-term memory\n3122: Biochemical studies on the nootropic drug, oxiracetam, in brain\n3125: [Effects of oxiracetam and piracetam on the electrical activity of neurons of the cerebral cortex]\n3127: Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia\n3130: A decrease in brain catecholamines prevents oxiracetam antagonism of the effects of scopolamine on memory and brain acetylcholine\n3134: Effect of alaptide, its analogues and oxiracetam on memory for an elevated plus-maze in mice\n3136: Synergistic effects of oxiracetam and piracetam in combination with antiepileptic drugs\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug50_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Aceticacid\" (also known as \"aceticacid\"), here are the article headings along with their IDs:\n2958: DNA-binding, cleavage, antibacterial andin vitroanticancer activity of copper(II) mixed ligand complexes of 2-(((6-chloro-1H-benzo[d]imidazol-2-yl)methyl)amino)aceticacid and polypyridyl ligands\n2960: 177Lu-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-human serum albumin-Ac-Cys-ZEGFR:1907\n2962: Ethylene diamine tetra aceticacid pseudothrombocytopenia: A must to know entity for Anaesthesiologists\n2964: Acetic-acid chromoendoscopy for Barrett's esophagus: the \"pros\"\n2966: [The improved method of getting the cyano-aceticacid-methylester in good yield by the liquid-chromatography]\n2968: Can Rodent Model of Acetic Acid-Induced Colitis be Used to Study the Pathogenesis of Colitis-Associated Intestinal Fibrosis?\n2970: Detection of Cervical Precancer Using Visual Inspection Method with Acetic Acid\n2973: Mentha longifolia protects against acetic-acid induced colitis in rats\n2976: Acetic-Acid Plasma-Polymerization on Polymeric Substrates for Biomedical Application\n2979: Comparison of white-light endoscopy, optical-enhanced and acetic-acid magnifying endoscopy for detecting gastric intestinal metaplasia: A randomized trial\n2982: Visual inspection with acetic-acid (VIA) service utilization and associated factors among women in Hawassa city, southern Ethiopia: a community based cross-sectional study\n2985: Proteome and metabolome profiling of wild-type and YCA1-knock-out yeast cells during acetic acid-induced programmed cell death\n2988: YCA1 participates in the acetic acid induced yeast programmed cell death also in a manner unrelated to its caspase-like activity\n2991: Analgesic effect of Chinese herbal formula Hua-Jian-Ba-Du ointment on visceral pain in mice induced by acetic acid\n2993: Yeast growth in raffinose results in resistance to acetic-acid induced programmed cell death mostly due to the activation of the mitochondrial retrograde pathway\n2997: Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. University of Zimbabwe/JHPIEGO Cervical Cancer Project\n2998: Assessment of the antinociceptive effects of pregabalin alone or in combination with morphine during acetic acid-induced writhing in mice\n3001: Anti-inflammatory and immunomodulatory effects of Spirulina platensis in comparison to Dunaliella salina in acetic acid-induced rat experimental colitis\n3003: DNA flow cytometry of breast carcinoma after acetic-acid fixation\n3008: The effect of melatonin on plasma markers of inflammation and on expression of nuclear factor-kappa beta in acetic acid-induced colitis in the rat\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug51_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Pramiracetam\" (also known as \"pramiracetam\"), here are the article headings along with their IDs:\n2972: [Pharmacokinetics of pramiracetam in animals]\n2974: The effect of pramiracetam (CI-879) on the acquisition of a radial arm maze task\n2978: The action of pramiracetam on consequences of hypobaric hypoxia is only moderate\n2981: Pharmacokinetics of pramiracetam in healthy volunteers after oral administration\n2984: Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers\n2987: Systemic administration of pramiracetam increases nitric oxide synthase activity in the cerebral cortex of the rat\n2990: Pramiracetam and epileptic after-discharges in young rats after hypoxia\n2994: A new one-trial test for neurobiological studies of memory in rats. II: Effects of piracetam and pramiracetam\n2996: Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam\n3000: Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia\n3004: Pharmacokinetics of oral pramiracetam in normal volunteers\n3007: Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam\n3010: Pharmacologic therapeutic window of pramiracetam demonstrated in behavior, EEG, and single neuron firing rates\n3012: Reversal of scopolamine-induced alterations of choline transport across the blood-brain barrier by the nootropics piracetam and pramiracetam\n3014: Arousal deficit shown in aged rat's quantitative EEG and ameliorative action of pramiracetam compared to piracetam\n3018: Gas chromatographic assay of pramiracetam in human plasma using nitrogen specific detection\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug52_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Levothyroxine\" (also known as \"levothyroxine\"), here are the article headings along with their IDs:\n3048: Levothyroxine for the Treatment of Subclinical Hypothyroidism and Cardiovascular Disease\n3050: Levothyroxine Sodium Pentahydrate Tablets - Formulation Considerations\n3053: Editorial: Levothyroxine Therapy in Patients With Hypothyroidism\n3055: Oral levothyroxine therapy postbariatric surgery: Biopharmaceutical aspects and clinical effects\n3057: Levothyroxine Sodium - Thyroid Hormone Replacement Therapy for Hypothyroidism: A Review of Patent Literature\n3060: Liquid levothyroxine formulations in patients taking drugs interfering with L-T4 absorption\n3062: The emergence of levothyroxine as a treatment for hypothyroidism\n3063: Levothyroxine Prescribing: Why Simple Is so Complex\n3066: Levothyroxine and Non-alcoholic Fatty Liver Disease: A Mini Review\n3068: Levothyroxine treatment and pregnancy outcomes in women with subclinical hypothyroidism: a systematic review and meta-analysis\n3071: Levothyroxine absorption in health and disease, and new therapeutic perspectives\n3075: Liquid levothyroxine and its potential use\n3077: Levothyroxine personalized treatment: is it still a dream?\n3081: Effect of Levothyroxine Supplementation on the Cardiac Morphology and Function in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis\n3084: Considerations for Generic-to-Generic Levothyroxine Switching\n3087: Considerations for Generic-to-Generic Levothyroxine Switching\n3089: Considerations for Generic-to-Generic Levothyroxine Switching-Reply\n3091: Alternative schedules of levothyroxine administration\n3094: New Formulations of Levothyroxine in the Treatment of Hypothyroidism: Trick or Treat?\n3097: Levothyroxine therapy in patients with thyroid disease\n3098: The dangerous trend of levothyroxine medicalization\n3101: Benefits and Harms of Levothyroxine/L-Triiodothyronine Versus Levothyroxine Monotherapy for Adult Patients with Hypothyroidism: Systematic Review and Meta-Analysis\n3104: Massive levothyroxine ingestion\n3107: [Effect of levothyroxine treatment on pregnancy outcomes in euthyroid women with thyroid autoantibody positive: a Meta-analysis]\n3108: Levothyroxine\n3111: Levothyroxine in psychiatry: issues related to absorption after oral dosing\n3114: Ionic Levothyroxine Formulations: Synthesis, Bioavailability, and Cytotoxicity Studies\n3116: Levothyroxine Dosing for Thyroid-Stimulating Hormone Suppression in Patients with Differentiated Thyroid Cancer after Total Thyroidectomy\n3119: Bioequivalence studies for levothyroxine\n3121: Treatment of hypothyroidism with levothyroxine or a combination of levothyroxine plus L-triiodothyronine\n3124: Systematic review and meta-analysis of levothyroxine effect on blood pressure in patients with subclinical hypothyroidism\n3126: Liquid and softgel levothyroxine use in clinical practice: state of the art\n3129: Levothyroxine supplementation in hypothyroid bitches during pregnancy\n3132: Probable interaction between levothyroxine and ritonavir: Case report and literature review\n3135: Levothyroxine a new drug? Since when? How could that be?\n3137: Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors\n3139: Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors\n3141: Levothyroxine use and longitudinal changes in thigh muscles in at-risk participants for knee osteoarthritis: preliminary analysis from Osteoarthritis Initiative cohort\n3142: The enigma of persistent symptoms in hypothyroid patients treated with levothyroxine: A narrative review\n3144: Thyroid Hormone Homeostasis in Levothyroxine-treated Patients: Findings From ELSA-Brasil\n3145: Metabolomic profile of patients on levothyroxine treatment for hypothyroidism\n3147: [Subcutaneous administration of levothyroxine in refractory hypothyroidism]\n3148: Levothyroxine bioequivalence\n3150: Levothyroxine therapy\n3152: Pharmacotherapy: Levothyroxine in the elderly-finding the breaking point\n3154: Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors. Reply\n3156: A review of the safety of triiodothyronine in combination with levothyroxine for the management of hypothyroidism\n3159: Generic levothyroxine\n3160: Levothyroxine-induced hyperthyroidism\n3162: Levothyroxine supplementation does not improve heart transplantation from brain-dead donors\n3165: Levothyroxine poisoning\n3166: Levothyroxine absorption test followed by directly observed treatment on an outpatient basis to address long-term high thyrotropin levels in a hypothyroid patient: a case report\n3168: Current evidence for the treatment of hypothyroidism with levothyroxine/levotriiodothyronine combination therapy versus levothyroxine monotherapy\n3170: Therapeutic efficacy and patient compliance of levothyroxine liquid and softgel formulations taken with meals: a systematic review\n3172: Risk of cancer in long-term levothyroxine users: Retrospective population-based study\n3174: Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review\n3175: Hemodynamic Effects of High-dose Levothyroxine and Methylprednisolone in Brain-dead Potential Organ Donors\n3177: Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate\n3179: Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules\n3181: Overuse of Levothyroxine in Patients With Subclinical Hypothyroidism: Time to \"Leve\"-Out-Thyroxine\n3184: The effects of levothyroxine combined with methimazole on the clinical efficacy of hyperthyroidism treatment\n3185: Pseudomalabsorption of levothyroxine\n3187: The Levothyroxine Absorption Test: A Four-Year Experience (2015-2018) at The Mayo Clinic\n3189: Evaluation of the therapeutic efficacy of different levothyroxine preparations in the treatment of human thyroid disease\n3191: The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature\n3193: Levothyroxine-induced liver injury followed by complete recovery upon cessation of the drug: a case report\n3195: [Primary hypothyroidism: Considerations for a rational use of levothyroxine therapy]\n3196: [Preference policy for levothyroxine: switch between brands may lead to symptoms and extra costs]\n3198: New formulations of levothyroxine in the treatment of hypothyroidism\n3200: Effect of levothyroxine on pregnancy outcomes in euthyroid women with antithyroid antibodies\n3202: Is long-term levothyroxine therapy safe?\n3204: A tale of two patients with hypersensitivity reactions to levothyroxine\n3207: Is levothyroxine requirement the same for tablet and soft gel formulations?\n3211: Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial\n3214: Phase II Clinical Trial of Intravenous Levothyroxine to Mitigate Pharyngocutaneous Fistula in Euthyroid Patients Undergoing Salvage Laryngectomy\n3217: Are multisource levothyroxine sodium tablets marketed in Egypt interchangeable?\n3221: Importance of right communication with healthcare providers and patients about the new levothyroxine formulation: an expert opinion from Asia Pacific Thyroid Advisory Board\n3225: Generic levothyroxine: What is all the fuss about?\n3226: Levothyroxine sodium tablets: chemical equivalence and bioequivalence\n3229: Fast Track Treatment of Hypothyroidism with Levothyroxine: Reaching Homeostasis within Four Weeks\n3233: Effect of levothyroxine treatment on fetal growth among women with mild subclinical hypothyroidism and thyroid peroxidase antibody negative: a cohort study\n3236: Frequency of over- and under-treatment with levothyroxine in primary care in Germany\n3239: Levothyroxine dose and risk of fractures in older adults: nested case-control study\n3240: Use of soy protein supplement and resultant need for increased dose of levothyroxine\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug53_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Synephrine\" (also known as \"synephrine\"), here are the article headings along with their IDs:\n3065: Synephrine and Its Derivative Compound A: Common and Specific Biological Effects\n3069: Effects ofp-Synephrine during Exercise: A Brief Narrative Review\n3072: [Synephrine in dietary supplements and specialized foodstuffs: biological activity, safety and methods of analysis]\n3074: p-Synephrine, ephedrine, p-octopamine and m-synephrine: Comparative mechanistic, physiological and pharmacological properties\n3079: Synephrine: from trace concentrations to massive consumption in weight-loss\n3082: The Safety and Efficacy ofCitrus aurantium(Bitter Orange) Extracts andp-Synephrine: A Systematic Review and Meta-Analysis\n3086: Review of Case Reports on Adverse Events Related to Pre-workout Supplements Containing Synephrine\n3088: [Risk assessment of synephrine in dietary supplements]\n3092: A review of the receptor-binding properties of p-synephrine as related to its pharmacological effects\n3095: Safety, Efficacy, and Mechanistic Studies Regarding Citrus aurantium (Bitter Orange) Extract and p-Synephrine\n3100: Review of Published Bitter Orange Extract andp-Synephrine Adverse Event Clinical Study Case Reports\n3102: p-Synephrine suppresses inflammatory responses in lipopolysaccharide-stimulated RAW264.7 cells and alleviates systemic inflammatory response syndrome in mice\n3106: Racemic synephrine found in Citrus aurantium-listing pre-workout supplements suggests a non-plant-based origin\n3110: p-Synephrine ameliorates alloxan-induced diabetes mellitus through inhibiting oxidative stress and inflammationviasuppressing the NF-kappa B and MAPK pathways\n3112: Synephrine - A potential biomarker for orange honey authenticity\n3115: Electrochemical determination of synephrine by using nafion/UiO-66/graphene-modified screen-printed carbon electrode\n3120: p-Synephrine, the main protoalkaloid ofCitrus aurantium, raises fat oxidation during exercise in elite cyclists\n3123: p-Synephrine exhibits anti-adipogenic activity by activating the Akt/GSK3\u03b2 signaling pathway in 3T3-L1 adipocytes\n3128: Phytochemical compounds in sport nutrition: Synephrine and hydroxycitric acid (HCA) as examples for evaluation of possible health risks\n3131: A review of the human clinical studies involving Citrus aurantium (bitter orange) extract and its primary protoalkaloid p-synephrine\n3133: Citrusp-Synephrine Improves Energy Homeostasis by Regulating Amino Acid Metabolism in HFD-Induced Mice\n3138: p-Synephrine suppresses glucose production but not lipid accumulation in H4IIE liver cells\n3140: Synephrine inhibits eotaxin-1 expression via the STAT6 signaling pathway\n3143: Effect ofp-Synephrine on Fat Oxidation Rate during Exercise of Increasing Intensity in Healthy Active Women\n3146: Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update\n3149: The safety of Citrus aurantium (bitter orange) and its primary protoalkaloid p-synephrine\n3151: Synephrine Hydrochloride Suppresses Esophageal Cancer Tumor Growth and Metastatic Potential through Inhibition of Galectin-3-AKT/ERK Signaling\n3153: p-Synephrine Indicates Internal Maturity ofCitrus grandis(L.) Osbeck cv. Mato Peiyu-Reclaiming Functional Constituents from Nonedible Parts\n3155: Stachydrine, a Bioactive Equilibrist for Synephrine, Identified from FourCitrusChinese Herbs\n3157: Synephrine and caffeine combination promotes cytotoxicity, DNA damage and transcriptional modulation of apoptosis-related genes in human HepG2 cells\n3158: p-Synephrine stimulates glucose consumption via AMPK in L6 skeletal muscle cells\n3161: Preparative enantioseparation of synephrine by conventional and pH-zone-refining counter-current chromatography\n3163: p-synephrine induces transcriptional changes via the cAMP/PKA pathway but not cytotoxicity or mutagenicity in human gastrointestinal cells\n3164: Combined Anti-Adipogenic Effects of Hispidulin andp-Synephrine on 3T3-L1 Adipocytes\n3167: Acute p-synephrine ingestion increases whole-body fat oxidation during 1-h of cycling at Fatmax\n3169: p-Synephrine: a novel agonist for neuromedin U2 receptor\n3171: Synephrine as a Specific Marker for Orange Consumption\n3173: p-Synephrine suppresses lipopolysaccharide-induced acute lung injury by inhibition of the NF-\u03baB signaling pathway\n3176: Acute p-synephrine ingestion increases fat oxidation rate during exercise\n3178: Synephrine, as a scavenger and promoter, cooperates with hesperidin to reduce acrolein levels\n3180: Phytochemical Combination (p-Synephrine,p-Octopamine Hydrochloride, and Hispidulin) for Improving Obesity in Obese Mice Induced by High-Fat Diet\n3182: Citrus aurantiumL. and synephrine improve brown adipose tissue function in adolescent mice programmed by early postnatal overfeeding\n3183: STEMI in a 24-year-old man after use of a synephrine-containing dietary supplement: a case report and review of the literature\n3186: Effects of p-Synephrine and Caffeine Ingestion on Substrate Oxidation during Exercise\n3188: Case report: Synephrine, a plant substance yielding classic environmental clusters of hay related identifications in equine urine\n3190: Effects of synephrine and beta-phenethylamine on human alpha-adrenoceptor subtypes\n3192: Separation of Synephrine Enantiomers in Citrus Fruits by a Reversed Phase HPLC after Chiral Precolumn Derivatization\n3194: Synephrine content of juice from Satsuma mandarins (Citrus unshiu Marcovitch)\n3197: Structural isomerization of synephrine influences its uptake and ensuing glutathione depletion in rat-isolated cardiomyocytes\n3199: Synephrine: from trace concentrations to massive consumption in weight-loss\n3201: Acute consumption of p-synephrine does not enhance performance in sprint athletes\n3203: Synephrine Inhibits Oxidative Stress and H2O2-Induced Premature Senescence\n3205: Establishing an Artificial Pathway for the Biosynthesis of Octopamine and Synephrine\n3209: Effects of hesperidin combined with synephrine on the capture of acrolein in a mouse model, or in humans by citrus consumption\n3212: synephrine, a component of Evodiae Fructus, constricts isolated rat aorta via adrenergic and serotonergic receptors\n3215: Does the Time of Day Play a Role in the Acute Effect ofp-Synephrine on Fat Oxidation Rate during Exercise in Women? A Randomized, Crossover and Double-Blind Study\n3219: Profound Hyperthermia Associated With Fentanyl and Cocaine Use With Suspected Synephrine Adulteration\n3220: \"Gate Effect\" in p-Synephrine Electrochemical Sensing with a Molecularly Imprinted Polymer and Redox Probes\n3224: Characterization of antidepressant-like effects of p-synephrine stereoisomers\n3227: A green separation mode of synephrine fromCitrus aurantiumL. (Rutaceae) by nanofiltration technology\n3230: Load mechanism and release behaviour of synephrine-loaded calcium pectinate beads: Experiments characterizations, theoretical calculations and mathematical modeling\n3231: Determination of synephrine in bitter orange raw materials, extracts, and dietary supplements by liquid chromatography with ultraviolet detection: single-laboratory validation\n3234: Transcriptome analysis ofCitrus AurantiumL. to study synephrine biosynthesis during developmental stages\n3235: Actions of p-synephrine on hepatic enzyme activities linked to carbohydrate metabolism and ATP levels in vivo and in the perfused rat liver\n3238: The effects of supplementation with P-Synephrine alone and in combination with caffeine on resistance exercise performance\n3241: Activities of octopamine and synephrine stereoisomers on octopaminergic receptor subtypes in locust skeletal muscle\n3242: Application of Synephrine to Grape Increases Anthocyanin via Production of Hydrogen Peroxide, Not Phytohormones\n3243: Synephrine and phenylephrine act as \u03b1-amylase, \u03b1-glycosidase, acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase enzymes inhibitors\n3244: Hemodynamic effects of synephrine treatment in portal hypertensive rats\n3245: Safety evaluation of p-synephrine following 15 days of oral administration to healthy subjects: A clinical study\n3246: Exactly which synephrine alkaloids does Citrus aurantium (bitter orange) contain?\n3247: Ultrasound-assisted aqueous two-phase extraction of synephrine, naringin, and neohesperidin fromCitrus aurantiumL. fruitlets\n3248: m-Synephrine: normal occurrence in adrenal gland\n3249: Cardiovascular Safety of Oral p-Synephrine (Bitter Orange) in Healthy Subjects: A Randomized Placebo-Controlled Cross-over Clinical Trial\n3250: Effects of p-synephrine alone and in combination with selected bioflavonoids on resting metabolism, blood pressure, heart rate and self-reported mood changes\n3251: Temperature Cycling Induced Deracemization ofp-Synephrine in the Presence of Degradation\n3252: Interaction of p-synephrine on the pharmacodynamics and pharmacokinetics of gliclazide in animal models\n3253: The mammalian metabolism of R-(-)-m-synephrine\n3254: Determination of synephrine and octopamine in bitter orange peel by HPTLC with densitometry\n3255: Necrosis following intravenous use of neo-synephrine\n3256: Co-Existence of Hypertensive and Anti-Hypertensive Constituents, Synephrine, and Nobiletin inCitrus unshiuPeel\n3257: Subchronic toxicity of Citrus aurantium L. (Rutaceae) extract and p-synephrine in mice\n3258: Scavenging Glyoxal and Methylglyoxal by Synephrine Alone or in Combination with Neohesperidin at High Temperatures\n3259: Simultaneous determination of synephrine, arecoline, and norisoboldine in Chinese patent medicine Si-Mo-Tang oral liquid preparation by strong cation exchange high performance liquid chromatography\n3260: Effects of Citrus aurantium (bitter orange) fruit extracts and p-synephrine on metabolic fluxes in the rat liver\n3261: Molecularly imprinted polymers for selective extraction of synephrine from Aurantii Fructus Immaturus\n3262: Dose-Response Effects of p-Synephrine on Fat Oxidation Rate During Exercise of Increasing Intensity\n3263: Fast hepatic biotransformation of p-synephrine and p-octopamine and implications for their oral intake\n3264: Synephrine-containing dietary supplement precipitating apical ballooning syndrome in a young female\n3265: Scavenging Glyoxal and Methylglyoxal by Synephrine and Neohesperidin from Flowers ofCitrus aurantiumL. var.amaraEngl. in Mice and Humans\n3266: Effects of acute ingestion of a pre-workout dietary supplement with and withoutp-synephrine on resting energy expenditure, cognitive function and exercise performance\n3267: The action of p-synephrine on hepatic carbohydrate metabolism and respiration occurs via both Ca(2+)-mobilization and cAMP production\n3268: Acute cardiovascular effects of bitter orange extract (p-synephrine) consumed alone and in combination with caffeine in human subjects: A placebo-controlled, double-blind study\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug54_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"NAD+\" (also known as \"nad+\"), here are the article headings along with their IDs:\n3206: NAD+-Increasing Strategies to Improve Cardiometabolic Health?\n3208: Host NAD+ metabolism and infections: therapeutic implications\n3210: NAD+ and NADH in neuronal death\n3213: NAD+ and vitamin B3: from metabolism to therapies\n3216: NAD+ and NADH in brain functions, brain diseases and brain aging\n3218: The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways\n3222: The urocanase story: a novel role of NAD+ as electrophile\n3223: Pathway analysis of NAD+ metabolism\n3228: [The pathophysiological importance and therapeutic potential of NAD+ biosynthesis in age-related diseases]\n3232: Nicotinamide adenine dinucleotide (NAD+). Formal potential of the NA+/NAD couple and NAD dimerization rate\n3237: In vitro characterization of the NAD+ synthetase NadE1 from Herbaspirillum seropedicae\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug55_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Bemethyl\" (also known as \"bemethyl\"), here are the article headings along with their IDs:\n3271: Investigation of Bemethyl Biotransformation Pathways by Combination of LC-MS/HRMS and In Silico Methods\n3273: [Effects of bemethyl, ethomersol, and yakton on the liver regeneration after partial hepatectomy]\n3274: [Structural analysis of the functional status of the brain as affected by bemethyl using pattern recognition theory]\n3275: [Effect of bemethyl on the glutathione system in the rat liver in acute hypoxia]\n3276: [Effect of bemethyl on cytochrome P-450-dependent monoxygenases in the human liver and lymphocytes]\n3277: [Efficiency of preventive use of bemethyl during long-term voyages]\n3278: [Membrane mechanisms of effects of antihypoxic agents bemethyl and almide on neurons of Mollusca]\n3279: [Features of the effect of bemethyl on glycogen metabolism in hepatocytes of pathological changed human liver]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug56_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Fasoracetam\" (also known as \"fasoracetam\"), here are the article headings along with their IDs:\n3269: Fasoracetam. LAM 105, NS 105\n3270: Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling\n3272: A Study of Fasoracetam's Solid State Forms: A Potential Anti-Alzheimer Pharmaceutical\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug57_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"L-theanine\" (also known as \"l-theanine\"), here are the article headings along with their IDs:\n3280: The Cognitive-Enhancing Outcomes of Caffeine and L-theanine: A Systematic Review\n3281: L-Theanine and Immunity: A Review\n3282: L-theanine, a natural constituent in tea, and its effect on mental state\n3283: Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial\n3284: GABA and l-theanine mixture decreases sleep latency and improves NREM sleep\n3285: L-Theanine reduces psychological and physiological stress responses\n3286: L-theanine, unique amino acid of tea, and its metabolism, health effects, and safety\n3287: The Effects of Green Tea Amino Acid L-Theanine Consumption on the Ability to Manage Stress and Anxiety Levels: a Systematic Review\n3290: L-Theanine: A Unique Functional Amino Acid in Tea (Camellia sinensisL.) With Multiple Health Benefits and Food Applications\n3293: The combined effects of L-theanine and caffeine on cognitive performance and mood\n3295: A Novel Theanine Complex, Mg-L-Theanine Improves Sleep QualityviaRegulating Brain Electrochemical Activity\n3297: L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trial\n3299: L-theanine: an astounding sui generis amino acid in poultry nutrition\n3302: Effects of l-Theanine on Cognitive Function in Middle-Aged and Older Subjects: A Randomized Placebo-Controlled Study\n3305: Effects of L-theanine-caffeine combination on sustained attention and inhibitory control among children with ADHD: a proof-of-concept neuroimaging RCT\n3307: Immune-boosting role of L-theanine in broiler poultry production under stress conditions\n3308: l-Theanine: An astounding sui generis integrant in tea\n3310: Anti-Stress, Behavioural and Magnetoencephalography Effects of an L-Theanine-Based Nutrient Drink: A Randomised, Double-Blind, Placebo-Controlled, Crossover Trial\n3311: Use of Nutritional Supplements Based on L-Theanine and Vitamin B6 in Children with Tourette Syndrome, with Anxiety Disorders: A Pilot Study\n3313: l-Theanine Inhibits (-)-Epigallocatechin-3-gallate Oxidation via Chelating Copper\n3315: L-theanine attenuates nicotine reward and withdrawal signs in mice\n3317: An L-Glutamine Transporter Isoform for Neurogenesis Facilitated by L-Theanine\n3319: Effect of a Combination of Magnesium, B Vitamins, Rhodiola, and Green Tea (L-Theanine) on Chronically Stressed Healthy Individuals-A Randomized, Placebo-Controlled Study\n3320: L-Theanine adjunct to risperidone in the treatment of chronic schizophrenia inpatients: a randomized, double-blind, placebo-controlled clinical trial\n3322: Functional roles of taurine, L-theanine, L-citrulline, and betaine during heat stress in poultry\n3324: L-Theanine alleviates MPTP-induced Parkinson's disease by targeting Wnt/\u03b2-catenin signaling mediated by the MAPK signaling pathway\n3326: L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial\n3328: l-theanine adjunct to sertraline for major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial\n3330: An overview of biological production of L-theanine\n3332: L-Theanine Improves Locomotor Function in a Model of Multiple Sclerosis Mice\n3333: From Tea Leaves to Factories: A Review of Research Progress in l-Theanine Biosynthesis and Production\n3335: L-Theanine: properties, synthesis and isolation from tea\n3337: The effects of L-theanine supplementation on the outcomes of patients with mental disorders: a systematic review\n3338: L-theanine suppresses the metastasis of prostate cancer by downregulating MMP9 and Snail\n3340: l-Theanine Prevents Colonic Damage via NF-\u03baB/MAPK Signaling Pathways Induced by a High-Fat Diet in Rats\n3342: l-Theanine Alleviates Ulcerative Colitis by Regulating Colon Immunity via the Gut Microbiota in an MHC-II-Dependent Manner\n3344: L-theanine inhibits foam cell formation via promoting the scavenger receptor A degradation\n3347: L-theanine intervention enhances human gammadeltaT lymphocyte function\n3349: L-theanine alleviates myocardial ischemia/reperfusion injury by suppressing oxidative stress and apoptosis through activation of the JAK2/STAT3 pathway in mice\n3351: Production of l-Theanine by Escherichia coli in the Absence of Supplemental Ethylamine\n3353: Protective Effect of l-Theanine on Cyclophosphamide-Induced Testicular Toxicity in Mice\n3355: L-Theanine inhibits melanoma cell growth and migration via regulating expression of the clock gene BMAL1\n3357: L-theanine exuded from Camellia sinensis roots regulates element cycling in soil by shaping the rhizosphere microbiome assembly\n3359: L-Theanine regulates glutamine metabolism and immune function by binding to cannabinoid receptor 1\n3361: L-Theanine mediates the p38MAPK signaling pathway to alleviate heat-induced oxidative stress and inflammation in mice\n3363: Effects of L-Theanine on Hepatic Ischemia-Reperfusion Injury in Rats\n3365: L-theanine prevents progression of nonalcoholic hepatic steatosis by regulating hepatocyte lipid metabolic pathways via the CaMKK\u03b2-AMPK signaling pathway\n3367: Impact of L-theanine and L-tyrosine on markers of stress and cognitive performance in response to a virtual reality based active shooter training drill\n3369: An L-theanine derivative targets against SARS-CoV-2 and its Delta and Omicron variants\n3371: L-theanine regulates the immune function of SD rats fed high-protein diets through the FABP5/IL-6/STAT3/PPAR\u03b1 pathway\n3373: L-theanine improves neurophysiological measures of attention in a dose-dependent manner: a double-blind, placebo-controlled, crossover study\n3376: l-Theanine attenuates neointimal hyperplasia via suppression of vascular smooth muscle cell phenotypic modulation\n3379: The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent\n3382: Effect of Combined Ingestion of L-Theanine and L-Arginine for Short-Term Psychological Stress in Young Adults: A Randomized Placebo-Controlled Study\n3384: l-Theanine Activates the Browning of White Adipose Tissue Through the AMPK/\u03b1-Ketoglutarate/Prdm16 Axis and Ameliorates Diet-Induced Obesity in Mice\n3387: L-theanine attenuates LPS-induced motor deficit in experimental rat model of Parkinson's disease: emphasis on mitochondrial activity, neuroinflammation, and neurotransmitters\n3390: l-Theanine regulates glucose, lipid, and protein metabolism via insulin and AMP-activated protein kinase signaling pathways\n3392: l-Theanine Goes Greener: A Highly Efficient Bioprocess Catalyzed by the Immobilized \u03b3-Glutamyl Transferase from Bacillus subtilis\n3396: L-Theanine promotes cultured human Sertoli cells proliferation and modulates glucose metabolism\n3399: L-Theanine Prolongs the Lifespan by Activating Multiple Molecular Pathways in Ultraviolet C-ExposedCaenorhabditis elegans\n3401: L-theanine protects rat kidney from D-galactose-induced injury via inhibition of the AGEs/RAGE signaling pathway\n3405: L-Theanine Inhibits Chemoresistance of Lung Cancer Cells to Cisplatin by Regulating STAT3/NOTCH1-BMAL1 Signaling\n3407: L-Theanine alleviates heat stress-induced impairment of immune function by regulating the p38 MAPK signalling pathway in mice\n3410: L-theanine attenuates porcine intestinal tight junction damage induced by LPS via p38 MAPK/NLRP3 signaling in IPEC-J2 cells\n3412: L-theanine and Neumentix mixture improves sleep quality and modulates brain neurotransmitter levels in mice\n3415: l-Theanine Protects Bladder Function by Suppressing Chronic Sympathetic Hyperactivity in Spontaneously Hypertensive Rat\n3419: L-Theanine regulates lipid metabolism by modulating gut microbiota and bile acid metabolism\n3422: Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis\n3425: Effect of dietary L-theanine supplementation on skeletal muscle fiber type transformation in vivo\n3428: l-Theanine Prevents Long-Term Affective and Cognitive Side Effects of Adolescent \u0394-9-Tetrahydrocannabinol Exposure and Blocks Associated Molecular and Neuronal Abnormalities in the Mesocorticolimbic Circuitry\n3431: L-Theanine Attenuates Isoflurane-Induced Injury in Neural Stem Cells and Cognitive Impairment in Neonatal Mice\n3433: The effect of L-theanine and S-ketamine on d-serine cellular uptake\n3436: Efficient fermentative production of L-theanine by Corynebacterium glutamicum\n3438: L-Theanine Alleviates IMQ-Induced Psoriasis Like Skin Inflammation by Downregulating the Production of IL-23 and Chemokines\n3440: L-Theanine Metabolism in Tea Plants: Biological Functions and Stress Tolerance Mechanisms\n3442: L-Theanine Reduced the Development of Knee Osteoarthritis in Rats via Its Anti-Inflammation and Anti-Matrix Degradation Actions: In Vivo and In Vitro Study\n3445: Effects of L-theanine on intestinal morphology, barrier function, and MAPK signaling pathways in diquat-challenged piglets\n3448: L-Theanine-Treated Adipose-Derived Mesenchymal Stem Cells Alleviate the Cytotoxicity Induced by N-Nitrosodiethylamine in Liver\n3450: l-theanine: From tea leaf to trending supplement - does the science match the hype for brain health and relaxation?\n3452: Safety and Efficacy of AlphaWave\u00aeL-Theanine Supplementation for 28 Days in Healthy Adults with Moderate Stress: A Randomized, Double-Blind, Placebo-Controlled Trial\n3455: The beneficial health effects of green tea amino acid l-theanine in animal models: Promises and prospects for human trials\n3457: L-Theanine Mitigates the Harmful Effects of Excess High-Protein Diet in Rats by Regulating Protein Metabolism\n3459: L-theanine ameliorate depressive-like behavior in a chronic unpredictable mild stress rat model via modulating the monoamine levels in limbic-cortical-striatal-pallidal-thalamic-circuit related brain regions\n3461: L-theanine induces skeletal muscle fiber type transformation by activation of prox1/CaN signaling pathway in C2C12 myotubes\n3463: l-Theanine protects against excess dopamine-induced neurotoxicity in the presence of astrocytes\n3465: Ultrasound enhanced biosynthesis of L-theanine from L-glutamine and ethylamine by recombinant \u03b3-glutamyltranspeptidase\n3467: Effect of L-theanine on glutamatergic function in patients with schizophrenia\n3469: L-Theanine Modulates Intestine-Specific Immunity by Regulating the Differentiation of CD4+ T Cells in Ovalbumin-Sensitized Mice\n3470: Adsorption Behavior of the L-Theanine onto Cation Exchange Resin ZGSPC106Na and D001SD\n3472: The protective effect of L-theanine on the intestinal barrier in heat-stressed organisms\n3474: Effects of single-dose L-theanine on motor cortex excitability\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug58_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"TUDCA\" (also known as \"tudca\"), here are the article headings along with their IDs:\n3288: Insights by which TUDCA is a potential therapy against adiposity\n3291: TUDCA receptors and their role on pancreatic beta cells\n3294: The bile acid TUDCA and neurodegenerative disorders: An overview\n3298: UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications\n3301: Synthesis of TUDCA from chicken bile: immobilized dual-enzymatic system for producing artificial bear bile substitute\n3304: The bile acid TUDCA reduces age-related hyperinsulinemia in mice\n3306: TUDCA inhibits HSV-1 replication by the modulating unfolded protein response pathway\n3309: Neuroprotective Effect of Tauroursodeoxycholic Acid (TUDCA) onIn VitroandIn VivoModels of Retinal Disorders: A Systematic Review\n3312: TUDCA inhibits EV71 replication by regulating ER stress signaling pathway and suppressing autophagy\n3314: TUDCA Ameliorates Liver Injury Via Activation of SIRT1-FXR Signaling in a Rat Hemorrhagic Shock Model\n3316: TUDCA-treated chronic kidney disease-derived hMSCs improve therapeutic efficacy in ischemic disease via PrPC\n3318: SEPN1-related myopathy depends on the oxidoreductase ERO1A and is druggable with the chemical chaperone TUDCA\n3321: A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial\n3323: Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson's disease\n3325: TUDCA modulates drug bioavailability to regulate resistance to acute ER stress inSaccharomyces cerevisiae\n3327: TUDCA attenuates intestinal injury and inhibits endoplasmic reticulum stress-mediated intestinal cell apoptosis in necrotizing enterocolitis\n3329: Tauroursodeoxycholic Acid (TUDCA) Regulates Inflammation and Hypoxia in Autonomic Tissues of Rats with Seizures\n3331: TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effects\n3334: Tauroursodeoxycholic acid (TUDCA) disparate pharmacological effects to lung tissue-resident memory T cells contribute to alleviated silicosis\n3336: Tauroursodeoxycholic acid (TUDCA) abolishes chronic high salt-induced renal injury and inflammation\n3339: Energy homeostasis deregulation is attenuated by TUDCA treatment in streptozotocin-induced Alzheimer's disease mice model\n3341: TUDCA-Treated Mesenchymal Stem Cells Protect against ER Stress in the Hippocampus of a Murine Chronic Kidney Disease Model\n3343: Possible Role of Tauroursodeoxycholic Acid (TUDCA) and Antibiotic Administration in Modulating Human Gut Microbiota in Home Enteral Nutrition Therapy for the Elderly: A Case Report\n3345: TUDCA Promotes Phagocytosis by Retinal Pigment Epithelium via MerTK Activation\n3346: TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-\u03b2 deposition in APP/PS1 mice\n3348: Tauroursodeoxycholic Acid (TUDCA) Relieves Streptozotocin (STZ)-Induced Diabetic Rat Model via Modulation of Lipotoxicity, Oxidative Stress, Inflammation, and Apoptosis\n3350: Drug Tissue Distribution of TUDCA From a Biodegradable Suprachoroidal Implant versus Intravitreal or Systemic Delivery in the Pig Model\n3352: TUDCA: An Agonist of the Bile Acid Receptor GPBAR1/TGR5 With Anti-Inflammatory Effects in Microglial Cells\n3354: Tauroursodeoxycholic acid (TUDCA) counters osteoarthritis by regulating intracellular cholesterol levels and membrane fluidity of degenerated chondrocytes\n3356: Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKC\u03b1-mediated MKP-1 induction\n3358: The effect of tauroursodeoxycholic Acid (TUDCA) treatment on placental endoplasmic reticulum (ER) stress in a rat model of advanced maternal age\n3360: TUDCA slows retinal degeneration in two different mouse models of retinitis pigmentosa and prevents obesity in Bardet-Biedl syndrome type 1 mice\n3362: Tauroursodeoxycholic acid (TUDCA) enhanced intracytoplasmic sperm injection (ICSI) embryo developmental competence by ameliorating endoplasmic reticulum (ER) stress and inhibiting apoptosis\n3364: The effect of Tauroursodeoxycholic acid (TUDCA) and gut microbiota on murine gallbladder stone formation\n3366: Tauroursodeoxycholic acid (TUDCA) attenuates pressure overload-induced cardiac remodeling by reducing endoplasmic reticulum stress\n3368: Effect of SCD probiotics supplemented with tauroursodeoxycholic acid (TUDCA) application on the aged rat gut microbiota composition\n3370: Tauroursodeoxycholate (TUDCA), chemical chaperone, enhances function of islets by reducing ER stress\n3374: TUDCA prevents cholestasis and canalicular damage induced by ischemia-reperfusion injury in the rat, modulating PKCalpha-ezrin pathway\n3377: Tauroursodeoxycholic acid (TUDCA) alleviates endoplasmic reticulum stress of nuclear donor cells under serum starvation\n3380: The Taurine-Conjugated Bile Acid (TUDCA) Normalizes Insulin Secretion in Pancreatic \u03b2-Cells Exposed to Fatty Acids: The Role of Mitochondrial Metabolism\n3383: Can endoplasmic reticulum stress observed in the PTZ-kindling model seizures be prevented with TUDCA and 4-PBA?\n3386: Chemical chaperone TUDCA selectively inhibits production of allergen-specific IgE in a low-dose model of allergy\n3388: Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease\n3391: Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice\n3394: Chemical chaperone TUDCA prevents apoptosis and improves survival during polymicrobial sepsis in mice\n3398: Molecular and Cellular Effects of Chemical Chaperone-TUDCA on ER-Stressed NHAC-kn Human Articular Chondrocytes Cultured in Normoxic and Hypoxic Conditions\n3402: Chemical chaperone, TUDCA unlike PBA, mitigates protein aggregation efficiently and resists ER and non-ER stress induced HepG2 cell death\n3404: Bile acid TUDCA improves insulin clearance by increasing the expression of insulin-degrading enzyme in the liver of obese mice\n3408: Investigating the effects of tauroursodeoxycholic acid (TUDCA) in mitigating endoplasmic reticulum stress and cellular responses in Pak choi\n3411: Chemical chaperone TUDCA preserves cone photoreceptors in a mouse model of Leber congenital amaurosis\n3414: Promoting longevity in aged liver through NLRP3 inflammasome inhibition using tauroursodeoxycholic acid (TUDCA) and SCD probiotics\n3416: Aberrant MUC1 accumulation in salivary glands of Sj\u00f6gren's syndrome patients is reversed by TUDCA in vitro\n3418: Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degeneration\n3421: Tauroursodeoxycholic acid (TUDCA) protects photoreceptors from cell death after experimental retinal detachment\n3423: Administration of tauroursodeoxycholic acid (TUDCA) reduces apoptosis following myocardial infarction in rat\n3426: The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic beta cells\n3429: Co-delivery of glial cell-derived neurotrophic factor (GDNF) and tauroursodeoxycholic acid (TUDCA) from PLGA microspheres: potential combination therapy for retinal diseases\n3432: Effect of tauroursodeoxycholic acid (TUDCA) on biliary lipid composition\n3435: Polyhexamethyleneguanidine Phosphate-Induced Cytotoxicity in Liver Cells Is Alleviated by Tauroursodeoxycholic Acid (TUDCA) via a Reduction in Endoplasmic Reticulum Stress\n3439: Microglia activation in a model of retinal degeneration and TUDCA neuroprotective effects\n3443: A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis\n3447: Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug59_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"RU58841\" (also known as \"ru58841\"), here are the article headings along with their IDs:\n3289: Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques\n3292: A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice\n3296: RU 58841-myristate--prodrug development for topical treatment of acne and androgenetic alopecia\n3300: Local inhibition of sebaceous gland growth by topically applied RU 58841\n3303: RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug60_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Pregnenolone\" (also known as \"pregnenolone\"), here are the article headings along with their IDs:\n3372: Pregnenolone\n3375: Pregnenolone sulfate analogues differentially modulate GABAAreceptor closed/desensitised states\n3378: Hypothalamic pregnenolone mediates recognition memory in the context of metabolic disorders\n3381: Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence\n3385: Nongenomic actions of neurosteroid pregnenolone and its metabolites\n3389: Therapeutic potential of pregnenolone and pregnenolone methyl ether on depressive and CDKL5 deficiency disorders: Focus on microtubule targeting\n3393: Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials\n3395: Pregnenolone sulfate in the brain: a controversial neurosteroid\n3397: A review on synthesis and biological activities of D-ring modified pregnenolone\n3400: Neurosteroids and potential therapeutics: Focus on pregnenolone\n3403: Pregnenolone sulfate induces transcriptional and immunoregulatory effects on T cells\n3406: The neurosteroid pregnenolone is synthesized by a mitochondrial P450 enzyme other than CYP11A1 in human glial cells\n3409: Addiction: pregnenolone limits effects of cannabis\n3413: Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice\n3417: Individual differences in cognitive aging: implication of pregnenolone sulfate\n3420: Discovery and biological evaluation of pregnenolone selenocyanoamides with potential anticancer and antimicrobial activities\n3424: [Pregnenolone, pregnenolone sulfate]\n3427: [Pregnenolone, pregnenolone sulfate]\n3430: Neurosteroids: biosynthesis, metabolism and function of pregnenolone and dehydroepiandrosterone in the brain\n3434: Pregnenolone for cognition and mood in dual diagnosis patients\n3437: Intranasal pregnenolone increases acetylcholine in frontal cortex, hippocampus, and amygdala-Preferentially in the hemisphere ipsilateral to the injected nostril\n3441: The Sulfated Steroids Pregnenolone Sulfate and Dehydroepiandrosterone Sulfate Inhibit the\u03b11\u03b23\u03b32L GABAAReceptor by Stabilizing a Novel Nonconducting State\n3444: Effect of Pregnenolone vs Placebo on Self-reported Chronic Low Back Pain Among US Military Veterans: A Randomized Clinical Trial\n3446: Biosynthesis of pregnenolone from 22-hydroxycholesterol\n3449: Pregnenolone activates CLIP-170 to promote microtubule growth and cell migration\n3451: Pregnenolone in rheumatoid arthritis\n3453: Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial\n3454: Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial\n3456: Novel pregnenolone derivatives modulate apoptosis via Bcl-2 family genes in hepatocellular carcinoma in vitro\n3458: Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia\n3460: Pregnenolone derivatives as potential anticancer agents\n3462: Studies with pregnenolone. 2. Clinical applications\n3464: CLICK-chemoproteomics and molecular dynamics simulation reveals pregnenolone targets and their binding conformations in Th2 cells\n3466: Pregnenolone in arthritis\n3468: Pregnenolone sulfate potentiates the inwardly rectifying K channel Kir2.3\n3471: Pregnenolone biosynthesis in the rat salivary gland and its inhibitory effect on secretion\n3473: Microbial hydroxylation of pregnenolone derivatives\n3475: Pregneolone--from Selye to Alzheimer and a model of the pregnenolone sulfate binding site on the GABAA receptor\n3476: Corticosteroid Biosynthesis Revisited: No Direct Hydroxylation of Pregnenolone by Steroid 21-Hydroxylase\n3477: Polymorphism of pregnenolone acetate\n3478: Design, synthesis, antiproliferative activity, estrogen receptors binding affinity of C-3 pregnenolone-dihydropyrimidine derivatives for the treatment of breast cancer\n3479: Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? - A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study\n3480: Synthesis and biological evaluation of 17-cyanopyridine derivatives of pregnenolone as potential anti-prostate cancer agents\n3481: Pregnenolone sulfate enhances post-training memory processes when injected in very low doses into limbic system structures: the amygdala is by far the most sensitive\n3482: Pregnenolone sulfate antagonizes barbiturate-induced hypnosis\n3483: Pregnenolone, dehydroepiandrosterone, and their sulfate and fatty acid esters in the rat brain\n3484: Synthesis, Aromatase Inhibitory, Antiproliferative and Molecular Modeling Studies of Functionally Diverse D-Ring Pregnenolone Pyrazoles\n3485: Pregnenolone in the treatment of rheumatoid arthritis\n3486: Pregnenolone in the treatment of rheumatoid arthritis\n3487: [Pregnenolone, pregnenolone sulfate]\n3488: Further observations on the use of pregnenolone in rheumatoid arthritis\n3489: 3\u03b2-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders\n3490: Acetoxypregnenolone\n3491: Rescuing tri-heteromeric NMDA receptor function: the potential of pregnenolone-sulfate in loss-of-function GRIN2B variants\n3492: Synthetic pregnenolone derivatives as antiviral agents against acyclovir-resistant isolates of Herpes Simplex Virus Type 1\n3493: Pregnenolone sulfate antagonizes dizocilpine amnesia: role for allopregnanolone\n3495: Studies with pregnenolone. 1. Nitrogen and electrolyte balance\n3497: The Fungus Trichoderma Regulates Submerged Conidiation Using the Steroid Pregnenolone\n3499: Why pregnenolone and progesterone, two structurally similar steroids, exhibit remarkably different cocrystallization with aromatic molecules\n3501: Influence of pregnenolone-16-alpha-carbonitrile on spermatogenesis and on the spermatogenic activity of pregnenolone\n3503: Assessment of pregnenolone effects on alcohol intake and preference in male alcohol preferring (P) rats\n3505: Aethiopinolones A-E, New Pregnenolone Type Steroids from the East African Basidiomycete Fomitiporia aethiopica\n3507: Intradermal pregnenolone sulfate attenuates capsaicin-induced nociception in rats\n3509: Advances in steroid research from the pioneering neurosteroid concept to metabolomics: New insights into pregnenolone function\n3511: Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity\n3512: Synthesis of [3\u03b1-(3) H] 17\u03b1-hydroxy pregnenolone and [3\u03b1-(3) H] pregnenolone\n3515: Synthesis, 17\u03b1-hydroxylase-C17,20-lyase Inhibitory and 5AR Reductase Activity of Novel Pregnenolone Derivatives\n3517: Pregnenolone and pregnenolone sulfate metabolism in vivo and uterine extraction at midgestation\n3518: The effect of pregnenolone sulfate on uterine contractility\n3521: Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy?\n3526: Treatment of experimental spinal cord injury with 3\u03b2-methoxy-pregnenolone\n3528: Quantum-Mechanical/Molecular-Mechanical Studies of CYP11A1-Catalyzed Biosynthesis of Pregnenolone from Cholesterol Reveal a C-C Bond Cleavage Reaction That Occurs by a Compound I-Mediated Electron Transfer\n3531: Conversion of 20-alpha-hydroxycholesterol to pregnenolone\n3532: Precise and accurate assay of pregnenolone and five other neurosteroids in monkey brain tissue by LC-MS/MS\n3533: Pregnenolone metabolism in Y-1 mouse adrenal cells: HPLC analysis and identification of metabolites by gas chromatography-mass spectrometry\n3534: Brief report: an open-label study of the neurosteroid pregnenolone in adults with autism spectrum disorder\n3535: Pregnenolone therapy in uveitis\n3536: The use of delta 5-pregnenolone in various clinical disorders\n3537: ACTH, cortisone and pregnenolone in arthritis and allied diseases\n3538: Assessing the Inhibitory Potential of Pregnenolone Sulfate on Pentraxin 3 in Diabetic Kidney Disease: A Molecular Docking and Simulation Study\n3539: Synthesis, pharmacological evaluation and Molecular modelling studies of pregnenolone derivatives as inhibitors of human dihydrofolate reductase\n3540: The addition of a pregnenolone pendant group enhances the anticancer properties of titanocene dichloride in a mcf-7 xenograft model\n3541: Measurement of testosterone and pregnenolone in nails using gas chromatography-mass spectrometry\n3542: [Pregnenolone in male sterility caused by oligospermia]\n3543: A new pregnenolone analogues as privileged scaffolds in inhibition of CYP17 hydroxylase enzyme. Synthesis and in silico molecular docking study\n3544: A role for picomolar concentrations of pregnenolone sulfate in synaptic activity-dependent Ca2+ signaling and CREB activation\n3545: Synthesis of 16\u03b1-amino-pregnenolone derivatives via ionic liquid-catalyzed aza-Michael addition and their evaluation as C17,20-lyase inhibitors\n3546: Luteinizing hormone receptor mediates neuronal pregnenolone production via up-regulation of steroidogenic acute regulatory protein expression\n3547: Effects of a neurosteroid, pregnenolone, during the neonatal period on adenosine A1 receptor, dopamine metabolites in the fronto-parietal cortex and behavioral response in the open field\n3548: Novel lipoidal derivatives of pregnenolone and dehydroepiandrosterone and absence of their sulfated counterparts in rodent brain\n3549: Inhibition by pregnenolone sulphate, a metabolite of the neurosteroid pregnenolone, of voltage-gated sodium channels expressed in Xenopus oocytes\n3550: Pregnenolone metabolism in mammary carcinoma\n3551: Synthesis and biological evaluation of heterocyclic analogues of pregnenolone as novel anti-osteoporotic agents\n3552: Radioimmunoassay of serum and ovarian pregnenolone in immature rats\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug61_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"GHK-Cu\" (also known as \"ghk-cu\"), here are the article headings along with their IDs:\n3494: Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data\n3496: Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application\n3498: Phenothiazine-Based Cu(II)-Selective Fluorescent Sensor: GHK-Cu Sensing Applications\n3500: Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex-vivo skin tests\n3502: GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis\n3504: Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways\n3506: The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health\n3508: Electrophoretic deposition of GHK-Cu loaded MSN-chitosan coatings with pH-responsive release of copper and its bioactivity\n3510: The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice\n3513: Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?\n3514: Enhanced biological properties of collagen/chitosan-coated poly(\u03b5-caprolactone) scaffold by surface modification with GHK-Cu peptide and 58S bioglass\n3516: Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction\n3519: Efficient Ternary Polymer Solar Cells with Tunable Crystallinity and Phase Separation of Active Layers via Incorporating GHK-Cu\n3522: In Vitro and in Vivo Studies of pH-Sensitive GHK-Cu-Incorporated Polyaspartic and Polyacrylic Acid Superabsorbent Polymer\n3525: Polyaspartic acid, 2-acrylamido-2-Methyl propane sulfonic acid and sodium alginate based biocompatible stimuli responsive polymer gel for controlled release of GHK-Cu peptide for wound healing\n3527: Novel Applications of CE-ICP-MS/MS: Monitoring of Antiaging GHK-Cu Cosmetic Component Encapsulation in Liposomes\n3530: In vitro evaluation of compression-coated glycyl-L-histidyl-L-lysine-Cu(II) (GHK-Cu2+)-loaded microparticles for colonic drug delivery\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug62_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"DMHA\" (also known as \"dmha\"), here are the article headings along with their IDs:\n3520: A novel amidohydrolase (DmhA) from Sphingomonas sp. that can hydrolyze the organophosphorus pesticide dimethoate to dimethoate carboxylic acid and methylamine\n3523: Elucidating the formation of 6-deoxyheptose: biochemical characterization of the GDP-D-glycero-d-manno-heptose C6 dehydratase, DmhA, and its associated C4 reductase, DmhB\n3524: Wild-type p53 protein potentiates phototoxicity of 2-BA-2-DMHA in HT29 cells expressing endogenous mutant p53\n3529: A novel photosensitizer, 2-butylamino-2-demethoxy-hypocrellin A (2-BA-2-DMHA). 1. Synthesis of 2-BA-2-DMHA and its phototoxicity to MGC803 cells\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug64_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Sunifiram\" (also known as \"sunifiram\"), here are the article headings along with their IDs:\n3553: Novel Sunifiram-carbamate hybrids as potential dual acetylcholinesterase inhibitor and NMDAR co-agonist: simulation-guided analogue design and pharmacological screening\n3554: Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers\n3555: DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer\n3556: Novel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice\n3557: Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine-binding site of N-methyl-D-aspartate receptor\n3558: Design, synthesis and nootropic activity of new analogues of sunifiram and sapunifiram, two potent cognition-enhancers\n3559: Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators\n3561: Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs\n3563: AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram)\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug65_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Kisspeptin-10\" (also known as \"kisspeptin-10\"), here are the article headings along with their IDs:\n3560: Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src\n3562: Kisspeptin-10 increases collagen content in the myocardium by focal adhesion kinase activity\n3564: Kisspeptin-10 in cryodiluent improves the post-thaw quality of Nili-Ravi buffalo (Bubalus bubalis) bull spermatozoa\n3565: Kisspeptin-10 and gonadotropin inhibiting hormone during pregnancy in dairy cows\n3566: Kisspeptin-10 Rescues Cholinergic Differentiated SHSY-5Y Cells from \u03b1-Synuclein-Induced Toxicity In Vitro\n3567: Kisspeptin-10 Promotes Progesterone Synthesis in Bovine Ovarian Granulosa Cells via Downregulation of microRNA-1246\n3568: Intraperitoneal kisspeptin-10 administration ameliorates sodium arsenite-induced reproductive toxicity in adult male mice\n3569: Kisspeptin-10 Mitigates \u03b1-Synuclein-Mediated Mitochondrial Apoptosis in SH-SY5Y-Derived Neurons via a Kisspeptin Receptor-Independent Manner\n3570: Kisspeptin-10 inhibits OHSS by suppressing VEGF secretion\n3571: Intraperitoneal administration of mouse kisspeptin-10 to mice during estrus stage induces pseudopregnancy\n3572: Kisspeptin-10 (KP-10) stimulates osteoblast differentiation through GPR54-mediated regulation of BMP2 expression and activation\n3573: Role of kisspeptin-10 and betacellulin in control of feline ovarian cell functions\n3574: Effects of kisspeptin-10 on the reproductive performance of sows in a fixed-time artificial insemination programme\n3575: Kisspeptin-10 Maintains the Activation of the mTOR Signaling Pathway by Inhibiting SIRT6 to Promote the Synthesis of Milk in Bovine Mammary Epithelial Cells\n3576: Provocative tests with Kisspeptin-10 and GnRH set the scene for determining social status and environmental impacts on reproductive capacity in male African lions (Panthera leo)\n3577: A kisspeptin-10 analog with greater in vivo bioactivity than kisspeptin-10\n3578: Level of kisspeptin-10 in patients with multiple sclerosis and the association between third ventricle diameter size and vitamin D level\n3579: The effects of kisspeptin-10 on serum metabolism and myocardium in rats\n3580: Effects of Kisspeptin-10 on Hypothalamic Neuropeptides and Neurotransmitters Involved in Appetite Control\n3581: Kisspeptin-10 inhibits the migration of breast cancer cells by regulating epithelial-mesenchymal transition\n3582: Kisspeptin-10 treatment generated specific GnRH expression in cells differentiated from rhesus monkey derived Lyon NSCs\n3583: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men\n3584: Correlation of Kisspeptin-10 level and fetal well-being in preeclamptic patients\n3585: Kisspeptin-10 potentiates miniature excitatory postsynaptic currents in the rat supraoptic nucleus\n3586: Dose-Dependent Degeneration of Leydig Cells Following Kisspeptin-10 Administration: An Ultrastructural Study\n3587: Kisspeptin-10 induces endothelial cellular senescence and impaired endothelial cell growth\n3588: Kisspeptin-10 Improves Testicular Redox Status but Does Not Alter the Unfolded Protein Response (UPR) That Is Downregulated by Hypothyroidism in a Rat Model\n3589: Maternal plasma kisspeptin-10 level in preeclamptic pregnant women and its relation in changing their reproductive hormones\n3590: Effect of Kisspeptin-10 on plasma luteinizing hormone concentrations and follicular dynamics during the luteal phase in cattle\n3591: The effect of Kisspeptin-10 on mesenchymal stem cells migration in vitro and in vivo\n3592: Kisspeptin-10 stimulation of gonadotrophin secretion in women is modulated by sex steroid feedback\n3593: Kisspeptin-10 inhibits cell migration in vitro via a receptor-GSK3 beta-FAK feedback loop in HTR8SVneo cells\n3596: The vasoactive potential of kisspeptin-10 in the peripheral vasculature\n3598: Kisspeptin-10 enhanced egg production in quails associated with the increase of triglyceride synthesis in liver\n3599: Kisspeptin-10 inhibits proliferation and regulates lipolysis and lipogenesis processes in 3T3-L1 cells and isolated rat adipocytes\n3600: Kisspeptin-10 inhibits stromal-derived factor 1-induced invasion of human endometrial cancer cells\n3603: The effects of kisspeptin-10 on migration and proliferation of endothelial cell\n3604: Gametogenic and steroidogenic action of kisspeptin-10 in the Asian catfish, Clarias batrachus: Putative underlying mechanistic cascade\n3607: What is the protective effect of preischemic kisspeptin-10 administration against ischemia/reperfusion injury of striatum on mice?\n3609: Kisspeptin-10 stimulates the secretion of growth hormone and prolactin directly from cultured bovine anterior pituitary cells\n3610: Kisspeptin-10 and the G protein-coupled receptor 54 are differentially expressed in the canine pregnant uterus and trophoblast cells\n3612: Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men\n3614: Effects of kisspeptin-10 on progesterone secretion in cultured chicken ovarian granulosa cells from preovulatory (F1-F3) follicles\n3616: Potent Vasoconstrictor Kisspeptin-10 Induces Atherosclerotic Plaque Progression and Instability: Reversal by its Receptor GPR54 Antagonist\n3618: Kisspeptin 10 inhibits the Warburg effect in breast cancer through the Smad signaling pathway: both in vitro and in vivo\n3620: The antidepressant-like effects of kisspeptin-10 are reversed by kisspeptin antagonist peptide 234 in male rats\n3622: Kisspeptin-10 inhibits angiogenesis in human placental vessels ex vivo and endothelial cells in vitro\n3624: Kisspeptin-10 Induces \u03b2-Casein Synthesis via GPR54 and Its Downstream Signaling Pathways in Bovine Mammary Epithelial Cells\n3626: Effects of kisspeptin-10 on lipid metabolism in cultured chicken hepatocytes\n3628: Kisspeptin-10 inhibits bone-directed migration of GPR54-positive breast cancer cells: Evidence for a dose-window effect\n3630: Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation\n3632: Effects of kisspeptin-10 on in vitro proliferation and kisspeptin receptor expression in primary epithelial cell cultures isolated from bovine placental cotyledons of fetuses at the first trimester of pregnancy\n3634: Intraperitoneal administration of kisspeptin-10 modulates follicle maturation, gonadal steroids, calcium and metabolites in Sterlet sturgeon, Acipenser ruthenus\n3636: The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans\n3638: Ameliorating effect of kisspeptin-10 on methotrexate-induced sperm damages and testicular oxidative stress in rats\n3640: Intraperitoneal kisspeptin-10 administration induces dose-dependent degenerative changes in maturing rat testes\n3642: Age-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men\n3645: Direct kisspeptin-10 stimulation on luteinizing hormone secretion from bovine and porcine anterior pituitary cells\n3646: The effect of oxytocin and Kisspeptin-10 in ovary and uterus of ischemia-reperfusion injured rats\n3648: Kisspeptin-10-induced signaling of GPR54 negatively regulates chemotactic responses mediated by CXCR4: a potential mechanism for the metastasis suppressor activity of kisspeptins\n3651: Inhibition of SDF-1/CXCR4-induced epithelial-mesenchymal transition by kisspeptin-10\n3653: Kisspeptin-10 induces dose dependent degeneration in prepubertal rat prostate gland\n3655: Kisspeptin-10 stimulates the release of luteinizing hormone and testosterone in pre- and post-pubertal male goats\n3657: Effect of kisspeptin-10, LH and hCG on serum testosterone concentrations in stallions, donkeys and mules\n3658: Author Correction: Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src\n3661: Kisspeptin-10 facilitates a plasma membrane-driven calcium oscillator in gonadotropin-releasing hormone-1 neurons\n3662: Cross-Linking Furan-Modified Kisspeptin-10 to the KISS Receptor\n3666: Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts\n3670: Central and peripheral administration of kisspeptin-10 stimulates the hypothalamic-pituitary-gonadal axis\n3673: CHANGES IN IRISIN RELEASE IN RESPONSE TO PERIPHERAL KISSPEPTIN-10 ADMINISTRATION IN HEALTHY AND OBESE ADULT MEN\n3677: Investigation of the effects of kisspeptin-10 in methionine-induced lipid peroxidation in testicle tissue of young rats\n3680: Kisspeptin-10 modulates the proliferation and differentiation of the rhesus monkey derived stem cell line: R366.4\n3682: Molecular characterization of kisspeptin gene and effect of nano-encapsulted kisspeptin-10 on reproductive maturation in Catla catla\n3685: Kisspeptin-10 elicits triphasic cytosolic calcium responses in immortalized GT1-7 GnRH neurones\n3688: Luteal activity of Abadeh ecotype does in summer and winter and the effect of kisspeptin-10 on luteinizing hormone secretion in the anestrus does\n3692: Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea\n3695: Postacute effects of kisspeptin-10 on neuronal injury induced by L-methionine in rats\n3698: Effects of repeated injection of kisspeptin-10 on the initiation of egg-laying in juvenile quail\n3700: Effects of kisspeptin-10 on the electrophysiological manifestation of gonadotropin-releasing hormone pulse generator activity in the female rat\n3705: Central administration of kisspeptin-10 inhibits natriuresis and diuresis induced by blood volume expansion in anesthetized male rats\n3709: Association of kisspeptin-10 levels with abortus imminens: a preliminary study\n3711: Central administration of kisspeptin-10 inhibits water and sodium excretion of anesthetized male rats and the involvement of arginine vasopressin\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug67_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"MGF\" (also known as \"mgf\"), here are the article headings along with their IDs:\n3594: MgF2:Mn2+: novel material with mechanically-induced luminescence\n3595: African swine fever virus MGF-360-10L is a novel and crucial virulence factor that mediates ubiquitination and degradation of JAK1 by recruiting the E3 ubiquitin ligase HERC5\n3597: Mechanochemical coupling of MGF mediates periodontal regeneration\n3601: MGF-19E peptide promoted proliferation, differentiation and mineralization of MC3T3-E1 cell and promoted bone defect healing\n3602: African Swine Fever Virus MGF-505-7R Negatively Regulates cGAS-STING-Mediated Signaling Pathway\n3605: MgF2- containing glasses as a coating for titanium dental implant. I- Glass powder\n3606: Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting\n3608: MGF E peptide improves anterior cruciate ligament repair by inhibiting hypoxia-induced cell apoptosis and accelerating angiogenesis\n3611: MGF-net: Multi-channel group fusion enhancing boundary attention for polyp segmentation\n3613: Mid-infrared ChG-on-MgF2waveguide gas sensor based on wavelength modulation spectroscopy\n3615: Green nanotechnology of MGF-AuNPs for immunomodulatory intervention in prostate cancer therapy\n3617: Involvement of the MGF 110-11L Gene in the African Swine Fever Replication and Virulence\n3619: Mechanically induced photons from ultraviolet-C to near-infrared in Tm3+-doped MgF2\n3621: African swine fever virus protein MGF-505-7R promotes virulence and pathogenesis by inhibiting JAK1- and JAK2-mediated signaling\n3623: MGF enhances tenocyte invasion through MMP-2 activity via the FAK-ERK1/2 pathway\n3625: A Novel PLLA/MgF2Coating on Mg Alloy by Ultrasonic Atomization Spraying for Controlling Degradation and Improving Biocompatibility\n3627: MGF E peptide pretreatment improves the proliferation and osteogenic differentiation of BMSCs via MEK-ERK1/2 and PI3K-Akt pathway under severe hypoxia\n3629: A Ca-deficientca-deficient hydroxyapatite (CDHA)/MgF2bi-layer coating with unique nano-scale topography on biodegradable high-purity Mg\n3631: Bioinspired Near-Full Transmittance MgF2Window for Infrared Detection in Extremely Complex Environments\n3633: Optimization of MgF2-deposition temperature for far UV Al mirrors\n3635: An amorphous MgF2anti-reflective thin film for enhanced performance of inverted organic-inorganic perovskite solar cells\n3637: Extrusion-based 3D printed magnesium scaffolds with multifunctional MgF2and MgF2-CaP coatings\n3639: Identification of Two Linear Epitopes on MGF_110-13L Protein of African Swine Fever Virus with Monoclonal Antibodies\n3641: Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations\n3643: Fabrication of an ultra-high quality MgF2micro-resonator for a single soliton comb generation\n3644: Rational design of MgF2catalysts with long-term stability for the dehydrofluorination of 1,1-difluoroethane (HFC-152a)\n3647: In vitro investigation of growth factors including MGF and IGF-1 in neural stem cell activation, proliferation, and migration\n3649: MGF E peptide pretreatment improves collagen synthesis and cell proliferation of injured human ACL fibroblasts via MEK-ERK1/2 signaling pathway\n3650: The Effects of IGF1 and MGF on Neural Stem Cells in Hypoxic Conditions\n3652: Entanglementviarotational blockade of MgF molecules in a magic potential\n3654: Hyperfine-resolved optical spectroscopy of the A2\u03a0 \u2190 X2\u03a3+transition in MgF\n3656: Impaired Skeletal Muscle Regeneration Induced by Macrophage Depletion Could Be Partly Ameliorated by MGF Injection\n3659: Evaluation of the performance of Ca-deficient hydroxyapatite (CDHA)/MgF2bilayer coating on biodegradable high-purity magnesium in a femoral condyle defect model in rabbits\n3660: Improved green thermal activated delayed fluorescence OLEDs based on thermally evaporated distributed Bragg reflector (DBR) of MgF2/ZnS\n3663: Sustained delivery of MGF peptide from microrods attracts stem cells and reduces apoptosis of myocytes\n3665: MGF-Based Mutual Approximation of Hybrid Fading: Performance of Wireless/Power Line Relaying Communication for IoT\n3668: MGF- and myostatin-mRNA regulation in masseter muscle after orthognathic surgery\n3671: An in vitro and in vivo comparison of Mg(OH)2-, MgF2- and HA-coated Mg in degradation and osteointegration\n3674: The MGF expression of osteoblasts in response to mechanical overload\n3676: Fabrication of Metal-Insulator-Metal Nanostructures Composed of Au-MgF2-Au and Its Potential in Responding to Two Different Factors in Sample Solutions Using Individual Plasmon Modes\n3678: Hollow Rodlike MgF2with an Ultralow Refractive Index for the Preparation of Multifunctional Antireflective Coatings\n3681: Generation and Genetic Stability of a PolX and 5' MGF-Deficient African Swine Fever Virus Mutant for Vaccine Development\n3684: A Dendrite-Free Lithium-Metal Anode Enabled by Designed Ultrathin MgF2Nanosheets Encapsulated Inside Nitrogen-Doped Graphene-Like Hollow Nanospheres\n3686: Effects of MgF2anti-reflection coating on optical losses in metal halide perovskite solar cells\n3689: Mechano growth factor (MGF) and transforming growth factor (TGF)-\u03b23 functionalized silk scaffolds enhance articular hyaline cartilage regeneration in rabbit model\n3691: Analysis of ZnS and MgF2layered nanostructures grown by glancing angle deposition for optical design\n3694: Mechano growth factor (MGF) promotes proliferation and inhibits differentiation of porcine satellite cells (PSCs) by down-regulation of key myogenic transcriptional factors\n3696: MgF2nanoparticle-coated teeth inhibit Streptococcus mutans biofilm formation on a tooth model\n3701: Effect of enhanced masticatory force on OPG, RANKL and MGF in alveolar bone of ovariectomized rats\n3703: Stabilizing Lithium-Metal Host Anodes by Covalently Binding MgF2Nanodots to Honeycomb Carbon Nanofibers\n3706: Calcination-Controlled Synthesis of Carbon Dots@MgF2Composites with Yellow, White, and Ultraviolet-Blue Thermally Activated Delayed Fluorescence for Multilevel Information Encryption\n3708: A tailored ratiometric fluorescent sensor based on CdTe and MgF2quantum dots for trace N-ethylpentylone detection\n3712: Stable Zn Metal Anodes with Limited Zn-Doping in MgF2Interphase for Fast and Uniformly Ionic Flux\n3713: The nuclear localization of MGF receptor in osteoblasts under mechanical stimulation\n3714: Effect of porosity on thickness uniformity of MgF2films on spherical substrates\n3715: The Effects of Various Parameters of the Microwave-Assisted Solvothermal Synthesis on the Specific Surface Area and Catalytic Performance of MgF2Nanoparticles\n3716: MgF(2)-Ag tunable reflection retarder\n3717: Milk growth factor (MGF)-induced differentiation of NT2/D1 cells\n3718: ERK1/2 and Akt phosphorylation were essential for MGF E peptide regulating cell morphology and mobility but not proangiogenic capacity of BMSCs under severe hypoxia\n3719: Producing human mechano growth factor (MGF) in Escherichia coli\n3720: A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia\n3721: Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response\n3722: Characterization and identification of a C-terminal amidated mechano growth factor (MGF) analogue in black market products\n3723: IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro\n3724: Terahertz dual-band metamaterial absorber based on graphene/MgF(2) multilayer structures\n3725: Insulinlike growth factor-1Ec (MGF) expression in eutopic and ectopic endometrium: characterization of the MGF E-peptide actions in vitro\n3726: Analysis of melanocyte precursors in Nf1 mutants reveals that MGF/KIT signaling promotes directed cell migration independent of its function in cell survival\n3727: Atomic details of near-transition state conformers for enzyme phosphoryl transfer revealed by MgF-3 rather than by phosphoranes\n3728: High Pressure-Temperature Study of MgF2, CaF2, and BaF2by Raman Spectroscopy: Phase Transitions and Vibrational Properties of AF2Difluorides\n3729: In vitro and in vivo corrosion, mechanical properties and biocompatibility evaluation of MgF2-coated Mg-Zn-Zr alloy as cancellous screws\n3730: Determination of the normal A2\u03a0 state in MgF with application to direct laser cooling of molecules\n3731: Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity\n3732: In vitro cytocompatibility evaluation of MGF-Ct24E chemically grafted and physically blended with maleic anhydride modified poly(D, L-lactic acid)\n3733: Efficient cw optically pumped Ni:MgF(2) laser\n3734: A missense mutation in the bovine MGF gene is associated with the roan phenotype in Belgian Blue and Shorthorn cattle\n3735: Reflectance of Aluminum Overcoated with MgF(2) and LiF in the Wavelength Region from 1600 A to 300 A at Various Angles of Incidence\n3736: Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription\n3737: Mangiferin functionalized radioactive gold nanoparticles (MGF-198AuNPs) in prostate tumor therapy: green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug69_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"KPV\" (also known as \"kpv\"), here are the article headings along with their IDs:\n3664: A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon\n3667: KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy\n3669: Self-Cross-Linked Hydrogel of Cysteamine-Grafted \u03b3-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats\n3672: In situmucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis\n3675: Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis\n3679: Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin\n3683: Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates\n3687: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation\n3690: Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease\n3693: Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides\n3697: Structural modification of the tripeptide KPV by reductive \"glycoalkylation\" of the lysine residue\n3699: alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells\n3702: Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists\n3704: Inhibitory effects of the peptide (CKPV)2 on endotoxin-induced host reactions\n3707: Three-dimensional structure of the alpha-MSH-derived candidacidal peptide [Ac-CKPV]2\n3710: Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug70_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"7,8-dihydroxyflavone\" (also known as \"7,8-dihydroxyflavone\"), here are the article headings along with their IDs:\n3738: 7,8-Dihydroxyflavone modulates bone formation and resorption and ameliorates ovariectomy-induced osteoporosis\n3739: 7,8-Dihydroxyflavone and Neuropsychiatric Disorders: A Translational Perspective from the Mechanism to Drug Development\n3741: Suggesting 7,8-dihydroxyflavone as a promising nutraceutical against CNS disorders\n3743: 7,8-Dihydroxyflavone attenuates the virulence of Staphylococcus aureus by inhibiting alpha-hemolysin\n3745: Treatment with the flavonoid 7,8-Dihydroxyflavone: a promising strategy for a constellation of body and brain disorders\n3747: 7,8-Dihydroxyflavone alleviates Endoplasmic Reticulum Stress in cafeteria diet-induced metabolic syndrome\n3749: 7,8-Dihydroxyflavone as a pro-neurotrophic treatment for neurodevelopmental disorders\n3751: 7,8-Dihydroxyflavone alleviates cardiac fibrosis by restoring circadian signals via downregulating Bmal1/Akt pathway\n3753: 7,8-Dihydroxyflavone suppresses proliferation and induces apoptosis of human osteosarcoma cells\n3754: 7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders\n3757: 7,8-dihydroxyflavone enhances long-term spatial memory and alters brain volume in wildtype mice\n3759: 7,8-Dihydroxyflavone protects neurons against oxygen-glucose deprivation induced apoptosis and activates the TrkB/Akt pathway\n3760: 7,8-Dihydroxyflavone Enhanced Colonic Cholinergic Contraction and Relieved Loperamide-Induced Constipation in Rats\n3762: 7,8-Dihydroxyflavone Protects High Glucose-Damaged Neuronal Cells against Oxidative Stress\n3765: 7,8-Dihydroxyflavone activates Nrf2/HO-1 signaling pathways and protects against osteoarthritis\n3767: 7,8-Dihydroxyflavone induces mitochondrial apoptosis and down-regulates the expression of ganglioside GD3 in malignant melanoma cells\n3769: Utility of 7,8-dihydroxyflavone in preventing astrocytic and synaptic deficits in the hippocampus elicited by PTSD\n3772: 7,8-Dihydroxyflavone Attenuates Inflammatory Response and Insulin Resistance Induced by the Paracrine Interaction between Adipocytes and Macrophages\n3774: 7,8-Dihydroxyflavone ameliorates mitochondrial impairment and motor dysfunction in the \u03b1-synuclein 1-103 transgenic mice\n3775: 7,8-Dihydroxyflavone is a direct inhibitor of human and murine pyridoxal phosphatase\n3777: BDNF mimetic 7,8-dihydroxyflavone rescues rotenone-induced cytotoxicity in cardiomyocytes by ameliorating mitochondrial dysfunction\n3780: 7,8-Dihydroxyflavone Protects Nigrostriatal Dopaminergic Neurons from Rotenone-Induced Neurotoxicity in Rodents\n3784: Small-molecule 7,8-dihydroxyflavone counteracts compensated and decompensated cardiac hypertrophy via AMPK activation\n3786: 7,8-dihydroxyflavone-functionalized gold nanoparticles target the arginase enzyme ofLeishmania donovani\n3788: 7,8-Dihydroxyflavone protects retinal ganglion cells against chronic intermittent hypoxia-induced oxidative stress damage via activation of the BDNF/TrkB signaling pathway\n3792: Low-dose 7,8-Dihydroxyflavone Administration After Status Epilepticus Prevents Epilepsy Development\n3793: 7,8-Dihydroxyflavone Simultaneously Provides Neuroprotection of Retinal Explants and Proangiogenesis of Human Umbilical Vein Endothelial Cells via the Tropomyosin-Related Kinase Receptor B Signaling PathwayIn Vitro\n3795: 7,8-dihydroxyflavone ameliorates motor deficits via regulating autophagy in MPTP-induced mouse model of Parkinson's disease\n3798: The TrkB agonist, 7,8-dihydroxyflavone, impairs fracture healing in mice\n3799: 7,8-Dihydroxyflavone Alleviates Anxiety-Like Behavior Induced by Chronic Alcohol Exposure in Mice Involving Tropomyosin-Related Kinase B in the Amygdala\n3802: 7,8-Dihydroxyflavone potentiates ongoing epileptiform activity in mice brain slices\n3804: 7,8-Dihydroxyflavone Enhances Cue-Conditioned Alcohol Reinstatement in Rats\n3806: Baicalein, 7,8-Dihydroxyflavone and Myricetin as Potent Inhibitors of Human Ornithine Decarboxylase\n3809: 7,8-Dihydroxyflavone improves cognitive functions in ICV-STZ rat model of sporadic Alzheimer's disease by reversing oxidative stress, mitochondrial dysfunction, and insulin resistance\n3811: 7,8-dihydroxyflavone ameliorates scopolamine-induced Alzheimer-like pathologic dysfunction\n3813: 7,8-Dihydroxyflavone accelerates recovery of Brown-Sequard syndrome in adult female rats with spinal cord lateral hemisection\n3816: 7,8-Dihydroxyflavone alleviates apoptosis and inflammation induced by retinal ischemia-reperfusion injury via activating TrkB/Akt/NF-kB signaling pathway\n3818: Effects of 7,8-dihydroxyflavone on rat jejunal dynamics subjected to ischaemia-reperfusion injury\n3820: 7,8-Dihydroxyflavone reverses the depressive symptoms in mouse chronic mild stress\n3822: 7, 8-dihydroxyflavone Ameliorates Cholinergic Dysfunction, Inflammation, Oxidative Stress, and Apoptosis in a Rat Model of Vascular Dementia\n3825: 7,8-Dihydroxyflavone Attenuates Alcohol-Related Behavior in Rat Models of Alcohol Consumption via TrkB in the Ventral Tegmental Area\n3827: Effects of 7,8-Dihydroxyflavone on Lipid Isoprenoid and Rho Protein Levels in Brains of Aged C57BL/6 Mice\n3828: 7, 8-Dihydroxyflavone Protects an Endothelial Cell Line from H2O2 Damage\n3830: Investigating 7,8-Dihydroxyflavone to combat maternal immune activation effects on offspring gene expression and behaviour\n3831: 7,8-Dihydroxyflavone inhibits adipocyte differentiation via antioxidant activity and induces apoptosis in 3T3-L1 preadipocyte cells\n3833: 7,8-Dihydroxyflavone Ameliorates Cognitive Impairment by Inhibiting Expression of Tau Pathology in ApoE-Knockout Mice\n3836: Early 7,8-Dihydroxyflavone Administration Ameliorates Synaptic and Behavioral Deficits in the Young FXS Animal Model by Acting on BDNF-TrkB Pathway\n3838: 7,8-dihydroxyflavone enhanced cholinergic contraction of rat gastric smooth muscle via augmenting muscarinic M3 receptor expression\n3839: The TrkB agonist 7,8-dihydroxyflavone improves sensory-motor performance and reduces lipid peroxidation in old mice\n3841: 7,8-dihydroxyflavone protects PC12 cells against 6-hydroxydopamine-induced cell death through modulating PI3K/Akt and JNK pathways\n3843: 7,8-Dihydroxyflavone facilitates the action exercise to restore plasticity and functionality: Implications for early brain trauma recovery\n3845: 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease\n3847: 7,8-Dihydroxyflavone improves neuropathological changes in the brain of Tg26 mice, a model for HIV-associated neurocognitive disorder\n3849: 7,8-dihydroxyflavone protects 6-OHDA and MPTP induced dopaminergic neurons degeneration through activation of TrkB in rodents\n3851: 7,8-Dihydroxyflavone improves memory consolidation processes in rats and mice\n3853: 7,8-Dihydroxyflavone attenuates TNF-\u03b1-induced skin aging in Hs68 human dermal fibroblast cells via down-regulation of the MAPKs/Akt signaling pathways\n3856: Impact of dietary plant flavonoids on 7,8-dihydroxyflavone transepithelial transport in human intestinal Caco-2 cells\n3860: 7, 8-Dihydroxyflavone, a TrkB receptor agonist, provides minimal protection against retinal vascular damage during oxygen-induced ischemic retinopathy\n3864: 7,8-Dihydroxyflavone leads to survival of cultured embryonic motoneurons by activating intracellular signaling pathways\n3866: 7,8-dihydroxyflavone rescues spatial memory and synaptic plasticity in cognitively impaired aged rats\n3870: TrkB Receptor Agonist 7,8 Dihydroxyflavone is Protective Against the Inner Retinal Deficits Induced by Experimental Glaucoma\n3871: 7,8-Dihydroxyflavone, a TrkB agonist, attenuates behavioral abnormalities and neurotoxicity in mice after administration of methamphetamine\n3875: 7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington's disease mouse model through specific activation of the PLC\u03b31 pathway\n3878: 7,8-Dihydroxyflavone blocks the development of behavioral sensitization to MDPV, but not to cocaine: Differential role of the BDNF-TrkB pathway\n3881: 7,8-dihydroxyflavone, a small-molecule tropomyosin-related kinase B (TrkB) agonist, attenuates cerebral ischemia and reperfusion injury in rats\n3882: 7,8-Dihydroxyflavone, a Tropomyosin-Kinase Related Receptor B Agonist, Produces Fast-Onset Antidepressant-Like Effects in Rats Exposed to Chronic Mild Stress\n3885: The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease\n3888: 7, 8-Dihydroxyflavone induces synapse expression of AMPA GluA1 and ameliorates cognitive and spine abnormalities in a mouse model of fragile X syndrome\n3891: 7,8-Dihydroxyflavone ameliorates cognitive impairment induced by repeated neonatal sevoflurane exposures in mice through increasing tau O-GlcNAcylation\n3894: Methylation and subsequent glycosylation of 7,8-dihydroxyflavone\n3897: Vasorelaxing and antihypertensive effects of 7,8-dihydroxyflavone\n3901: 7,8-dihydroxyflavone exhibits therapeutic efficacy in a mouse model of Rett syndrome\n3903: Brain-derived neurotrophic factor mimetic, 7,8-dihydroxyflavone, protects against myocardial ischemia by rebalancing optic atrophy 1 processing\n3907: 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease\n3910: Rescue of Long-Term Spatial Memory by 7,8-Dihydroxyflavone in Mice with Reduced Oligodendrogenesis\n3912: 3D printed elastic hydrogel conduits with 7,8-dihydroxyflavone release for peripheral nerve repair\n3916: Optimized integration of fluoxetine and 7, 8-dihydroxyflavone as an efficient therapy for reversing depressive-like behavior in mice during the perimenopausal period\n3919: Recovery of neurosurgical high-frequency electroporation injury in the canine brain can be accelerated by 7,8-dihydroxyflavone\n3922: Transepithelial transport mechanisms of 7,8-dihydroxyflavone, a small molecular TrkB receptor agonist, in human intestinal Caco-2 cells\n3925: 7,8-dihydroxyflavone, a TrkB receptor agonist, blocks long-term spatial memory impairment caused by immobilization stress in rats\n3929: Neuroprotective Effects of 7, 8-dihydroxyflavone on Midbrain Dopaminergic Neurons in MPP+-treated Monkeys\n3931: Hepatoprotective potential of 7,8-Dihydroxyflavone against alcohol and high-fat diet induced liver toxicity via attenuation of oxido-nitrosative stress and NF-\u03baB activation\n3934: Anticancer activity of 7,8-dihydroxyflavone in melanoma cells via downregulation of \u03b1-MSH/cAMP/MITF pathway\n3937: 7,8-dihydroxyflavone displayed antioxidant effect through activating HO-1 expression and inhibiting caspase-3/PARP activation in RAW264.7 cells\n3941: 7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis\n3945: Antioxidant action of 7,8-dihydroxyflavone protects PC12 cells against 6-hydroxydopamine-induced cytotoxicity\n3947: TrkB agonist 7,8-dihydroxyflavone reverses an induced prepulse inhibition deficit selectively in maternal immune activation offspring: implications for schizophrenia\n3951: 7,8-Dihydroxy Flavone Induces Apoptosis via Upregulation of Caspase-3 in Human Hepatocarcinoma Cell\n3954: Post-injury treatment with 7,8-dihydroxyflavone attenuates white matter pathology in aged mice following focal traumatic brain injury\n3958: 7,8-Dihydroxyflavone attenuates the release of pro-inflammatory mediators and cytokines in lipopolysaccharide-stimulated BV2 microglial cells through the suppression of the NF-\u03baB and MAPK signaling pathways\n3961: Exploring the Molecular Interactions of 7,8-Dihydroxyflavone and Its Derivatives with TrkB and VEGFR2 Proteins\n3964: Metabolic protection by the dietary flavonoid 7,8-dihydroxyflavone requires an intact gut microbiome\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug71_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Myostatin\" (also known as \"myostatin\"), here are the article headings along with their IDs:\n3740: Myostatin and the Heart\n3742: Myostatin: Basic biology to clinical application\n3744: Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs\n3746: Metformin induces muscle atrophy by transcriptional regulation of myostatin via HDAC6 and FoxO3a\n3748: Myostatin: expanding horizons\n3750: Myostatin's marvels: From muscle regulator to diverse implications in health and disease\n3752: Myostatin: a multifunctional role in human female reproduction and fertility - a short review\n3755: Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases\n3756: Serum Myostatin among Excessive Drinkers\n3758: The myostatin gene: an overview of mechanisms of action and its relevance to livestock animals\n3761: Improved Strength Recovery and Reduced Fatigue with Suppressed Plasma Myostatin Following Supplementation of aVicia fabaHydrolysate, in a Healthy Male Population\n3763: The elusive promise of myostatin inhibition for muscular dystrophy\n3764: Myostatin - From the Mighty Mouse to cardiovascular disease and cachexia\n3766: Myostatin--the holy grail for muscle, bone, and fat?\n3768: Molecular basis and therapeutic potential of myostatin on bone formation and metabolism in orthopedic disease\n3770: Myostatin and sarcopenia: opportunities and challenges - a mini-review\n3771: Association of Myostatin Gene Polymorphisms with Strength and Muscle Mass in Athletes: A Systematic Review and Meta-Analysis of the MSTN rs1805086 Mutation\n3773: Myostatin: a novel insight into its role in metabolism, signal pathways, and expression regulation\n3776: Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting\n3778: Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders\n3781: Myostatin as a therapeutic target in Amyotrophic lateral sclerosis\n3782: Similar sequences but dissimilar biological functions of GDF11 and myostatin\n3785: When Less Is More: Targeting theMyostatinGene in Livestock for Augmenting Meat Production\n3787: Caveolin-3 regulates myostatin signaling. Mini-review\n3789: Targeting the myostatin signaling pathway to treat muscle wasting diseases\n3790: Fecal transplant from myostatin deletion pigs positively impacts the gut-muscle axis\n3791: Discovery of a follistatin-derived myostatin inhibitory peptide\n3794: Myostatin: an overlooked player in heart failure?\n3796: Myostatin Mutation Enhances Bovine Myogenic Differentiation through PI3K/AKT/mTOR Signalling via Removing DNA Methylation of RACK1\n3797: Muscular myostatin gene expression and plasma concentrations are decreased in critically ill patients\n3800: Expression and function of myostatin in obesity, diabetes, and exercise adaptation\n3801: Enzymatic Stability of Myostatin Inhibitory 16-mer Peptides\n3803: Effects of Myostatin on Nuclear Morphology at the Myotendinous Junction\n3805: Genetic variants in myostatin and its receptors promote elite athlete status\n3807: Myostatin inhibits porcine intramuscular preadipocyte differentiation in vitro\n3808: Myostatin increases the expression of matrix metalloproteinase genes to promote preadipocytes differentiation in pigs\n3810: Myostatin Deficiency Enhances Antioxidant Capacity of Bovine Muscle via the SMAD-AMPK-G6PD Pathway\n3812: Myostatin Overexpression and Smad Pathway in Detrusor Derived from Pediatric Patients with End-Stage Lower Urinary Tract Dysfunction\n3814: Effects of myostatin gene knockout on porcine extraocular muscles\n3815: The Growth Differentiation Factor 11 (GDF11) and Myostatin (MSTN) in tissue specific aging\n3817: The expression and potential functions of placental myostatin\n3819: Myostatin: Regulator of muscle wasting in heart failure and treatment target for cardiac cachexia\n3821: Myostatin site-directed mutation and simultaneous PPAR\u03b3 site-directed knockin in bovine genome\n3823: Serum myostatin in patients on maintenance haemodialysis: a useful biomarker of muscle wasting?\n3824: Clinical, agricultural, and evolutionary biology of myostatin: a comparative review\n3826: Inactivation of myostatin by photo-oxygenation using catalyst-functionalized peptides\n3829: Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation\n3832: Local myostatin inhibition improves skeletal muscle glucose uptake in insulin-resistant high-fat diet-fed mice\n3834: Muscle and serum myostatin expression in type 1 diabetes\n3835: Generation of myostatin-knockout chickens mediated by D10A-Cas9 nickase\n3837: The central role of myostatin in skeletal muscle and whole body homeostasis\n3840: Myostatin inhibition for treatment of sarcopenia\n3842: INVITED REVIEW: Inhibitors of myostatin as methods of enhancing muscle growth and development\n3844: Myostatin regulates miR-431 expression via the Ras-Mek-Erk signaling pathway\n3846: Myostatin inhibits insulin-like growth factor 1-dependent citrate secretion and osteogenesis via nicotinamide adenine dinucleotide phosphate oxidase-4 in a mouse mesenchymal stem cell line\n3848: Myostatin is localized in extravillous trophoblast and up-regulates migration\n3850: Development of antisense-mediated myostatin knockdown for the treatment of insulin resistance\n3852: Functional replacement of myostatin with GDF-11 in the germline of mice\n3855: Revisiting the paradigm of myostatin in vertebrates: insights from fishes\n3858: Silencing myostatin increases area fraction of smooth muscle in the corpus cavernosum of pigs\n3861: Myostatin serum concentrations are correlated with the severity of knee osteoarthritis\n3863: The Correlation of Serum Myostatin Levels with Gait Speed in Kidney Transplantation Recipients\n3867: Design and synthesis of potent myostatin inhibitory cyclic peptides\n3869: Myostatin-mediated regulation of skeletal muscle damage post-acute Aeromonas hydrophila infection in Nile tilapia (Oreochromis niloticus L.)\n3873: Myostatin in the placentae of pregnancies complicated with gestational diabetes mellitus\n3876: [Role of Activin A and Myostatin in cancer cachexia]\n3879: Myostatin: The Missing Link between Sarcopenia and Cardiovascular Disease in Chronic Kidney Disease?\n3883: Myostatin Changes in Females with UI after Magnetic Stimulation: A Quasi-Experimental Study\n3887: MIF1 and MIF2 Myostatin Peptide Inhibitors as Potent Muscle Mass Regulators\n3889: Licochalcone A and B enhance muscle proliferation and differentiation by regulating Myostatin\n3892: Myostatin Attenuation In Vivo Reduces Adiposity, but Activates Adipogenesis\n3895: Myostatin serum levels depends on age and diet in athletic and no athletic dogs\n3898: Myostatin promotes the epithelial-to-mesenchymal transition of the dermomyotome during somitogenesis\n3900: Quadriceps myostatin expression in COPD\n3905: Myostatin in tendon maintenance and repair\n3908: Myocardial myostatin in spontaneously hypertensive rats with heart failure\n3911: Myostatin knockout in bovine fetal fibroblasts by using TALEN\n3914: Expression of myostatin in human hematopoietic cells unveils novel autocrine/paracrine actions for the hormone\n3917: Myostatin levels in skeletal muscle of hibernating ground squirrels\n3920: Myostatin inhibits proliferation of human urethral rhabdosphincter satellite cells\n3923: Regulation of muscle size in humans: role of myostatin?\n3926: Sex-specific role of myostatin signaling in neonatal muscle growth, denervation atrophy, and neuromuscular contractures\n3928: Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt\n3932: Serum myostatin levels in chronic heart failure\n3935: Strategic structure-activity relationship study on a follistatin-derived myostatin inhibitory peptide\n3938: Myostatin promotes the terminal differentiation of embryonic muscle progenitors\n3940: Myostatin Activates the Ubiquitin-Proteasome and Autophagy-Lysosome Systems Contributing to Muscle Wasting in Chronic Kidney Disease\n3943: Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume\n3946: Proposal for the binding mode of the 23-mer inhibitory peptide to myostatin\n3948: Development of functionalized peptides for efficient inhibition of myostatin by selective photooxygenation\n3950: Myostatin is a key mediator between energy metabolism and endurance capacity of skeletal muscle\n3953: [Myostatin blockade therapy for muscular atrophy]\n3956: Loss of Myostatin Alters Mitochondrial Oxidative Phosphorylation, TCA Cycle Activity, and ATP Production in Skeletal Muscle\n3959: Latent myostatin has significant activity and this activity is controlled more efficiently by WFIKKN1 than by WFIKKN2\n3962: Myostatin expression is regulated by underfeeding and neonatal programming in rats\n3965: Inactivation of Myostatin Delays Senescence via TREX1-SASP in Bovine Skeletal Muscle Cells\n3969: Modulation of Myostatin/Hepatocyte Growth Factor Balance by Different Hemodialysis Modalities\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug72_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Ace-031\" (also known as \"ace-031\"), here are the article headings along with their IDs:\n3779: Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial\n3783: A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug73_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Amentoflavone\" (also known as \"amentoflavone\"), here are the article headings along with their IDs:\n3854: Insights Into Amentoflavone: A Natural Multifunctional Biflavonoid\n3857: Potential of amentoflavone with antiviral properties in COVID-19 treatment\n3859: Amentoflavone mitigates doxorubicin-induced cardiotoxicity by suppressing cardiomyocyte pyroptosis and inflammation through inhibition of the STING/NLRP3 signalling pathway\n3862: Chemopreventive mechanisms of amentoflavone: recent trends and advancements\n3865: Amentoflavone for treating cardiocerebrovascular diseases and neurological disorders\n3868: Unraveling Amentoflavone's Therapeutic Potential in Alzheimer's Disease: A Preclinical Assessment\n3872: Amentoflavone attenuates Listeria monocytogenes pathogenicity through an LLO-dependent mechanism\n3874: Amentoflavone inhibits colorectal cancer epithelial-mesenchymal transition via the miR-16-5p/HMGA2/\u03b2-catenin pathway\n3877: Amentoflavone Induces Autophagy and Modulates p53\n3880: Amentoflavone reverses epithelial-mesenchymal transition in hepatocellular carcinoma cells by targeting p53 signalling pathway axis\n3884: Amentoflavone, a potent natural matrix metalloproteinase 2 inhibitor\n3886: Amentoflavone-loaded nanoparticles enhanced chemotherapy efficacy by inhibition of AKR1B10\n3890: Amentoflavone Exerts Anti-Neuroinflammatory Effects by Inhibiting TLR4/MyD88/NF-\u03baB and Activating Nrf2/HO-1 Pathway in Lipopolysaccharide-Induced BV2 Microglia\n3893: Amentoflavone as an Ally in the Treatment of Cutaneous Leishmaniasis: Analysis of Its Antioxidant/Prooxidant Mechanisms\n3896: Amentoflavone attenuates homocysteine-induced neuronal ferroptosis-mediated inflammatory response: Involvement of the SLC7A11/GPX4 axis activation\n3899: Amentoflavone isolated from Selaginella sellowii Hieron induces mitochondrial dysfunction in Leishmania amazonensis promastigotes\n3902: Amentoflavone Ameliorates Memory Deficits and Abnormal Autophagy in A\u03b225-35-Induced Mice by mTOR Signaling\n3904: Amentoflavone inhibits hepatitis B virus infection via the suppression of preS1 binding to host cells\n3906: Amentoflavone Inhibits HSV-1 and ACV-Resistant Strain Infection by Suppressing Viral Early Infection\n3909: Amentoflavone inhibits tumor necrosis factor-\u03b1-induced migration and invasion through AKT/mTOR/S6k1/hedgehog signaling in human breast cancer\n3913: Amentoflavone Induces Cell-cycle Arrest, Apoptosis, and Invasion Inhibition in Non-small Cell Lung Cancer Cells\n3915: A Review on the Phytochemistry, Pharmacology, and Pharmacokinetics of Amentoflavone, a Naturally-Occurring Biflavonoid\n3918: Amentoflavone impairs the reconsolidated fear memories through inhibition of ERK pathway\n3921: Amentoflavone Induces Apoptosis and Reduces Expression of Anti-apoptotic and Metastasis-associated Proteins in Bladder Cancer\n3924: Amentoflavone induces caspase-dependent/-independent apoptosis and dysregulates cyclin-dependent kinase-mediated cell cycle in colorectal cancer in vitro and in vivo\n3927: Amentoflavone Ameliorates Streptococcus suis-Induced InfectionIn VitroandIn Vivo\n3930: Amentoflavone maintaining extracellular matrix homeostasis and inhibiting subchondral bone loss in osteoarthritis by inhibiting ERK, JNK and NF-\u03baB signaling pathways\n3933: Amentoflavone, a novel cyanobacterial killing agent from Selaginella tamariscina\n3936: Amentoflavone Promotes Cellular Uptake and Degradation of Amyloid-Beta in Neuronal Cells\n3939: Amentoflavone Affects Epileptogenesis and Exerts Neuroprotective Effects by Inhibiting NLRP3 Inflammasome\n3942: An overview on therapeutic and medicinal potential of poly-hydroxy flavone viz. Heptamethoxyflavone, Kaempferitrin, Vitexin and Amentoflavone for management of Alzheimer's and Parkinson's diseases: a critical analysis on mechanistic insight\n3944: Amentoflavone prevents ox-LDL-induced lipid accumulation by suppressing the PPAR\u03b3/CD36 signal pathway\n3949: Amentoflavone Inhibits Hepatocellular Carcinoma Progression Through Blockage of ERK/NF-\u0138B Activation\n3952: Amentoflavone protects the hematopoietic system of mice against \u03b3-irradiation\n3955: [Amentoflavone inhibits M1 polarization of THP-1-derived foam cells by activating PPAR-\u03b1/\u03b3]\n3957: Amentoflavone-EnrichedSelaginella rossiiProtects against Ultraviolet- and Oxidative Stress-Induced Aging in Skin Cells\n3960: Amentoflavone derivatives significantly act towards the main protease (3CLPRO/MPRO) of SARS-CoV-2: in silico admet profiling, molecular docking, molecular dynamics simulation, network pharmacology\n3963: Amentoflavone alleviated cartilage injury and inflammatory response of knee osteoarthritis through PTGS2\n3966: Amentoflavone Mitigates Cyclophosphamide-Induced Pulmonary Toxicity: Involvement of -SIRT-1/Nrf2/Keap1 Axis, JAK-2/STAT-3 Signaling, and Apoptosis\n3967: Amentoflavone attenuates cell proliferation and induces ferroptosis in human gastric cancer by miR-496/ATF2 axis\n3968: Amentoflavone induces cell cycle arrest, apoptosis, and autophagy in BV-2 cells\n3970: Amentoflavone fromSelaginella tamariscinainhibits SARS-CoV-2 RNA-dependent RNA polymerase\n3971: Amentoflavone Ameliorates Carrageenan-Induced Pleurisy and Lung Injury by Inhibiting the NF-\u03baB/STAT3 Pathways via Nrf2 Activation\n3972: Amentoflavone AttenuatesClostridium perfringensGas Gangrene by Targeting Alpha-Toxin and Perfringolysin O\n3973: Amentoflavone Effectively Blocked the Tumor Progression of Glioblastoma via Suppression of ERK/NF-\u03baB Signaling Pathway\n3974: Amentoflavone enhances osteogenesis of human mesenchymal stem cells through JNK and p38 MAPK pathways\n3975: Potential cardioprotective effects of Amentoflavone in doxorubicin-induced cardiotoxicity in mice\n3976: Amentoflavone and methyl hesperidin, novel lead molecules targeting epitranscriptomic modulator in acute myeloid leukemia: in silico drug screening and molecular dynamics simulation approach\n3977: Amentoflavone attenuates oxidative stress and neuroinflammation induced by cerebral ischemia/reperfusion in rats by targeting HMGB1-mediated TLR4/NF-\u03baB signaling pathway\n3978: Amentoflavone promotes ferroptosis by regulating reactive oxygen species (ROS) /5'AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) to inhibit the malignant progression of endometrial carcinoma cells\n3979: Amentoflavone protects hippocampal neurons: anti-inflammatory, antioxidative, and antiapoptotic effects\n3980: Amentoflavone-EnrichedSelaginella rossiiWarb. Suppresses Body Weight and Hyperglycemia by Inhibiting Intestinal Lipid Absorption in Mice Fed a High-Fat Diet\n3981: Amentoflavone ameliorates cold stress-induced inflammation in lung by suppression of C3/BCR/NF-\u03baB pathways\n3982: Amentoflavone stimulates mitochondrial dysfunction and induces apoptotic cell death in Candida albicans\n3983: Preparation of amentoflavone-loaded DSPE-PEG2000micelles with improved bioavailability and in vitro antitumor efficacy\n3984: Amentoflavone Inhibits ERK-modulated Tumor Progression in Hepatocellular CarcinomaIn Vitro\n3986: Amentoflavone: A Bifunctional Metal Chelator that Controls the Formation of Neurotoxic Soluble A\u03b242Oligomers\n3988: Amentoflavone Induces Apoptosis and Inhibits NF-\u0138B-modulated Anti-apoptotic Signaling in Glioblastoma Cells\n3990: Anticytotoxin Effects of Amentoflavone to Pneumolysin\n3992: Assessment of Amentoflavone Loaded Sub-Micron Particle Preparation using Supercritical Antisolvent for its Antitumor Activity\n3994: Antiviral amentoflavone from Selaginella sinensis\n3996: Antiviral Effect of Amentoflavone Against Influenza Viruses\n3998: Amentoflavone Induces Ferroptosis to Alleviate Proliferation, Migration, Invasion and Inflammation in Rheumatoid Arthritis Fibroblast-like Synoviocytes by Inhibiting PIN1\n3999: Evaluation of amentoflavone metabolites on PARP-1 inhibition and the potentiation on anti-proliferative effects of carboplatin in A549 cells\n4002: Amentoflavone mediated hepatoprotection to counteract paraquat instigated hepatotoxicity via modulating Nrf2/keap1 pathway: A biochemical, inflammatory, apoptotic and histopathological study\n4004: Amentoflavone Induces Anti-angiogenic and Anti-metastatic Effects Through Suppression of NF-\u03baB Activation in MCF-7 cells\n4006: Amentoflavone from Selaginella tamariscina as a potent inhibitor of gut bacterial \u03b2-glucuronidase: Inhibition kinetics and molecular dynamics stimulation\n4008: Amentoflavone suppresses cell proliferation and induces cell death through triggering autophagy-dependent ferroptosis in human glioma\n4010: Amentoflavone suppresses amyloid \u03b21-42 neurotoxicity in Alzheimer's disease through the inhibition of pyroptosis\n4012: Amentoflavone Promotes Apoptosis in Non-Small-Cell Lung Cancer by Modulating Cancerous Inhibitor of PP2A\n4014: Amentoflavone, active compound of Selaginella tamariscina, inhibits in vitro and in vivo TGF-\u03b2-induced metastasis of human cancer cells\n4015: Amentoflavone, a plant biflavone: a new potential anti-inflammatory agent\n4017: Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular CarcinomaIn Vivo\n4019: Amentoflavone inhibits the induction of nitric oxide synthase by inhibiting NF-kappaB activation in macrophages\n4022: Amentoflavone Inhibits Metastatic Potential Through Suppression of ERK/NF-\u03baB Activation in Osteosarcoma U2OS Cells\n4024: Amentoflavone suppresses tumor growth in ovarian cancer by modulating Skp2\n4026: Amentoflavone, a biflavonoid with potential anticancer properties against viral oncoprotein E6 in Human papilloma virus-16 (HPV-16) positive cervical cancer cells\n4028: Amentoflavone regulates the miR-124-3p/CAPN2 axis to promote mitochondrial autophagy in HCC cells\n4029: Amentoflavone inhibits UVB-induced matrix metalloproteinase-1 expression through the modulation of AP-1 components in normal human fibroblasts\n4031: Amentoflavone triggers cell cycle G2/M arrest by interfering with microtubule dynamics and inducing DNA damage in SKOV3 cells\n4032: In vitroevaluation of estrogenic, antiestrogenic and antitumor effects of amentoflavone\n4034: Antioxidant and anticholinesterase activities of amentoflavone isolated fromOuratea fieldingiana(Gardner) Engl. throughin vitroand chemical-quantum studies\n4036: AMPK/mTOR-driven autophagy & Nrf2/HO-1 cascade modulation by amentoflavone ameliorates indomethacin-induced gastric ulcer\n4038: Amentoflavone enhances sorafenib-induced apoptosis through extrinsic and intrinsic pathways in sorafenib-resistant hepatocellular carcinoma SK-Hep1 cellsin vitro\n4041: Anticancer Efficacy and Mechanism of Amentoflavone for Sensitizing Oral Squamous Cell Carcinoma to Cisplatin\n4044: Reinforcement of Sorafenib Anti-osteosarcoma Effect by Amentoflavone Is Associated With the Induction of Apoptosis and Inactivation of ERK/NF-\u03baB\n4049: Amentoflavone induces apoptosis and suppresses glycolysis in glioma cells by targeting miR-124-3p\n4052: Amentoflavone prevents sepsis-associated acute lung injury through Nrf2-GCLc-mediated upregulation of glutathione\n4056: Transport and metabolic profiling studies of amentoflavone in Caco-2 cells by UHPLC-ESI-MS/MS and UHPLC-ESI-Q-TOF-MS/MS\n4059: Amentoflavone induces cell-cycle arrest and apoptosis in MCF-7 human breast cancer cells via mitochondria-dependent pathway\n4062: Polyphenol amentoflavone affords neuroprotection against neonatal hypoxic-ischemic brain damage via multiple mechanisms\n4065: Systematic Strategy for Metabolites of AmentoflavoneIn VivoandIn VitroBased on UHPLC-Q-TOF-MS/MS Analysis\n4069: Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib\n4073: Amentoflavone inhibits angiogenesis of endothelial cells and stimulates apoptosis in hypertrophic scar fibroblasts\n4075: Amentoflavone Inhibits Osteoclastogenesis and Wear Debris-Induced Osteolysis via Suppressing NF-\u03baB and MAPKs Signaling Pathways\n4077: Amentoflavone Ameliorates A\u03b21-42-Induced Memory Deficits and Oxidative Stress in Cellular and Rat Model\n4080: Evaluation on absorption risks of amentoflavone after oral administration in rats\n4084: Antidiabetic Activity and Potential Mechanism of Amentoflavone in Diabetic Mice\n4088: Amentoflavone inhibits iNOS, COX-2 expression and modulates cytokine profile, NF-\u03baB signal transduction pathways in rats with ulcerative colitis\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug74_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Dihydromyricetin\" (also known as \"dihydromyricetin\"), here are the article headings along with their IDs:\n3985: Dihydromyricetin\n3987: Mechanism of Dihydromyricetin on Inflammatory Diseases\n3989: Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism\n3991: Dihydromyricetin Attenuates Cerebral Ischemia Reperfusion Injury by Inhibiting SPHK1/mTOR Signaling and Targeting Ferroptosis\n3993: Dihydromyricetin attenuates intracerebral hemorrhage by reversing the effect of LCN2 via the system Xc- pathway\n3995: Research progress of dihydromyricetin in the treatment of diabetes mellitus\n3997: Dihydromyricetin Acts as a Potential Redox Balance Mediator in Cancer Chemoprevention\n4000: Dihydromyricetin ameliorates hepatic steatosis and insulin resistance via AMPK/PGC-1\u03b1 and PPAR\u03b1-mediated autophagy pathway\n4001: The Versatile Effects of Dihydromyricetin in Health\n4003: Preclinical Research of Dihydromyricetin for Brain Aging and Neurodegenerative Diseases\n4005: Dihydromyricetin attenuates cisplatin-induced acute kidney injury by reducing oxidative stress, inflammation and ferroptosis\n4007: Dihydromyricetin: A review on identification and quantification methods, biological activities, chemical stability, metabolism and approaches to enhance its bioavailability\n4009: Molecular mechanisms and promising role of dihydromyricetin in cardiovascular diseases\n4011: Identification of dihydromyricetin as a natural DNA methylation inhibitor with rejuvenating activity in human skin\n4013: Dihydromyricetin supplementation improves ethanol-induced lipid accumulation and inflammation\n4016: Recent update on application of dihydromyricetin in metabolic related diseases\n4018: Dihydromyricetin ameliorates experimental ulcerative colitis by inhibiting neutrophil extracellular traps formation via the HIF-1\u03b1/VEGFA signaling pathway\n4020: Dihydromyricetin Alleviates Ischemic Brain Injury by Antagonizing Pyroptosis in Rats\n4021: Multitarget and promising role of dihydromyricetin in the treatment of metabolic diseases\n4023: Dihydromyricetin Ameliorates Inflammation-Induced Insulin Resistance via Phospholipase C-CaMKK-AMPK Signal Pathway\n4025: Molecular mechanisms and therapeutic implications of dihydromyricetin in liver disease\n4027: Dihydromyricetin Inhibits Ferroptosis to Attenuate Cisplatin-Induced Muscle Atrophy\n4030: Molecular mechanism and therapeutic significance of dihydromyricetin in nonalcoholic fatty liver disease\n4033: Dihydromyricetin Attenuates Inflammation through TLR4/NF-kappaB Pathway\n4035: Dihydromyricetin resists inflammation-induced muscle atrophy via ryanodine receptor-CaMKK-AMPK signal pathway\n4037: Dihydromyricetin regulates RIPK3-CaMKII to prevent necroptosis in high glucose-stimulated cardiomyocytes\n4039: Dihydromyricetin treats pulmonary hypertension by modulating CKLF1/CCR5 axis-induced pulmonary vascular cell pyroptosis\n4042: Dihydromyricetin-loaded oxidized polysaccharide/L-arginine chitosan adhesive hydrogel promotes bone regeneration by regulating PI3K/AKT signaling pathway and MAPK signaling pathway\n4046: Dihydromyricetin confers cerebroprotection against subarachnoid hemorrhage via the Nrf2-dependent Prx2 signaling cascade\n4048: Does dihydromyricetin impact on alcohol metabolism\n4051: A Drug-Drug Cocrystal of Dihydromyricetin and Pentoxifylline\n4055: Dihydromyricetin Protects Intestinal Barrier Integrity by Promoting IL-22 Expression in ILC3s through the AMPK/SIRT3/STAT3 Signaling Pathway\n4058: Dihydromyricetin is a new inhibitor of influenza polymerase PB2 subunit and influenza-induced inflammation\n4061: Effect of dihydromyricetin on SARS-CoV-2 viral replication and pulmonary inflammation and fibrosis\n4064: Dihydromyricetin attenuates hypertrophic scar formation by targeting activin receptor-like kinase 5\n4067: Dihydromyricetin inhibits African swine fever virus replication by downregulating toll-like receptor 4-dependent pyroptosis in vitro\n4070: Dihydromyricetin Attenuates Diabetic Cardiomyopathy by Inhibiting Oxidative Stress, Inflammation and Necroptosis via Sirtuin 3 Activation\n4072: Dihydromyricetin protects against high glucose-induced endothelial dysfunction: Role of HIF-1\u03b1/ROR2/NF-\u03baB\n4076: Dihydromyricetin protects against Doxorubicin-induced cardiotoxicity through activation of AMPK/mTOR pathway\n4078: Dihydromyricetin improves social isolation-induced cognitive impairments and astrocytic changes in mice\n4081: Dihydromyricetin ameliorates diabetic renal fibrosis via regulating SphK1 to suppress the activation of NF-\u03baB pathway\n4083: Dihydromyricetin affect the pharmacokinetics of triptolide in rats\n4086: Dihydromyricetin ameliorated nonalcoholic steatohepatitis in mice by regulating the composition of serous lipids, bile acids and ileal microflora\n4089: Dihydromyricetin inhibits cell proliferation, migration, invasion and promotes apoptosisviaregulating miR-21 in Human Cholangiocarcinoma Cells\n4092: Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway\n4093: Recent Update on the Pharmacological Effects and Mechanisms of Dihydromyricetin\n4095: Dihydromyricetin Improves High-Fat Diet-Induced Hyperglycemia through ILC3 Activation via a SIRT3-Dependent Mechanism\n4097: Strategic developments in the drug delivery of natural product dihydromyricetin: applications, prospects, and challenges\n4100: Dihydromyricetin suppresses endothelial NLRP3 inflammasome activation and attenuates atherogenesis by promoting mitophagy\n4101: Dihydromyricetin ameliorates chronic liver injury by reducing pyroptosis\n4103: Dihydromyricetin-Encapsulated Liposomes Inhibit Exhaustive Exercise-Induced Liver Inflammation by Orchestrating M1/M2 Macrophage Polarization\n4105: Dihydromyricetin Enhances Exercise-Induced GLP-1 Elevation through Stimulating cAMP and Inhibiting DPP-4\n4107: Dihydromyricetin ameliorates atherosclerosis in LDL receptor deficient mice\n4109: Dihydromyricetin Modulates Nrf2 and NF-\u03baB Crosstalk to Alleviate Methotrexate-Induced Lung Toxicity\n4110: Dihydromyricetin promotes GLP-1 release and glucose uptake by STC-1 cells and enhances the effects of metformin upon STC-1 cells and diabetic mouse model\n4112: Dihydromyricetin Ameliorates Cardiac Ischemia/Reperfusion Injury through Sirt3 Activation\n4114: Dihydromyricetin Attenuates Depressive-like Behaviors in Mice by Inhibiting the AGE-RAGE Signaling Pathway\n4116: Dihydromyricetin Inhibits M1 Macrophage Polarization in Atherosclerosis by Modulating miR-9-Mediated SIRT1/NF-\u03baB Signaling Pathway\n4118: Dihydromyricetin functions as a tumor suppressor in hepatoblastoma by regulating SOD1/ROS pathway\n4120: Dihydromyricetin Prevents Diabetic Cardiomyopathy via miR-34a Suppression by Activating Autophagy\n4122: Dihydromyricetin improves LPS-induced sickness and depressive-like behaviors in mice by inhibiting the TLR4/Akt/HIF1a/NLRP3 pathway\n4124: Stability profiling and degradation products of dihydromyricetin in Dulbecco's modified eagle's medium\n4126: Dihydromyricetin supplementation during in vitro culture improves porcine oocyte developmental competence by regulating oxidative stress\n4128: Dihydromyricetin Protects Against Ethanol-Induced Toxicity in SH-SY5Y Cell Line: Role of GABAAReceptor\n4130: Mechanisms of dihydromyricetin against hepatocellular carcinoma elucidated by network pharmacology combined with experimental validation\n4132: Dihydromyricetin Alleviates Pulmonary Fibrosis by Regulating Abnormal Fibroblasts Through the STAT3/p-STAT3/GLUT1 Signaling Pathway\n4134: Dihydromyricetin incorporated active films based on konjac glucomannan and gellan gum\n4136: Dihydromyricetin Enhances Intestinal Antioxidant Capacity of Growing-Finishing Pigs by Activating ERK/Nrf2/HO-1 Signaling Pathway\n4138: Dihydromyricetin Improves Cognitive Impairments in d-Galactose-Induced Aging Mice through Regulating Oxidative Stress and Inhibition of Acetylcholinesterase\n4140: Molecular Level Insight Into the Benefit of Myricetin and Dihydromyricetin Uptake in Patients With Alzheimer's Diseases\n4142: Dihydromyricetin Inhibits Pseudorabies Virus Multiplication In Vitro by Regulating NF-\u03baB Signaling Pathway and Apoptosis\n4144: Dihydromyricetin: an emerging compound with comprehensive effects on multiple systems\n4146: Dihydromyricetin alleviates cerebral ischemia-reperfusion injury by attenuating apoptosis and astrogliosis in peri-infarct cortex\n4148: Dihydromyricetin suppresses TNF-\u03b1-induced NF-\u03baB activation and target gene expression\n4151: Dihydromyricetin alters myosin heavy chain expressionviaAMPK signaling pathway in porcine myotubes\n4154: Dihydromyricetin Protects Against Gentamicin-Induced Ototoxicity via PGC-1\u03b1/SIRT3 Signalingin vitro\n4156: Dihydromyricetin ameliorates vascular calcification in chronic kidney disease by targeting AKT signaling\n4161: Dihydromyricetin Exhibits Antitumor Activity in Nasopharyngeal Cancer Cell Through Antagonizing Wnt/\u03b2-catenin Signaling\n4163: Dihydromyricetin contributes to weight loss via pro-browning mediated by mitochondrial fission in white adipose\n4167: Dihydromyricetin Alleviates H9C2 Cell Apoptosis and Autophagy by Regulating CircHIPK3 Expression and PI3K/AKT/mTOR Pathway\n4169: Dihydromyricetin alleviates Escherichia coli lipopolysaccharide-induced hepatic injury in chickens by inhibiting the NLRP3 inflammasome\n4171: Dihydromyricetin alleviates methotrexate-induced hepatotoxicity via suppressing the \u200eTLR4/NF-\u03baB pathway and NLRP3 inflammasome/caspase 1 axis\n4175: Erratum: Dihydromyricetin-encapsulated liposomes inhibit exhaustive exercise-induced liver inflammation by orchestrating M1/M2 macrophage polarization\n4179: Dihydromyricetin ameliorates memory impairment induced by acute sleep deprivation\n4181: Dihydromyricetin Protects Against Salsolinol-Induced Toxicity in Dopaminergic Cell Line: Implication for Parkinson's Disease\n4185: Dihydromyricetin ameliorates social isolation-induced anxiety by modulating mitochondrial function, antioxidant enzymes, and BDNF\n4188: Dihydromyricetin ameliorates diet-induced obesity and promotes browning of white adipose tissue by upregulating IRF4/PGC-1\u03b1\n4190: Multiple molecular and cellular mechanisms of the antitumour effect of dihydromyricetin (Review)\n4193: Dihydromyricetin Inhibits Tumor Growth and Epithelial-Mesenchymal Transition through regulating miR-455-3p in Cholangiocarcinoma\n4196: Dihydromyricetin ameliorates oxygen\u2011glucose deprivation and re\u2011oxygenation\u2011induced injury in HT22 cells by activating the Wnt/\u03b2\u2011catenin signaling pathway\n4200: Retraction on \"Dihydromyricetin attenuates inflammation through TLR4/NF-kappa B pathway\"\n4203: Dihydromyricetin Inhibited Migration and Invasion by Reducing S100A4 Expression through ERK1/2/\u03b2-Catenin Pathway in Human Cervical Cancer Cell Lines\n4205: Dihydromyricetin alleviates hippocampal ferroptosis in type 2 diabetic cognitive impairment rats via inhibiting the JNK-inflammatory factor pathway\n4208: Dihydromyricetin inhibits Hepatitis B virus replication by activating NF-\u03baB, MAPKs, and autophagy in HepG2.2.15 cells\n4211: Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1\n4212: [Dihydromyricetin improves Parkinson's disease-like lesions in T2DM rats by activating AMPK/ULK1 pathway]\n4216: Dihydromyricetin protects against gentamicin-induced nephrotoxicity via upregulation of renal SIRT3 and PAX2\n4220: Dihydromyricetin promotes longevity and activates the transcription factors FOXO and AOP inDrosophila\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug76_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Quercetin\" (also known as \"quercetin\"), here are the article headings along with their IDs:\n4040: Health Benefits of Quercetin in Age-Related Diseases\n4043: The role of quercetin in plants\n4045: Quercetin and metabolic syndrome: A review\n4047: Quercetin derivatives: Drug design, development, and biological activities, a review\n4050: Safety Aspects of the Use of Quercetin as a Dietary Supplement\n4053: Antimicrobial Activity of Quercetin: An Approach to Its Mechanistic Principle\n4054: Quercetin's Effects on Glutamate Cytotoxicity\n4057: Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential\n4060: The Potential Benefits of Quercetin for Brain Health: A Review of Anti-Inflammatory and Neuroprotective Mechanisms\n4063: Quercetin Loaded Nanoparticles in Targeting Cancer: Recent Development\n4066: Quercetin: A Potential Candidate for the Treatment of Arthritis\n4068: Senescence-mediated anticancer effects of quercetin\n4071: Quercetin alleviates ferroptosis accompanied by reducing M1 macrophage polarization during neutrophilic airway inflammation\n4074: Quantification of the Quercetin Nanoemulsion Technique Using Various Parameters\n4079: Quercetin in Osteoporosis Treatment: A Comprehensive Review of Its Mechanisms and Therapeutic Potential\n4082: Quercetin improves diabetic kidney disease by inhibiting ferroptosis and regulating the Nrf2 in streptozotocin-induced diabetic rats\n4085: Quercetin: Putative effects on the function of cryopreserved sperms in domestic animals\n4087: Neuropharmacological interventions of quercetin and its derivatives in neurological and psychological disorders\n4090: Quercetin-loaded mesoporous nano-delivery system remodels osteoimmune microenvironment to regenerate alveolar bone in periodontitis via the miR-21a-5p/PDCD4/NF-\u03baB pathway\n4091: Quercetin in Food: Possible Mechanisms of Its Effect on Memory\n4094: Quercetin and its Natural Sources in Wound Healing Management\n4096: Quercetin: A Functional Food-Flavonoid Incredibly Attenuates Emerging and Re-Emerging Viral Infections through Immunomodulatory Actions\n4098: The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis\n4099: Therapeutic Potential of Quercetin and its Derivatives in Epilepsy: Evidence from Preclinical Studies\n4102: Actions of Quercetin, a Polyphenol, on Blood Pressure\n4104: Therapeutic potential of senolytic agent quercetin in osteoarthritis: A systematic review and meta-analysis of preclinical studies\n4106: Neoteric Role of Quercetin in Visual Disorders\n4108: Quercetin as a Promising Antiprotozoan Phytochemical: Current Knowledge and Future Research Avenues\n4111: Exploring the therapeutic potential of quercetin: A focus on its sirtuin-mediated benefits\n4113: Nanoparticle-delivered quercetin for cancer therapy\n4115: Unlocking Quercetin's Neuroprotective Potential: A Focus on Bee-Collected Pollen\n4117: Therapeutic potential of quercetin on human breast cancer in different dimensions\n4119: Mechanism of action of quercetin in rheumatoid arthritis models: meta-analysis and systematic review of animal studies\n4121: A Critical Analysis of Quercetin as the Attractive Target for the Treatment of Parkinson's Disease\n4123: The therapeutic potential of quercetin for cigarette smoking-induced chronic obstructive pulmonary disease: a narrative review\n4125: Effect and Mechanisms of Quercetin for Experimental Focal Cerebral Ischemia: A Systematic Review and Meta-Analysis\n4127: Therapeutic potential of quercetin as a cardiovascular agent\n4129: Unraveling Quercetin's Potential: A Comprehensive Review of Its Properties and Mechanisms of Action, in Diabetes and Obesity Complications\n4131: The Antidiabetic Potential of Quercetin: Underlying Mechanisms\n4133: [Quercetin for the treatment of prostate cancer: Progress in studies]\n4135: Novel quercetin derivatives: From redox properties to promising treatment of oxidative stress related diseases\n4137: Dual role of quercetin in enhancing the efficacy of cisplatin in chemotherapy and protection against its side effects: a review\n4139: Quercetin and endurance exercise capacity: a systematic review and meta-analysis\n4141: Quercetin's Potential in MASLD: Investigating the Role of Autophagy and Key Molecular Pathways in Liver Steatosis and Inflammation\n4143: Mechanistic insights and perspectives involved in neuroprotective action of quercetin\n4145: A comprehensive view on the quercetin impact on bladder cancer: Focusing on oxidative stress, cellular, and molecular mechanisms\n4147: Expanding Arsenal against Neurodegenerative Diseases Using Quercetin Based Nanoformulations: Breakthroughs and Bottlenecks\n4149: Therapeutic potentials and targeting strategies of quercetin on cancer cells: Challenges and future prospects\n4152: Therapeutic Potential of Quercetin in Diabetic Neuropathy and Retinopathy: Exploring Molecular Mechanisms\n4155: Application of Quercetin and its Novel Formulations in the Treatment of Malignancies of Central Nervous System: An Updated Review of Current Evidence based on Molecular Mechanisms\n4157: Quercetin and AMPK: A Dynamic Duo in Alleviating MG-Induced Inflammation via the AMPK/SIRT1/NF-\u03baB Pathway\n4159: Dietary quercetin protects Cherax quadricarinatus against white spot syndrome virus infection\n4164: Quercetin: a potential drug to reverse multidrug resistance\n4166: Research Progress in the Modification of Quercetin Leading to Anticancer Agents\n4170: Targets Involved in the Anti-Cancer Activity of Quercetin in Breast, Colorectal and Liver Neoplasms\n4173: Quercetin Inhibits the Proliferation and Aflatoxins Biosynthesis ofAspergillus flavus\n4176: Molecular and Biological Functions of Quercetin as a Natural Solution for Cardiovascular Disease Prevention and Treatment\n4178: MicroRNAs as molecular targets of quercetin and its derivatives underlying their biological effects: A preclinical strategy\n4182: Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications\n4184: The Role of Quercetin for the Treatment of Endometriosis and Endometrial Cancer: A Comprehensive Review\n4187: Multitargeted cancer prevention by quercetin\n4191: Quercetin protective potential against nanoparticle-induced adverse effects\n4194: Quercetin as a systemic chemopreventative agent: structural and functional mechanisms\n4195: Drug design strategies that aim to improve the low solubility and poor bioavailability conundrum in quercetin derivatives\n4199: Cardiovascular Disease: A Target for the Pharmacological Effects of Quercetin\n4202: Metabolic effects of quercetin on inflammatory and autoimmune responses in rheumatoid arthritis are mediated through the inhibition of JAK1/STAT3/HIF-1\u03b1 signaling\n4206: Hyaluronic acid-quercetin pendant drug conjugate for wound healing applications\n4209: Autophagy and exosomes coordinately mediate quercetin's protective effects on alcoholic liver disease\n4213: Quercetin inhibits carbapenemase and efflux pump activities among carbapenem-resistant Gram-negative bacteria\n4215: A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability\n4218: From nature to clinic: Quercetin's role in breast cancer immunomodulation\n4219: Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism\n4222: Mechanistic study of quercetin in the treatment of hepatocellular carcinoma with diabetes via MEK/ERK pathway\n4223: Quercetin's effects on colon cancer cells apoptosis and proliferation in a rat model of disease\n4224: Quercetin Enhances the Availability of 5-Heptadecylresorcinol by Inhibiting the Expression of P-gp\n4226: Quercetin Alleviates Asthma-Induced Airway Inflammation and Remodeling through Downregulating Periostin via Blocking TGF-\u03b21/Smad Pathway\n4228: Drug delivery based pharmacological enhancement and current insights of quercetin with therapeutic potential against oral diseases\n4230: Targeting mTOR/YY1 signaling pathway by quercetin through CYP7A1-mediated cholesterol-to-bile acids conversion alleviated type 2 diabetes mellitus induced hepatic lipid accumulation\n4232: A critical evaluation of risk to reward ratio of quercetin supplementation for COVID-19 and associated comorbid conditions\n4234: Ameliorative properties of quercetin in the treatment of traumatic brain injury: a mechanistic review based on underlying mechanisms\n4236: Exploring the current advancements of quercetin nanoformulations alleviating respiratory diseases\n4237: Quercetin and its derivatives: synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability\n4239: Bioactive effects of quercetin in the central nervous system: Focusing on the mechanisms of actions\n4242: Quercetin ameliorates renal tubulointerstitial transformation and renal fibrosis by regulating NLRP3 in obstructive nephropathy\n4244: Quercetin Inhibits Hsp70 Blocking of Bovine Viral Diarrhea Virus Infection and Replication in the Early Stage of Virus Infection\n4246: Quercetin-functionalized nanomaterials: Innovative therapeutic avenues for Alzheimer's disease management\n4248: Quercetin Alleviates Lipopolysaccharide-Induced Cell Oxidative Stress and Inflammatory Responses via Regulation of the TLR4-NF-\u03baB Signaling Pathway in Bovine Rumen Epithelial Cells\n4250: New opportunities and advances in quercetin-added functional packaging films for sustainable packaging applications: a mini-review\n4252: Therapeutic Effects of Quercetin on Inflammation, Obesity, and Type 2 Diabetes\n4254: Exploring the therapeutic potential of quercetin in cancer treatment: Targeting long non-coding RNAs\n4256: Natural Product Glycosylation: Biocatalytic Synthesis of Quercetin-3,4'-O-diglucoside\n4258: The bioavailability, absorption, metabolism, and regulation of glucolipid metabolism disorders by quercetin and its important glycosides: A review\n4260: CETSA-MS-based target profiling of anti-aging natural compound quercetin\n4262: Dietary Quercetin Supplementation Attenuates Diarrhea and Intestinal Damage by Regulating Gut Microbiota in Weanling Piglets\n4264: Quercetin protects endothelial function from inflammation induced by localized disturbed flow by inhibiting NRP2 -VEGFC complex\n4266: The effects of quercetin on nicotine-induced reward effects in mice\n4268: Quercetin-loaded nanoparticles enhance cytotoxicity and antioxidant activity on C6 glioma cells\n4269: Quercetin Administration Suppresses the Cytokine Storm in Myeloid and Plasmacytoid Dendritic Cells\n4272: Therapeutic effect of oral quercetin in hamsters infected withLeishmania Viannia braziliensis\n4273: Quercetin Protected from Aluminum Phosphide-induced Acute and Subacute Cardio- and Hepatotoxicity in Rats\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug77_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Oleoylethanolamide\" (also known as \"oleoylethanolamide\"), here are the article headings along with their IDs:\n4150: Oleoylethanolamide, Neuroinflammation, and Alcohol Abuse\n4153: Oleoylethanolamide alleviates hyperlipidaemia-mediated vascular calcification via attenuating mitochondrial DNA stress triggered autophagy-dependent ferroptosis by activating PPAR\u03b1\n4158: Oleoylethanolamide: A fat ally in the fight against obesity\n4160: Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review\n4162: Gut microbiota and oleoylethanolamide in the regulation of intestinal homeostasis\n4165: Oleoylethanolamide: The role of a bioactive lipid amide in modulating eating behaviour\n4168: A Duet Between Histamine and Oleoylethanolamide in the Control of Homeostatic and Cognitive Processes\n4172: Oleoylethanolamide facilitates PPAR\u03b1 and TFEB signaling and attenuates A\u03b2 pathology in a mouse model of Alzheimer's disease\n4174: Oleic acid-derived oleoylethanolamide: A nutritional science perspective\n4177: The effects of oleoylethanolamide, an endogenous PPAR-\u03b1 agonist, on risk factors for NAFLD: A systematic review\n4180: Oleoylethanolamide attenuates acute-to-chronic kidney injury: in vivo and in vitro evidence of PPAR-\u03b1 involvement\n4183: Oleoylethanolamide as a New Therapeutic Strategy to Alleviate Doxorubicin-Induced Cardiotoxicity\n4186: GPR119 and GPR55 as Receptors for Fatty Acid Ethanolamides, Oleoylethanolamide and Palmitoylethanolamide\n4189: Oleoylethanolamide and Palmitoylethanolamide Enhance IFN\u03b2-Induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells\n4192: Oleoylethanolamide induces eosinophilic airway inflammation in bronchial asthma\n4197: Identification of oleoylethanolamide as an endogenous ligand for HIF-3\u03b1\n4198: Oleoylethanolamide Alleviates Hepatic Ischemia-Reperfusion Injury via Inhibiting Endoplasmic Reticulum Stress-Associated Apoptosis\n4201: Oleoylethanolamide Ameliorates Dextran Sulfate Sodium-Induced Colitis in Rats\n4204: A systematic review of the effects of oleoylethanolamide, a high-affinity endogenous ligand of PPAR-\u03b1, on the management and prevention of obesity\n4207: Regulation of food intake by oleoylethanolamide\n4210: Oleoylethanolamide attenuates cocaine-primed reinstatement and alters dopaminergic gene expression in the striatum\n4214: Biological functions and metabolism of oleoylethanolamide\n4217: Oleoylethanolamide Protects against Acute Ischemic Stroke by Promoting PPAR\u03b1-Mediated Microglia/Macrophage M2 Polarization\n4221: Examining the oleoylethanolamide supplement effects on glycemic status, oxidative stress, inflammation, and anti-mullerian hormone in polycystic ovary syndrome\n4225: Oleoylethanolamide restores stress-induced prepulse inhibition deficits and modulates inflammatory signaling in a sex-dependent manner\n4227: Oleoylethanolamide ameliorates motor dysfunction through PPAR\u03b1-mediates oligodendrocyte differentiation and white matter integrity after ischemic stroke\n4229: Oleoylethanolamide facilitates PPARa and TFEB signaling and attenuates Ab pathology in a mouse model of Alzheimer's disease\n4231: Oleoylethanolamide attenuates the stress-mediated potentiation of rewarding properties of cocaine associated with an increased TLR4 proinflammatory response\n4233: N-oleoylethanolamide treatment of lymphoblasts deficient in Tafazzin improves cell growth and mitochondrial morphology and dynamics\n4235: Feeding regulation by oleoylethanolamide synthesized from dietary oleic acid\n4238: Oleoylethanolamide stabilizes atherosclerotic plaque through regulating macrophage polarization via AMPK-PPAR\u03b1 pathway\n4240: Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19\n4241: Effects of oleoylethanolamide supplementation on the expression of lipid metabolism-related genes and serum NRG4 levels in patients with non-alcoholic fatty liver disease: A randomized controlled trial\n4243: Oleoylethanolamide alleviates macrophage formation via AMPK/PPAR\u03b1/STAT3 pathway\n4245: Oleoylethanolamide mitigates cardiometabolic disruption secondary to obesity induced by high-fat diet in mice\n4247: Oleoylethanolamide protects mesenchymal stem/stromal cells (MSCs) from oxidative stress and reduces adipogenic related genes expression in adipose-derived MSCs undergoing adipocyte differentiation\n4249: Oleoylethanolamide Reduces Hepatic Oxidative Stress and Endoplasmic Reticulum Stress in High-Fat Diet-Fed Rats\n4251: Oleoylethanolamide and human neural responses to food stimuli in obesity\n4253: Oleoylethanolamide Treatment Modulates Both Neuroinflammation and Microgliosis, and Prevents Massive Leukocyte Infiltration to the Cerebellum in a Mouse Model of Neuronal Degeneration\n4255: Oleoylethanolamide restores alcohol-induced inhibition of neuronal proliferation and microglial activity in striatum\n4257: Oleoylethanolamide Protects Against Acute Liver Injury by Regulating Nrf-2/HO-1 and NLRP3 Pathways in Mice\n4259: Central mechanisms mediating the hypophagic effects of oleoylethanolamide and N-acylphosphatidylethanolamines: different lipid signals?\n4261: Oleoylethanolamide Exhibits GPR119-Dependent Inhibition of Osteoclast Function and GPR119-Independent Promotion of Osteoclast Apoptosis\n4263: Diet-Induced Obesity Disrupts Histamine-Dependent Oleoylethanolamide Signaling in the Mouse Liver\n4265: STING1-accelerated vascular smooth muscle cell senescence-associated vascular calcification in diabetes is ameliorated by oleoylethanolamide via improved mitochondrial DNA oxidative damage\n4267: Oleoylethanolamide Delays the Dysfunction and Death of Purkinje Cells and Ameliorates Behavioral Defects in a Mouse Model of Cerebellar Neurodegeneration\n4270: Brain molecules and appetite: the case of oleoylethanolamide\n4271: Oleoylethanolamide Increases Glycogen Synthesis and Inhibits Hepatic Gluconeogenesis via the LKB1/AMPK Pathway in Type 2 Diabetic Model\n4274: Endogenous Oleoylethanolamide Crystals Loaded Lipid Nanoparticles with Enhanced Hydrophobic Drug Loading Capacity for Efficient Stroke Therapy\n4275: Oleoylethanolamide inhibits glial activation via moudulating PPAR\u03b1 and promotes motor function recovery after brain ischemia\n4276: Attenuation of oleoylethanolamide-induced reduction of alcohol consumption in adult rats exposed intermittently to alcohol during adolescence\n4277: Effect of Oleoylethanolamide-Based Dietary Supplement on Systemic Inflammation in the Development of Alimentary-Induced Obesity in Mice\n4278: Oleoylethanolamide decreases frustration stress-induced binge-like eating in female rats: a novel potential treatment for binge eating disorder\n4279: Oleoylethanolamide and Palmitoylethanolamide Protect Cultured Cortical Neurons Against Hypoxia\n4280: Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-\u03b1, UCP1, and UCP2 genes\n4281: Cannabinoid receptor 2 as a regulator of inflammation induced oleoylethanolamide in eosinophilic asthma\n4282: The 16\u03b1-hydroxylated Bile Acid, Pythocholic Acid Decreases Food Intake and Increases Oleoylethanolamide in Male Mice\n4283: Oleoylethanolamide differentially regulates glycerolipid synthesis and lipoprotein secretion in intestine and liver\n4284: Immunomodulatory effect of oleoylethanolamide in dendritic cells via TRPV1/AMPK activation\n4285: Chronic Oleoylethanolamide Treatment Decreases Hepatic Triacylglycerol Level in Rat Liver by a PPAR\u03b3/SREBP-Mediated Suppression of Fatty Acid and Triacylglycerol Synthesis\n4286: Chronic oleoylethanolamide treatment attenuates diabetes-induced mice encephalopathy by triggering peroxisome proliferator-activated receptor alpha in the hippocampus\n4287: Engineering yeast phospholipid metabolism for de novo oleoylethanolamide production\n4288: Ethanolamine Produced from Oleoylethanolamide Degradation Contributes to Acetylcholine/Dopamine Balance Modulating Eating Behavior\n4289: Effects of oleoylethanolamide supplementation on inflammatory biomarkers, oxidative stress and antioxidant parameters of obese patients with NAFLD on a calorie-restricted diet: A randomized controlled trial\n4290: Dysfunctional oleoylethanolamide signaling in a mouse model of Prader-Willi syndrome\n4291: Oleoylethanolamide Modulates BDNF-ERK Signaling and Neurogenesis in the Hippocampi of Rats Exposed to \u03949-THC and Ethanol Binge Drinking During Adolescence\n4292: Oleoylethanolamide, an endogenous PPAR-\u03b1 ligand, attenuates liver fibrosis targeting hepatic stellate cells\n4293: N-oleoylethanolamide suppresses intimal hyperplasia after balloon injury in rats through AMPK/PPAR\u03b1 pathway\n4294: Oleoylethanolamide protects human sperm cells from oxidation stress: studies on cases of idiopathic infertility\n4295: Effects of Alcohol Binge Drinking and Oleoylethanolamide Pretreatment in the Gut Microbiota\n4296: Oleoylethanolamide-induced anorexia in rats is associated with locomotor impairment\n4297: Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice\n4298: Oleoylethanolamide: a novel potential pharmacological alternative to cannabinoid antagonists for the control of appetite\n4299: Gastrointestinal regulation of food intake: general aspects and focus on anandamide and oleoylethanolamide\n4300: Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPAR\u03b1 receptor-independent mechanism\n4301: Oleoylethanolamide treatment reduces neurobehavioral deficits and brain pathology in a mouse model of Gulf War Illness\n4302: The Effect of Oleoylethanolamide (OEA) Add-On Treatment on Inflammatory, Oxidative Stress, Lipid, and Biochemical Parameters in the Acute Ischemic Stroke Patients: Randomized Double-Blind Placebo-Controlled Study\n4304: Oleoylethanolamide Supplementation Reduces Inflammation and Oxidative Stress in Obese People: A Clinical Trial\n4306: Oleoylethanolamide treatment affects gut microbiota composition and the expression of intestinal cytokines in Peyer's patches of mice\n4308: Synthesis of oleoylethanolamide using lipase\n4310: Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson\u00b4s disease\n4312: Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats\n4314: Oleoylethanolamide: effects on hypothalamic transmitters and gut peptides regulating food intake\n4316: A sensitive LC-MS/MS method for the study of exogenously administered13C-oleoylethanolamide in rat plasma and brain tissue\n4317: Brain histamine and oleoylethanolamide restore behavioral deficits induced by chronic social defeat stress in mice\n4319: Chronic oleoylethanolamide treatment improves spatial cognitive deficits through enhancing hippocampal neurogenesis after transient focal cerebral ischemia\n4322: Oleoylethanolamide enhances \u03b2-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat\n4324: Simultaneous quantification of endocannabinoids, oleoylethanolamide and steroid hormones in human plasma and saliva\n4325: Oleic acid and oleoylethanolamide decrease interferon-\u03b3-induced expression of PD-L1 and induce apoptosis in human lung carcinoma cells\n4326: Mast Cell-Derived Histamine Regulates Liver Ketogenesis via Oleoylethanolamide Signaling\n4327: Oleoylethanolamide exerts anti-inflammatory effects on LPS-induced THP-1 cells by enhancing PPAR\u03b1 signaling and inhibiting the NF-\u03baB and ERK1/2/AP-1/STAT3 pathways\n4328: Oleoylethanolamide inhibits \u03b1-melanocyte stimulating hormone-stimulated melanogenesis via ERK, Akt and CREB signaling pathways in B16 melanoma cells\n4329: Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration\n4330: Role of the satiety factor oleoylethanolamide in alcoholism\n4331: A role for oleoylethanolamide in chronic lymphocytic leukemia\n4332: Possible therapeutic effects of boron citrate and oleoylethanolamide supplementation in patients with COVID-19: A pilot randomized, double-blind, clinical trial\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug79_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Cagrilintide\" (also known as \"cagrilintide\"), here are the article headings along with their IDs:\n4303: Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial\n4305: Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial\n4307: Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity\n4309: Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial\n4311: Development of Cagrilintide, a Long-Acting Amylin Analogue\n4313: Cagrilintide plus semaglutide for obesity management\n4315: Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis\n4318: Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants\n4320: Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models\n4323: A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide's Effects on Energy Balance\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug80_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Cagrisema\" (also known as \"cagrisema\"), here are the article headings along with their IDs:\n4321: CagriSema and the link between obesity and type 2 diabetes\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug81_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"GHRP-2\" (also known as \"ghrp-2\"), here are the article headings along with their IDs:\n4333: Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN\n4334: GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1\n4335: On the road of dried blood spot sampling for antidoping tests: Detection of GHRP-2 abuse\n4336: Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation\n4337: Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice\n4338: Laparoscopic Sleeve Gastrectomy Resolves Low GHRP-2-Stimulated Growth Hormone Levels in Obese Patients\n4340: Effect of GHRH and GHRP-2 treatment in vitro on GH secretion and levels of GH, pituitary transcription factor-1, GHRH-receptor, GH-secretagogue-receptor and somatostatin receptor mRNAs in ovine pituitary cells\n4343: Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH\n4344: The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients: a comparison\n4346: Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats\n4348: GHRP-2 attenuates burn-induced dysfunctions in rodents\n4350: The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone\n4353: Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men\n4356: Influence of intravenous administration of growth hormone releasing peptide-2 (GHRP-2) on detection of growth hormone doping: growth hormone isoform profiles in Japanese male subjects\n4358: Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement\n4360: GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans\n4364: Effect of growth hormone-releasing peptide-2 (GHRP-2) and GH-releasing hormone (GHRH) on the the cAMP levels and GH release from cultured acromegalic tumours\n4367: Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells\n4370: The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine\n4372: Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial\n4375: Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle\n4378: Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp\n4380: Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry\n4381: Concordant and discordant adrenocorticotropin (ACTH) responses induced by growth hormone-releasing peptide-2 (GHRP-2), corticotropin-releasing hormone (CRH) and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders: evidence for direct ACTH releasing activity of GHRP-2\n4382: Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans\n4385: Effects of growth hormone-releasing peptide-2 (GHRP-2) on membrane Ca2+ permeability in cultured ovine somatotrophs\n4387: General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide\n4389: Is GHRH receptor essential to GHRP-2-induced GH secretion in primary cultured rat pituitary cells?\n4391: Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide\n4393: Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise\n4396: Effects of the administration of growth hormone-releasing peptide-2 (GHRP-2) orally by gavage and in feed on growth hormone release in swine\n4399: Identification and quantification of the doping agent GHRP-2 in seized unlabelled vials by NMR and MS: a case-report\n4401: Ghrelin receptor agonist, GHRP-2, attenuates burn injury-induced MuRF-1 and MAFbx expression and muscle proteolysis in rats\n4403: Differential regulation of GHRH-receptor and GHS-receptor expression by long-term in vitro treatment of ovine pituitary cells with GHRP-2 and GHRH\n4405: The effect of GH-releasing peptide-2 (GHRP-2 or KP 102) on GH secretion from primary cultured ovine pituitary cells can be abolished by a specific GH-releasing factor (GRF) receptor antagonist\n4407: Effects of muscarinic and adrenergic blockade on growth hormone secretion induced by growth hormone-releasing peptide-2 (GHRP-2) in ovariectomized ewes\n4409: Effects of dietary protein and growth hormone-releasing peptide (GHRP-2) on plasma IGF-1 and IGFBPs in Holstein steers\n4410: Characteristics of growth hormone secretion responsiveness to growth hormone-releasing peptide-2 (GHRP-2 or KP102) in calves\n4411: Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children\n4412: The effect of two-day treatment of primary cultured ovine somatotropes with GHRP-2 on membrane voltage-gated K+ currents\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug83_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Ipamorelin\" (also known as \"ipamorelin\"), here are the article headings along with their IDs:\n4339: Ipamorelin, the first selective growth hormone secretagogue\n4341: Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats\n4342: Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus\n4345: Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus\n4347: Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption\n4349: Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers\n4351: The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats\n4354: The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus\n4357: Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients\n4361: Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro\n4363: The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism\n4366: The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats\n4369: Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats\n4373: A new series of highly potent growth hormone-releasing peptides derived from ipamorelin\n4376: Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug84_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Melanotan-II\" (also known as \"melanotan-ii\"), here are the article headings along with their IDs:\n4352: Melanotan II: a possible cause of renal infarction: review of the literature and case report\n4355: Melanotan II User Experience: A Qualitative Study of Online Discussion Forums\n4359: Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice\n4362: Melanotan II injection resulting in systemic toxicity and rhabdomyolysis\n4365: Melanotan II causes hypothermia in mice by activation of mast cells and stimulation of histamine 1 receptors\n4368: Melanotan II overdose associated with priapism\n4371: Analogue of Melanotan II (MTII): A Novel Melanotropin with Superpotent Action on Frog Skin\n4374: LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs\n4377: Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II\n4379: Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress\n4383: Combining MALDI mass spectrometry imaging and droplet-base surface sampling analysis for tissue distribution, metabolite profiling, and relative quantification of cyclic peptide melanotan II\n4384: Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet\n4386: Systemic delivery of melanotan II through the ocular route in rabbits\n4388: Intracerebroventricular administration of melanotan II increases insulin sensitivity of glucose disposal in mice\n4390: The medial preoptic nucleus as a site of the thermogenic and metabolic actions of melanotan II in male rats\n4392: Melanocortinergic activation by melanotan II inhibits feeding and increases uncoupling protein 1 messenger ribonucleic acid in the developing rat\n4394: Effects of melanotan II, a melanocortin agonist, on grooming and exploration in rats after repeated restraint/immobilization\n4395: Response to letter to the editor regarding \"melanotan II injection resulting in systemic toxicity and rhabdomyolysis\" in Clinical Toxicology 2012; 50(10):1169-73\n4397: The first preparative solution phase synthesis of melanotan II\n4398: The melanocortin agonist melanotan II increases insulin sensitivity in OLETF rats\n4400: Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery\n4402: Food intake reductions and increases in energetic responses by hindbrain leptin and melanotan II are enhanced in mice with POMC-specific PTP1B deficiency\n4404: Unabated anorexic and enhanced thermogenic responses to melanotan II in diet-induced obese rats despite reduced melanocortin 3 and 4 receptor expression\n4406: Determination of melanotan II in rabbit urine using solid-phase extraction sample preparation followed by reversed-phase high-performance liquid chromatography\n4408: Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug85_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"PT-141\" (also known as \"pt-141\"), here are the article headings along with their IDs:\n4413: PT-141 Palatin\n4414: PT-141: a melanocortin agonist for the treatment of sexual dysfunction\n4415: Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra\n4416: Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response\n4417: Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction\n4418: An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug86_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Retatrutide\" (also known as \"retatrutide\"), here are the article headings along with their IDs:\n4420: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial\n4422: Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA\n4424: Retatrutide showing promise in obesity (and type 2 diabetes)\n4426: Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?\n4428: Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial\n4430: Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply\n4431: A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity\n4433: Retatrutide\n4435: Retatrutide: a triple incretin receptor agonist for obesity management\n4437: At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide\n4439: The power of three: Retatrutide's role in modern obesity and diabetes therapy\n4440: Triple-Hormone-Receptor Agonist Retatrutide for Obesity\n4442: Triple-Hormone-Receptor Agonist Retatrutide for Obesity\n4444: Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials\n4445: Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss\n4447: The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying\n4449: Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence\n4451: Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide\n4452: Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials\n4454: The First Triple Agonist for Antiobesity: Retatrutide\n4456: Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice\n4459: The \"Weight\" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity\n4461: Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis\n4464: Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug87_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Semaglutide\" (also known as \"semaglutide\"), here are the article headings along with their IDs:\n4419: Safety of Semaglutide\n4421: Wegovy (semaglutide): a new weight loss drug for chronic weight management\n4423: Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis\n4425: Semaglutide for the treatment of obesity\n4427: Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial\n4429: Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial\n4432: Semaglutide lowers body weight in rodents via distributed neural pathways\n4434: Semaglutide (Ozempic) for weight loss\n4436: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide\n4438: As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss\n4441: Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide\n4443: Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity\n4446: Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation\n4448: Semaglutide as a promising antiobesity drug\n4450: Semaglutide: First Global Approval\n4453: Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial\n4455: Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial\n4458: Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials\n4462: Semaglutide and pregnancy\n4466: Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial\n4467: A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes\n4468: Semaglutide: a new drug for the treatment of obesity\n4469: The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity\n4470: Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial\n4471: Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist\n4472: Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial\n4473: Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model\n4474: Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis\n4475: Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review\n4476: The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission\n4477: Efficacy and safety of semaglutide for weight management: evidence from the STEP program\n4478: Clinical review of subcutaneous semaglutide for obesity\n4479: Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial\n4480: Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes\n4481: A systematic review of the effect of semaglutide on lean mass: insights from clinical trials\n4482: Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist\n4483: Semaglutide inhibits ischemia/reperfusion-induced cardiomyocyte apoptosis through activating PKG/PKC\u03b5/ERK1/2 pathway\n4484: Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials\n4485: Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats\n4486: Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species\n4487: Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)\n4488: Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial\n4489: Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials\n4490: Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial\n4491: A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes\n4492: Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials\n4493: Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials\n4495: Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report\n4496: Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5\n4499: Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes\n4503: Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats\n4505: Semaglutide (Wegovy) for weight loss\n4508: Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide\n4510: Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes\n4512: Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial\n4514: Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction\n4515: Clinical Pharmacokinetics of Semaglutide: A Systematic Review\n4517: Oral semaglutide in type 2 diabetes\n4518: Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes\n4521: Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss\n4523: Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity\n4525: Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial\n4527: Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial\n4529: Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes\n4530: Semaglutide for Weight Loss: Was It Worth the Weight?\n4532: Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole\u2011kindled mice\n4533: Semaglutide and heart failure: Updated meta-analysis\n4536: Semaglutide alters gut microbiota and improves NAFLD in db/db mice\n4538: Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial\n4539: Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging\n4542: Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis\n4545: Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report\n4548: Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss\n4550: Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database\n4551: Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study)\n4553: Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials\n4556: Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial\n4558: Semaglutide and obesity: beyond the nutritional and lifestyle intervention?\n4560: Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity\n4562: Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison\n4565: Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice\n4566: Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis\n4568: Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis\n4570: An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism\n4571: Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States\n4575: A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes\n4578: Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6\n4580: Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review\n4583: Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment\n4585: Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel\n4588: Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis\n4593: Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet\n4596: Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme\n4599: Administration errors of compounded semaglutide reported to a poison control center-Case series\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug88_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"TB-500\" (also known as \"tb-500\"), here are the article headings along with their IDs:\n4457: Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro\n4460: Doping control analysis of TB-500, a synthetic version of an active region of thymosin \u03b2\u2084, in equine urine and plasma by liquid chromatography-mass spectrometry\n4463: Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5\n4465: Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug89_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Tirzepatide\" (also known as \"tirzepatide\"), here are the article headings along with their IDs:\n4498: Tirzepatide: A Systematic Update\n4501: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes\n4506: Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis\n4509: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial\n4511: Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity\n4513: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial\n4516: Tirzepatide Once Weekly for the Treatment of Obesity\n4519: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial\n4520: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics\n4522: Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction\n4524: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes\n4526: Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial\n4528: Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management\n4531: Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis\n4534: Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial\n4535: Tirzepatide and prevention of chronic kidney disease\n4537: Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist\n4540: Tirzepatide\n4541: Tirzepatide\n4543: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial\n4544: Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis\n4546: Tirzepatide for Obesity Treatment and Diabetes Prevention\n4547: Tirzepatide: First Approval\n4549: Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial\n4552: Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial\n4554: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity\n4555: Tirzepatide: A Review in Type 2 Diabetes\n4557: Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review\n4559: New Drug: Tirzepatide (Mounjaro\u2122)\n4561: Beyond glycemia: Comparing tirzepatide to GLP-1 analogues\n4563: Tirzepatide\n4564: Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program\n4567: Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity\n4569: Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial\n4572: Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis\n4574: Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial\n4577: Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial\n4581: Tirzepatide (Zepbound) for chronic weight management\n4584: Tirzepatide (Mounjaro) for type 2 diabetes\n4586: Tirzepatide for type 2 diabetes\n4589: Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue\n4591: Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist\n4594: Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes\n4598: Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis\n4600: Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial\n4603: Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective\n4604: GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice\n4606: Tirzepatide for type 2 diabetes\n4607: Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial\n4609: The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide\n4611: The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials\n4613: Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond\n4615: Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial\n4617: Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway\n4619: Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity\n4622: The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome\n4624: Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus\n4626: Tirzepatide (Mounjaro\u00ae, Zepbound\u00ae)\n4628: The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets\n4629: Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity\n4632: Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials\n4634: Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes\n4635: Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide\n4638: Tirzepatide: Clinical review of the \"twincretin\" injectable\n4640: Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP\n4641: The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?\n4644: Tirzepatide-Friend or Foe in Diabetic Cancer Patients?\n4645: Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial\n4647: Tirzepatide for overweight and obesity management\n4649: Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents\n4651: Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials\n4652: Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis\n4654: Tirzepatide (Mounjaro) - a novel Pharmacotherapeutic Agent for Obesity\n4656: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis\n4658: Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes\n4660: Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial\n4661: The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists\n4664: Adverse Events Related to Tirzepatide\n4666: Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens\n4669: Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis\n4670: Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes\n4673: Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor\n4677: Structural determinants of dual incretin receptor agonism by tirzepatide\n4680: Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence\n4683: A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes\n4687: Tirzepatide for Weight Loss: Can Medical Therapy \"Outweigh\" Bariatric Surgery?\n4690: Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison\n4691: Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis\n4694: Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials\n4697: The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception\n4700: Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial\n4702: Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy)\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug90_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"AOD-9604\" (also known as \"aod-9604\"), here are the article headings along with their IDs:\n4494: AOD-9604 Metabolic\n4497: AOD-9604 does not influence the WADA hGH isoform immunoassay\n4500: Detection and in vitro metabolism of AOD9604\n4502: Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model\n4504: Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604\n4507: The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug91_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"SS-31\" (also known as \"ss-31\"), here are the article headings along with their IDs:\n4573: SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease\n4576: Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice\n4579: Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages\n4582: SS-31 inhibits mtDNA-cGAS-STING signaling to improve POCD by activating mitophagy in aged mice\n4587: SS-31 Protects Liver from Ischemia-Reperfusion Injury via Modulating Macrophage Polarization\n4590: SS-31 alleviated nociceptive responses and restored mitochondrial function in a headache mouse model via Sirt3/Pgc-1\u03b1 positive feedback loop\n4592: SS-31 as a Mitochondrial Protectant in the Treatment of Tendinopathy: Evaluation in a Murine Supraspinatus Tendinopathy Model\n4595: SS-31 Improves Cognitive Function in Sepsis-Associated Encephalopathy by Inhibiting the Drp1-NLRP3 Inflammasome Activation\n4597: Mitochondrial protein interaction landscape of SS-31\n4601: Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model\n4602: SS-31 does not prevent or reduce muscle atrophy 7 days after a 65 kdyne contusion spinal cord injury in young male mice\n4605: SS-31 efficacy in a mouse model of Friedreich ataxia by upregulation of frataxin expression\n4608: SS-31 protect retinal pigment epithelial cells from H2O2-induced cell injury by reducing apoptosis\n4610: SS-31 modification alleviates ferroptosis induced by superparamagnetic iron oxide nanoparticles in hypoxia/reoxygenation cardiomyocytes\n4612: SS-31 reduces inflammation and oxidative stress through the inhibition of Fis1 expression in lipopolysaccharide-stimulated microglia\n4614: SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome\n4616: SS-31 Provides Neuroprotection by Reversing Mitochondrial Dysfunction after Traumatic Brain Injury\n4618: SS-31 mitigates oxidative stress and restores mitochondrial function in cigarette smoke-damaged oral epithelial cells via PINK1-mediated mitophagy\n4620: Mitochondria-targeting peptide SS-31 attenuates ferroptosis via inhibition of the p38 MAPK signaling pathway in the hippocampus of epileptic rats\n4621: Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins\n4623: Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in Diabetes Mellitus and Alzheimer's disease\n4625: SS-31 and NMN: Two paths to improve metabolism and function in aged hearts\n4627: SS-31 inhibits the inflammatory response by increasing ATG5 and promoting autophagy in lipopolysaccharide-stimulated HepG2 cells\n4630: Mitochondrial-Targeting Antioxidant SS-31 Suppresses Airway Inflammation and Oxidative Stress Induced by Cigarette Smoke\n4631: Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction\n4633: Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice\n4636: Targeting Mitochondria by SS-31 Ameliorates the Whole Body Energy Status in Cancer- and Chemotherapy-Induced Cachexia\n4637: Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31\n4639: Mitochondria-targeted antioxidant peptide SS-31 mediates neuroprotection in a rat experimental glaucoma model\n4642: SS-31 ameliorates hepatic injury in rats subjected to severe burns plus delayed resuscitation via inhibiting the mtDNA/STING pathway in Kupffer cells\n4643: Increased Survival Time With SS-31 After Prolonged Cardiac Arrest in Rats\n4646: The mitochondrial antioxidant SS-31 attenuated lipopolysaccharide-induced apoptosis and pyroptosis of nucleus pulposus cells via scavenging mitochondrial ROS and maintaining the stability of mitochondrial dynamics\n4648: SS-31 Peptide Reverses the Mitochondrial Fragmentation Present in Fibroblasts From Patients With DCMA, a Mitochondrial Cardiomyopathy\n4650: The Mitochondrial Antioxidant SS-31 Modulates Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Type 2 Diabetes\n4653: Targeting mitochondria in the aged cerebral vasculature with SS-31, a proteomic study of brain microvessels\n4655: The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT)\n4657: Elamipretide (SS-31) Improves Functional Connectivity in Hippocampus and Other Related Regions Following Prolonged Neuroinflammation Induced by Lipopolysaccharide in Aged Rats\n4659: The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action\n4662: SS-31 attenuates TNF-\u03b1 induced cytokine release from C2C12 myotubes\n4663: Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice\n4667: SS-31 peptide enables mitochondrial targeting drug delivery: a promising therapeutic alteration to prevent hair cell damage from aminoglycosides\n4671: Protective effects of SS-31 against SDHB suppression-mitochondrial dysfunction-EndMT axis-modulated CBT sclerosis and progression\n4674: SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting\n4678: The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age\n4681: Role of AQP3 in the Vascular Leakage of Sepsis and the Protective Effect of Ss-31\n4684: Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy\n4686: Protective effects of mitochondrion-targeted peptide SS-31 against hind limb ischemia-reperfusion injury\n4689: Mitochondria targeted peptide SS-31 prevent on cisplatin-induced acute kidney injury via regulating mitochondrial ROS-NLRP3 pathway\n4692: Enhanced efficiency of mitochondria-targeted peptide SS-31 for acute kidney injury by pH-responsive and AKI-kidney targeted nanopolyplexes\n4695: A 50 kdyne contusion spinal cord injury with or without the drug SS-31 was not associated with major changes in muscle mass or gene expression 14 d after injury in young male mice\n4699: Novel SS-31 modified liposomes for improved protective efficacy of minocycline against drug-induced hearing loss\n4703: The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes\n4706: Peptide SS-31 upregulates frataxin expression and improves the quality of mitochondria: implications in the treatment of Friedreich ataxia\n4708: Mitochondria-Targeted Antioxidant SS-31 is a Potential Novel Ophthalmic Medication for Neuroprotection in Glaucoma\n4710: Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice\n4712: Mitochondrion-Targeted Peptide SS-31 Inhibited Oxidized Low-Density Lipoproteins-Induced Foam Cell Formation through both ROS Scavenging and Inhibition of Cholesterol Influx in RAW264.7 Cells\n4714: The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin\n4716: Age-related disruption of the proteome and acetylome in mouse hearts is associated with loss of function and attenuated by elamipretide (SS-31) and nicotinamide mononucleotide (NMN) treatment\n4718: Differential Effects of the Mitochondria-Active Tetrapeptide SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2) and Its Peptidase-Targeted Prodrugs in Experimental Acute Kidney Injury\n4720: Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH2) derivatives as potent agents to ameliorate inflammation and increase mitochondrial ATP synthesis\n4721: Elamipretide (SS-31) Ameliorates Isoflurane-Induced Long-Term Impairments of Mitochondrial Morphogenesis and Cognition in Developing Rats\n4722: [Protective effect of mitochondria-targeted antioxidant peptide SS-31 in sepsis-induced acute kidney injury]\n4723: Protective Effects of Antioxidant Peptide SS-31 Against Multiple Organ Dysfunctions During Endotoxemia\n4724: Chronic administration of mitochondrion-targeted peptide SS-31 prevents atherosclerotic development in ApoE knockout mice fed Western diet\n4725: Mitochondria-targeted reactive oxygen species blockor SS-31 blocks hepatic stellate cell activation and alleviates hepatic fibrosis by regulating NLRP3 inflammasomes\n4726: Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function\n4727: Protective Effect of Bendavia (SS-31) Against Oxygen/Glucose-Deprivation Stress-Induced Mitochondrial Damage in Human Brain Microvascular Endothelial Cells\n4728: Correction: Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31\n4729: Hypertension Exacerbates Cerebrovascular Oxidative Stress Induced by Mild Traumatic Brain Injury: Protective Effects of the Mitochondria-Targeted Antioxidative Peptide SS-31\n4730: BDNF pathway is involved in the protective effects of SS-31 on isoflurane-induced cognitive deficits in aging mice\n4731: Treatment with the mitochondrial-targeted antioxidant peptide SS-31 rescues neurovascular coupling responses and cerebrovascular endothelial function and improves cognition in aged mice\n4732: Role of mitochondrial dysfunction in renal fibrosis promoted by hypochlorite-modified albumin in a remnant kidney model and protective effects of antioxidant peptide SS-31\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug92_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Epithalon\" (also known as \"epithalon\"), here are the article headings along with their IDs:\n4665: Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice\n4668: Epithalon inhibits tumor growth and expression of HER-2/neu oncogene in breast tumors in transgenic mice characterized by accelerated aging\n4672: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells\n4675: Effect of epithalon on the incidence of chromosome aberrations in senescence-accelerated mice\n4676: Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology\n4679: Effects of epithalon on activities gastrointestinal enzymes in young and old rats\n4682: Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeys\n4685: Effect of Vilon and Epithalon on glucose and glycine absorption in various regions of small intestine in aged rats\n4688: Effect of epithalon on age-specific changes in the retina in rats with hereditary pigmentary dystrophy\n4693: Effect of vilon and epithalon on activity of enzymes in epithelial and subepithelial layers in small intestine of old rats\n4696: Reparative effect of epithalon on pineal gland ultrastructure in gamma-irradiated rats\n4698: Modulating effects of epithalamin and epithalon on the functional morphology of the spleen in old pinealectomized rats\n4701: [Effects of epithalon and cortagene on immunity and hemostasis in neonatally hypophysectomized chicken and old birds]\n4704: Expression of argyrophilic proteins in the nucleolar organizer regions of human thymocytes and thymic epitheliocytes under conditions of coculturing with vilon and epithalon peptides\n4705: Immunohistochemical and morphometric analysis of effects of vilon and epithalon on functional morphology of radiosensitive organs\n4707: Retinoprotective effect of Epithalon in campbell rats of various ages\n4709: Fluorescent microscopic study of epithalon binding in maternal and fetal rabbit tissues in health and under conditions of placental insufficiency\n4711: [Protective effect of melatonin and epithalon on hypothalamic regulation of reproduction in female rats in its premature aging model and on estrous cycles in senescent animals in various lighting regimes]\n4713: [The influence of melatonin and epithalon on blood leukocyte count and leukocyte alkaline phosphatase in rats under different lighting conditions during ontogenesis]\n4715: Regulating effect of epithalone on gastric endocrine cells in pinealectomized rats\n4717: Effect of epithalone on the age-specific changes in the time course of lipid peroxidation in Drosophila melanogaster\n4719: [Effect of vilon and epithalone on induction and growth of induced bladder neoplasms in rats]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug94_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"thymosinalpha1\" (also known as \"thymosinalpha1\"), here are the article headings along with their IDs:\n4733: Thymosinalpha1 stimulates cell proliferation by activating ERK1/2, JNK, and increasing cytokine secretion in human pancreatic cancer cells\n4734: Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice\n4735: Immune modulation via dendritic cells by the effect of Thymosin-alpha-1 on immune synapse in HCMV infection\n4736: Enhanced Immunomodulatory Effects of Thymosin-Alpha-1 in Combination with Polyanionic Carbosilane Dendrimers against HCMV Infection\n4737: Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B\n4738: Thymosin alpha1 enhanced cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression\n4739: Thymosin-alpha1 promotes the apoptosis of regulatory T cells and survival rate in septic mice\n4740: Elevated plasma thymosin-alpha1 levels in lung cancer patients\n4741: A role of the thymus and thymosin-alpha1 in brain NGF levels and NGF receptor expression\n4742: Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching\n4743: Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial\n4744: Thymosin-alpha1 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14+ monocytes\n4745: A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B\n4746: Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma\n4747: [Prevention Effect of Thymosin-alpha1 Aganist Early Ventilator-associated Pneumonia in Patients with Mechanical Ventilation]\n4748: Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level\n4749: Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris\n4750: Effect of recombinant human thymosin-alpha1, an immuno-modulating peptide with 28 amino acids, on the activity of cytochrome P450s\n4751: Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase\n4752: Thymosin-alpha1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model\n4755: In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B\n4757: Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B\n4759: A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B\n4762: A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B\n4766: In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C\n4768: [Effects of thymosin-alpha1 on cell immunity function in patients with septic shock]\n4770: Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma\n4774: Modulatory role of thymosin-alpha-1 in normal bone-marrow haematopoiesis and its effect on myelosuppression in T-cell lymphoma bearing mice\n4775: Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B\n4777: Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study\n4781: Effect of thymosin-alpha1 on the production of nitric oxide by tumor-associated macrophages\n4782: [Purification of recombinant proteins with an example of tumor necrosis factor thymosin-alpha1]\n4785: [Expression and activity analysis of interferonalpha-con and thymosin-alpha1]\n4787: [Impact of thymosin-alpha1 on reproduction of herpes simplex virus in cell system and on course of acute experimental infection in mice]\n4789: Activation of murine bone-marrow derived macrophages in vitro with Thymosin-alpha-1 to tumoricidal state: a comparative study on normal and tumour-bearing hosts\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug95_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"DSIP\" (also known as \"dsip\"), here are the article headings along with their IDs:\n4753: Delta-sleep-inducing peptide (DSIP): an update\n4754: Delta sleep-inducing peptide (DSIP): a still unresolved riddle\n4756: DSIP in insomnia\n4758: DSIP--a tool for investigating the sleep onset mechanism: a review\n4760: DSIP in sleep disturbances\n4763: Delta-sleep-inducing peptide (DSIP): a review\n4765: [DSIP: the sleep peptide or an unknown hypothalamic hormone?]\n4767: Entry of DSIP peptides into dog CSF: role of physicochemical and pharmacokinetic parameters\n4771: DSIP in the treatment of withdrawal syndromes from alcohol and opiates\n4773: DSIP reduces amphetamine-induced hyperthermia in mice\n4776: CSF-plasma relationships for DSIP and some other neuropeptides\n4778: Characterization of the release and metabolism of delta sleep-inducing peptide (DSIP) in the rat brain\n4779: Radioimmunoassay of DSIP-like material in human blood: possible protein binding\n4780: DSIP occurs in free form in mammalian plasma, human CSF and urine\n4783: Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP)\n4784: DSIP/DSIP-P and circadian motor activity of rats under continuous light\n4786: Pichia pastorissecreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models\n4788: Modulation of immunoactive levels of DSIP and blood-brain permeability by lighting and diurnal rhythm\n4790: DSIP-like material in brain parts of rats running a complex maze\n4791: The effect of delta sleep-inducing peptide (DSIP) and phosphorylated DSIP (P-DSIP) on the apomorphine-induced hypothermia in rats\n4792: Effects of DSIP on narcolepsy\n4793: Sleep-promoting effect of the sleep-promoting substance (SPS) and delta sleep-inducing peptide (DSIP) in the mouse\n4794: Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP)\n4795: Delta-sleep inducing peptide (DSIP) and ACTH (4-10) analogue influence fos-induction in the limbic structures of the rat brain under emotional stress\n4796: Effects of repeated DSIP and DSIP-P administration on the circadian locomotor activity of rats\n4797: Differential penetration of DSIP peptides into rat brain\n4798: Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs\n4799: DSIP-induced changes of the daily concentrations of brain neurotransmitters and plasma proteins in rats\n4800: Structure-activity relationship in the effects of delta-sleep-inducing peptide (DSIP) on rat sleep\n4801: DSIP-like immunoreactivity in the developing rat brain\n4802: Delta sleep-inducing peptide (DSIP) stimulates LH release in steroid-primed ovariectomized rats\n4803: Purification and characterization of DSIP-like material from ovine pineal glands: possible peptide-protein interaction\n4804: Some pharmacological effects of delta-sleep-inducing peptide (DSIP)\n4805: A clinical trial with DSIP\n4806: [Olygopeptide KND as a putative endogenous prototype of delta sleep inducing peptide (DSIP). Comparative study of biological properties]\n4807: JmjC-domain-containing histone demethylases of the JMJD1B type as putative precursors of endogenous DSIP\n4808: Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum\n4809: Delta sleep-inducing peptide (DSIP)-like material is absorbed by the gastrointestinal tract of the neonatal rat\n4810: Comparison of DSIP- (delta sleep-inducing peptide) and P-DSIP-like (phosphorylated) immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type, multi-infarct syndrome, communicating hydrocephalus and Parkinson's disease\n4811: Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain\n4812: Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep\n4813: Human plasma DSIP decreases at the initiation of sleep at different circadian times\n4815: Amphetamine-induced locomotor behavior of mice is influenced by DSIP\n4816: Effects of delta-sleep inducing peptide (DSIP) and some analogues on the activity of monoamine oxidase type A in rat brain under hypoxia stress\n4818: Circadian effects of beta-endorphin, melatonin, DSIP, and amphetamine on pentylenetetrazol-induced seizures\n4819: Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs\n4821: Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia\n4823: Human pheochromocytoma cells studied in culture contain large amounts of DSIP-like material\n4826: The effect of subcutaneous administration of delta sleep-inducing peptide (DSIP) on some parameters of sleep in the cat\n4829: Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior\n4832: Sleep-promoting effect following intracerebroventricular injection of a phosphorylated analogue of delta sleep-inducing peptide (DSIP-P) in rats\n4834: Delta sleep inducing peptide (DSIP) stimulates the release of LH but not FSH via a hypothalamic site of action in the rat\n4839: Radioimmunoassay of DSIP-like material in rat brain\n4841: The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide\n4842: DSIP affects adrenergic stimulation of rat pineal N-acetyltransferase in vivo and in vitro\n4844: Delta sleep-inducing-peptide-like immunoreactivity (DSIP-LI) and delta sleep in schizophrenic volunteers\n4845: Thermoregulatory and locomotor effects of DSIP: paradoxical interaction with d-amphetamine\n4847: The circadian cycle effects of DSIP on colonic temperature, blood pressure, and heart rate in control and area postrema-lesioned rats\n4850: The effects of DSIP on pain threshold during light and dark periods in rats are not naloxone-sensitive\n4852: The phosphorylated analogue of DSIP enhances slow wave sleep and paradoxical sleep in unrestrained rats\n4855: The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat\n4856: Delta-sleep-inducing peptide (DSIP) stimulates the release of immunoreactive Met-enkephalin from rat lower brainstem slices in vitro\n4859: Aluminium increases permeability of the blood-brain barrier to labelled DSIP and beta-endorphin: possible implications for senile and dialysis dementia\n4861: Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study\n4862: [Effects of intraventricular injection of anti-DSIP serum on sleep in rats]\n4864: Immunohistochemical localization of delta sleep-inducing peptide (DSIP) in the brain and pituitary of the cartilaginous fish Scyliorhinus canicula\n4866: Delta sleep-inducing peptide (DSIP) has potent analgesic activity in mice\n4867: Passage of delta sleep-inducing peptide (DSIP) across the blood-cerebrospinal fluid barrier\n4869: Separation of tryptophan from DSIP, a Trp-nonapeptide, by adsorption to aluminum oxide\n4871: Effects of intracerebroventricular injection of delta sleep-inducing peptide (DSIP) and an analogue on sleep and brain temperature in rats at night\n4873: [The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia]\n4875: Synthesis of delta sleep-inducing peptide (DSIP) and its physiological activity\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug97_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Melanotani\" (also known as \"melanotani\"), here are the article headings along with their IDs:\n4761: Discovery and development of novel melanogenic drugs. Melanotan-I and -II\n4764: Skin pigmentation and pharmacokinetics of melanotan-I in humans\n4769: Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407\n4772: Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug98_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"GHK\" (also known as \"ghk\"), here are the article headings along with their IDs:\n4814: The potential of GHK as an anti-aging peptide\n4817: GHK peptide prevents sleep-deprived learning impairment in aging mice\n4820: GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration\n4822: Analyses of HH and GHK equations with another perspective: Can ion adsorption also govern trans-membrane potential?\n4824: Intranasal GHK peptide enhances resilience to cognitive decline in aging mice\n4827: In situ photo-crosslinkable hyaluronic acid-based hydrogel embedded with GHK peptide nanofibers for bioactive wound healing\n4830: The human tri-peptide GHK and tissue remodeling\n4833: Ultrasensitive and Label-Free Detection of Copper Ions by GHK-Modified Asymmetric Nanochannels\n4835: Evaluation of GHK peptide-heparin interactions in multifunctional liposomal covering\n4838: GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGF\u03b21/Smad-Mediated Epithelial-to-Mesenchymal Transition\n4840: Copper-GHK increases integrin expression and p63 positivity by keratinocytes\n4843: Expression and Purification of Recombinant GHK Tripeptides Are Able to Protect against Acute Cardiotoxicity from Exposure to Waterborne-Copper in Zebrafish\n4846: Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide\n4848: Glycine-Histidine-Lysine (GHK) Alleviates Astrocytes Injury of Intracerebral Hemorrhage via the Akt/miR-146a-3p/AQP4 Pathway\n4849: GHK and DNA: resetting the human genome to health\n4851: Coassemble dopamine and GHK tripeptide into fluorescent nanoparticles for pH sensing\n4853: New Biotinylated GHK and Related Copper(II) Complex: Antioxidant and Antiglycant Properties In Vitro against Neurodegenerative Disorders\n4854: Glycine-Histidine-Lysine (GHK) Alleviates Neuronal Apoptosis Due to Intracerebral Hemorrhage via the miR-339-5p/VEGFA Pathway\n4857: Biotinylated GHK peptide incorporated collagenous matrix: A novel biomaterial for dermal wound healing in rats\n4858: Oxidized alginate hydrogels with the GHK peptide enhance cord blood mesenchymal stem cell osteogenesis: A paradigm for metabolomics-based evaluation of biomaterial design\n4860: The copper(II)-binding tripeptide GHK, a valuable crystallization and phasing tag for macromolecular crystallography\n4863: Ternary Cu(II) Complex with GHK Peptide andCis-Urocanic Acid as a Potential Physiologically Functional Copper Chelate\n4865: Enhanced angiogenic effects of RGD, GHK peptides and copper (II) compositions in synthetic cryogel ECM model\n4868: Tripeptides Ghk and GhkCu-modified silver nanoparticles for enhanced antibacterial and wound healing activities\n4870: GHK eq. and HH eq. for a real system is mathematically associable to each other but their physiological interpretation needs a reconsideration\n4872: Enhanced trophic factor secretion by mesenchymal stem/stromal cells with Glycine-Histidine-Lysine (GHK)-modified alginate hydrogels\n4874: New GHK hydrophobic derivatives: interaction with phospholipid bilayers\n4876: Intermediate Cu(II)-Thiolate Species in the Reduction of Cu(II)GHK by Glutathione: A Handy Chelate for Biological Cu(II) Reduction\n4877: X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties\n4878: The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline\n4879: ESR studies of the interaction of copper(II)GHK, histidine, and Ehrlich cells\n4880: A new fluorescent chemosensor for copper ions based on tripeptide glycyl-histidyl-lysine (GHK)\n4881: Glycyl-histidyl-lysine (GHK) is a quencher of alpha,beta-4-hydroxy-trans-2-nonenal: a comparison with carnosine. insights into the mechanism of reaction by electrospray ionization mass spectrometry, 1H NMR, and computational techniques\n4882: Mass spectral and theoretical investigations of the transient proton-bound dimers on the cleavage processes of the peptide GHK and its analogues\n4883: A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK\n4884: Acrolein sequestering ability of the endogenous tripeptide glycyl-histidyl-lysine (GHK): characterization of conjugation products by ESI-MSn and theoretical calculations\n4885: Next-generation personalized drug discovery: the tripeptide GHK hits center stage in chronic obstructive pulmonary disease\n4886: Thermodynamic study of Cu2+ binding to the DAHK and GHK peptides by isothermal titration calorimetry (ITC) with the weaker competitor glycine\n4887: A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug100_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Mazdutide\" (also known as \"mazdutide\"), here are the article headings along with their IDs:\n4825: A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity\n4828: Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial\n4831: Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial\n4836: Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials\n4837: Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug101_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Thymalin\" (also known as \"thymalin\"), here are the article headings along with their IDs:\n4888: Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells\n4889: [Geroprotective effect of thymalin and epithalamin]\n4890: The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19\n4891: Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo\n4892: [Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin]\n4893: [Thymalin in the treatment of herpetic stomatitis in children]\n4894: [Thymalin in the combined treatment of patients with chronic lympholeukemia]\n4895: Reparative osteogenesis in mandible in cases of filling a bone defect with hydroxyapatite-containing osteotropic material and injecting the surrounding soft tissues with thymalin: experimental and morphological study\n4896: Expression features of T-lymphocytes, B-lymphocytes and macrophages in the post-traumatic regenerate of the mandible rats under conditions of filling a bone defect with hydroxyapatite-containing osteotropic material and thymalin injecting the surrounding soft tissues\n4897: Age-related changes of thymalin content in human epidermis\n4898: [Thymalin as a modulator of immunogenesis and hemostasis]\n4899: Thymalin in developing respiratory organs of human fetus\n4900: [The efficacy of using thymalin in diabetes mellitus in children]\n4901: [Use of thymalin in the complex treatment of patients with cancer of the uterus]\n4902: [Effect of a levopromazine-thymalin combination on the development of toxic edema and swelling in the brain]\n4903: [Thymalin in the treatment of patients with erysipelas]\n4904: [Use of thymalin in trauma patients]\n4905: [Effect of thymagen, thymalin and vilosen on the cAMP and cGMP levels and phosphodiesterase activity in spleen lymphocytes during sensitization and anaphylactic shock]\n4907: [Effect of thymalin on immunologic reactivity of patients with non-specific lung diseases]\n4908: [Use of thymalin in treating periodontitis patients]\n4909: [Use of thymalin and heparin in acute peritonitis]\n4910: [Effect of thymalin on the immunological indices and morphofunctional structure of the uterus in guinea pigs with endometrial hyperplasia]\n4911: [Effect of thymalin on blood coagulation and fibrinolysis]\n4912: [Effect of thymalin on the function of the blood kallikrein-kinin system in thymectomized rats]\n4913: [Effect of thymalin on the cyclic nucleotide system in the mouse spleen]\n4914: [Effect of thymalin on the development of experimental hyperlipidemia and atherosclerosis]\n4915: [Effect of thymalin on the thymus and immunologic indices of irradiated animals]\n4916: [Effectiveness of thymalin and prodigiozan in the complex treatment of patients with dysentery]\n4917: [Efficacy of thymalin in the treatment of patients with traumatic osteomyelitis of the lower jaw]\n4918: [Effect of thymalin in young children with acute pneumonia]\n4919: [Comparative study of immunomodulatory activity of peptides, tinrostim and thymalin]\n4920: [Thymalin in the combined treatment of parkinsonism patients]\n4921: [Use of thymalin for preventing postoperative suppurative and inflammatory complications]\n4922: [Significance of thymalin, dekaris and theophylline tests in evaluating T-lymphocytes]\n4923: Experimental and clinical study of the thymus polypeptide factor thymalin\n4924: [Immunomodulating drugs, thymalin and T-activin in the treatment of chronic liver diseases]\n4926: [Use of thymalin in treating severe forms of inflammatory diseases of the maxillofacial area]\n4928: [Use of thymalin in the complex treatment of infantile cerebral palsy]\n4931: [The effect of thymalin on the development of sensitization with a soluble microbial antigen and on the phenotypic composition of lymphocyte subpopulations in the organs of immunity]\n4933: [Use of thymalin and kontrikal in the treatment of patients with injuries of the abdominal organs]\n4934: [Thymalin correction of the immunologic deficiency state in children with congenital 1st and 2d branchial arch syndrome]\n4936: [Use of thymalin in a patient with immunologic deficiency state after thymectomy]\n4938: [Use of T-activin and thymalin in the treatment of ophthalmic herpes]\n4940: [Homeostatic effect of thymalin in multiple sclerosis]\n4943: [Use of the immunomodulator thymalin in the treatment of nonspecific ulcerative colitis]\n4945: [Clinico-immunologic changes in patients with cervical cancer after treatment with thymalin]\n4946: [Effect of thyroxin and thymalin on proliferation and apoptosis of thymocytes in rats after thyroidectomy]\n4949: [Colony-forming units of the bone marrow and spleen of immunodeficient mice after stimulation of the cells with thymalin]\n4951: [The immunomodulating and metabolic actions of thymalin in an experimental herpetic infection]\n4953: [Use of the thymus preparation thymalin in suppurative-inflammatory processes with an allergic anamnesis]\n4955: [Immunomodulators in the therapy of rheumatoid arthritis. I. The use of thymalin]\n4957: [Experimental and clinical study of a new immunoregulator preparation thymalin]\n4958: [Comparative study of the effect of the thymus preparations thymoptin and thymalin on fibrin-monomer polymerization]\n4960: [Immunological disorders and their correction with thymalin in the surgical treatment of patients with 1st and 2nd branchial arch syndromes]\n4963: [Efficacy of using thymalin in different types of peritonitis in obstetrical practice]\n4966: [Preventive efficacy of thymalin in combination with vaccine preparations]\n4967: [Thymic polypeptide factor--thymalin in experiments and in clinical use]\n4972: [Combined treatment of suppurative inflammatory diseases of the maxillofacial area using thymalin]\n4973: [Prospects for using thymalin in treating bacterial intestinal infections]\n4976: [Use of the thymus preparation thymalin in the complex prevention of postoperative infectious complications after reconstructive biliary surgery]\n4979: [Clinical use of thymalin in the prophylaxis and treatment of infectious-inflammatory diseases of the maxillofacial region]\n4984: [Changes in cell immunity indexes under the influence of thymalin, thyroxine and fibronectin in patients with hyperplastic diseases of thyroid gland before and after the surgery]\n4987: [The dynamics of thymalin localization in human thymus cells in embryogenesis]\n4989: [The effect of thymalin on biochemical and immunological indices of lymphocyte differentiation and functional activity]\n4992: [The effect of thymalin on indices of immunity and hemostasis in patients with disseminated forms of psoriasis]\n4995: [The use of thymalin in the combined chemotherapy of patients with infiltrative destructive pulmonary tuberculosis]\n4997: [The use of thymalin in the combined treatment of patients with disseminated cancer of the cervix uteri]\n4998: [The lymphocyte subpopulation in patients with duodenal ulcer and the immunocorrective activity of thymalin and dalargin]\n5002: [The effect of combined therapy with the use of thymalin and piracetam on the level of middle-molecule peptides in the blood and on the lipid peroxidation activity in patients with diffuse toxic goiter]\n5003: [Immunogenesis and hemostasis in patients with exacerbated chronic glomerulonephritis treated with thymalin]\n5006: [Dynamics of immunological indices in patients with chronic viral hepatitis B and the effect of thymalin therapy]\n5007: [Effect of thymalin and epithalamin on the metastasis of experimental tumors irradiated with pulsed laser radiation]\n5009: [Structural and cytochemical changes in cerebral cortical neurons of the offspring of neurosensitized female rats after prenatal administration of thymalin]\n5011: [Use of thymalin in preventing respiratory infections]\n5013: [Effect of thymalin on the functional activity of circulating leukocytes]\n5014: [Effect of thymalin on the status of immunogenesis and hemostasis in patients with ischemic heart disease]\n5016: [Use of thymalin in the complex treatment of frostbite]\n5018: [Effect of thymalin on the motor activity of the progeny of neurosensitized rats]\n5020: [Use of thymalin in the diseases of early infancy]\n5022: [Use of thymalin in the treatment of diffuse suppurative peritonitis]\n5024: [Effect of thymalin on protein synthesis in the brain and conditioned-reflex activity of the progeny of neurosensitized female rats]\n5026: [Effect of thymalin on the course of suppurative peritonitis in children]\n5028: [Use of thymalin in appendicular peritonitis in children]\n5030: [Effects of thymalin on blood coagulation and contents of proinflammatory and anti-inflammatory cytokines in patients with burns]\n5032: [Effect of thymalin on thrombocyte aggregation and the antiaggregation activity of the vascular wall in intact and thymectomized rats]\n5034: Application of thymic factor \"Thymalin\" in complex treatment of endometrial cancer patients\n5036: [Effect of thymalin on the clinical course of influenza and the development of bacterial complications in young people]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug102_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Adamax\" (also known as \"adamax\"), here are the article headings along with their IDs:\n4906: Enhancing accuracy in brain stroke detection: Multi-layer perceptron with Adadelta, RMSProp and AdaMax optimizers\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug103_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"LL-37\" (also known as \"ll-37\"), here are the article headings along with their IDs:\n4925: LL-37 transports immunoreactive cGAMP to activate STING signaling and enhance interferon-mediated host antiviral immunity\n4927: Therapeutic Potential of Cathelicidin Peptide LL-37, an Antimicrobial Agent, in a Murine Sepsis Model\n4929: Regulation of LL-37 in Bone and Periodontium Regeneration\n4930: Antibiofilm properties of cathelicidin LL-37: an in-depth review\n4932: Antifungal properties of cathelicidin LL-37: current knowledge and future research directions\n4935: The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent\n4937: Cathelicidin LL-37: A new important molecule in the pathophysiology of systemic lupus erythematosus\n4939: LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity\n4941: Structural Plasticity of LL-37 Indicates Elaborate Functional Adaptation Mechanisms to Bacterial Target Structures\n4942: LL-37-dsRNA Complexes Modulate Immune Response via RIG-I in Oral Keratinocytes\n4944: LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunity\n4947: The Role of Cathelicidin LL-37 in Cancer Development\n4948: Serum LL-37 and inflammatory cytokines levels in psoriasis\n4950: Molecular mechanisms of LL-37-induced receptor activation: An overview\n4952: LL-37-Coupled Porous Composite Scaffold for the Treatment of Infected Segmental Bone Defect\n4954: Design of Antimicrobial Peptides: Progress Made with Human Cathelicidin LL-37\n4956: Roles and Mechanisms of Human Cathelicidin LL-37 in Cancer\n4959: Nanomolar LL-37 induces permeability of a biomimetic mitochondrial membrane\n4961: The Roles of Cathelicidin LL-37 in Inflammatory Bowel Disease\n4964: LL-37 Might Promote Local Invasion of Melanoma by Activating Melanoma Cells and Tumor-Associated Macrophages\n4968: LL-37 restored glucocorticoid sensitivity impaired by virus dsRNA in lung\n4970: Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections\n4975: Cathelicidin LL-37 Activates Human Keratinocyte Autophagy through the P2X\u2087, Mechanistic Target of Rapamycin, and MAPK Pathways\n4977: The chemistry and biology of LL-37\n4980: Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity\n4982: Unique features of human cathelicidin LL-37\n4985: LL-37-induced caspase-independent apoptosis is associated with plasma membrane permeabilization in human osteoblast-like cells\n4988: Cathelicidin LL-37: a multitask antimicrobial peptide\n4991: Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial\n4994: Long-Term Administration of LL-37 Can Induce Irreversible Rosacea-like Lesion\n4996: Human Cathelicidin Peptide LL-37 Induces Cell Death in Autophagy-Dysfunctional Endothelial Cells\n4999: The potentials of short fragments of human anti-microbial peptide LL-37 as a novel therapeutic modality for diseases\n5000: Antimicrobial Peptide LL-37 Drives Rosacea-Like Skin Inflammation in an NLRP3-Dependent Manner\n5004: Antimicrobial peptide cathelicidin LL-37 preserves intestinal barrier and organ function in rats with heat stroke\n5008: LL-37 promotes neutrophil extracellular trap formation in chronic rhinosinusitis with nasal polyps\n5010: LL-37 antimicrobial peptide and heterologous prime-boost vaccination regimen significantly induce HIV-1 Nef-Vpr antigen- and virion-specific immune responses in mice\n5012: Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome\n5015: Construction of exosome-loaded LL-37 and its protection against zika virus infection\n5017: LL-37-Induced Autophagy Contributed to the Elimination of LivePorphyromonas gingivalisInternalized in Keratinocytes\n5019: An in silico scientific basis for LL-37 as a therapeutic for Covid-19\n5021: Cathelicidin hCAP18/LL-37 promotes cell proliferation and suppresses antitumor activity of 1,25(OH)2D3in hepatocellular carcinoma\n5023: LL-37 and Double-Stranded RNA Synergistically Upregulate Bronchial Epithelial TLR3 Involving Enhanced Import of Double-Stranded RNA and Downstream TLR3 Signaling\n5025: Between good and evil: Complexation of the human cathelicidin LL-37 with nucleic acids\n5027: What can we learn about functional importance of human antimicrobial peptide LL-37 in the oral environment from severe congenital neutropenia (Kostmann disease)?\n5029: LL-37 as a Powerful Molecular Tool for Boosting the Performance of Ex Vivo-Produced Human Dendritic Cells for Cancer Immunotherapy\n5031: Human host-defense peptide LL-37 targets stealth siderophores\n5033: LL-37 and its analog FF/CAP18 attenuate neutrophil migration in sepsis-induced acute lung injury\n5035: The ratio of serum LL-37 levels to blood leucocyte count correlates with COVID-19 severity\n5037: Cathelicidin LL-37 promotes EMT, migration and metastasis of hepatocellular carcinoma cells in vitro and mouse model\n5038: The Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer Drugs\n5039: Cathelicidin LL-37 improves bone metabolic balance in rats with ovariectomy-induced osteoporosis via the Wnt/beta-catenin pathway\n5040: LL-37-induced human mast cell activation through G protein-coupled receptor MrgX2\n5041: Carbamylated LL-37 as a modulator of the immune response\n5042: The antimicrobial peptide LL-37 triggers release of apoptosis-inducing factor and shows direct effects on mitochondria\n5043: Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model\n5044: Cathelicidin (LL-37) causes expression of inflammatory factors in coronary artery endothelial cells of Kawasaki disease by activating TLR4-NF-\u03baB-NLRP3 signaling\n5045: Plant-Derived Polyphenol and LL-37 Peptide-Modified Nanofibrous Scaffolds for Promotion of Antibacterial Activity, Anti-Inflammation, and Type-H Vascularized Bone Regeneration\n5046: Vitamin D-induced LL-37 modulates innate immune responses of human primary macrophages during DENV-2 infection\n5047: Human cathelicidin LL-37 exerts amelioration effects against EHEC O157:H7 infection regarding inflammation, enteric dysbacteriosis, and impairment of gut barrier function\n5048: Exogenous LL-37 but not homogenates of desquamated oral epithelial cells shows activity againstStreptococcus mutans\n5049: LL-37 boosts immunosuppressive function of placenta-derived mesenchymal stromal cells\n5050: Role of LL-37 in Oral Bacterial DNA Accumulation in Dental Plaque\n5051: Residual Interactions of LL-37 with POPC and POPE:POPG Bilayer Model Studied by All-Atom Molecular Dynamics Simulation\n5052: LL-37 modulates human neutrophil responses to influenza A virus\n5053: Inactivation of the antimicrobial peptide LL-37 by pathogenic Leptospira\n5054: The roles of cathelicidin LL-37 in immune defences and novel clinical applications\n5055: LL-37 alone and in combination with IL17A enhances proinflammatory cytokine expression in parallel with hyaluronan metabolism in human synovial sarcoma cell line SW982-A step toward understanding the development of inflammatory arthritis\n5057: Cathelicidin LL-37 (an antimicrobial peptide)-induced colistin dependence in Acinetobacter baumannii\n5059: LL-37 attenuates inflammatory impairment via mTOR signaling-dependent mitochondrial protection\n5060: Oligomer Dynamics of LL-37 Truncated Fragments Probed by \u03b1-Hemolysin Pore and Molecular Simulations\n5062: The Human Antimicrobial Peptides Dermcidin and LL-37 Show Novel Distinct Pathways in Membrane Interactions\n5065: Cathelicidin LL-37 Expression in Human Breast Implant Capsules\n5067: Cathelicidin LL-37 promotes wound healing in diabetic mice by regulating TFEB-dependent autophagy\n5069: Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/\u03b2-catenin signaling\n5071: Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial\n5073: Human Host Defense Peptide LL-37 Suppresses TNF\u03b1-Mediated Matrix Metalloproteinases MMP9 and MMP13 in Human Bronchial Epithelial Cells\n5075: Efficacy of antimicrobial peptide LL-37 against biofilm forming Staphylococcus aureus strains obtained from chronic wound infections\n5077: Antimicrobial peptide LL-37 and its pro-form, hCAP18, in desquamated epithelial cells of human whole saliva\n5080: Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial\n5082: Application of Antimicrobial Peptide LL-37 as an Adjuvant for Middle East Respiratory Syndrome-Coronavirus Antigen Induces an Efficient Protective Immune Response Against Viral Infection After Intranasal Immunization\n5084: Interaction of LL-37 human cathelicidin peptide with a model microbial-like lipid membrane\n5085: SP-LL-37, human antimicrobial peptide, enhances disease resistance in transgenic rice\n5088: LL-37 Triggers Formation of Streptococcus pyogenes Extracellular Vesicle-Like Structures with Immune Stimulatory Properties\n5090: The effects of LL-37 on virulence factors related to the quorum sensing system ofPseudomonas aeruginosa\n5091: The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung\n5094: Evaluation of antimicrobial peptide LL-37 for treatment of Staphylococcus aureus biofilm on titanium plate\n5096: LL-37-induced host cell cytotoxicity depends on cellular expression of the globular C1q receptor (p33)\n5098: Studies on citrullinated LL-37: detection in human airways, antibacterial effects and biophysical properties\n5100: LL-37 but Not 25-Hydroxy-Vitamin D Serum Level Correlates with Healing of Venous Leg Ulcers\n5103: Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications\n5105: The human cathelicidin peptide LL-37 inhibits pancreatic cancer growth by suppressing autophagy and reprogramming of the tumor immune microenvironment\n5107: Synergy between Human Peptide LL-37 and Polymyxin B against Planktonic and Biofilm Cells ofEscherichia coliandPseudomonas aeruginosa\n5109: The antimicrobial peptides LL-37, KR-20, FK-13 and KR-12 inhibit the growth of a sensitive and a metronidazole-resistant strain of Trichomonas vaginalis\n5112: High Human Antimicrobial Peptide LL-37 Level Predicts Lower Major Adverse Cardiovascular Events after an Acute ST-Segment Elevation Myocardial Infarction\n5114: Antimicrobial peptide LL-37 ameliorates a murine sepsis model via the induction of microvesicle release from neutrophils\n5116: IL-27 induces LL-37/CRAMP expression from intestinal epithelial cells: implications for immunotherapy ofClostridioides difficileinfection\n5118: Citrullination-Resistant LL-37 Is a Potent Antimicrobial Agent in the Inflammatory Environment High in Arginine Deiminase Activity\n5120: Nonviral Expression of LL-37 in a Human Skin Equivalent to Prevent Infection in Skin Wounds\n5122: Cathelicidin LL-37 in periodontitis: current research advances and future prospects - A review\n5124: Cathelicidin LL-37: LPS-neutralizing, pleiotropic peptide\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug104_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Survodutide\" (also known as \"survodutide\"), here are the article headings along with their IDs:\n4962: A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis\n4965: Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial\n4969: Dose-response effects on HbA1cand bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial\n4971: Perspectives in weight control in diabetes - Survodutide\n4974: The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection\n4978: Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis\n4981: Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction\n4983: Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial\n4986: Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials\n4990: Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE\u2122-1 and -2)\n4993: Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial\n5001: Correction to: Dose-response effects on HbA1cand bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial\n5005: Subgroup analysis by sex and baseline BMI in people with a BMI \u226527 kg/m2in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug106_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"P21\" (also known as \"p21\"), here are the article headings along with their IDs:\n5056: p21 in Cancer Research\n5058: Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage\n5061: p21: A Two-Faced Genome Guardian\n5063: CDKN1A/p21 in Breast Cancer: Part of the Problem, or Part of the Solution?\n5064: p21Waf1/Cip1: its paradoxical effect in the regulation of breast cancer\n5066: Multifaceted p21 in carcinogenesis, stemness of tumor and tumor therapy\n5068: A p21-ATD mouse model for monitoring and eliminating senescent cells and its application in liver regeneration post injury\n5070: Peptides That Block RAS-p21 Protein-Induced Cell Transformation\n5072: CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication\n5074: p21-activated kinases and gastrointestinal cancer\n5076: P21 activated kinases: structure, regulation, and functions\n5078: p21-activated kinase 1: PAK'ed with potential\n5079: p21--negative regulator of the cell cycle\n5081: P21 deficiency exhibits delayed endochondral ossification during fracture healing\n5083: p21 facilitates chronic lung inflammation via epithelial and endothelial cells\n5086: p21-/-Mice Exhibit Spontaneous Articular Cartilage Regeneration Post-Injury\n5087: LincRNA-p21 exon 1 expression correlates with Cdkn1a expression in vivo\n5089: Less understood issues: p21(Cip1) in mitosis and its therapeutic potential\n5092: The Emerging Role of p21 in Diabetes and Related Metabolic Disorders\n5093: LincRNA-p21 promotes p21-mediated cell cycle arrest in benzene-induced hematotoxicity by sponging miRNA-17-5p\n5095: p21 can be a barrier to ferroptosis independent of p53\n5097: p21 Protein Outperforms Clinico-pathological Criteria in Predicting Liver Metastases in Pancreatic Endocrine Tumors\n5099: Involvement of the p53/p21 complex in p53-dependent gene expression\n5101: The immunoregulatory role of p21 in the development of the temporomandibular joint-osteoarthritis\n5102: Sirt1-inducible deacetylation of p21 promotes cardiomyocyte proliferation\n5104: An update on long intergenic noncoding RNA p21: a regulatory molecule with various significant functions in cancer\n5106: p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775\n5108: MDM2-Mediated p21 Proteasomal Degradation Promotes Fluoride Toxicity in Ameloblasts\n5110: Azurin Regulates P21 and Enhances the Sensitivity of Osteosarcoma Cells to Cisplatin\n5111: Biology of the cell cycle inhibitor p21(CDKN1A): molecular mechanisms and relevance in chemical toxicology\n5113: Lost in transcription: p21 repression, mechanisms, and consequences\n5115: The intricacies of p21 phosphorylation: protein/protein interactions, subcellular localization and stability\n5117: p21-/-mice exhibit enhanced bone regeneration after injury\n5119: LincRNA-p21leads to G1 arrest by p53 pathway in esophageal squamous cell carcinoma\n5121: The kinetic mechanism of the GAP-activated GTPase of p21 ras\n5123: Examination of the expanding pathways for the regulation of p21 expression and activity\n5125: Inhibition of p21 activates Akt kinase to trigger ROS-induced autophagy and impacts on tumor growth rate\n5126: Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts\n5127: A dual role of p21 in stem cell aging\n5128: p21(WAF1) (/Cip1) limits senescence and acinar-to-ductal metaplasia formation during pancreatitis\n5129: P21 deficiency delays regeneration of skeletal muscular tissue\n5130: Functional role of p21 during the cellular response to stress\n5131: Poly-ADP ribosylation of p21 by tankyrases promotes p21 degradation and regulates cell cycle progression\n5132: LincRNA-p21 acts as a mediator of ING1b-induced apoptosis\n5133: The biochemistry of ras p21\n5134: p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury\n5135: Effects of histone acetylation and DNA methylation on p21( WAF1) regulation\n5136: Anti-oncogenic PTEN induces ovarian cancer cell senescence by targeting P21\n5137: LncRNA\u2011p21 promotes chondrocyte apoptosis in osteoarthritis by acting as a sponge for miR\u2011451\n5138: p21 WAF1 and hypoxia/reoxygenation-induced premature senescence of H9c2 cardiomyocytes\n5139: Targeted p21 activation by a new double stranded RNA suppresses human prostate cancer cells growth and metastasis\n5140: p21 gene polymorphisms in systemic lupus erythematosus\n5141: p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1\n5142: Local and transient inhibition of p21 expression ameliorates age-related delayed wound healing\n5143: Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer\n5144: The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis\n5145: High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear-cell Carcinoma\n5146: p21(WAF1/CIP1) acts as a brake in osteoblast differentiation\n5147: Absence of p21(WAF1/CIP1/SDI1) protects against osteopenia and minimizes bone loss after ovariectomy in a mouse model\n5148: Generation of a p21 Reporter Mouse and Its Use to Identify and Eliminate p21highCells In Vivo\n5149: Slug promotes p53 and p21 protein degradation by inducing Mdm2 expression in HCT116 colon cancer cells\n5150: P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor\n5151: P21(Waf1/Cip1) plays a critical role in furazolidone-induced apoptosis in HepG2 cells through influencing the caspase-3 activation and ROS generation\n5152: Plasma and urinary p21: potential biomarkers of AKI and renal aging\n5153: LincRNA-p21 inhibits invasion and metastasis of hepatocellular carcinoma through miR-9/E-cadherin cascade signaling pathway molecular mechanism\n5154: p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption\n5155: lincRNA-p21 inhibits hepatic stellate cell activation and liver fibrogenesis via p21\n5156: Neutrophil-Expressed p21/waf1 Favors Inflammation Resolution in Pseudomonas aeruginosa Infection\n5157: p21 as a transcriptional co-repressor of S-phase and mitotic control genes\n5158: p21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis\n5159: p21(Cip1) regulates cell-substrate adhesion and interphase microtubule dynamics in untransformed human mammary epithelial cells\n5160: The Distinct Function of p21Waf1/Cip1With p16Ink4ain Modulating Aging Phenotypes of Werner Syndrome by Affecting Tissue Homeostasis\n5161: p21(Waf1/Cip1) regulates proliferation and apoptosis in airway epithelial cells and alternative forms have altered binding activities\n5162: Deletion of p21 expression accelerates cartilage tissue repair via chondrocyte proliferation\n5163: A novel p21 attenuator which is structurally related to sorafenib\n5164: p21(waf1/CIP1), a CDK inhibitor and a negative feedback system that controls macrophage activation\n5165: The Cell-Cycle Regulatory Protein p21CIP1/WAF1Is Required for Cytolethal Distending Toxin (Cdt)-Induced Apoptosis\n5166: Thr55 phosphorylation of p21 by MPK38/MELK ameliorates defects in glucose, lipid, and energy metabolism in diet-induced obese mice\n5167: p21(Waf1/Cip1) deficiency stimulates centriole overduplication\n5168: p21 is dispensable for AID-mediated class switch recombination and mutagenesis of immunoglobulin genes during somatic hypermutation\n5169: Identification of a Novel lincRNA-p21-miR-181b-PTEN Signaling Cascade in Liver Fibrosis\n5170: p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation\n5171: p21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity\n5172: Loss of p21 promoted tumorigenesis in the background of telomere dysfunctions induced by TRF2 and Wrn deficiency\n5173: Absence of E2f1 Negates Pro-osteogenic Impacts of p21 Absence\n5174: p21 is essential for normal myogenic progenitor cell function in regenerating skeletal muscle\n5175: LincRNA-p21 sponges miR-18b to promote the progression of diabetic nephropathy\n5176: H3K9 histone methyltransferase G9a-mediated transcriptional activation of p21\n5177: AUF1 ligand circPCNX reduces cell proliferation by competing with p21 mRNA to increase p21 production\n5178: p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation\n5179: M-ds-P21 induces cell apoptosis in bladder cancer T24 cells through P53 independent pathway\n5180: Studies on the structure and mechanism of H-ras p21\n5181: p21 provides stage specific DNA damage control to preimplantation embryos\n5182: Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z\n5183: P21(WAF1/CIP1) may be a tumor suppressor after all\n5184: p21 expression in colorectal carcinomas: a study on 103 cases with analysis of p53 gene mutation/expression and clinic-pathological correlations\n5185: UV-triggered p21 degradation facilitates damaged-DNA replication and preserves genomic stability\n5186: p21(WAF\u00b9/C\u00b9P\u00b9) deficiency induces mitochondrial dysfunction in HCT116 colon cancer cells\n5187: Prx1+MPCs Accumulate in the Dura Mater of Wild-Type and p21-/-Mice Followed by a Specific Reduction in p21-/-Dural MPCs\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug110_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Vitamin B12\" (also known as \"vitaminb12\"), here are the article headings along with their IDs:\n5188: Vitamin B12, folic acid, and the nervous system\n5189: Reversible Melanonychia Revealing Nutritional Vitamin-B12 Deficiency\n5190: High Burden of Vitamin B12 Deficiency among Adults and Elderly\n5191: Maternal Vitamin B12 Status During Pregnancy and Its Association With Outcomes of Pregnancy and Health of the Offspring: A Systematic Review and Implications for Policy in India\n5192: Letter: Vitamin-B12 deficiency\n5193: Vitamin-B12 deficiency and diabetic neuropathy\n5194: Cerebral manifestations of vitamin-B12 deficiency\n5195: Synthesis of Vitamin B12-Antibiotic Conjugates with Greatly Improved Activity against Gram-Negative Bacteria\n5196: A vitamin-B12 preparation with retarded absorption\n5197: Vitamin-B12 deficiency due to defective diet\n5198: Before an abducens palsy can be attributed to a congenital vitamin-B12 deficiency, alternative causes must be ruled out\n5199: Association of plasma folic acid, vitamin-B12 and homocysteine with recurrent pregnancy loss. \"A case control study\"\n5200: Observations on vitamin-B12 absorption in the rat\n5201: Vitamin-B12 absorption and excretion in the rat\n5202: Vitamin B12 as a cholinergic system modulator and blood brain barrier integrity restorer in Alzheimer's disease\n5203: Improving stability of vitamin B12 (Cyanocobalamin) using microencapsulation by spray chilling technique\n5204: In vitro effect of vitaminB12on embyro growth by induction of hypoxia in culture\n5205: The role of Helicobacter pylori in vitamin-B12deficiency due to metformin use\n5206: Natural biomass carbon Dots-Based fluorescence sensor for high precision detection of vitamin B12 in serum\n5207: Long-term effects of folic acid and vitamin-B12 supplementation on fracture risk and cardiovascular disease: Extended follow-up of the B-PROOF trial\n5208: Vitamin-B12 deficiency in Asian immigrants\n5209: VITAMIN-B12 ACTIVITY IN RED CELLS\n5210: Serum folate and vitamin-B12 levels in the elderly\n5211: Hyperpigmentation of skin. A sign of vitamin-B12 deficiency\n5212: Methylmalonic acid excretion: an index of vitamin-B12 deficiency\n5213: Metabolic precursors of methylmalonic acid in vitamin-B12 deficiency\n5214: Vitamin-B12 status of patients on long-term metformin therapy\n5215: The neurology of vitamin B12 deficiency. Metabolic mechanisms\n5216: Rationale for vitamin-B12 treatment of retinoblastoma\n5217: Status of B-vitamins and homocysteine in diabetic retinopathy: association with vitamin-B12 deficiency and hyperhomocysteinemia\n5218: Veganism: a clinical survey with observations on vitamin-B12 metabolism\n5219: Role of N-vinyl-2-pyrrolidinone on the thermoresponsive behavior of PNIPAm hydrogel and its release kinetics using dye and vitamin-B12 as model drug\n5220: Vitamin-B12 metabolism in man using cobalt 58 (58Co) as a tracer\n5221: Response of dietary vitamin-B12 deficiency to physiological oral doses of cyanocobalamin\n5222: Megaloblastic anaemia and vitamin-B12 deficiency after anticonvulsant therapy; report of two cases\n5223: The Revised D-A-CH-Reference Values for the Intake of Vitamin B12: Prevention of Deficiency and Beyond\n5224: Subtle vitamin-B12 deficiency and psychiatry: a largely unnoticed but devastating relationship?\n5225: Vitamin-B12 deficiency in pregnancy and the puerperium\n5226: Vitamin B12Enhances Nerve Repair and Improves Functional Recovery After Traumatic Brain Injury by Inhibiting ER Stress-Induced Neuron Injury\n5227: Effect of oral contraceptives on vitamin-B12 metabolism\n5228: The efficacy of gastrodin in combination with folate and vitamin B12 on patients with epilepsy after stroke and its effect on HMGB-1, IL-2 and IL-6 serum levels\n5229: A vitamin B-12 supplement of 500 \u03bcg/d for eight weeks does not normalize urinary methylmalonic acid or other biomarkers of vitamin B-12 status in elderly people with moderately poor vitamin B-12 status\n5230: Comparative Assessment of Vitamin-B12, Folic Acid and Homocysteine Levels in Relation to p53 Expression in Megaloblastic Anemia\n5231: An electron microscope study of the unmyelinated nerve fibres in normal baboon median nerves: negative effect of vitamin-B12 depletion\n5232: Reversible neuropathy of vitamin-B12 deficiency with normal haemoglobin and serum-vitamin-B12\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug111_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Vitamin B-Complex\" (also known as \"vitaminb-complex\"), here are the article headings along with their IDs:\n5236: Therapeutic Potential of Vitamin B Complex in Peripheral Nerve Injury Recovery: An Experimental Rat Model Study\n5239: Alpha-lipoic acid and vitamin B complex slow down the changes in mice diabetic cardiomyopathy\n5243: Aseptic meningitis induced by vitamin B complex\n5247: The effect of 90 day administration of a high dose vitamin B-complex on work stress\n5251: [Vitamin B complex metabolism]\n5255: Resistance to tumour growth in rats fed on vitamin-B complex\n5259: Randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension\n5263: [Vitamin B complex in therapy of vertigo]\n5267: Effect of vitamin B complex on the teratogenic activity of hypervitaminosis A\n5271: Effect of vitamin-B complex on healthy people in a warm climate\n5277: [Vitamin B complex and antibiotics]\n5282: [Vitamin B complex, metabolism and allergy]\n5286: A Randomized Pilot Trial to Evaluate the Bioavailability of Natural versus Synthetic Vitamin B Complexes in Healthy Humans and Their Effects on Homocysteine, Oxidative Stress, and Antioxidant Levels\n5291: The role of protein and vitamin B complex factors in the prevention of liver damage in pneumonia\n5294: Choice of diet by rats. V. Choice of diets containing various members of the vitamin B complex\n5297: [Vitamin B complex in the treatment of enterocolic diseases]\n5300: Treatment of viral enteritis with vitamin B complex\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug112_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Vitamin C\" (also known as \"vitaminc\"), here are the article headings along with their IDs:\n5242: The vitaminC status of alcoholics\n5246: Assessment of the use of vitamin C and E supplements concomitantly to antibiotic treatment against Helicobacter pylori: A systematic review and meta-analysis\n5250: Vitamin-C deficiency\n5253: Vitamin-C Requirements\n5256: [DISORIENTATION AFTER THE 1ST CONFINEMENT AND VITAMINC]\n5261: Atherosclerosis and vitamin C\n5266: Improving the oxidative stability of virgin olive oil using microformulated vitamin-C\n5270: Comparative kinetic analysis of ascorbate (Vitamin-C) recycling dehydroascorbate reductases from plants and humans\n5274: Invited Response on: Autologous Biological Vitamin-C added (ABC) Filler for Facial Volume Restoration\n5278: Vitamin-C content of fruit-squash concentrates\n5283: Blood lipids and vitamin-C status\n5288: The Role of Vitamin C: From Prevention of Pneumonia to Treatment of Covid-19\n5293: The influence of vitamin-C intake on blood glucose measurements in COVID-19 pandemic\n5296: Long-term use of Vitamin-C in chronic obstructive pulmonary disease: Early pilot observation\n5301: STUDIES OF VITAMIN-C IN ULCERATIVE STOMATITIS\n5304: Aspirin, vitamin-C deficiency, and gastric haemorrhage\n5308: Synergistic activity of vitamin-C and vitamin-E to ameliorate the efficacy of stored erythrocytes\n5311: High-dose vitamin C on sepsis: Protocol of a prospective, multi-centered, double-blinded, randomized, and placebo-controlled superiority study\n5314: Vitamin C supplementation ameliorates liver function profile and antiviral treatment response in Hepatitis C patients\n5317: Global epigenetic alterations of mesenchymal stem cells in obesity: the role of vitamin C reprogramming\n5319: The incidence of vitamin-C deficiency in meningomyelocele\n5322: Screening for vitamin-C status\n5325: Vitamin C mitigates hematological and biochemical alterations caused by di(2-ethylhexyl) phthalate toxicity in female albino mice,Mus musculus\n5327: Vitamin-C supplementation and coeliac disease\n5331: Vitamin C and E supplementation and high intensity interval training induced changes in lipid profile and haematological variables of young males\n5333: Plasma Vitamin C Concentrations and Cognitive Function: A Cross-Sectional Study\n5335: GCMS analysis ofsadagura(smokeless tobacco), its enhanced genomic instability causing potential due to arsenic co-exposure, and vitamin-C supplementation as a possible remedial measure: a study involving multiple model test systems\n5339: Oral Administration of Vitamin C, Cimetidine and Famotidine on Micronuclei Induced by Low Dose Radiation in Mouse Bone Marrow Cells\n5343: Urinary oxalate and vitamin-C supplements\n5345: Vitamin-C deficiency and gallstone formation\n5350: Co-Treatment with Cranberry and Vitamin-C Mitigates Reproductive Toxicities Induced by Phenobarbital in Male Rats\n5352: Sensitive and highly selective colorimetric biosensing of vitamin-C and vitamin-B1 by flavoring agent-based silver nanoparticles\n5355: Proteomic analysis of differentially expressed proteins in vitamin C-treated AGS cells\n5359: High-dose vitamin-C induced prolonged factitious hyperglycemia in a peritoneal dialysis patient: a case report\n5363: Vitamin-C as anti-Helicobacter pylori agent: More prophylactic than curative- Critical review\n5366: Mortality from atherosclerosis and vitamin-C intake\n5369: Vitamin-C deficiency and ulceration of face\n5371: Carbohydrate and collagen-based doubly-grafted interpenetrating terpolymer hydrogel via N-H activated in situ allocation of monomer for superadsorption of Pb(II), Hg(II), dyes, vitamin-C, and p-nitrophenol\n5375: Dietary vitamin C, beta-carotene and 30-year risk of stroke: results from the Western Electric Study\n5376: Biosynthesis of vitamin C stabilized tin oxide nanoparticles and their effect on body weight loss in neonatal rats\n5379: Comparing Effectiveness of Combination of Collagen Peptide Type-1, Low Molecular Weight Chondroitin Sulphate, Sodium Hyaluronate, and Vitamin-C Versus Oral Diclofenac Sodium in Achilles Tendinopathy: A Prospective Randomized Control Trial\n5382: Role of anti-oxidant (vitamin-C) in post-operative pain relief in foot and ankle trauma surgery: A prospective randomized trial\n5386: Vitamin-C deficiency in the elderly and its manifestations\n5389: Vitamin-C delivery from CoCr alloy surfaces using polymer-free and polymer-based platforms for cardiovascular stent applications\n5392: Effect of oral administration of vitamin C on human aqueous humor ascorbate concentration\n5394: Serum vitamin c and iron levels in oral submucous fibrosis\n5396: Effects of vitamin C and E on liver enzymes and biochemical parameters of rabbits exposed to aflatoxin B1\n5400: Local vitamin-C injection reduced tendon adhesion in a chicken model of flexor digitorum profundus tendon injury\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug113_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Avanafil\" (also known as \"avanafil\"), here are the article headings along with their IDs:\n5233: Avanafil\n5234: Avanafil for erectile dysfunction\n5238: Avanafil: A comprehensive drug profile\n5241: Avanafil for the treatment of erectile dysfunction\n5245: Avanafil for the Treatment of men With Erectile Dysfunction: A Systematic Review and Meta-analysis of Randomized Controlled Trials\n5249: Avanafil - a further step to tailoring patient needs and expectations\n5252: Avanafil for erectile dysfunction\n5258: Avanafil for treatment of erectile dysfunction: review of its potential\n5262: Avanafil for male erectile dysfunction: a systematic review and meta-analysis\n5265: Avanafil: a review of its use in patients with erectile dysfunction\n5269: Avanafil for the treatment of erectile dysfunction. An updated review\n5272: The Efficacy and Safety of Avanafil During a Treatment of Male Erectile Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials\n5276: Avanafil Inhibits the Contractility of the Isolated Caprine Detrusor Muscle\n5280: Avanafil for the treatment of erectile dysfunction\n5285: Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction\n5289: The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis\n5290: The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis\n5298: Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction\n5303: Avanafil as a Novel Therapeutic Agent Against LPS-Induced Acute Lung Injury via Increasing CGMP to Downregulate the TLR4-NF-\u03baB-NLRP3 Inflammasome Signaling Pathway\n5306: Avanafil mediated dual inhibition of IKK\u03b2 and TNFR1 in an experimental paradigm of Alzheimer's disease:in silicoandin vivoapproach\n5310: A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil\n5312: Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility\n5315: Zaprinast and avanafil increase the vascular endothelial growth factor, vitamin D3, bone morphogenic proteins 4 and 7 levels in the kidney tissue of male rats applied the glucocorticoid\n5318: Can zaprinast and avanafil induce the levels of angiogenesis, bone morphogenic protein 2, 4 and 7 in kidney of ovariectomised rats?\n5321: Avanafil Mitigates Testicular Ischemia/Reperfusion Injury via NLRP3 Pathway Modulation in Rats\n5324: Future prospects in the treatment of erectile dysfunction: focus on avanafil\n5328: Efficacy and safety of avanafil as compared with sildenafil in the treatment of erectile dysfunction: A randomized, double blind, multicenter clinical trial\n5330: Evaluation of daily avanafil efficacy in improving the endothelial function in Egyptian males with erectile dysfunction\n5334: Effect of avanafil on rat and human corpus cavernosum\n5337: Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus\n5340: Evaluation of the Effect on Sexual Performance of a Nutraceutical Combination Containing Alpha Lipoic Acid,Vitis viniferaL. andGinkgo biloba, Compared to Placebo, Avanafil or a Combination of Nutraceutical Plus Avanafil in Males With Type 2 Diabetes Mellitus With Erectile Dysfunction\n5341: Identification, synthesis and characterization of avanafil process impurities and determination by UPLC\n5344: Efficacy and safety of avanafil 200 mg versus sildenafil 100 mg in the treatment of erectile dysfunction after robot-assisted unilateral nerve-sparing prostatectomy: A prospective multicentre study\n5347: Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study\n5349: A real-world pilot study assessing treatment satisfaction with avanafil in patients with erectile dysfunction\n5351: Hemodynamic effect of avanafil and glyceryl trinitrate coadministration\n5354: A Bioequivalence Study of Avanafil in Healthy Chinese Male Subjects Under Fasting and Fed Conditions: Results of a Randomized, Open-Label, Single-Dose, 2-Sequence, 2-Period Crossover Study\n5357: Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties\n5360: Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs\n5362: Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial\n5365: [Avanafil for the treatment of erectile dysfunction in practice. Non-interventional study AVANTI]\n5368: Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers\n5370: Simultaneous determination of Avanafil and Dapoxetine in human plasma using liquid chromatography/tandem mass spectrometry (LC-MS/MS) based on a protein precipitation technique\n5373: Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability\n5378: Renoprotective Effect of Vardenafil and Avanafil in Contrast-Induced Nephropathy: Emerging Evidence from an Animal Model\n5380: Synthesis and mutagenic risk of avanafil's potential genotoxic impurities\n5384: Avanafil (Stendra)--another PDE5 inhibitor for erectile dysfunction\n5387: A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction\n5390: Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial\n5395: Formulation of avanafil in a solid self-nanoemulsifying drug delivery system for enhanced oral delivery\n5398: Inflammation in cerebral ischemia reperfusion improved by avanafil via nod-like receptor protein-3 inflammasome: an experimental study in rats\n5401: Transdermal Film Loaded with Avanafil Ultra-deformable Nanovesicles to Enhance its Percutaneous Absorption and Bioavailability\n5403: Formulation and Optimization of Avanafil Biodegradable Polymeric Nanoparticles: A Single-Dose Clinical Pharmacokinetic Evaluation\n5405: Second derivative synchronous fluorescence determination of avanafil in the presence of its acid-induced degradation product aided by powerful Lean Six Sigma tools augmented with D-optimal design\n5409: Preparation and evaluation of radioiodinated avanafil: A novel potential radiopharmaceutical for the diagnostic evaluation of erectile dysfunction\n5411: A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy\n5413: Dapagliflozin propanediol, avanafil, and conjugated estrogens/bazedoxifene\n5415: The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction\n5417: Correction: Incorporating sodium deoxycholate endorsed the buccal administration of avanafil to heighten the bioavailability and duration of action\n5418: A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil in the clinical practice\n5422: Structure of Human Phosphodiesterase 5A1 Complexed with Avanafil Reveals Molecular Basis of Isoform Selectivity and Guidelines for Targeting \u03b1-Helix Backbone Oxygen by Halogen Bonding\n5425: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Therapeutic Confirmatory Study to Evaluate the Safety and Efficacy of Avanafil in Korean Patients with Erectile Dysfunction\n5428: Sexual medicine: Rapid-onset avanafil effective for ED\n5430: A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction\n5434: Preparation, Optimization and Evaluation of Chitosan-Based Avanafil Nanocomplex Utilizing Antioxidants for Enhanced Neuroprotective Effect on PC12 Cells\n5435: Environmentally benign first derivative synchronous spectrofluorimetry for the analysis of two binary mixtures containing duloxetine with avanafil or tadalafil in spiked plasma samples\n5438: Investigating the Potential of Transdermal Delivery of Avanafil Using Vitamin E-TPGS Based Mixed Micelles Loaded Films\n5440: LC-MS/MS determination of avanafil and its metabolites in rat plasma and brain: pharmacokinetic study after oral administration and transdermal film application\n5443: Native and synchronous fluorescence spectroscopy for determination of avanafil in presence of its co-formulated drug (dapoxetine hydrochloride): Application to pharmaceutical product, biological fluid and content uniformity\n5446: An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction\n5449: Development of Validated and Stability-Indicating LC-DAD and LC-MS/MS Methods for Determination of Avanafil in Pharmaceutical Preparations and Identification of a Novel Degradation Product by LCMS-IT-TOF\n5452: Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis\n5456: Development of an optimized avanafil-loaded invasomal transdermal film: Ex vivo skin permeation and in vivo evaluation\n5459: Fast and simple voltammetric sensing of avanafil in the pharmaceutical formulation by using unmodified boron-doped diamond electrode\n5462: EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil\n5465: D-optimal design as a useful tool response surface methodology for the optimization of signals from synchronous fluorescence prior to simultaneous determination of avanafil and tadalafil\n5468: Simultaneous measurement of duloxetine hydrochloride and avanafil at dual-wavelength using novel ecologically friendly TLC-densitometric method: application to synthetic mixture and spiked human plasma with evaluation of greenness and blueness\n5472: Core-shell particles and monolithic columns; tools for simultaneous LC analysis of avanafil, sildenafil, apomorphine, trazodone, yohimbine, tramadol and dapoxetine in pharmaceutical dosage forms, counterfeit products and human plasma\n5476: The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor\n5479: Accurate and sensitive determination of sildenafil, tadalafil, vardenafil, and avanafil in illicit erectile dysfunction medications and human urine by LC with quadrupole-TOF-MS/MS and their behaviors in simulated gastric conditions\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug114_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Cabergoline\" (also known as \"cabergoline\"), here are the article headings along with their IDs:\n5235: Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial\n5237: Pituitary acting drugs: cabergoline and pasireotide\n5240: Cabergoline: a review of its use in the inhibition of lactation for women living with HIV\n5244: Real-world value of cabergoline in the treatment of acromegaly\n5248: Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy\n5254: Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism\n5257: Safety of Cabergoline for Postpartum Lactation Inhibition or Suppression: A Systematic Review\n5260: Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review\n5264: Calcium versus cabergoline for prevention of ovarian hyperstimulation syndrome: A systematic review and meta-analysis\n5268: Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature\n5273: Cabergoline for hyperprolactinemia: getting to the heart of it\n5275: Cabergoline for preventing ovarian hyperstimulation syndrome\n5279: Cabergoline: a new drug for the treatment of hyperprolactinaemia\n5281: Cabergoline for postpartum lactation suppression: Effect on blood pressure and pulse\n5284: Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials\n5287: Cabergoline treatment for surgery-na\u00efve non-functioning pituitary macroadenomas\n5292: Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies\n5295: Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis\n5299: Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required\n5302: Cabergoline targets multiple pathways to inhibit PRL secretion and increases stromal fibrosis\n5305: Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications\n5307: Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis\n5309: Efficacy of cabergoline and triptans for cluster-like headache caused by prolactin-secreting pituitary adenoma: A literature review and case report\n5313: [Cabergoline]\n5316: Effects of combined metformin and cabergoline versus metformin alone on ovarian and hormonal activities in Iraqi patients with PCOS and hyperprolactinemia: a randomized clinical trial\n5320: Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma\n5323: Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas\n5326: Effect of Cabergoline Treatment on Disease Control in Acromegaly Patients\n5329: Cabergoline versus calcium infusion in the prevention of ovarian hyperstimulation syndrome: a randomised controlled study\n5332: Cabergoline possesses a beneficial effect on blood-brain barrier (BBB) integrity against lipopolysaccharide (LPS)\n5336: Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study\n5338: Cabergoline treatment in acromegaly: pros\n5342: Cabergoline treatment in acromegaly: cons\n5346: Cabergoline may act as a radioprotective agent in Cushing's disease\n5348: Long-term low-dose cabergoline usage: Another association with cardiac valvulopathy\n5353: Impulse Control Disorders with Short-term Use of Cabergoline in Macroprolactinomas: A Prospective Study with a Brief Review of Literature\n5356: Comparative efficacy of metformin combined with cabergoline versus metformin alone in patients with PCOS and hyperprolactinemia: A systematic review and meta-analysis of randomized controlled trials\n5358: Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease\n5361: CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma\n5364: Cabergoline : a review of its use in the treatment of Parkinson's disease\n5367: Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition - A systematic review of clinical trials\n5372: Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study\n5374: Evaluation of cabergoline for lactation inhibition in women living with HIV\n5377: Cabergoline in the Treatment of Peripartum Cardiomyopathy\n5381: Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease\n5383: Does cabergoline administration affect endometrial VEGFR-2 expression in a rat model of ovarian hyperstimulation syndrome?\n5385: Cabergoline and mitral regurgitation\n5388: Cabergoline in Parkinson's disease\n5391: Cabergoline-associated erythema nodosum\n5393: Cabergoline in Treatment of Methamphetamine-Dependent Patients and Its Effect on Serum Level of Glial Cell-Derived Neurotrophic Factor: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial\n5397: Cabergoline Stimulates Human Endometrial Stromal Cell Decidualization and Reverses Effects of Interleukin-1\u03b2 In Vitro\n5399: Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma\n5402: A prolactinoma resistant to cabergoline: The important role of surgery\n5404: Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints\n5406: Cabergoline for hyperprolactinemia\n5407: Prolactinoma - which patients react favorably to cabergoline medication?\n5408: Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial\n5410: Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia\n5412: The efficiency of cabergoline vs pyridoxine for lactation inhibition-a randomized controlled trial\n5414: Use of the dopamine agonist cabergoline in the treatment of movement disorders\n5419: Cabergoline inhibits prolactin secretion and accelerates involution in dairy cows after dry-off\n5421: Cabergoline treatment in prolactinoma: Amelioration in obstructive and central sleep apneas\n5424: Different Cabergoline Effect on Metabolic and Anthropometric Parameters in Female Prolactinoma Patients Versus Idiopathic Hyperprolactinemia Patients\n5427: Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report\n5431: Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly\n5433: Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia\n5437: Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience\n5441: Medical treatment in Cushing's syndrome: dopamine agonists and cabergoline\n5444: Effects of cabergoline therapy on serum IGF-1 concentrations in prolactinoma patients\n5447: Cabergoline and quinagolide therapy for prolactinomas\n5448: Effectiveness of Cabergoline Treatment in Patients with Acromegaly Uncontrolled with SSAs: Experience of a Single Tertiary Center\n5451: Peripartum Cardiomyopathy with the Cardiac Function Restored by Cabergoline\n5454: Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model\n5457: Syndrome of inappropriate antidiuretic hormone with recurrent giant cabergoline-resistant prolactinoma\n5461: Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter?\n5464: Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies\n5466: Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report\n5470: Effect of the Prolactin Inhibitor Cabergoline and the Gonadotropin Releasing-Hormone Agonist Deslorelin in the Suppression of Plasma Prolactin Concentrations and Egg Laying in Quail (Coturnix japonica)\n5473: Know Your Enemy: Potential Role of Cabergoline to Target Neoangiogenesis in Endometriosis\n5475: Cabergoline and gallbladder motility in healthy men\n5477: Cabergoline therapy for Cushing disease throughout pregnancy\n5481: Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma\n5483: Spontaneous coronary artery dissection in association with cabergoline therapy\n5485: Cabergoline-induced pneumocephalus in a medically treated macroprolactinoma\n5488: Use of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome\n5489: Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis\n5491: DA agonists -- ergot derivatives: cabergoline: management of Parkinson's disease\n5493: Use of cabergoline for oestrus induction in multiparous anoestrous Beagle bitches\n5495: Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review\n5497: Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively\n5499: Efficacy of cabergoline in a double-blind randomized clinical trial on milk leakage reduction at drying-off and new intramammary infections across the dry period and postcalving\n5501: Risk of impulse control disorders in patients with Cushing's disease: do not blame cabergoline but do not give up caution\n5502: Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure\n5504: Cabergoline can induce mania with psychotic features in bipolar I disorder: a case report\n5506: [Cushing's disease in pregnancy and treatment with cabergoline: obstetric and neonatal results]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug115_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Exemestane\" (also known as \"exemestane\"), here are the article headings along with their IDs:\n5416: Exemestane\n5420: Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis\n5423: Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence\n5426: Unravelling exemestane: From biology to clinical prospects\n5429: Exemestane for breast cancer prevention: a critical shift?\n5432: Exemestane (FCE 24304), a new steroidal aromatase inhibitor\n5436: Exemestane: a novel aromatase inactivator for breast cancer\n5439: Exemestane in postmenopausal women with early or advanced breast cancer: a review\n5442: Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer\n5445: Exemestane in advanced breast cancer\n5450: Exemestane: one part of the chemopreventive spectrum for ER-positive breast cancer\n5453: Exemestane, a new steroidal aromatase inhibitor of clinical relevance\n5455: Experience with exemestane in the treatment of early and advanced breast cancer\n5458: Resveratrol-Exemestane Beneficial Regimen to Overcome the Complications over Existing Therapies for the Management of Breast Cancer\n5460: Exemestane induced cholestatic liver injury - A case report\n5463: Exemestane: a review of its use in postmenopausal women with advanced breast cancer\n5467: Exemestane: a milestone against breast cancer\n5469: Exemestane: a review of its use in postmenopausal women with breast cancer\n5471: Exemestane in breast cancer: current status and future directions\n5474: A review of exemestane in the management of breast cancer\n5478: A case of exemestane induced pseudocellulitis\n5480: Aromatase inhibitors in the breast cancer clinic: focus on exemestane\n5482: Pharmacology and clinical experience with exemestane\n5484: Exemestane for breast-cancer prevention\n5486: Exemestane for breast-cancer prevention\n5487: Exemestane: treatment of breast cancer with selective inactivation of aromatase\n5490: Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2\n5492: The effect of exemestane administration on the lipid profile in women: Meta-analysis of randomized controlled trials\n5494: Endocrine and clinical endpoints of exemestane as neoadjuvant therapy\n5496: Methylome Variation Predicts Exemestane Resistance in Advanced ER+Breast Cancer\n5498: Exemestane or tamoxifen?\n5500: Exemestane or tamoxifen?\n5503: Exemestane or tamoxifen?\n5505: Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis\n5507: Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment\n5508: [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option]\n5511: Exemestane and aromatase inhibitors in the management of advanced breast cancer\n5514: Drug safety evaluation of exemestane\n5515: Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer\n5517: Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study)\n5519: Exemestane-induced corneal epithelial changes\n5521: Incorporation of exemestane into ternary nanosponge system for enhanced anti-tumor potential in breast cancer\n5523: Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial\n5525: Everolimus and exemestane in hormone receptor positive advanced breast cancer: A comprehensive cancer center's experience\n5527: Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion\n5529: Exemestane for breast-cancer prevention in postmenopausal women\n5531: Exemestane encapsulated polymer-lipid hybrid nanoparticles for improved efficacy against breast cancer: optimization,in vitrocharacterization and cell culture studies\n5533: Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial\n5535: Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer\n5536: An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane\n5539: Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer\n5541: Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial\n5543: Exemestane experience in breast cancer treatment\n5545: Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer\n5547: Exemestane for breast-cancer prevention\n5549: Triggering of Suicidal Erythrocyte Death by Exemestane\n5551: Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer\n5556: Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors\n5559: p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane\n5561: Acute generalized exanthematous pustulosis induced by exemestane during adjuvant radiotherapy for breast cancer\n5564: Thermoresponsive liquid crystalline formulation of Exemestane: Design and structural characterization\n5567: Lyophilized mixed micelles of exemestane: A novel paradigm to improve its absorption and anticancer activity\n5570: Effect of variables on exemestane-loaded albumin nanoparticles: statistical optimization and anti-cancer activity in MCF-7 cell lines\n5573: Effect of Aromatase Inhibition (Exemestane) on Urine Concentration of Osteoprotegerin in Healthy Postmenopausal Women\n5575: XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease\n5578: Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2\n5582: Long-Term Follow-Up of the Intergroup Exemestane Study\n5586: To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?\n5588: Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease\n5591: Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line\n5593: Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy\n5594: Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety\n5598: Insights on the interaction mechanism of exemestane to three digestive enzymes by multi-spectroscopy and molecular docking\n5600: [Pharmacological and clinical profile of exemestane (Aromasin), a novel irreversible aromatase inhibitor]\n5602: Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer\n5605: A simple UPLC-MS/MS assay with a core-shell column for the determination of exemestane in human plasma for clinical application\n5606: Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability\n5608: Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study\n5609: Overview of the pharmacology of the aromatase inactivator exemestane\n5611: Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer\n5613: Exemestane for breast cancer prevention: a feasible strategy?\n5615: Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial\n5617: Polymer-lipid hybrid nanoparticles of exemestane for improved oral bioavailability and anti-tumor efficacy: An extensive preclinical investigation\n5619: [Combination of exemestane and everolimus may produce toxic side effects: a new treatment option for metastatic hormone-sensitive breast cancer]\n5621: Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial\n5623: Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study\n5625: Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial\n5627: Exemestane loaded self-microemulsifying drug delivery system (SMEDDS): development and optimization\n5629: Statin use in patients with hormone receptor-positive metastatic breast cancer treated with everolimus and exemestane\n5631: Exemestane-induced subclinical hypothyroidism : a case report\n5633: Exemestane for advanced breast cancer\n5635: Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors\n5637: Exemestane Attenuates Hepatic Fibrosis in Rats by Inhibiting Activation of Hepatic Stellate Cells and Promoting the Secretion of Interleukin 10\n5638: Exemestane and chemotherapy as first-line treatment of metastatic breast cancer: results of a phase II study\n5640: Exemestane loaded alginate nanoparticles for cancer treatment: Formulation and in vitro evaluation\n5643: Exemestane for primary prevention of breast cancer in postmenopausal women\n5645: Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug117_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Hexarelin\" (also known as \"hexarelin\"), here are the article headings along with their IDs:\n5509: Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway\n5510: The cardiovascular action of hexarelin\n5512: Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation\n5513: Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury\n5516: Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases\n5518: Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity\n5520: Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophyviathe regulation of autophagy\n5522: Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-\u03baB signaling pathway-mediated macrophage ox-LDL uptake in ApoE-/-mice\n5524: Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats\n5526: Hexarelin treatment in male ghrelin knockout mice after myocardial infarction\n5528: Hexarelin: a multi-receptor peptide\n5530: Hexarelin protects H9c2 cardiomyocytes from doxorubicin-induced cell death\n5532: Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice\n5534: Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats\n5537: Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat\n5538: Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion\n5540: Hexarelin protects rat cardiomyocytes from angiotensin II-induced apoptosis in vitro\n5542: Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients\n5544: Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats\n5546: Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers\n5550: Protective Effects of Hexarelin and JMV2894 in a Human Neuroblastoma Cell Line Expressing the SOD1-G93A Mutated Protein\n5553: Hexarelin Signaling to PPARgamma in Metabolic Diseases\n5555: Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat\n5557: Growth hormone status during long-term hexarelin therapy\n5560: One dose of oral hexarelin protects chronic cardiac function after myocardial infarction\n5563: Hexarelin--evaluation of factors influencing oral bioavailability and ways to improve absorption\n5565: Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study\n5568: Desmopressin and hexarelin tests in alcohol-induced pseudo-Cushing's syndrome\n5571: Hexarelin as a test of pituitary reserve in patients with pituitary disease\n5574: Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction\n5577: Hexarelin suppresses cardiac fibroblast proliferation and collagen synthesis in rat\n5580: Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats\n5584: Modulation of growth hormone-releasing activity of hexarelin in man\n5590: Hexarelin Protects Rodent Pancreatic \u0392-Cells Function from Cytotoxic Effects of Streptozotocin Involving Mitochondrial Signalling Pathways In Vivo and In Vitro\n5592: Hexarelin stimulation of growth hormone release and mRNA levels in an infant and adult rat model of impaired GHRH function\n5595: The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin\n5596: Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models\n5597: The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway\n5599: Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin\n5601: Hexarelin, a growth hormone - releasing peptide, counteracts bone loss in gonadectomized male rats\n5603: Endocrine, metabolic and cardioprotective effects of hexarelin in obese Zucker rats\n5604: Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery\n5607: Interaction of the growth hormone releasing peptide hexarelin with somatostatin\n5610: Hexarelin, but not growth hormone, protects heart from damage induced in vitro by calcium deprivation replenishment\n5612: Does desensitization to hexarelin occur?\n5614: Novel hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release\n5616: Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly\n5618: Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects\n5620: Feeding behavior during long-term hexarelin administration in young and old rats\n5622: Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation\n5624: Hexarelin, a growth hormone secretagogue, protects the isolated rat heart from ventricular dysfunction produced by exposure to calcium-free medium\n5626: The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity\n5628: Enhanced Pulsatile Growth Hormone Secretion and Altered Metabolic Hormones by in Vivo Hexarelin Treatment in Streptozotocin-Induced Diabetic Rats\n5630: Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects\n5632: Growth hormone-independent cardioprotective effects of hexarelin in the rat\n5634: Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans\n5636: Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro\n5639: Hexarelin modulates the expression of growth hormone secretagogue receptor type 1a mRNA at hypothalamic and pituitary sites\n5641: Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man\n5642: Permeability of the peptidic GH secretagogues hexarelin and EP 51389, across rat jejunum\n5644: The In Vivo Effect of Transcellular Permeation Enhancers on the Intestinal Permeability of Two Peptide Drugs Enalaprilat and Hexarelin\n5646: Hexarelin exhibits protective activity against cardiac ischaemia in hearts from growth hormone-deficient rats\n5647: GH responsiveness to repeated GHRH or hexarelin administration in normal adults\n5648: Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in rats\n5649: Hexarelin, a potent GHRP analogue: interactions with GHRH and clonidine in young and aged dogs\n5651: Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia\n5652: The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin\n5653: Beneficial effects of desacyl-ghrelin, hexarelin and EP-80317 in models of status epilepticus\n5654: Lack of effect of hexarelin on TRH-induced TSH response in normal adult man\n5655: Acute administration of hexarelin stimulates GH secretion during day and night in normal men\n5656: Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats\n5657: Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa\n5658: Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man\n5659: The effects of a continuous infusion of hexarelin on pulsatile growth hormone release, growth axis and galanin gene expression and on the response of the growth axis to growth hormone-releasing hormone\n5660: Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test\n5661: Role of endothelial cells in modulation of contractility induced by hexarelin in rat ventricle\n5662: Cardiac effects of hexarelin in hypopituitary adults\n5663: The effect of body composition on hexarelin-induced growth hormone release in normal elderly subjects\n5664: Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency\n5665: Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin)\n5666: Growth hormone-releasing peptide hexarelin reduces neonatal brain injury and alters Akt/glycogen synthase kinase-3beta phosphorylation\n5667: Growth hormone secretagogue (GHS) analogue, hexarelin stimulates GH from peripheral lymphocytes\n5668: Direct nose-to-brain transfer of a growth hormone releasing neuropeptide, hexarelin after intranasal administration to rabbits\n5669: The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary GH reserve in man\n5670: EP 60761 and EP 50885, two hexarelin analogues, induce penile erection in rats\n5671: Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa\n5672: Reproductive performance and fertility in male and female adult mice chronically treated with hexarelin\n5673: Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug118_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"LGD-4033\" (also known as \"lgd-4033\"), here are the article headings along with their IDs:\n5548: Ligandrol (LGD-4033)-Induced Liver Injury\n5552: Human in vivo metabolism study of LGD-4033\n5554: Human in vivo metabolism study of LGD-4033\n5558: Detection of LGD-4033 and its metabolites in athlete urine samples\n5562: Variation of Sequential Ligandrol (LGD-4033) Metabolite Levels in Routine Anti-Doping Urine Samples Detected with or without Other Xenobiotics\n5566: Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes\n5569: Investigation of in vitro generated metabolites of LGD-4033, a selective androgen receptor modulator, in homogenized camel liver for anti-doping applications\n5572: LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults\n5576: Equine in vivo-derived metabolites of the SARM LGD-4033 and comparison with human and fungal metabolites\n5579: Investigations into the concentration and metabolite profiles of stanozolol and LGD-4033 in blood plasma and seminal fluid using liquid chromatography high-resolution mass spectrometry\n5581: Investigation of the metabolism of the selective androgen receptor modulator LGD-4033 in equine urine, plasma and hair following oral administration\n5585: Detection of LGD-4033 Metabolites in Camel Urine, Plasma, and Hair Following Oral Administration for Doping Control\n5587: The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men\n5589: In vitro metabolism study of a black market product containing SARM LGD-4033\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug119_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Matrixyl\" (also known as \"matrixyl\"), here are the article headings along with their IDs:\n5583: Matrixyl Patch vs Matrixyl Cream: A Comparative In Vivo Investigation of Matrixyl (MTI) Effect on Wound Healing\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug121_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"MK-2866\" (also known as \"mk-2866\"), here are the article headings along with their IDs:\n5650: Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR- \u03b4) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine)\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug124_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"S4\" (also known as \"s4\"), here are the article headings along with their IDs:\n5674: GPR56 S4 variant is required for microglia-mediated synaptic pruning\n5675: A second S4 movement opens hyperpolarization-activated HCN channels\n5676: Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity\n5677: Carbonic anhydrase IX inhibitor S4 triggers release of DAMPs related to immunogenic cell death in glioma cells via endoplasmic reticulum stress pathway\n5678: S4-S5 linker movement during activation and inactivation in voltage-gated K+channels\n5679: Apratoxin S4 Inspired by a Marine Natural Product, a New Treatment Option for Ocular Angiogenic Diseases\n5680: Metal Bridge in S4 Segment Supports Helix Transition in Shaker Channel\n5681: Astaxanthin and eicosapentaenoic acid production by S4, a new mutant strain of Nannochloropsis gaditana\n5684: hERG S4-S5 linker acts as a voltage-dependent ligand that binds to the activation gate and locks it in a closed state\n5687: Uncharged S4 residues and cooperativity in voltage-dependent potassium channel activation\n5690: Plasmodium yoelii S4/CelTOS is important for sporozoite gliding motility and cell traversal\n5693: A selective androgen receptor modulator, S4, displays robust anti-cancer activity on hepatocellular cancer cells by negatively regulating PI3K/AKT/mTOR signalling pathway\n5695: The S4 voltage sensor packs against the pore domain in the KAT1 voltage-gated potassium channel\n5698: Probing \u03b1-3(10) transitions in a voltage-sensing S4 helix\n5700: S4 charges move close to residues in the pore domain during activation in a K channel\n5704: Pathogenic and genomic characterisation of a rabbit sourced Pasteurella multocida serogroup F isolate s4\n5708: Split-Lobe for Tumor between Left S3 and S4 by Uniportal Video-Assisted Thoracoscopy\n5711: S4(13)-PV cell-penetrating peptide induces physical and morphological changes in membrane-mimetic lipid systems and cell membranes: implications for cell internalization\n5715: The S4-S5 linker acts as a signal integrator for HERG K+ channel activation and deactivation gating\n5718: The S4-S5 loop contributes to the ion-selective pore of potassium channels\n5722: S4 movement in a mammalian HCN channel\n5725: Hydrophobic interactions between the HA helix and S4-S5 linker modulate apparent Ca2+sensitivity of SK2 channels\n5728: Cross-cultural Adaptation of Self-report S4-5 Sensory and Motor Function Questionnaire (S4-5Q) in People with Spinal Cord Injury to Portuguese\n5731: S4-alpha mRNA translation repression complex. I. Thermodynamics of formation\n5734: Mechanism of A. oleivorans S4 treating soluble phosphorus deficiency and hydrocarbon contamination simultaneously\n5737: S1 constrains S4 in the voltage sensor domain of Kv7.1 K+ channels\n5740: Antimalarial activities of dermaseptin S4 derivatives\n5743: Enzyme dimension of the ribosomal protein S4 across plant and animal kingdoms\n5745: Laparoscopic anatomic S4 segmentectomy for hepatocellular carcinoma\n5748: Regional flexibility in the S4-S5 linker regulates hERG channel closed-state stabilization\n5751: Integrated Metabolomic, Molecular Networking, and Genome Mining Analyses Uncover Novel Angucyclines FromStreptomycessp. RO-S4 Strain Isolated From Bejaia Bay, Algeria\n5753: Identification of an Attenuated Substrain ofFrancisella tularensisSCHU S4 by Phenotypic and Genotypic Analyses\n5757: The concerted contribution of the S4-S5 linker and the S6 segment to the modulation of a Kv channel by 1-alkanols\n5759: Identification and characterization of novel short-type BmPGRP-S4 from the silkworm, Bombyx mori, involved in innate immunity\n5761: Superior Lingular S4Segmentectomy\n5764: Up-regulation of voltage-gated sodium channels by peptides mimicking S4-S5 linkers reveals a variation of the ligand-receptor mechanism\n5767: The Voltage-Dependent Deactivation of the KvAP Channel Involves the Breakage of Its S4 Helix\n5770: Role of the S4 in cooperativity of voltage-dependent potassium channel activation\n5775: Ribosomal protein S4 is a transcription factor with properties remarkably similar to NusA, a protein involved in both non-ribosomal and ribosomal RNA antitermination\n5777: The topogenic function of S4 promotes membrane insertion of the voltage-sensor domain in the KvAP channel\n5779: Antibacterial properties of dermaseptin S4 derivatives with in vivo activity\n5782: Ribosomal protein S4 acts in trans as a translational repressor to regulate expression of the alpha operon in Escherichia coli\n5784: Position and motions of the S4 helix during opening of the Shaker potassium channel\n5786: The soluble pyocins S2 and S4 from Pseudomonas aeruginosa bind to the same FpvAI receptor\n5788: BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis\n5790: Modulation of decoding fidelity by ribosomal proteins S4 and S5\n5793: Coupling of S4 helix translocation and S6 gating analyzed by molecular-dynamics simulations of mutated Kv channels\n5795: Specific contacts between protein S4 and ribosomal RNA are required at multiple stages of ribosome assembly\n5797: Linker flexibility of IVS3-S4 loops modulates voltage-dependent activation of L-type Ca2+channels\n5798: Transmembrane movement of the shaker K+ channel S4\n5801: Changes in local S4 environment provide a voltage-sensing mechanism for mammalian hyperpolarization-activated HCN channels\n5803: S4-16 S ribosomal RNA complex. Binding constant measurements and specific recognition of a 460-nucleotide region\n5805: NiCo2S4Materials for Supercapacitor Applications\n5807: Functional analysis of the stem loop S3 and S4 structures in the coronavirus 3'UTR\n5809: Atomic proximity between S4 segment and pore domain in Shaker potassium channels\n5810: Supercapacitive Performances of Ternary CuCo2S4Sulfides\n5811: The role of S4 charges in voltage-dependent and voltage-independent KCNQ1 potassium channel complexes\n5812: Mutations in the S4 region isolate the final voltage-dependent cooperative step in potassium channel activation\n5813: Participation of the S4 voltage sensor in the Mg2+-dependent activation of large conductance (BK) K+ channels\n5814: A hydrophobic element secures S4 voltage sensor in position in resting Shaker K+ channels\n5815: State-dependent electrostatic interactions of S4 arginines with E1 in S2 during Kv7.1 activation\n5816: Phospholipid membrane-interaction of a peptide from S4 segment of KvAP K(+) channel and the influence of the positive charges and an identified heptad repeat in its interaction with a S3 peptide\n5818: KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer\n5820: Improving on polygenic scores across complex traits using select and shrink with summary statistics (S4) and LDpred2\n5822: Screening for Depression in Old Age With Very Short Instruments: The DIA-S4 Compared to the GDS5 and GDS4\n5824: A minimized rRNA-binding site for ribosomal protein S4 and its implications for 30S assembly\n5827: Total anatomical laparoscopic liver resection of segment 4 (S4), extended S4, and subsegments S4a and S4b for hepatocellular carcinoma\n5828: Slow formation of stable complexes during coincubation of minimal rRNA and ribosomal protein S4\n5829: Structure and function of ribosomal protein S4 genes on the human and mouse sex chromosomes\n5830: Virulence difference between the prototypic Schu S4 strain (A1a) and Francisella tularensis A1a, A1b, A2 and type B strains in a murine model of infection\n5831: 3\u2081\u2080-helix conformation facilitates the transition of a voltage sensor S4 segment toward the down state\n5832: Hydrophobic substitution mutations in the S4 sequence alter voltage-dependent gating in Shaker K+ channels\n5833: Cysteine protease attribute of eukaryotic ribosomal protein S4\n5835: Mutations in ribosomal proteins S4 and S12 influence the higher order structure of 16 S ribosomal RNA\n5837: Localization of the extracellular end of the voltage sensor S4 in a potassium channel\n5839: Periodic perturbations in Shaker K+ channel gating kinetics by deletions in the S3-S4 linker\n5842: Localization of Escherichia coli ribosomal proteins S4 and S14 by electron microscopy of antibody-labeled subunits\n5844: Voltage-sensing residues in the S4 region of a mammalian K+ channel\n5846: Association of ataxin-7 with the proteasome subunit S4 of the 19S regulatory complex\n5848: Structural interactions between lipids, water and S1-S4 voltage-sensing domains\n5850: Modulation of the Shaker K(+) channel gating kinetics by the S3-S4 linker\n5853: Coupling between residues on S4 and S1 defines the voltage-sensor resting conformation in NaChBac\n5855: Measurement of the movement of the S4 segment during the activation of a voltage-gated potassium channel\n5857: Tumor microenvironmental changes induced by the sulfamate carbonic anhydrase IX inhibitor S4 in a laryngeal tumor model\n5859: Unveiling the Potential of S4 on Non-small Cell Lung Cancer Cells: Impact on Proliferation, Apoptosis, Senescence, and Metabolome Profile\n5861: Synergistic ameliorative effect of iron oxide nanoparticles andBacillus subtilisS4 against arsenic toxicity inCucurbita moschata: polyamines, antioxidants, and physiochemical studies\n5866: Comparison of the efficiency of complexes based on S4(13)-PV cell-penetrating peptides in plasmid DNA and siRNA delivery\n5869: Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4\n5872: Functional extension of amino acid triads from the fourth transmembrane segment (S4) into its external linker in Shaker K(+) channels\n5874: Independent versus coupled inactivation in sodium channels. Role of the domain 2 S4 segment\n5878: Self-assembly of a M4L6 complex with unexpected S4 symmetry\n5881: The Fast Component of hERG Gating Charge: An Interaction between D411 in the S1 and S4 Residues\n5883: The diagnostic accuracy of self-report for determining S4-5 sensory and motor function in people with spinal cord injury\n5887: S4(13)-PV cell-penetrating peptide forms nanoparticle-like structures to gain entry into cells\n5888: Molecular coupling of S4 to a K(+) channel's slow inactivation gate\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug126_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"SR9009\" (also known as \"sr9009\"), here are the article headings along with their IDs:\n5686: SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXR\u03b1/FOXM1 pathway independently of REV-ERBs\n5689: SR9009 attenuates inflammation-related NPMSC pyroptosis and IVDD through NR1D1/NLRP3/IL-1\u03b2 pathway\n5694: SR9009 has REV-ERB-independent effects on cell proliferation and metabolism\n5697: SR9009 Regulates Acute Lung Injury in Mice Induced by Sepsis\n5702: SR9009 improves heart function after pressure overload independent of cardiac REV-ERB\n5705: REV-ERB\u03b1 Agonist SR9009 Promotes a Negative Energy Balance in Goldfish\n5707: SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy\n5709: Rev-erb\u03b1 agonist SR9009 protects against cerebral ischemic injury through mechanisms involving Nrf2 pathway\n5712: SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome\n5714: SR9009 attenuates TGF-\u03b21-induced renal fibrotic responses by inhibiting the NOX4/p38 signaling pathway in NRK-49F cells\n5717: Circadian Clock REV-ERBs Agonist SR9009 Induces Synergistic Antitumor Activity in Multiple Myeloma by Suppressing Glucose-Regulated Protein 78-Dependent Autophagy and Lipogenesis\n5720: Time-dependent effect of REV-ERB\u03b1 agonist SR9009 on nonalcoholic steatohepatitis and gut microbiota in mice\n5723: REV-ERB Agonist SR9009 Regulates the Proliferation and Neurite Outgrowth/Suppression of Cultured Rat Adult Hippocampal Neural Stem/Progenitor Cells in a Concentration-Dependent Manner\n5726: Chemotherapeutic Effect of SR9009, a REV-ERB Agonist, on the Human Glioblastoma T98G Cells\n5730: REV-ERB\u03b1 agonist SR9009 suppresses IL-1\u03b2 production in macrophages through BMAL1-dependent inhibition of inflammasome\n5732: In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011\n5735: A quantitative method for the simultaneous detection of SR9009 and SR9011 in equine plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry\n5738: Identification of a small molecule SR9009 that activates NRF2 to counteract cellular senescence\n5742: Rev-erbs agonist SR9009 alleviates ischemia-reperfusion injury by heightening endogenous cardioprotection at onset of type-2 diabetes in rats: Down-regulating ferritinophagy/ferroptosis signaling\n5746: Regulation of exercise ability and glycolipid metabolism by synthetic SR9009 analogues as new REV-ERB-\u03b1 agonists\n5750: Anti-influenza virus activity of the REV-ERB\u03b1 agonist SR9009 and related analogues\n5754: The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock\n5756: Production of certified reference materials for the sports doping control of the REV-ERB agonist SR9009\n5760: A further insight into the metabolic profile of the nuclear receptor Rev-erb agonist, SR9009\n5763: REV-ERB\u03b2 is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009\n5766: Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipogenesis modulation\n5769: Time of day dependent reduction in stroke infarct volume by the Reverb agonist SR9009 in mice\n5772: Rapid investigating of phase I metabolites of SR9009 in vitro horse liver microsomes via feature-based molecular networking approach: Potential applications in doping control\n5774: In vitro metabolism of the REV-ERB agonist SR-9009 and subsequent detection of metabolites in associated routine equine plasma and urine doping control samples\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug127_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Tamoxifen Citrate\" (also known as \"tamoxifencitrate\"), here are the article headings along with their IDs:\n5682: Tamoxifen citrate: a glimmer of hope for silicosis\n5683: Does tamoxifen citrate prevent pulmonary fibrosis due to silica inhalation?\n5685: Tamoxifen citrate-loaded poly(d,l) lactic acid nanoparticles: Evaluation for their anticancer activity in vitro and in vivo\n5688: Tamoxifen citrate loaded ethosomes for transdermal drug delivery system: preparation and characterization\n5691: Tamoxifen citrate loaded amphiphilic beta-cyclodextrin nanoparticles: in vitro characterization and cytotoxicity\n5692: An Approach to Enhance Dissolution Rate of Tamoxifen Citrate\n5696: Effects of tamoxifen citrate on postoperative intra-abdominal adhesion in a rat model\n5699: Hyaluronic Acid and Graphene Oxide-incorporated Hyaluronic Acid Hydrogels for Electrically Stimulated Release of Anticancer Tamoxifen Citrate\n5701: Tamoxifen citrate loaded chitosan-gellan nanocapsules for breast cancer therapy: development, characterisation and in-vitro cell viability study\n5703: Long-term tamoxifen citrate use and potential ocular toxicity\n5706: A combination of semi-purified L-methioninase with tamoxifen citrate to ameliorate breast cancer in athymic nude mice\n5710: Response of patients with indolent systemic mastocytosis to tamoxifen citrate\n5713: Tamoxifen citrate loaded solid lipid nanoparticles (SLN): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation\n5716: Tamoxifen citrate therapy in male infertility\n5719: Box-Behnken Design-Aided Validation and Optimization of a Stability-Indicating Reverse Phase-HPLC Method for the Estimation of Tamoxifen Citrate in Lipidic Nano-Vesicles\n5721: Practical issues in counseling healthy women about their breast cancer risk and use of tamoxifen citrate\n5724: Comparative Study of the Effects of Tamoxifen Citrate and Folate on Semen Quality of the Infertile Male with Semen Abnormality\n5727: Tamoxifen citrate for women with unexplained infertility\n5729: Synthesis and characterization of Tamoxifen citrate modified reduced graphene oxide nano sheets for breast cancer therapy\n5733: A clomiphene citrate and tamoxifen citrate combination therapy: a novel therapy for ovulation induction\n5736: Enhancing Sperm Motility Parameters in Patients with Asthenospermia: A Combined Approach of Acupuncture at Fusiguan Point and Tamoxifen Citrate Tablets\n5739: Cellular uptake, cytotoxicity and in-vivo evaluation of Tamoxifen citrate loaded niosomes\n5741: Lecithin/chitosan controlled release nanopreparations of tamoxifen citrate: loading, enzyme-trigger release and cell uptake\n5744: Development and evaluation of polymeric micelle containing tablet formulation for poorly water-soluble drug: tamoxifen citrate\n5747: Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in-vitro evaluation\n5749: Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy\n5752: In Vitro Cytotoxicity and Cellular Uptake of Tamoxifen Citrate-Loaded Polymeric Micelles\n5755: Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro\n5758: Effect of tamoxifen citrate on reproductive parameters of male dogs\n5762: Self-nanoemulsifying drug delivery systems of tamoxifen citrate: design and optimization\n5765: Enhancing the Therapeutic Efficacy of Tamoxifen Citrate Loaded Span-Based Nano-Vesicles on Human Breast Adenocarcinoma Cells\n5768: Effect of tamoxifen citrate on canine immobilization (disuse) osteoporosis\n5771: Tamoxifen citrate induced sperm shape abnormalities in the in vivo mouse\n5773: Efficacy and toxicity of tamoxifen citrate for prevention and termination of pregnancy in bitches\n5776: Genotoxicity of tamoxifen citrate and 4-nitroquinoline-1-oxide in the wing spot test of Drosophila melanogaster\n5778: Controlled release of tamoxifen citrate encapsulated in cross-linked guar gum nanoparticles\n5780: Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia\n5781: Biochemical and immunohistochemical investigations on bone formation and remodelling in ovariectomised rats with tamoxifen citrate administration\n5783: Treatment of idiopathic and postvaricocelectomy oligozoospermia with oral tamoxifen citrate\n5785: Folic acid grafted mixed polymeric micelles as a targeted delivery strategy for tamoxifen citrate in treatment of breast cancer\n5787: In vitro cytotoxicity and bioavailability of solid lipid nanoparticles containing tamoxifen citrate\n5789: The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia\n5791: Penetration of tamoxifen citrate loaded ethosomes and liposomes across human skin: a comparative study with confocal laser scanning microscopy\n5792: Polymorphs of tamoxifen citrate: detailed structural characterization of the stable form\n5794: Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells\n5796: Genetic polymorphisms of CYP2D6*10 and the effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in infertile men with idiopathic oligozoospermia\n5799: Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene\n5800: Preparation, characterization and in-vivo evaluation of microemulsions containing tamoxifen citrate anti-cancer drug\n5802: Optimization of spatiotemporal gene inactivation in mouse heart by oral application of tamoxifen citrate\n5804: Simultaneous TLC-densitometric determination of tamoxifen citrate and medroxyprogesterone acetate and UV-degradation kinetic study of medroxyprogesterone acetate\n5806: QbD-Driven Development and Validation of a HPLC Method for Estimation of Tamoxifen Citrate with Improved Performance\n5808: Self nanoprecipitating preconcentrate of tamoxifen citrate for enhanced bioavailability\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug129_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Toremifene Citrate\" (also known as \"toremifenecitrate\"), here are the article headings along with their IDs:\n5817: Toremifene citrate (Fareston)\n5819: In vitro release behavior of toremifene citrate from sol-gel processed sintered silica xerogels\n5821: Silica xerogel carrier material for controlled release of toremifene citrate\n5823: In vitro evaluation of biodegradable epsilon-caprolactone-co-D, L-lactide/silica xerogel composites containing toremifene citrate\n5825: [Plasma concentrations of toremifene citrate and N-desmethyltoremifene in postmenopausal patients with breast cancer--comparison of 120 mg of toremifene citrate administered once a day and divided into 3 separate doses (t.i.d.)]\n5826: Effect of the molecular weight of poly(epsilon-caprolactone-co-DL-lactide) on toremifene citrate release from copolymer/silica xerogel composites\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug130_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Albuterol\" (also known as \"albuterol\"), here are the article headings along with their IDs:\n5834: Levalbuterol versus albuterol\n5836: Airsupra: An inhaled albuterol/budesonide combination for asthma\n5838: A review of the toxicology of salbutamol (albuterol)\n5840: Large-volume, preservative-free albuterol concentrate\n5841: The cost effectiveness of levalbuterol versus racemic albuterol\n5843: Levalbuterolvs.albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis\n5845: Levalbuterol and racemic albuterol: are there therapeutic differences?\n5847: Best evidence topic report. Nebulised levalbuterol or albuterol for lowering serum potassium\n5849: Levalbuterol hydrochloride\n5851: Levalbuterol nebulizer solution: is it worth five times the cost of albuterol?\n5852: Albuterol and levalbuterol use and spending in Medicare beneficiaries with chronic obstructive pulmonary disease\n5854: (R)-albuterol for asthma: pro [a.k.a. (S)-albuterol for asthma: con]\n5856: Albuterol vs. levalbuterol for asthma treatment in children\n5860: Levalbuterol\n5863: Efficacy of Inhaled Levalbuterol Compared to Albuterol in Horses with Recurrent Airway Obstruction\n5864: Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison with Levalbuterol in Healthy Adult Volunteers\n5868: Effects of albuterol (salbutamol) on esophageal motility and gastroesophageal reflux in healthy volunteers\n5871: Levalbuterol is as effective as racemic albuterol in lowering serum potassium\n5876: Clinical outcomes of levalbuterol versus racemic albuterol in pediatric patients with asthma: Propensity score matching approach in a medicaid population\n5877: Comparison of racemic albuterol and levalbuterol for treatment of acute asthma\n5880: Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma\n5884: Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma\n5886: Single-isomer levalbuterol: a review of the acute data\n5889: The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients\n5890: Levalbuterol vs racemic albuterol: science or drug company propaganda?\n5892: Levalbuterol for asthma: a better treatment?\n5894: Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED\n5896: Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma\n5897: Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma\n5898: Hypokalemia after normal doses of neubulized albuterol (salbutamol)\n5899: A comparison of heart rate changes associated with levalbuterol and racemic albuterol in pediatric cardiology patients\n5900: Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study\n5901: Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease\n5902: Clinical experience with levalbuterol\n5903: A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects\n5904: The effects of racemic albuterol versus levalbuterol in very low birth weight infants\n5905: Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol\n5906: Changes in heart rate associated with nebulized racemic albuterol and levalbuterol in intensive care patients\n5907: Mirror images: is levalbuterol the fairest of them all?\n5908: Solid-state characterization of two polymorphic forms of R-albuterol sulfate\n5909: A preliminary comparison of levalbuterol and albuterol in prehospital care\n5910: Acute Levalbuterol Toxicity With Use of Metered Dose Inhaler\n5911: Paradoxical response to levalbuterol\n5912: Correspondence regarding levalbuterol and racemic albuterol, July 2004 Supplement\n5913: Liquid chromatographic methods for the determination of albuterol (salbutamol), albuterol sulphate and related compounds in drug raw materials, tablets and inhalers\n5914: Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique\n5915: Point-counterpoint: A comparison of levalbuterol and racemic albuterol in the treatment of pediatric asthma\n5916: Dose-related bronchodilator response to aerosolized salbutamol (albuterol) in ventilator-dependent premature infants\n5917: Worldwide experience with albuterol (salbutamol)\n5918: A comparison of responses to albuterol delivered by two aerosol devices\n5919: Cost of using levalbuterol in the emergency room\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug131_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Argireline\" (also known as \"argireline\"), here are the article headings along with their IDs:\n5858: Argireline: Needle-Free Botox as Analytical Challenge\n5862: Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia\u00aeComplexion Analysis camera system for objective skin analysis\n5865: Polydioxanone Bioactive Sutures-Acetyl Hexapeptide-8 (Argireline): An Intelligent System for Controlled Release in Facial Harmonization\n5867: The anti-wrinkle efficacy of Argireline\n5870: The study of cellular cytotoxicity of argireline - an anti-aging peptide\n5873: Mycobacterium abscessusinfection after facial injection of argireline: A case report\n5875: Influence of the modification of the cosmetic peptide Argireline on the affinity toward copper(II) ions\n5879: The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects\n5882: The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study\n5885: A synthetic hexapeptide (Argireline) with antiwrinkle activity\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug132_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Dapoxetine HCl\" (also known as \"dapoxetinehcl\"), here are the article headings along with their IDs:\n5891: Mitigation of Rheumatic Arthritis in a Rat Model via Transdermal Delivery of Dapoxetine HCl Amalgamated as a Nanoplatform: In vitro and in vivo Assessment\n5893: Novel Enhanced Therapeutic Efficacy of Dapoxetine HCl by Nano-Vesicle Transdermal Gel for Treatment of Carrageenan-Induced Rat Paw Edema\n5895: Stability indicating HPLC-UV method for determination of dapoxetine HCl in pharmaceutical product\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug133_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Methylene Blue\" (also known as \"methyleneblue\"), here are the article headings along with their IDs:\n5920: [The effect of methyleneblue on insulin and glucagon release stimulated by glucose and arginine in the isolated perfused rat pancreas]\n5921: A Rare Case of Delayed Pulmonary Oedema due to Methemoglobinemia Following Laparoscopic Chromopertubation with Methyleneblue\n5922: Methylene-Blue in Fevers\n5923: IS METHYLENE-BLUE ANTI-CARCINOGENIC?\n5924: [The methyleneblue reduction disc test (M.R.D.-test): a simplified method for the identification of Pseudomonas species (author's transl)]\n5925: The methylene-blue baby\n5926: THE SELECTIVE BACTERICIDAL ACTION OF METHYLENE-BLUE\n5927: Computed tomography-guided localization for lung nodules: methylene-blue versus coil localization\n5930: [Comparative study ofmethylene blue tracer and double tracer containing nuclide in sentinel lymph node biopsy of breast cancer]\n5932: Nanoencapsulation of Methylene-Blue for Enhanced Skin Cancer Cell Phototoxicity and Cutaneous Penetration in Association with Sonophoresis\n5934: Methylene-blue in alcohol-induced hypoglycaemia\n5936: Oral dose of methylene-blue\n5940: Evaluation of Axilla With Sentinel Lymph Node Biopsy (Using Methylene-Blue) and Reverse Axillary Mapping (Using Fluorescein) to Validate Optimum and Safe Axillary Dissection in Breast Cancer\n5943: The Role of Methylene Blue Spray to Keep Parathyroid Gland and Recurrent Laryngeal Nerve Safe During Thyroidectomy\n5946: Effects of methylene-blue staining on the extent of pilonidal sinus excision\n5949: Synthesis of activated carbon-surfactant modified montmorillonite clay-alginate composite membrane for methylene blue adsorption\n5953: Comparison between the efficacy of Intense Pulsed Light (I.P.L.) versus Photo-Dynamic Therapy (P.D.T.) with methylene-blue in the treatment of psoriatic nails\n5955: Methylene-blue test for gastroesophageal reflux\n5958: Accuracy of Methylene Blue Test as Single Technique for Sentinel Lymph Node Biopsy in Early Stages Breast Cancer\n5961: Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue\n5966: Long-term follow-up of intradermal injection of methylene blue for intractable, idiopathic pruritus ani\n5969: Efficient Removal of Methylene Blue and Ciprofloxacin from Aqueous Solution Using Flower-like, Nanostructured ZnO Coating under UV Irradiation\n5972: Evaluation of the hemostatic capacity of methylene blue-treated liquid (not frozen) plasma stored up 14 days at 2\u00b0 to 6\u00b0C\n5975: Possible explanation for therapeutic action of lithium, and a possible substitute (methylene-blue)\n5978: Methylene-blue for riboflavin-unresponsive glutaricaciduria type II\n5981: CT-guided methylene-blue labelling before thoracoscopic resection of pulmonary nodules\n5985: A methylene-blue technique for staining muscle spindles\n5986: Submucosal tunneling endoscopic resection using methylene-blue guidance for cardial subepithelial tumors originating from the muscularis propria layer\n5988: Carbon aerogels derived from sodium lignin sulfonate embedded in carrageenan skeleton for methylene-blue removal\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug135_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Gonadorelin\" (also known as \"gonadorelin\"), here are the article headings along with their IDs:\n5938: Advances and perspectives in the analytical technology for small peptide hormones analysis: A glimpse to gonadorelin\n5941: Gonadorelin and erythropoiesis\n5942: [Gonadorelin antagonists: present and future]\n5945: [Micropump infusion of gonadorelin in the treatment of hypogonadotropic hypogonadism in patients with pituitary stalk interruption syndrome: cases analysis and literature review]\n5948: Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty\n5951: Gonadorelin--synthetic LH-RH\n5954: Reproductive performance of goats treated with free gonadorelin or nanoconjugated gonadorelin at estrus\n5957: Gonadorelin increases semen production and does not affect its quality in Leporinus obtusidens\n5960: GnRH agonists: gonadorelin, leuprolide and nafarelin\n5963: Effect of using 200 \u03bcg of gonadorelin at the first gonadotropin-releasing hormone of the breeding-Ovsynch on ovulatory response and pregnancies per artificial insemination in first-service lactating Holstein cows\n5965: Gonadorelin-induced testosterone release: a biological assay for quality assurance of gonadorelin in veterinary medicine\n5968: Effect of different gonadorelin (GnRH) products used for the first or resynchronized timed artificial insemination on pregnancy rates in postpartum dairy cows\n5971: Stability of gonadorelin and triptorelin in aqueous solution\n5973: [Research progress in immune regulation of gonadorelin]\n5976: [Effects of neuropeptides and neurotransmitters on the regulation of gonadorelin neurons endings in hypothalamic median eminence]\n5979: Zn2+-triggered self-assembly of Gonadorelin [6-D-Phe] to produce nanostructures and fibrils\n5982: The effects of 3 gonadorelin products on luteinizing hormone release, ovulation, and follicular wave emergence in cattle\n5983: Degradation kinetics of gonadorelin in aqueous solution\n5984: Gonadorelin for induction of ovulation\n5987: Spray congealed solid lipid microparticles as a sustained release delivery system for Gonadorelin [6-D-Phe]: Production, optimization and in vitro release behavior\n5989: Biological assay of luteinizing hormone-releasing hormone (gonadorelin)\n5990: Impact of phase of the estrous cycle and season on LH surge profile and fertility in dairy cows treated with different GnRH analogs (gonadorelin vs. buserelin)\n5991: Estimation of human effective absorbed dose of 67Ga-cDTPA-gonadorelin based on biodistribution rat data\n5992: Modulatory effects of gonadorelin on GABA-induced depolarization and GABA-activated current in rat spinal ganglion neurons\n5993: The adjuvant effect of bacitracin on nasal absorption of gonadorelin and buserelin in rats\n5994: [Intranasal gonadorelin in the treatment of cryptorchism]\n5995: Immunoglobulin-mediated hypersensitivity in response to long-term treatment with gonadorelin hydrochloride (Factrel) in a female patient\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug136_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"C60Fullerene\" (also known as \"c60fullerene\"), here are the article headings along with their IDs:\n5928: C60fullerene improves the contractile activity of the injured ratmuscle gastrocnemius\n5929: Formation of a soluble stable complex between pristine C60-fullerene and a native blood protein\n5931: Development and application of C60-fullerene bound silica for solid-phase extraction of biomolecules\n5933: Molecular self-healing mechanisms between C60-fullerene and anthracene unveiled by Raman and two-dimensional correlation spectroscopy\n5935: The first molecular dumbbell consisting of an endohedral Sc3N@C80and an empty C60-fullerene building block\n5937: C60-fullerene bound silica for the preconcentration and the fractionation of multiphosphorylated peptides\n5939: Corannulene and its penta-tert-butyl derivative co-crystallize 1:1 with pristine C60-fullerene\n5944: Lysine-Based C60-Fullerene Nanoconjugates for Monomethyl Fumarate Delivery: A Novel Nanomedicine for Brain Cancer Cells\n5947: The C60-fullerene porphyrin adducts for prevention of the doxorubicin-induced acute cardiotoxicity in rat myocardial cells\n5950: C60-fullerene binds with the ATP binding domain of human DNA topoiosmerase II alpha\n5952: Analysis of C60-fullerene derivatives and pristine fullerenes in environmental samples by ultrahigh performance liquid chromatography-atmospheric pressure photoionization-mass spectrometry\n5956: Comparative computational study of interaction of C60-fullerene and tris-malonyl-C60-fullerene isomers with lipid bilayer: relation to their antioxidant effect\n5959: Corannulene vs. C60-fullerene in metal binding reactions: a direct DFT and X-ray structural comparison\n5962: C60-Fullerene monomalonate adducts selectively inactivate neuronal nitric oxide synthase by uncoupling the formation of reactive oxygen intermediates from nitric oxide production\n5964: Porous polymer monoliths functionalized through copolymerization of a C60 fullerene-containing methacrylate monomer for highly efficient separations of small molecules\n5967: Bisaziridine tetracarboxylates as building blocks in the stereoselective synthesis of C60-fullerene diads and dumbbell-like bis-C60-fullerene triads\n5970: Linear pi-conjugated systems derivatized with C60-fullerene as molecular heterojunctions for organic photovoltaics\n5974: Gas-phase halo alkylation of C60-fullerene by ion-molecule reaction under chemical ionization\n5977: Conclusive determination of the absolute configuration of chiral C60-fullerene cis-3 bisadducts by X-ray crystallography and circular dichroism\n5980: Insights into metal-pi arene interactions of the highly Lewis acidic Rh2(4+) core with a broad set of pi-ligands: from ethylene to corannulene and C60-fullerene\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug138_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Demoxytocin\" (also known as \"demoxytocin\"), here are the article headings along with their IDs:\n5996: Oral oxytocics for induction of labor. A randomized study of prostaglandin E2 tablets and demoxytocin resoriblets\n5997: Use of oral oxytocics for stimulation of labor in cases of premature rupture of the membranes at term. A randomized comparative study of prostaglandin E2 tablets and demoxytocin resoriblets\n5998: Induction of labor with oral prostaglandin E2 and buccal demoxytocin without amniotomy\n6000: A comparative study of labor induced by oral prostaglandin E2 and buccal tablets of demoxytocin\n6003: [Labor induction with buccal oxytocin and demoxytocin]\n6007: [Induction of labor by means of oral prostaglandin E2, buccal demoxytocin or automatic oxytocin infusion system]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug139_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Triptorelin\" (also known as \"triptorelin\"), here are the article headings along with their IDs:\n5999: Triptorelin for the treatment of endometriosis\n6002: Triptorelin embonate (6-month formulation)\n6005: Triptorelin depot for the treatment of children 2 years and older with central precocious puberty\n6008: Triptorelin in the management of prostate cancer\n6010: Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer\n6012: Triptorelin embonate: a 6-month formulation for prostate cancer\n6013: Triptorelin (Triptodur) for central precocious puberty\n6016: Three cases of transient hyperthyroidism after triptorelin treatment - case report and literature review\n6017: Evaluating triptorelin as a treatment option for breast cancer\n6022: [Pharmacodynamics of triptorelin]\n6024: [Pharmacokinetics and pharmacodynamics of triptorelin]\n6026: Triptorelin acetate administration in early pregnancy: case reports and review of the literature\n6028: Triptorelin-functionalized PEG-coated biosynthesized gold nanoparticles: Effects of receptor-ligand interactions on adhesion to triple negative breast cancer cells\n6029: An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer\n6030: Triptorelin pamoate (Trelstar)\n6033: Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center\n6035: Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study\n6037: Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty\n6039: Stability of triptorelin in the presence of dermis and epidermis\n6042: The efficacy and safety of triptorelin-therapy following conservative surgery for deep infiltrating endometriosis: A multicenter, prospective, non-interventional study in China\n6044: GnRH analogue triptorelin acetate induces ovulation in jennies during oestrus\n6046: Familial male-limited precocious puberty (testotoxicosis): Usefulness of treatment with ketoconazole and triptorelin\n6048: Investigation of Specific Targeting of Triptorelin-Conjugated Dextran-Coated Magnetite Nanoparticles as a Targeted Probe in GnRH+Cancer Cells in MRI\n6050: Triptorelin improves intestinal symptoms among patients with colorectal endometriosis\n6052: Effects of triptorelin versus placebo on the symptoms of endometriosis\n6054: Cost-Effectiveness Analysis of Triptorelin, Goserelin, and Leuprolide in the Treatment of Patients With Metastatic Prostate Cancer: A Societal Perspective\n6056: Single injection of triptorelin or buserelin acetate in saline solution induces ovulation in mares the same as a single injection of hCG\n6059: Long-acting triptorelin for the treatment of endometriosis\n6061: A single blood sample for stimulated LH assayed by ICMA is useful for monitoring the treatment efficacy of triptorelin depot in girls\n6063: Triptorelin approved for prostate cancer treatment\n6064: A crossover study of triptorelin and leuprorelin acetate\n6067: Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study\n6069: Effects of water-soluble additive on the release profile and pharmacodynamics of triptorelin loaded in PLGA microspheres\n6071: Effects of fixed-time artificial insemination using triptorelin on the reproductive performance of pigs: a meta-analysis\n6073: Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial\n6075: Pulmonary Delivery of Triptorelin Loaded in Pluronic Based Nanomicelles in Rat Model\n6076: Does the risk of arterial hypertension increase in the course of triptorelin treatment?\n6078: Micro-solid phase extraction and LC-MS3for the determination of triptorelin in rat plasma and application to a pharmacokinetic study\n6080: Central precocious puberty: treatment with triptorelin 11.25 mg\n6082: [Treatment of central precocious puberty with sustained-release triptorelin]\n6084: Gray hair in children on triptorelin treatment\n6086: [Triptorelin therapy in girls with central precocious puberty increases body mass index]\n6088: Design of triptorelin loaded nanospheres for transdermal iontophoretic administration\n6090: Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?\n6092: Does lower dose of long-acting triptorelin maintain pituitary suppression and produce good live birth rate in long down-regulation protocol for in-vitro fertilization?\n6093: Investigation of adhesive interactions in the specific targeting of Triptorelin-conjugated PEG-coated magnetite nanoparticles to breast cancer cells\n6095: Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer\n6098: Adult height in girls with idiopathic central precocious puberty treated with triptorelin\n6101: Fertility of Women Treated during Childhood with Triptorelin (Depot Formulation) for Central Precocious Puberty: The PREFER Study\n6104: A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty\n6107: Hypertension during therapy with triptorelin in a girl with precocious puberty\n6110: An analytical strategy to characterize the pharmacokinetics and pharmacodynamics of triptorelin in rats based on simultaneous LC-MS/MS analysis of triptorelin and endogenous testosterone in rat plasma\n6114: Quantitation of slow release triptorelin in beagle dog plasma by liquid chromatography-tandem mass spectrometry\n6116: Reproductive endocrinology: triptorelin ovarian suppression during breast cancer chemotherapy\n6121: Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer\n6124: A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate\n6128: Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation\n6131: Hydrophilic interaction liquid chromatography-solid phase extraction directly combined with protein precipitation for the determination of triptorelin in plasma\n6136: Impact of age on cytotoxic-induced ovarian failure in breast cancer treated with adjuvant chemotherapy and triptorelin\n6139: An open and randomized study comparing the efficacy of standard danazol and modified triptorelin regimens for postoperative disease management of moderate to severe endometriosis\n6143: In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer\n6147: Treatment with triptorelin in mentally disordered sex offenders: experience from a maximum-security hospital\n6151: A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma\n6155: Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation\n6159: Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study\n6162: [Clinical trial on the effectiveness and safety of triptorelin in treatment of uterine leiomyoma]\n6166: Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty\n6170: Our experience with long-term triptorelin therapy in a large endometriosis nodule arising in an episiotomy scar\n6174: Central Precocious Puberty: Adult Height in Girls Treated with Quarterly or Monthly Gonadotropin-Releasing Hormone Analog Triptorelin\n6179: Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study\n6182: Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis\n6184: [Application of half-dose depot long-acting triptorelin in postoperative adjuvant therapy for endometriosis]\n6187: Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study\n6190: [Decapeptyl (triptorelin) in the treatment of endometriosis genitalis externa]\n6198: [Study of the beneficial effects of triptorelin on lower urinary tract symptoms in Algeria in patients with non-localized prostate cancer]\n6199: A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis\n6202: Efficacy of the subcutaneous reformulated triptorelin depot in children with central precocious puberty\n6205: Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone\n6210: Hair loss in children on long-acting gonadotropin-releasing hormone agonist triptorelin treatment\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug140_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Mirabegron\" (also known as \"mirabegron\"), here are the article headings along with their IDs:\n6001: Mirabegron: Pediatric First Approval\n6004: Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison\n6006: Mirabegron: The most promising adipose tissue beiging agent\n6009: Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis\n6011: Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis\n6014: Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial\n6015: Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study\n6018: Mirabegron in female patients with overactive bladder syndrome: What's new? A systematic review and meta-analysis\n6019: Mirabegron: A Review in Overactive Bladder Syndrome\n6020: Mirabegron: a safety review\n6021: Mirabegron\n6023: Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome\n6025: [Mirabegron, a breakthrough in overactive bladder syndrome?]\n6027: The use of mirabegron in neurogenic bladder: a systematic review\n6031: Mirabegron in the treatment of overactive bladder\n6032: Mirabegron: potential off target effects and uses beyond the bladder\n6034: Effect of Mirabegron on the Body's Exercise Capacity: A Review\n6036: Mirabegron: a Beta-3 agonist for overactive bladder\n6038: Activation of \u03b23-adrenergic receptor by mirabegron prevents aortic dissection/aneurysm by promoting lymphangiogenesis in perivascular adipose tissue\n6040: Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient\n6041: Cost-effectiveness evaluation of mirabegron versus anti-muscarinics and third-line therapies: a systematic review\n6043: Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability\n6045: Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia\n6047: Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis\n6049: The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis\n6051: Mirabegron safe and effective for NDO\n6053: Mirabegron: hypertension, stroke\n6055: Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis\n6057: Mirabegron: \u03b23-adrenergic receptor agonist for the treatment of overactive bladder\n6058: Mirabegron Add-On Tamsulosin for Men with Overactive Bladder Symptoms: A Pooled Analysis of Four Randomized Controlled Trials\n6060: Mirabegron attenuates porcine ureteral contractility via \u03b11-adrenoceptor antagonism\n6062: Profile of mirabegron in the treatment of overactive bladder: place in therapy\n6065: The Efficacy of Mirabegron in Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis\n6066: Mirabegron versus vibegron in previously untreated female patients with overactive bladder: A randomized, single-clinic, open-label trial\n6068: The efficacy and safety of mirabegron in treating ureteral stent-related symptoms: A systematic review and meta-analysis\n6070: Mirabegron, a \u03b2\u2083-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder\n6072: Adverse events associated with mirabegron 50mg versus placebo: A systematic review and meta-analysis\n6074: Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder: A systematic review and meta-analysis\n6077: Mirabegron: a review of its use in patients with overactive bladder syndrome\n6079: Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia\n6081: Effectiveness and tolerability of mirabegron in children with overactive bladder: A retrospective pilot study\n6083: Mirabegron for overactive bladder: a novel, first-in-class \u03b23-agonist therapy\n6085: Mirabegron-induced brown fat activation does not exacerbate atherosclerosis in mice with a functional hepatic ApoE-LDLR pathway\n6087: The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis\n6089: The efficacy and safety of mirabegron for adult and child patients with neurogenic lower urinary tract dysfunction: A systematic review and meta-analysis\n6091: Effects of mirabegron on brown adipose tissue and metabolism in humans: A systematic review and meta-analysis\n6094: Efficacy and safety of mirabegron for treatment of neurogenic detrusor overactivity in adults with spinal cord injury or multiple sclerosis: a systematic review\n6097: Mirabegron versus Antimuscarinics in the Treatment of Overactive Bladder: The Final Answer?\n6100: Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder\n6103: Urodynamic parameter improvements after mirabegron vs. antimuscarinics agents in non-neurogenic overactive bladder: a systematic review and meta-analysis of treatment effect\n6105: Mirabegron vs. solifenacin in control of endoscopically inserted ureteral stent-related symptoms\n6109: Distinct Conformations of Mirabegron Determined by MicroED\n6113: Mirabegron relaxes arteries from human visceral adipose tissue through antagonism of \u03b11-adrenergic receptors\n6119: Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response\n6123: Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis\n6127: Cost analysis for mirabegron use in the treatment of children with neurogenic bladder\n6132: The \u03b23-adrenoreceptor agonist mirabegron for the treatment of combined pre- and post-capillary pulmonary hypertension: new pathway or dead end?\n6135: Mirabegron alleviates acetic acid-induced colitis in rats: Role of adiponectin and GSTM1/GSH detoxification pathway\n6141: Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population\n6146: Mirabegron as effective as oxybutynin for ureteral stent symptoms\n6149: Use of mirabegron in treating overactive bladder\n6153: The role of mirabegron in overactive bladder: a systematic review and meta-analysis\n6157: Mirabegron causes vesical and urethral relaxation in rats with spinal cord injury\n6160: Mirabegron Ameliorated Atherosclerosis of ApoE-/-Mice in Chronic Intermittent Hypoxia but Not in Normoxia\n6164: Does mirabegron deteriorate spermatogenesis? A lesson from spinal cord injury cases\n6167: Safety and efficacy of an \u03b11-blocker plus mirabegron compared with an \u03b11-blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta-analysis\n6171: Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice\n6175: Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms-A randomized controlled trial\n6178: A drug safety evaluation of mirabegron in the management of overactive bladder\n6181: Overactive bladder medication: Anticholinergics versus mirabegron by specialty\n6186: Effects of mirabegron on depression, anxiety, learning and memory in mice\n6191: Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics\n6193: Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction: a 12-week pilot study\n6195: Treatment of Elderly Patients with Overactive Bladder: Has Mirabegron Come of Age?\n6196: Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)\n6200: Comparison Of Solifenacin And Mirabegron For The Treatment Of Overactive Bladder\n6203: Editorial Comment to Efficacy of mirabegron, a \u03b23-adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies\n6207: The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option\n6208: Editorial Comment from Dr Funahashi to Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial\n6211: Efficacy of mirabegron in medical expulsive therapy\n6215: Mirabegron has longer treatment persistence than antimuscarinics: Real-world data from a Korean national cohort database\n6217: Mirabegron induces relaxant effects via cAMP signaling-dependent and -independent pathways in detrusor smooth muscle\n6220: Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials\n6221: Effects of mirabegron on JJ stent-related symptoms: A multicentric study\n6223: Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial\n6225: Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review\n6227: Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study\n6229: MIRABEGRON INDUCED RELAXATION OF ISOLATED BOVINE CORONARY SEGMENTS: ROLE OF NO AND K+ CHANNEL\n6231: Efficacy of mirabegron, a \u03b23-adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies\n6233: Patient utilization survey of mirabegron prescribed for overactive bladder\n6235: Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors\n6237: Mirabegron, dependent on \u03b23-adrenergic receptor, alleviates mercuric chloride-induced kidney injury by reversing the impact on the inflammatory network, M1/M2 macrophages, and claudin-2\n6239: RE: mirabegron in medical expulsive therapy for distal ureteral stones: a prospective, randomized, controlled study\n6240: Better Persistence Rates with Mirabegron: Questions Raised\n6243: Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder\n6245: Mirabegron Toxicosis in Dogs: a Retrospective Study\n6247: Long-term beneficial effects of mirabegron in pediatric patients with therapy-refractory neurogenic lower urinary tract dysfunction\n6248: [The place of mirabegron in clinical practice]\n6251: Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug144_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"AICAR\" (also known as \"aicar\"), here are the article headings along with their IDs:\n6096: AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review\n6099: AICAR confers prophylactic cardioprotection in doxorubicin-induced heart failure in rats\n6102: AICAR stimulates mitochondrial biogenesis and BCAA catabolic enzyme expression in C2C12 myotubes\n6106: AICAR attenuates postoperative abdominal adhesion formation by inhibiting oxidative stress and promoting mesothelial cell repair\n6111: Aicar effect in early neuronal development\n6115: AICAR suppresses cell proliferation and synergizes with decitabine in myelodysplastic syndrome via DNA damage induction\n6118: AICAR Improves Outcomes of Metabolic Syndrome and Type 2 Diabetes Induced by High-Fat Diet in C57Bl/6 Male Mice\n6122: AICAR promotes endothelium-independent vasorelaxation by activating AMP-activated protein kinase via increased ZMP and decreased ATP/ADP ratio in aortic smooth muscle\n6126: AICAR Ameliorates Non-Alcoholic Fatty Liver Disease via Modulation of the HGF/NF-\u03baB/SNARK Signaling Pathway and Restores Mitochondrial and Endoplasmic Reticular Impairments in High-Fat Diet-Fed Rats\n6129: AICAR prolongs corneal allograft survival via the AMPK-mTOR signaling pathway in mice\n6134: AICAr to SAICAr ratio can serve as additional marker of AICAr use\n6137: AICAR, an AMPK activator, protects against cisplatin-induced acute kidney injury through the JAK/STAT/SOCS pathway\n6142: AICAR induces AMPK-independent programmed necrosis in prostate cancer cells\n6145: AMPK activation by AICAR reduces diet induced fatty liver in C57BL/6 mice\n6150: AICAR enhances the cytotoxicity of PFKFB3 inhibitor in an AMPK signaling-independent manner in colorectal cancer cells\n6154: AICAR activates ER stress-dependent apoptosis in gallbladder cancer cells\n6158: An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1\n6163: AICAR and nicotinamide treatment synergistically augment the proliferation and attenuate senescence-associated changes in mesenchymal stromal cells\n6168: AICAR upregulates ABCA1/ABCG1 expression in the retinal pigment epithelium and reduces Bruch's membrane lipid deposit in ApoE deficient mice\n6172: Chronic AICAR treatment prevents metabolic changes in cardiomyocytes exposed to free fatty acids\n6177: AICAR induces mitochondrial apoptosis in human osteosarcoma cells through an AMPK-dependent pathway\n6183: Whether AICAR in Pregnancy or Lactation Prevents Hypertension Programmed by High Saturated Fat Diet: A Pilot Study\n6188: AICAR and Decitabine Enhance the Sensitivity of K562 Cells to Imatinib by Promoting Mitochondrial Activity\n6192: AICAR attenuates organ injury and inflammatory response after intestinal ischemia and reperfusion\n6194: Exercise-mimetic AICAR transiently benefits brain function\n6197: AICAR inhibits oxygen consumption by intact skeletal muscle cells in culture\n6201: Characterization of AICAR transformylase/IMP cyclohydrolase (ATIC) from Staphylococcus lugdunensis\n6204: AICAR inhibits NF\u03baB DNA binding independently of AMPK to attenuate LPS-triggered inflammatory responses in human macrophages\n6206: New synthetic AICAR derivatives with enhanced AMPK and ACC activation\n6209: AMPK activator AICAR in combination with anti-mouse IL10 mAb restores the functionality of intra-tumoral Tfh cells in the 4T1 mouse model\n6212: AMPK activator AICAR promotes 5-FU-induced apoptosis in gastric cancer cells\n6213: AICAR and Metformin Exert AMPK-dependent Effects on INS-1E Pancreatic \u03b2-cell Apoptosis via Differential Downstream Mechanisms\n6214: Nucleosides block AICAR-stimulated activation of AMPK in skeletal muscle and cancer cells\n6216: AICAR-Induced AMPK Activation Inhibits the Noncanonical NF-\u03baB Pathway to Attenuate Liver Injury and Fibrosis in BDL Rats\n6218: Binding Studies of AICAR and Human Serum Albumin by Spectroscopic, Theoretical, and Computational Methodologies\n6219: AICAR administration affects glucose metabolism by upregulating the novel glucose transporter, GLUT8, in equine skeletal muscle\n6222: AICAR inhibits PPAR\u03b3 during monocyte differentiation to attenuate inflammatory responses to atherogenic lipids\n6224: AICAR, a small chemical molecule, primes osteogenic differentiation of adult mesenchymal stem cells\n6226: AICAR Enhances the Phagocytic Ability of Macrophages towards Apoptotic Cells through P38 Mitogen Activated Protein Kinase Activation Independent of AMP-Activated Protein Kinase\n6228: AICAR, an activator of AMPK, inhibits adipogenesis via the WNT/\u03b2-catenin pathway in 3T3-L1 adipocytes\n6230: AICAR, an activator of AMP-activated protein kinase, down-regulates the insulin receptor expression in HepG2 cells\n6232: Characterization of AICAR transformylase/IMP cyclohydrolase (ATIC) bifunctional enzyme from Candidatus Liberibacer asiaticus\n6234: Implementation of AICAR analysis by GC-C-IRMS for anti-doping purposes\n6236: AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model\n6238: AICAR-induced activation of AMPK negatively regulates myotube hypertrophy through the HSP72-mediated pathway in C2C12 skeletal muscle cells\n6241: AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner\n6242: AICAR inhibits cancer cell growth and triggers cell-type distinct effects on OXPHOS biogenesis, oxidative stress and Akt activation\n6244: Intravenous AICAR during hyperinsulinemia induces systemic hemodynamic changes but has no local metabolic effect\n6246: AICAR induced AMPK activation potentiates neuronal insulin signaling and glucose uptake\n6249: Identification of yeast and human 5-aminoimidazole-4-carboxamide-1-\u03b2-d-ribofuranoside (AICAr) transporters\n6250: AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) increases the production of toxic molecules and affects the profile of cytokines release in LPS-stimulated rat primary microglial cultures\n6252: AICAR induces Bax/Bak-dependent apoptosis through upregulation of the BH3-only proteins Bim and Noxa in mouse embryonic fibroblasts\n6253: AICAR inhibits proliferation and induced S-phase arrest, and promotes apoptosis in CaSki cells\n6254: Combinatorial treatment with exercise and AICAR potentiates the rescue of myotonic dystrophy type 1 mouse muscles in a sex-specific manner\n6255: AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats\n6256: AICAR sustains J1 mouse embryonic stem cell self-renewal and pluripotency by regulating transcription factor and epigenetic modulator expression\n6258: AICAR stimulation metabolome widely mimics electrical contraction in isolated rat epitrochlearis muscle\n6260: Urinary concentrations of AICAR and mannitol in athlete population\n6263: AICAR and Compound C regulate food intake independently of AMP-activated protein kinase in lines of chickens selected for high or low body weight\n6264: Prolonged AICAR-induced AMP-kinase activation promotes energy dissipation in white adipocytes: novel mechanisms integrating HSL and ATGL\n6265: AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat\n6266: Chronic AICAR-induced AMP-kinase activation regulates adipocyte lipolysis in a time-dependent and fat depot-specific manner in rats\n6267: Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy (DPN) by Regulating Mitophagy\n6268: AICAR treatment for 14 days normalizes obesity-induced dysregulation of TORC1 signaling and translational capacity in fasted skeletal muscle\n6269: AICAR induces astroglial differentiation of neural stem cells via activating the JAK/STAT3 pathway independently of AMP-activated protein kinase\n6270: Anti-cancer Effects of 5-Aminoimidazole-4-Carboxamide-1-\u03b2-D-Ribofuranoside (AICAR) on Triple-negative Breast Cancer (TNBC) Cells: Mitochondrial Modulation as an Underlying Mechanism\n6272: AICAR Attenuates TNF\u03b1-Induced Inappropriate Secretion of Monocyte Chemoattractant Protein-1 and Adiponectin in 3T3-L1 Adipocytes\n6274: [AICAR-Dependent Activation of AMPK Kinase Is Not Accompanied by G1/S Block in Mouse Embryonic Stem Cells]\n6276: AMPK activator, AICAR, inhibits palmitate-induced apoptosis in osteoblast\n6278: AICAR stimulates adiponectin and inhibits cytokines in adipose tissue\n6280: AMPK-independent inhibition of human macrophage ER stress response by AICAR\n6281: AMPK activator AICAR ameliorates ischaemia reperfusion injury in the rat kidney\n6282: Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients\n6283: The AMPK agonist AICAR inhibits TGF-\u03b21 induced activation of kidney myofibroblasts\n6284: AICAR stimulates IL-6 production via p38 MAPK in cardiac fibroblasts in adult mice: a possible role for AMPK\n6285: Treatment with AICAR inhibits blastocyst development, trophectoderm differentiation and tight junction formation and function in mice\n6286: AICAR-dependent AMPK activation improves scar formation in the aged heart in a murine model of reperfused myocardial infarction\n6287: AICAR inhibits the Na+/H+ exchanger in rat hearts--possible contribution to cardioprotection\n6288: Disruption of Nucleotide Homeostasis by the Antiproliferative Drug 5-Aminoimidazole-4-carboxamide-1-\u03b2-d-ribofuranoside Monophosphate (AICAR)\n6289: Effect of AICAR treatment on glycogen metabolism in skeletal muscle\n6290: AICAR preconditioning prevents postischemic leukocyte rolling and adhesion: role of K(ATP) channels and heme oxygenase\n6291: Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK\n6292: AICAR positively regulate glycogen synthase activity and LDL receptor expression through Raf-1/MEK/p42/44MAPK/p90RSK/GSK-3 signaling cascade\n6293: 5-Amino-1-\u03b2-D-Ribofuranosyl-Imidazole-4-Carboxamide (AICAR) Reduces Peripheral Inflammation by Macrophage Phenotype Shift\n6294: Case report of a rare purine synthesis disorder due to 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICAR) deficiency\n6295: Metabolomics and proteomics identify the toxic form and the associated cellular binding targets of the anti-proliferative drug AICAR\n6297: Long-term AICAR administration and exercise prevents diabetes in ZDF rats\n6300: Determination of \u00b9\u00b3C/\u00b9\u00b2 C ratios of endogenous urinary 5-amino-imidazole-4-carboxamide 1\u03b2-D-ribofuranoside (AICAR)\n6301: Wnt/\u03b2-Catenin Mediates AICAR Effect to Increase GATA3 Expression and Inhibit Adipogenesis\n6303: AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats\n6305: Doping control study of AICAR in post-race urine and plasma samples from horses\n6309: Urine levels of 5-aminoimidazole-4-carboxamide riboside (AICAR) in patients with type 2 diabetes\n6311: TBC1D4 Is Necessary for Enhancing Muscle Insulin Sensitivity in Response to AICAR and Contraction\n6313: Human AICAR transformylase: role of the 4-carboxamide of AICAR in binding and catalysis\n6316: The AMPK-activator AICAR in thyroid cancer: effects on CXCL8 secretion and on CXCL8-induced neoplastic cell migration\n6318: Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles\n6320: The AMPK Activator Aicar Ameliorates Age-Dependent Myocardial Injury in Murine Hemorrhagic Shock\n6322: AICAR and hyperosmotic stress increase insulin-stimulated glucose transport\n6323: 5-Aminoimidazole-4-carboxamide-1-\u03b2-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug145_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Ara-290\" (also known as \"ara-290\"), here are the article headings along with their IDs:\n6108: ARA 290 for treatment of small fiber neuropathy in sarcoidosis\n6112: ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception\n6117: Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression\n6120: ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes\n6125: Synthesis and evaluation of99mTc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region\n6130: A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets\n6133: ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density\n6138: ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response\n6140: Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study\n6144: Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the \u03b2-common receptor in mice with cerebral ischemic stroke\n6148: ARA290 inhibits high glucose-induced apoptosis of NRK-52E cells\n6152: Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways\n6156: An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress\n6161: ARA290 in a rat model of inflammatory pain\n6165: Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat\n6169: ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury\n6173: The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model\n6176: Renoprotective capacities of non-erythropoietic EPO derivative, ARA290, following renal ischemia/reperfusion injury\n6180: EPO Derivative ARA290 Attenuates Early Renal Allograft Injury in Rats by Targeting NF-\u03baB Pathway\n6185: Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action\n6189: ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors' Angiogenic Potential and Homing Ability\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug146_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"B7-33\" (also known as \"b7-33\"), here are the article headings along with their IDs:\n6257: B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin)\n6259: B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice\n6261: The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy\n6262: Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug148_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Bronchogen\" (also known as \"bronchogen\"), here are the article headings along with their IDs:\n6271: Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability\n6273: [Laparoscopic extirpation of retroperitoneal bronchogenic cyst]\n6275: [Neonatal bronchogenic cyst diagnosed by ultrasound]\n6277: [Giant bronchogenic air cyst in 4 month old infant]\n6279: [Simultaneous occurrence of bronchogenic carcinoma and bronchioloalveolar dysplasia]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug149_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Cardiogen\" (also known as \"cardiogen\"), here are the article headings along with their IDs:\n6296: Update on CardioGen-82\n6298: Recall of CardioGen-82\n6299: [Cardiomyopathy and ion channel diseases registry: the Szeged CardioGen Registry]\n6302: Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats\n6304: [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]\n6306: An Analysis of 3 Common CardioGen-82 82Rb Infusion System Injection Methods and Their Impact on Clinical Volume and Image Counts\n6307: [Experimental model for cardiogenic shock with pericardial tamponade]\n6308: Cardiogenetics and uncertainty: Evaluation of professional vulnerability in France\n6310: [On cardiogenic shock]\n6312: [Cardiogenic shock in myocardial infarct]\n6314: [Neurohistological changes in cardiogenic shock]\n6315: [Study of carbohydrate metabolism in cardiogenic stress]\n6317: [Clinical observations in patients with cardiogenic shock]\n6319: [Theoretical and practical aspects of the therapy of cardiogenic shock in acute myocardial infarct]\n6321: [Central venous pressure in control of cardiogenic shock]\n6324: [Acute ST segment elevation during noncardiogenic shock]\n6325: [Problems in the treatment of cardiogenic shock in myocardial infarct]\n6326: [Treatment of cardiogenic shock by combined noradrenaline-regitin infusion (preliminary report)]\n6327: [Cardiogenic shock caused by pulmonary gas embolism with cardiac arrest. Resuscitation]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug151_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Cerebrolysin\" (also known as \"cerebrolysin\"), here are the article headings along with their IDs:\n6328: Cerebrolysin for acute ischaemic stroke\n6329: Cerebrolysin for vascular dementia\n6330: Cerebrolysin for acute ischaemic stroke\n6331: Cerebrolysin for acute ischaemic stroke\n6332: Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes\n6333: Cerebrolysin: a multi-target drug for recovery after stroke\n6334: Cerebrolysin: a review of its use in dementia\n6335: Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis\n6336: Cerebrolysin for vascular dementia\n6337: Cerebrolysin for acute ischaemic stroke\n6338: Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease\n6339: Cerebrolysin for acute ischaemic stroke\n6340: Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use\n6341: [Cerebrolysin for acute ischemic stroke]\n6342: [Cerebrolysin peptides as mood stabilizers]\n6343: Cerebrolysin for acute ischaemic stroke\n6344: Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia\n6345: Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials\n6346: Cerebrolysin induces hair repigmentation associated to MART-1/Melan-A reactivation\n6347: Add-on treatment with Cerebrolysin improves clinical symptoms in patients with ALS: results from a prospective, single-center, placebo-controlled, randomized, double-blind, phase II study\n6348: Neuroprotective strategies of cerebrolysin for the treatment of infants with neonatal hypoxic-ischemic encephalopathy\n6349: Cerebrolysin Use in Patients with Liver Damage-A Translational Study\n6350: [Cerebrolysin in the treatment of cognitive impairment]\n6352: Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease\n6354: Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin\n6358: Nanowired Delivery of Cerebrolysin Together with Antibodies to Amyloid Beta Peptide, Phosphorylated Tau, and Tumor Necrosis Factor Alpha Induces Superior Neuroprotection in Alzheimer's Disease Brain Pathology Exacerbated by Sleep Deprivation\n6361: Cerebrolysin reduces excitotoxicity by modulation of cell-death proteins in delayed hours of ischemic reperfusion injury\n6362: Cerebrolysin in Alzheimer's disease\n6363: Neuroprotective Effects of Nanowired Delivery of Cerebrolysin with Mesenchymal Stem Cells and Monoclonal Antibodies to Neuronal Nitric Oxide Synthase in Brain Pathology Following Alzheimer's Disease Exacerbated by Concussive Head Injury\n6364: Cerebrolysin Amelioration of Spinal Cord Ischemia/ Reperfusion Injury in Rabbit Model\n6365: Effects of Cerebrolysin on Hippocampal Neuronal Death After Pilocarpine-Induced Seizure\n6366: Cerebrolysin as an Early Add-on to Reperfusion Therapy: Risk of Hemorrhagic Transformation after Ischemic Stroke (CEREHETIS), a prospective, randomized, multicenter pilot study\n6367: Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals\n6368: Cerebrolysin Reduces Astrogliosis and Axonal Injury and Enhances Neurogenesis in Rats After Closed Head Injury\n6369: Cerebrolysin provides effective protection on high glucose-induced neuropathy in cultured rat dorsal root ganglion neurons\n6370: Sleep deprivation exacerbates concussive head injury induced brain pathology: Neuroprotective effects of nanowired delivery of cerebrolysin with \u03b1-melanocyte-stimulating hormone\n6371: Cerebrolysin and repetitive transcranial magnetic stimulation (rTMS) in patients with traumatic brain injury: a three-arm randomized trial\n6373: Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials\n6375: Cerebrolysin prevents sleep deprivation induced memory impairment and oxidative stress\n6377: Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials\n6380: Nanowired delivery of antibodies to tau and neuronal nitric oxide synthase together with cerebrolysin attenuates traumatic brain injury induced exacerbation of brain pathology in Parkinson's disease\n6382: Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series\n6384: Efficacy, safety, and cost-effectiveness analysis of Cerebrolysin in acute ischemic stroke: A rapid health technology assessment\n6386: Effect of cerebrolysin on neurodevelopmental outcome of high risk preterm infants: A randomized controlled trial\n6387: Effect of Cerebrolysin in severe traumatic brain injury: A multi-center, retrospective cohort study\n6389: Clinical Efficacy of Cerebrolysin and Cerebrolysin plus Nootropics in the Treatment of Patients with Acute Ischemic Stroke in Vietnam\n6391: Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles\n6394: Cerebrolysin Prevents Brain Injury in a Mouse Model of Liver Damage\n6396: Intravenous Administration of Functionalized Magnetic Iron Oxide Nanoparticles Does Not Induce CNS Injury in the Rat: Influence of Spinal Cord Trauma and Cerebrolysin Treatment\n6398: Noninvasive monitoring in a patient with SAH diagnosis treated with Cerebrolysin - case report and review of the literature\n6400: Diabetes exacerbates brain pathology following a focal blast brain injury: New role of a multimodal drug cerebrolysin and nanomedicine\n6402: Cerebrolysin protects PC12 cells from CoCl2-induced hypoxia employing GSK3\u03b2 signaling\n6404: TiO2-Nanowired Delivery of Chinese Extract of Ginkgo biloba EGb-761 and Bilobalide BN-52021 Enhanced Neuroprotective Effects of Cerebrolysin Following Spinal Cord Injury at Cold Environment\n6405: Cerebrolysin enhances the expression of the synaptogenic protein LRRTM4 in the hippocampus and improves learning and memory in senescent rats\n6407: Cerebrolysin improves peripheral inflammatory pain: Sex differences in two models of acute and chronic mechanical hypersensitivity\n6410: Cost-Effectiveness of Cerebrolysin after Ischemic Stroke: Secondary Analysis of the CARS Study\n6411: Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide\n6413: Alzheimer's disease: cerebrolysin and nanotechnology as a therapeutic strategy\n6415: Mild traumatic brain injury exacerbates Parkinson's disease induced hemeoxygenase-2 expression and brain pathology: Neuroprotective effects of co-administration of TiO2nanowired mesenchymal stem cells and cerebrolysin\n6417: Cerebrolysin alleviates early brain injury after traumatic brain injury by inhibiting neuroinflammation and apoptosis via TLR signaling pathway\n6420: Novel Treatment Strategies Using TiO2-Nanowired Delivery of Histaminergic Drugs and Antibodies to Tau With Cerebrolysin for Superior Neuroprotection in the Pathophysiology of Alzheimer's Disease\n6421: Cerebrolysin\u00ae and Environmental Enrichment, Alone or in Combination, Ameliorate Anxiety- and Depressive-Like Behaviors in a Post-Ischemic Depression Model in Mice\n6423: Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial\n6425: Cerebrolysin for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Adults: A Retrospective Chart Review\n6427: Cerebrolysin ameliorates prefrontal cortex and hippocampus neural atrophy of spontaneous hypertensive rats with hyperglycemia\n6430: Cerebrolysin improves cognitive performance in rats after mild traumatic brain injury\n6431: Cerebrolysin potentiates the antidepressant effect of lithium in a rat model of depression\n6433: Effect of cerebrolysin on bladder function after spinal cord injury in female Wistar rats\n6435: The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders\n6437: Cerebrolysin in Patients Diagnosed with Subarachnoid Hemorrhage-The Results of an Observational Cohort Study\n6441: Cerebrolysin lowers kynurenic acid formation--an in vitro study\n6444: Cerebrolysin as a New Treatment Option for Post-Stroke Spasticity: Patient and Physician Perspectives\n6446: Superior neuroprotective effects of cerebrolysin in nanoparticle-induced exacerbation of hyperthermia-induced brain pathology\n6448: Cerebrolysin Ameliorates Focal Cerebral Ischemia Injury Through Neuroinflammatory InhibitionviaCREB/PGC-1\u03b1 Pathway\n6452: Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke\n6454: Efficacy of Cerebrolysin in the reduction of spasticity during stroke rehabilitation\n6457: Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients With Acute Ischemic Stroke Due to Large Vessel Occlusion: Study Protocol for a Prospective, Open Label, Single-Center Study With 12 Months of Follow-Up\n6462: Cerebrolysin administration reduces oxidative stress-induced apoptosis in lymphocytes from healthy individuals\n6467: Cerebrolysin restores balance between excitatory and inhibitory amino acids in brain following concussive head injury. Superior neuroprotective effects of TiO2nanowired drug delivery\n6472: Cerebrolysin enhances functional recovery following focal cerebral infarction in rats\n6476: Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke\n6480: Spotlight on cerebrolysin in dementia\n6484: Cerebrolysin reduces mechanical allodynia in a rodent model of peripheral inflammation\n6488: Neuroprotective effects of cerebrolysin, a combination of different active fragments of neurotrophic factors and peptides on the whole body hyperthermia-induced neurotoxicity: modulatory roles of co-morbidity factors and nanoparticle intoxication\n6492: Treatment with Cerebrolysin Prolongs Lifespan in a Mouse Model of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy\n6496: Effects of Cerebrolysin\u00ae in Patients With Minimally Conscious State After Stroke: An Observational Retrospective Clinical Study\n6499: Hope Dies Last-Evidence Again Fails to Support a Neuroprotectant: Cerebrolysin for Acute Ischemic Stroke\n6503: A retrospective study of Cerebrolysin in patients with moderate to severe traumatic brain injury: Cognitive and functional outcomes\n6507: Cerebrolysin attenuates ethanol-induced spatial memory impairments through inhibition of hippocampal oxidative stress and apoptotic cell death in rats\n6510: Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability\n6515: Cerebrolysin enhances spinal cord conduction and reduces blood-spinal cord barrier breakdown, edema formation, immediate early gene expression and cord pathology after injury\n6520: Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial\n6523: Protective effects of cerebrolysin against chemotherapy (carmustine) induced cognitive impairment in Albino mice\n6525: Cerebrolysin improves sciatic nerve dysfunction in a mouse model of diabetic peripheral neuropathy\n6528: [Evaluation of the antitumor potential of cerebrolysin]\n6532: The Effect of Cerebrolysin on Anxiety, Depression, and Cognition in Moderate and Severe Traumatic Brain Injury Patients: A CAPTAIN II Retrospective Trial Analysis\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug154_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Cortagen\" (also known as \"cortagen\"), here are the article headings along with their IDs:\n6351: [Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia]\n6353: Effect of tetrapeptide cortagen on regeneration of sciatic nerve\n6356: The delayed effect of cortagen on the restoration of injured nerve function\n6359: Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug155_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Decapeptide-12\" (also known as \"decapeptide-12\"), here are the article headings along with their IDs:\n6355: Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12\n6357: Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma\n6360: Combined topical delivery and dermalinfusion of decapeptide-12 accelerates resolution of post-inflammatory hyperpigmentation in skin of color\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug157_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"GHRH\" (also known as \"ghrh\"), here are the article headings along with their IDs:\n6372: GHRH and the prostate\n6374: GHRH in diabetes and metabolism\n6376: GHRH and sleep\n6378: Effects of GHRH and its analogues on the Vascular System\n6379: GHRH and its analogues in central nervous system diseases\n6381: GHRH and reproductive systems: Mechanisms, functions, and clinical implications\n6383: Hypothalamic GHRH\n6385: GHRH and GH secretagogues: clinical perspectives and safety\n6388: GHRH antagonists support lung endothelial barrier function\n6390: GHRH Neurons from the Ventromedial Hypothalamic Nucleus Provide Dynamic and Sex-Specific Input to the Brain Glucose-Regulatory Network\n6392: Effects of GHRH Deficiency and GHRH Antagonism on Emotional Disorders in Mice\n6393: Regulation of the pituitary somatotroph cell by GHRH and its receptor\n6395: Growth hormone response to GHRH during lifespan\n6397: GHRH secretion from a pancreatic neuroendocrine tumor causing gigantism in a patient with MEN1\n6399: Stimulation of GHRH Neuron Axon Growth by Leptin and Impact of Nutrition during Suckling in Mice\n6401: Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects\n6403: The history of an effective, specific and sensitive diagnostic test: the GHRH test in clinical practice\n6406: ER\u03b1 Signaling in GHRH/Kiss1 Dual-Phenotype Neurons Plays Sex-Specific Roles in Growth and Puberty\n6408: Familial Growth Hormone Deficiency and Mutations in the GHRH Receptor Gene\n6409: Antineoplastic action of growth hormone-releasing hormone (GHRH) antagonists\n6412: Growth hormone-releasing hormone receptor (GHRH-R) and its signaling\n6414: Interactions between GHRH and GABAARs in the brains of patients with epilepsy and in animal models of epilepsy\n6416: GHRH and wound healing\n6418: Potentiating effects of GHRH analogs on the response to chemotherapy\n6419: Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH)\n6422: Growth hormone-regulatory peptides (GHRH and somatostatin) and feeding: a model for the integration of central and peripheral function\n6424: Mixed gangliocytoma-pituitary adenoma containing GH and GHRH co-secreting adenoma cells\n6426: Expression of GHRH-R, a Potentially Targetable Biomarker, in Triple-negative Breast Cancer\n6428: Clinical studies with GHRH in man\n6429: [Isolated GH deficiency due to inactivating mutation of GHRH receptor]\n6432: Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer\n6434: Inhibitory effects of GHRH antagonists on human GH-secreting adenoma tissue\n6436: Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1\n6438: Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients\n6440: Growth hormone-releasing hormone (GHRH) and GHRH receptor (GHRH-R) isoform expression in ectopic acromegaly\n6443: Regulation of GHRH receptor gene expression in the neonatal and adult rat pituitary\n6447: The expression of GHRH and its receptors in breast carcinomas with apocrine differentiation-further evidence of the presence of a GHRH pathway in these tumors\n6451: Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells\n6455: Human GHRH reduces voltage-gated K+ currents via a non-cAMP-dependent but PKC-mediated pathway in human GH adenoma cells\n6459: pNET co-secreting GHRH and calcitonin: ex vivo hormonal studies in human pituitary cells\n6461: Difference in growth hormone response to growth hormone-releasing hormone (GHRH) testing following GHRH subacute treatment in normal aging and growth hormone-deficient adults: possible perspectives for therapeutic use of GHRH or its analogs in elderly subjects?\n6466: Effects of systemic GHRH on sleep in intact and hypophysectomized rats\n6470: Alterations in GHRH binding and GHRH receptor mRNA in the pituitary of adult dw/dw rats\n6475: The usefulness of the GHRH stimulation test in the diagnostics of growth hormone deficiency in children\n6478: Localization and regulation of a functional GHRH receptor in the rat renal medulla\n6481: Growth Hormone (GH) Deficient Mice With GHRH Gene Ablation Are Severely Deficient in Vaccine and Immune Responses AgainstStreptococcus pneumoniae\n6485: The effect of GHRH on TSH release in rats in vivo and in vitro\n6489: Substance P appears to affect growth via growth hormone-releasing hormone (GHRH) neurons in the human hypothalamus\n6493: Growth hormone (GH) and GH-releasing hormone (GHRH): Co-localization and action in the chicken testis\n6497: Absence of GH-releasing hormone (GHRH) mutations in selected patients with isolated GH deficiency\n6502: Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers\n6505: Systemic growth hormone-releasing hormone (GHRH) impairs sleep in healthy young women\n6509: Inhibitory effects of antagonistic analogs of GHRH on GH3 pituitary cells overexpressing the human GHRH receptor\n6513: The reduced release of GH by GHRH in 8 subjects aged 65-69 years is augmented considerably by rivastigmine, a drug for Alzheimer's disease\n6518: Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon\n6521: Pituitary somatotroph adenoma producing growth hormone (GH)-releasing hormone (GHRH) with an elevated plasma GHRH concentration: a model case for autocrine and paracrine regulation of GH secretion by GHRH\n6526: Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs\n6529: Identification of the chicken growth hormone-releasing hormone receptor (GHRH-R) mRNA and gene: regulation of anterior pituitary GHRH-R mRNA levels by homologous and heterologous hormones\n6533: Molecular characterization of the GHRH/GHRH-R and its effect on GH synthesis and release in orange-spotted grouper (Epinephelus coioides)\n6536: Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor\n6539: Growth hormone-releasing hormone (GHRH) neurons in the arcuate nucleus (Arc) of the hypothalamus are decreased in transgenic rats whose expression of ghrelin receptor is attenuated: Evidence that ghrelin receptor is involved in the up-regulation of GHRH expression in the arc\n6541: Juxtapositions between the somatostatinergic and growth hormone-releasing hormone (GHRH) neurons in the human hypothalamus\n6543: Molecular and functional analyses of growth hormone-releasing hormone (GHRH) from olive flounder (Paralichthys olivaceus)\n6546: Selective alteration at the growth-hormone- releasing-hormone nerve terminals during aging in GHRH-green fluorescent protein mice\n6549: Desensitisation of somatostatin, TRH and GHRH responses to glucose in the diabetic (Goto-Kakizaki) rat hypothalamus\n6552: Testosterone and GHRH gene expression in adult and old rats\n6555: Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors\n6558: Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers\n6561: Steroidogenic Factor-1 Regulation of Dorsomedial Ventromedial Hypothalamic Nucleus Ghrh Neuron Transmitter Marker and Estrogen Receptor Gene Expression in Male Rat\n6563: The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas\n6566: GHRH treatment: studies in an animal model\n6569: Effects of maternal plasmid GHRH treatment on offspring growth\n6572: Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine\n6576: Expression of growth hormone-releasing hormone (GHRH) and splice variant of GHRH receptors in normal mouse tissues\n6579: Effect of growth hormone releasing hormone (GHRH) and vasoactive intestinal peptide (VIP) on in vitro bovine oocyte maturation\n6582: Differential GH-releasing hormone regulation of GHRH receptor mRNA expression in the rat pituitary\n6585: Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers\n6588: Restoration of growth hormone-releasing hormone (GHRH) responsiveness in pituitary GH3 cells by adenovirus-directed expression of the human GHRH receptor\n6591: Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro\n6593: Effect of growth hormone-releasing hormone (GHRH) and GHRH antagonist (MZ-4-71) on interferon-gamma secretion from human peripheral blood mononuclear cells in vitro\n6596: Hypothalamic growth hormone-releasing hormone (GHRH) deficiency: targeted ablation of GHRH neurons in mice using a viral ion channel transgene\n6598: Interaction of clonidine and GHRH on GH secretion in vivo and in vitro\n6601: A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug158_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Humanin\" (also known as \"humanin\"), here are the article headings along with their IDs:\n6439: The role of humanin in the regulation of reproduction\n6442: Humanin and Its Pathophysiological Roles in Aging: A Systematic Review\n6445: Humanin and Alzheimer's disease: The beginning of a new field\n6449: Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives\n6450: Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases\n6456: Role of humanin, a mitochondrial-derived peptide, in cardiovascular disorders\n6460: Cardio-protective role of Humanin in myocardial ischemia-reperfusion\n6464: Humanin: Functional Interfaces with IGF-I\n6468: Humanin and diabetes mellitus: A review ofin vitroandin vivostudies\n6471: The role of humanin in natural stress tolerance: An underexplored therapeutic avenue\n6474: Humanin: A mitochondria-derived peptide with emerging properties\n6479: Humanin: after the discovery\n6482: Humanin and the receptors for humanin\n6486: Humanin signal for Alzheimer's disease\n6491: Humanin variant P3S is associated with longevity in APOE4 carriers and resists APOE4-induced brain pathology\n6494: Humanin derivative, HNG, enhances neurotransmitter release\n6498: Roles of humanin and derivatives on the pathology of neurodegenerative diseases and cognition\n6500: Humanin; a defender against Alzheimer's disease?\n6506: Humanin activates integrin \u03b1V-TGF\u03b2 axis and leads to glioblastoma progression\n6511: Humanin: A Potential Treatment for PCOS?\n6514: Humanin and age-related diseases: a new link?\n6517: Humanin Ameliorates Late-onset Hypogonadism in Aged Male Rats\n6522: Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases\n6527: Potential Roles of Humanin on Apoptosis in the Heart\n6531: The emerging role of mitochondrial derived peptide humanin in the testis\n6535: The humanin analogue (HNG) alleviates intrauterine adhesions by inhibiting endometrial epithelial cells ferroptosis: a rat model-based study\n6538: Protective Mechanism of Humanin Against Oxidative Stress in Aging-Related Cardiovascular Diseases\n6545: Humanin-induced autophagy plays important roles in skeletal muscle function and lifespan extension\n6547: Humanin: a possible linkage between Alzheimer's disease and type 2 diabetes\n6550: Humanin's impact on pain markers and neuronal viability in diabetic neuropathy model\n6553: Humanin regulates oxidative stress in the ovaries of polycystic ovary syndrome patients via the Keap1/Nrf2 pathway\n6556: The Molecular Structure and Role of Humanin in Neural and Skeletal Diseases, and in Tissue Regeneration\n6559: Humanin gene expression in subjects with Parkinson's disease\n6560: Humanin levels in human seminal plasma and spermatozoa are related to sperm quality\n6564: Humanin and colivelin: neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis\n6568: Humanin Alleviates Insulin Resistance in Polycystic Ovary Syndrome: A Human and Rat Model-Based Study\n6570: Humanin promotes mitochondrial biogenesis in pancreatic MIN6 \u03b2-cells\n6573: Humanin Ameliorates Free Fatty Acid-Induced Endothelial Inflammation by Suppressing the NLRP3 Inflammasome\n6575: Age-related Changes in Humanin Expression in the Ovarian Tissue of Rat\n6580: Humanin inhibits lymphatic endothelial cells dysfunction to alleviate myocardial infarction-reperfusion injury via BNIP3-mediated mitophagy\n6581: Unravelling the role of Humanin\n6584: Humanin vivoliver and tumor bioimpedance measured with biopsy needle\n6587: The protective effects of S14G-humanin on gestational diabetes mellitus symptoms\n6590: Effect of Humanin G (HNG) on inflammation in age-related macular degeneration (AMD)\n6594: Humanin, a Mitochondrial-Derived Peptide Released by Astrocytes, Prevents Synapse Loss in Hippocampal Neurons\n6597: Protective effects of Humanin and calmodulin-like skin protein in Alzheimer's disease and broad range of abnormalities\n6600: Mitochondrial Peptide Humanin Facilitates Chemoresistance in Glioblastoma Cells\n6603: Circulating humanin is lower in coronary artery disease and is a prognostic biomarker for major cardiac events in humans\n6605: PROTECTIVE EFFECTS OF HUMANIN-G IN HEMORRHAGIC SHOCK IN FEMALE MICE VIA AMPK\u03b11-INDEPENDENT MECHANISMS\n6606: Humanin P3S, haplogroup N1b and the risk of Alzheimer's disease\n6610: Humanin ameliorates TBI-related cognitive impairment by attenuating mitochondrial dysfunction and inflammation\n6611: The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan\n6613: Humanin gene expression in fibroblast of Down syndrome subjects\n6615: Humanin selectively prevents the activation of pro-apoptotic protein BID by sequestering it into fibers\n6618: S14G-humanin alleviates acute lung injury by inhibiting the activation of NF-\u03baB\n6620: An evidence of Humanin-like peptide and Humanin mediated cryosurvival of spermatozoa in buffalo bulls\n6622: Humanin Promotes Tumor Progression in Experimental Triple Negative Breast Cancer\n6624: Humanin prevents brain mitochondrial dysfunction in a cardiac ischaemia-reperfusion injury model\n6626: Humanin prevents high glucose-induced monocyte adhesion to endothelial cells by targeting KLF2\n6628: Humanin enhances the cellular response to stress by activation of chaperone-mediated autophagy\n6629: Humanin ameliorates diazepam-induced memory deficit in mice\n6632: Humanin attenuates metabolic, toxic, and traumatic neuropathic pain in mice by protecting against oxidative stress and increasing inflammatory cytokine\n6636: Advances in characterization of neuroprotective peptide, humanin\n6638: Apollon/Bruce is upregulated by Humanin\n6640: Endoplasmic reticulum-mitochondrial crosstalk: a novel role for the mitochondrial peptide humanin\n6643: Impaired Expression of Humanin during Adrenocortical Carcinoma\n6647: [Gly14]-Humanin inhibits an angiotensin II-induced vascular smooth muscle cell phenotypic switch via ameliorating intracellular oxidative stress\n6650: S14G-humanin confers cardioprotective effects against chronic adrenergic and pressure overload-induced heart failure in mice\n6651: Mitochondrial humanin peptide acts as a cytoprotective factor in granulosa cell survival\n6654: Mechanisms of protection of retinal pigment epithelial cells from oxidant injury by humanin and other mitochondrial-derived peptides: Implications for age-related macular degeneration\n6658: Intranasal delivery of mitochondrial protein humanin rescues cell death and promotes mitochondrial function in Parkinson's disease\n6659: Potent humanin analogue (HNG) protects human sperm from freeze-thaw-induced damage\n6662: Effectiveness of analog of Humanin in ameliorating streptozotocin-induced diabetic nephropathy in Sprague Dawley rats\n6665: Humanin Exerts Neuroprotection During Cardiac Ischemia-Reperfusion Injury\n6667: The emerging role of the mitochondrial-derived peptide humanin in stress resistance\n6671: Humanin is an endogenous activator of chaperone-mediated autophagy\n6673: Humanin-G Ameliorates Hemorrhage-Induced Acute Lung Injury in Mice Through AMPK\u03b11-Dependent and -Independent Mechanisms\n6677: Humanin Does Not Protect Against STZ-Induced Spatial Memory Impairment\n6679: Humanin protects cortical neurons from calyculin A-induced neurotoxicities by increasing PP2A activity and SOD\n6682: Humanin Treatment Protects Against Venetoclax-Induced Bone Growth Retardation inEx VivoCultured Rat Bones\n6684: Humanin analogue, HNG, inhibits platelet activation and thrombus formation by stabilizing platelet microtubules\n6686: [Gly14]-humanin exerts a protective effect against D-galactose-induced primary ovarian insufficiency in mice\n6689: Unbalanced circulating Humanin levels and cardiovascular risk in chronic hemodialysis patients: a pilot, prospective study\n6694: S14G-Humanin ameliorates ovalbumin-induced airway inflammation in asthma mediated by inhibition of toll-like receptor 4 (TLR4) expression and the nuclear factor \u03ba-B (NF-\u03baB)/early growth response protein-1 (Egr-1) pathway\n6698: Humanin Nanoparticles for Reducing Pathological Factors Characteristic of Age-Related Macular Degeneration\n6701: Colivelin, a synthetic derivative of humanin, ameliorates endothelial injury and glycocalyx shedding after sepsis in mice\n6707: Circulating humanin levels are associated with preserved coronary endothelial function\n6711: Stability Determination of Intact Humanin-G with Characterizations of Oxidation and Dimerization Patterns\n6716: New role for the mitochondrial peptide humanin: protective agent against chemotherapy-induced side effects\n6718: Protective Mechanisms of the Mitochondrial-Derived Peptide Humanin in Oxidative and Endoplasmic Reticulum Stress in RPE Cells\n6722: Humanin attenuates palmitate-induced hepatic lipid accumulation and insulin resistance via AMPK-mediated suppression of the mTOR pathway\n6724: SERUM HUMANIN IN PEDIATRIC SEPTIC SHOCK-ASSOCIATED MULTIPLE-ORGAN DYSFUNCTION SYNDROME\n6728: Humanin: a harbinger of mitochondrial-derived peptides?\n6731: A novel link between chronic inflammation and humanin regulation in children\n6734: S14G-humanin (HNG) protects retinal endothelial cells from UV-B-induced NLRP3 inflammation activation through inhibiting Egr-1\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug159_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Lipopeptide\" (also known as \"lipopeptide\"), here are the article headings along with their IDs:\n6453: Fungi-derived lipopeptide antibiotics developed since 2000\n6458: PseudomonasLipopeptide-Mediated Biocontrol: Chemotaxonomy and Biological Activity\n6463: Interdisciplinary Overview of Lipopeptide and Protein-Containing Biosurfactants\n6465: Lipopeptide(s) associated with human microbiome as potent cancer drug\n6469: Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort\n6473: Lipopeptide Pepducins as Therapeutic Agents\n6477: Lipopeptide surfactants: Production, recovery and pore forming capacity\n6483: Biophysical approaches for exploring lipopeptide-lipid interactions\n6487: Lipopeptide-Based Oral Vaccine Against Hookworm Infection\n6490: Lipopeptide detergents for membrane protein studies\n6495: Dendritic lipopeptide liposomes decorated with dual-targeted proteins\n6501: Lipopeptide-mediated bacterial interaction enables cooperative predator defense\n6504: Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection\n6508: A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens\n6512: Bacillus licheniformis: The unexplored alternative for the anaerobic production of lipopeptide biosurfactants?\n6516: Surotomycin (A Novel Cyclic Lipopeptide) vs. Vancomycin for the Treatment of Clostridioides difficile Infection: A Systematic Review and Meta-analysis\n6519: A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential\n6524: Disassembling ability of lipopeptide promotes the antibacterial activity\n6530: Lipopeptide Delivery of siRNA to the Central Nervous System\n6534: LPD-12: a promising lipopeptide to control COVID-19\n6537: Dosing Considerations for Combination Antistaphylococcal \u03b2-Lactam and Glyco/lipopeptide Salvage Therapy for Resistant Gram-Positive Infections: A Systematic Review\n6540: Bioinformatic prospecting and synthesis of a bifunctional lipopeptide antibiotic that evades resistance\n6542: Structural diversity and applications of lipopeptide biosurfactants as biocontrol agents against phytopathogens: A review\n6544: The structural diversity of acidic lipopeptide antibiotics\n6548: Anti-Toxoplasma gondiiEffects of Lipopeptide Derivatives of Lycosin-I\n6551: Linear Analogues of the Lipopeptide Battacin With Potent In Vitro Activity Against S. aureus\n6554: Synthetic Studies towards the Calcium-Dependent Lipopeptide Antibiotic Cadaside B\n6557: Characterization of lipopeptide produced by Bacillus altitudinis Q7 and inhibitory effect on Alternaria alternata\n6562: A cyclic lipopeptide from Fusarium graminearum targets plant membranes to promote virulence\n6565: Selecting lipopeptide-producing, Fusarium-suppressing Bacillus spp.: Metabolomic and genomic probing of Bacillus velezensis NWUMFkBS10.5\n6567: Effective utilization of wheat gluten by lipopeptide biosurfactant in the formulation of cookies\n6571: In-vitro antimicrobial susceptibility pattern of lipopeptide against drug resistant Vibrio species\n6574: Guanidinium-rich lipopeptide functionalized bacteria-absorbing sponge as an effective trap-and-kill system for the elimination of focal bacterial infection\n6577: Isolation of lipopeptide antibiotics fromBacillus siamensis: a potential biocontrol agent forFusarium graminearum\n6578: Regulation of daptomycin biosynthesis inStreptomyces roseosporus: new insights from genomic analysis and synthetic biology to accelerate lipopeptide discovery and commercial production\n6583: Covalently Immobilized Battacin Lipopeptide Gels with Activity against Bacterial Biofilms\n6586: Variochelins, Lipopeptide Siderophores from Variovorax boronicumulans Discovered by Genome Mining\n6589: Antimicrobial lipopeptide tridecaptin A1 selectively binds to Gram-negative lipid II\n6592: A cyclic lipopeptide produced by an antagonistic bacterium relies on its tail and transient receptor potential-type Ca2+channels to immobilize a green alga\n6595: Lipopeptide C17Fengycin B Exhibits a Novel Antifungal Mechanism by Triggering Metacaspase-Dependent Apoptosis inFusarium oxysporum\n6599: Genomics-Guided Exploitation of Lipopeptide Diversity in Myxobacteria\n6602: Combinatorial biosynthesis of cyclic lipopeptide antibiotics: a model for synthetic biology to accelerate the evolution of secondary metabolite biosynthetic pathways\n6604: A gelatinized lipopeptide diet effectively modulates immune response, disease resistance and gut microbiome in Penaeus vannamei challenged with Vibrio parahaemolyticus\n6607: Functionalized Lipopeptide Micelles as Highly Efficient NMR Depolarization Seed Points for Targeted Cell Labelling in Xenon MRI\n6608: Optical Control of Proteasomal Protein Degradation with a Photoswitchable Lipopeptide\n6609: Novel Cyclic Lipopeptide Antibiotics: Effects of Acyl Chain Length and Position\n6612: Intact plasma quantification of the large therapeutic lipopeptide bulevirtide\n6614: Polydopamine-Mediated Antimicrobial Lipopeptide Surface Coating for Medical Devices\n6616: A broad-spectrum bactericidal lipopeptide with anti-biofilm properties\n6617: Effectiveness of biosurfactant lipopeptide adhesive mucus paste on the healing process of oral wounds: a randomized controlled trial\n6619: Lipopeptide biosurfactant from Bacillus thuringiensis pak2310: A potential antagonist against Fusarium oxysporum\n6621: A Synthetic Multivalent Lipopeptide Derived from Pam3CSK4 with Irreversible Influenza Inhibition and Immuno-Stimulating Effects\n6623: Correlation between sporogenesis and lipopeptide production in Paenibacillus elgii\n6625: Antibacterial effect of synthetic ultra-short lipopeptide on Streptococcus agalactiae and its active on bacterial mastitis in mice\n6627: Modifying the Catalytic Activity of Lipopeptide Assemblies with Nucleobases\n6631: A novel family of non-secreted tridecaptin lipopeptide produced by Paenibacillus elgii\n6634: Transporter Gene-Mediated Typing for Detection and Genome Mining of Lipopeptide-Producing Pseudomonas\n6637: Ikoamide, an Antimalarial Lipopeptide from anOkeaniasp. Marine Cyanobacterium\n6641: The Microbial Lipopeptide Paenibacterin Disrupts Desiccation Resistance in Salmonella enterica Serovars Tennessee and Eimsbuettel\n6644: LC-MS and Transcriptome Analysis of Lipopeptide Biosynthesis byBacillus velezensisCMT-6 Responding to Dissolved Oxygen\n6646: Characterization of Antifungal Lipopeptide Biosurfactants Produced by Marine BacteriumBacillussp. CS30\n6649: Homo and Hetero-Branched Lipopeptide Dendrimers: Synthesis and Antimicrobial Activity\n6652: Diversity of nonribosomal peptide synthetases involved in the biosynthesis of lipopeptide biosurfactants\n6655: Stalobacin: Discovery of Novel Lipopeptide Antibiotics with Potent Antibacterial Activity against Multidrug-Resistant Bacteria\n6657: Generation of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response\n6660: [Pilot-scale purification of lipopeptide from marine-derived Bacillus marinus]\n6663: Isolation and characterization of a lipopeptide-producing Bacillus sp. strain JK08 with antagonistic activity against Vibrio parahaemolyticus\n6666: Dilarmycins A-C, Calcium-Dependent Lipopeptide Antibiotics with a Non-canonical Ca2+-Binding Motif\n6669: Lipopeptides for Vaccine Development\n6672: Broad-spectrum antifungal activity of lipopeptide brevilaterin B and its inhibition effects against Fusarium oxysporum and Penicillium chrysogenum\n6675: N-Desmethylmajusculamide B, a lipopeptide isolated from the Okinawan cyanobacterium Okeania hirsuta\n6680: Enhanced low-cost lipopeptide biosurfactant production by Bacillus velezensis from residual glycerin\n6683: Screening of Lipopeptide-Producing Strains of Bacillus sp. Using a New Automated and Sensitive Fluorescence Detection Method\n6687: A promising antifungal lipopeptide from Bacillus subtilis: its characterization and insight into the mode of action\n6690: Mucosal Vaccination with a Self-Adjuvanted Lipopeptide Is Immunogenic and Protective againstMycobacterium tuberculosis\n6695: Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19\n6699: Lipopeptide induces apoptosis in fungal cells by a mitochondria-dependent pathway\n6702: Biosynthesis of isonitrile lipopeptides\n6705: Structure-Activity Analysis of Cyclic Multicomponent Lipopeptide Self-Adjuvanting Vaccine Candidates Presenting Group AStreptococcusAntigens\n6709: Novel linear lipopeptide paenipeptin C' binds to lipopolysaccharides and lipoteichoic acid and exerts bactericidal activity by the disruption of cytoplasmic membrane\n6714: Interaction of the Lipopeptide Biosurfactant Lichenysin with Phosphatidylcholine Model Membranes\n6717: Improvement of lipopeptide production inBacillus subtilisHNDF2-3 by overexpression of thesfpandcomAgenes\n6720: Engineered Nanostructured Facial Lipopeptide as Highly Efficient Molecular Transporter\n6726: Structure-function relationships of protein-lipopeptide complexes and influence on immunogenicity\n6729: Using large-scale multi-module NRPS to heterologously prepare highly efficient lipopeptide biosurfactants in recombinant Escherichia coli\n6732: Self-Uptake Mechanism of Polymyxin-Based Lipopeptide against Gram-Negative Bacterial Membrane: Role of the First Adsorbed Lipopeptide\n6736: Distinct lipopeptide production systems for WLIP (white line-inducing principle) in Pseudomonas fluorescens and Pseudomonas putida\n6738: Structure optimization of dendritic lipopeptide based gene vectors with the assistance from molecular dynamic simulation\n6743: Total Synthesis and Structure Assignment of the Relacidine Lipopeptide Antibiotics and Preparation of Analogues with Enhanced Stability\n6744: Structure-Activity Relationships of Daptomycin Lipopeptides\n6746: Role of extremophilic Bacillus cereus KH1 and its lipopeptide in treatment of organic pollutant in wastewater\n6748: Cyclic lipopeptide profile of the plant-beneficial endophytic bacterium Bacillus subtilis HC8\n6750: Discovery of the Cyclic Lipopeptide Gacamide A by Genome Mining and Repair of the Defective GacA Regulator in Pseudomonas fluorescens Pf0-1\n6752: The lipopeptide antibiotic paenibacterin binds to the bacterial outer membrane and exerts bactericidal activity through cytoplasmic membrane damage\n6755: Anti-staphylococcal activity of a cyclic lipopeptide, C15-bacillomycin D, produced by Bacillus velezensis NST6\n6757: Minnamide A, a Linear Lipopeptide from the Marine Cyanobacterium Okeania hirsuta\n6758: Antibacterial Cyclic Lipopeptide Enamidonins with an Enamide-Linked Acyl Chain from a Streptomyces Species\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug160_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Liraglutide\" (also known as \"liraglutide\"), here are the article headings along with their IDs:\n6630: Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study\n6633: Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined\n6635: Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics\n6639: Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis\n6642: Liraglutide Attenuates Hepatic Ischemia-Reperfusion Injury by Modulating Macrophage Polarization\n6645: Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial\n6648: Liraglutide and obesity: a review of the data so far\n6653: Liraglutide attenuates hepatic iron levels and ferroptosis in db/db mice\n6656: Liraglutide in Children and Adolescents with Type 2 Diabetes\n6661: Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial\n6664: Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial\n6668: Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis\n6670: Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?\n6674: Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial\n6676: Liraglutide and learning\n6678: \u25be Liraglutide for weight management\n6681: Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway\n6685: Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway\n6688: Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study\n6691: Liraglutide for the Treatment of Obesity: Analyzing Published Reviews\n6693: Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence\n6697: Liraglutide for psychiatric disorders: clinical evidence and challenges\n6703: Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence\n6706: Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE-/-mice\n6710: Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial\n6713: Liraglutide in Prader Willi-Syndrome: The Importance of Placebo-Controlled Studies\n6715: Liraglutide restores impaired associative learning in individuals with obesity\n6719: Liraglutide: a review of its use in the management of obesity\n6721: Liraglutide innovations: a comprehensive review of patents (2014-2024)\n6723: Liraglutide and its Neuroprotective Properties-Focus on Possible Biochemical Mechanisms in Alzheimer's Disease and Cerebral Ischemic Events\n6725: Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials\n6727: Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial\n6730: Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality\n6733: Liraglutide for Type 2 diabetes and obesity: a 2015 update\n6735: Liraglutide: A New Option for the Treatment of Obesity\n6737: Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management\n6739: Potential contributors to variation in weight-loss response to liraglutide\n6740: Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats\n6741: Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes\n6742: Liraglutide-related cholelithiasis\n6745: Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes\n6747: The Current Role of Liraglutide in the Pharmacotherapy of Obesity\n6749: Liraglutide Improves Diabetic Cardiomyopathy by Downregulation of Cardiac Inflammatory and Apoptosis Markers\n6751: Liraglutide's Effect on Weight Management in Subjects With Pre-diabetes: A Systematic Review & Meta-Analysis\n6753: The effect of liraglutide on renal function in type 2 diabetes: a meta-analysis of randomized controlled studies\n6754: Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice\n6756: Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation\n6759: Efficacy of High-dose Liraglutide 3.0 mg in Patients with Poor Response to Bariatric Surgery: Real-world Experience and Updated Meta-analysis\n6760: Liraglutide toxicity presenting to the emergency department: A case report and literature review\n6761: Liraglutide suppresses atrial electrophysiological changes\n6762: Efficacy of liraglutide intervention in myocardial infarction : A meta-analysis of randomized controlled trials\n6763: Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes\n6764: Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials\n6765: Liraglutide Attenuates Glucolipotoxicity-Induced RSC96 Schwann Cells' Inflammation and Dysfunction\n6766: Liraglutide Nano-Preparation on Perioperative Neurocognitive Dysfunction in Aged Mice\n6767: Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function\n6768: Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility\n6769: GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells\n6770: Liraglutide versus colesevelam for treating bile acid diarrhoea\n6771: Cardiovascular safety of liraglutide for the treatment of type 2 diabetes\n6772: Liraglutide protects \u03b2-cells in novel human islet spheroid models of type 1 diabetes\n6773: The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis\n6774: Treating bile acid diarrhoea with liraglutide\n6775: Bullous Pemphigoid Triggered by Liraglutide\n6777: Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study\n6779: Liraglutide stimulates the \u03b2-catenin signaling cascade in mouse epididymal fat tissue\n6781: Liraglutide ameliorates oxidized LDL-induced endothelial dysfunction by GLP-1R-dependent downregulation of LOX-1-mediated oxidative stress and inflammation\n6783: Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review\n6785: Liraglutide improves sevoflurane-induced postoperative cognitive dysfunction via activating autophagy and inhibiting apoptosis\n6787: Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update\n6789: Effect of liraglutide on expression of inflammatory genes in type 2 diabetes\n6791: Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis\n6793: Liraglutide Ameliorates Cerebral Ischemia in Mice via Antipyroptotic Pathways\n6796: Liraglutide and Naringenin relieve depressive symptoms in mice by enhancing Neurogenesis and reducing inflammation\n6798: Liraglutide and Exercise Synergistically Attenuate Vascular Inflammation and Enhance Metabolic Insulin Action in Early Diet-Induced Obesity\n6801: Liraglutide improved the reproductive function of obese mice by upregulating the testicular AC3/cAMP/PKA pathway\n6803: Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner\n6805: A second case of liraglutide-type localised amyloidosis\n6806: Liraglutide prevents cellular senescence in human retinal endothelial cells (HRECs) mediated by SIRT1: an implication in diabetes retinopathy\n6809: [Liraglutide in the treatment of obesity : a multidisciplinary approach]\n6810: Liraglutide treatment effects on rat ovarian and uterine tissues\n6813: Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test\n6815: Liraglutide-Loaded Milk Exosomes Lower Blood Glucose When Given by Sublingual Route\n6818: [Effect of liraglutide in treatment of non-alcoholic fatty liver disease: mechanism of action and research advances]\n6820: Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats\n6821: Liraglutide versus colesevelam for treating bile acid diarrhoea - Authors' reply\n6823: Liraglutide, a TFEB-Mediated Autophagy Agonist, Promotes the Viability of Random-Pattern Skin Flaps\n6825: Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit\n6827: Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins\n6829: Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes\n6831: Liraglutide pharmacokinetics and exposure-response in pediatric patients with type 2 diabetes\n6833: HSP90-Mediates Liraglutide Preconditioning-Induced Cardioprotection by Inhibiting C5a and NF-\u03baB\n6835: Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism\n6837: Liraglutide modulates adhesion molecules and enhances cell properties in three-dimensional cultures of olfactory ensheathing cells\n6840: Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin-induced diabetic rats\n6842: Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug161_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Livagen\" (also known as \"livagen\"), here are the article headings along with their IDs:\n6692: Effects of Livagen peptide on chromatin activation in lymphocytes from old people\n6696: [Functional morphology of an organotypic liver culture exposed to the peptide livagen]\n6700: [Variability of radiation-induced adaptive response in old age individuals and their correction by Peptide bioregulator -Livagen]\n6704: [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]\n6708: [Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen]\n6712: [Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug162_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Longevity\" (also known as \"longevity\"), here are the article headings along with their IDs:\n6776: Longevity: Lesson from Model Organisms\n6778: Genetics of healthy aging and longevity\n6780: Dietary Phytochemicals that Can Extend Longevity by Regulation of Metabolism\n6782: How Important Are Genes to Achieve Longevity?\n6784: Cardiovascular Aging and Longevity: JACC State-of-the-Art Review\n6786: Diet and longevity\n6788: Longevity hormesis. A review\n6790: Advancing Longevity: Exploring Antiaging Pharmaceuticals in Contemporary Clinical Trials Amid Aging Dynamics\n6792: Genetic Support for Longevity-Enhancing Drug Targets: Issues, Preliminary Data, and Future Directions\n6794: Untangling the Genetics of Human Longevity-A Challenging Quest\n6795: Mediterranean mechanisms of longevity\n6797: Genes and longevity\n6799: Unravelling genetic components of longevity\n6800: The potential longevity-promoting hypoxic-hypercapnic environment as a measure for radioprotection\n6802: CD44 correlates with longevity and enhances basal ATF6 activity and ER stress resistance\n6804: Investigational drugs and nutrients for human longevity. Recent clinical trials registered in ClinicalTrials.gov and clinicaltrialsregister.eu\n6807: Editorial: Adipose Tissue: Which Role in Aging and Longevity?\n6808: Extreme Human Longevity: The Fraught Intersection of Historical and Scientific Research\n6811: Diet modulates genetic effects on longevity\n6812: Celebrating 15 Years: A Toast to Health, Longevity, and Metabolism\n6814: Longevity network: construction and implications\n6816: mTORC2 takes the longevity stAGE\n6817: Longevity and aging: beneficial effects of exposure to mild stress\n6819: Global analysis of aging-related protein structural changes uncovers enzyme-polymerization-based control of longevity\n6822: Human longevity: nature vs. nurture--fact or fiction\n6824: [The myth of longevity, from dream to unreality]\n6826: The role of mitochondria in mTOR-regulated longevity\n6828: Some naturally occurring compounds that increase longevity and stress resistance in model organisms of aging\n6830: Compounds that extend longevity are protective in neurodegenerative diseases and provide a novel treatment strategy for these devastating disorders\n6832: Articulating the Case for the Longevity Dividend\n6834: Patterns of longevity across a sociality gradient in vespid wasps\n6836: Accelerated transcriptional elongation during aging impairs longevity\n6838: Cellular and molecular longevity pathways: the old and the new\n6839: The role of the TOR pathway in mediating the link between nutrition and longevity\n6841: Hunt for longevity drugs gets new life\n6843: Longevity Escape Velocity Medicine: A New Medical Specialty for Longevity?\n6844: The extreme longevity: the state of the art in Italy\n6845: Selection for sow longevity\n6846: The mitochondrial integrated stress response: A novel approach to anti-aging and pro-longevity\n6847: Longevity-Promoting Pharmaceuticals: Is it a Time for Implementation?\n6848: Biology of longevity: role of the innate immune system\n6849: Longevity and ageing in parasitic and free-living nematodes\n6850: [Touch, a crucial sense in social interactions to improve homeostasis in aging and promote healthy longevity]\n6851: Genetic scores for predicting longevity in the Croatian oldest-old population\n6852: Enhanced cellular longevity arising from environmental fluctuations\n6853: Enhancing longevity: novel caloric restriction mimetics\n6854: Search for mechanisms of exceptional human longevity\n6855: Genetics of longevity in model organisms: debates and paradigm shifts\n6856: Pursuing the longevity dividend: scientific goals for an aging world\n6857: The effects of gamma rays on longevity\n6858: Uncoupling the relationship between fatty acids and longevity\n6859: Validation requirements for AI-based intervention-evaluation in aging and longevity research and practice\n6860: Four novel genes associated with longevity found in Cane corso purebred dogs\n6861: Genome size and longevity\n6862: Estetrol, molecular chaperones, and the epigenetics of longevity and cancer resistance\n6863: Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity\n6864: The ins and outs of aging and longevity\n6865: Structure and function analysis of adiponectin receptors toward development of novel antidiabetic agents promoting healthy longevity\n6866: The molecular basis of longevity, and clinical implications\n6867: Functional longevity in five rabbit lines founded on different criteria: Comparison at foundation and at fixed times after selection\n6868: Analysis of Epigenetic Age Acceleration and Healthy Longevity Among Older US Women\n6869: Mitochondrial genotype associated with longevity and its inhibitory effect on mutagenesis\n6870: The human life span is not that limited: the effect of multiple longevity phenotypes\n6872: The Longevity Consortium: Harnessing diverse approaches to understand the genetic basis of human longevity and healthy aging. An introduction to a series of articles\n6873: Genetic and environmental influences on exceptional longevity and the AGE nomogram\n6874: SuperAger Initiative: unlocking the genetic potential of exceptional longevity\n6875: Calorie restriction and longevity: fast and loose?\n6876: Aging and longevity. A paradigm of complementation between homeostatic mechanisms and genetic control?\n6877: Masters of longevity: lessons from long-lived bivalves--a mini-review\n6878: Conservation of pro-longevity genes among mammals\n6879: The role of insulin/IGF-like signaling in C. elegans longevity and aging\n6881: Assessing the effects of deprenyl on longevity and antioxidant defenses in different animal models\n6882: R0: Host Longevity Matters\n6883: Minireview: the role of oxidative stress in relation to caloric restriction and longevity\n6884: Recent advances in human gene-longevity association studies\n6885: Birth month affects longevity\n6886: Evaluation of longevity modeling censored records in Nellore\n6887: The endeavor of high maintenance homeostasis: resting metabolic rate and the legacy of longevity\n6888: Broad spectrum detoxification: the major longevity assurance process regulated by insulin/IGF-1 signaling?\n6889: Maternal inheritance of longevity\n6890: Cloning approaches for identifying aging and longevity-related genes in mammals\n6891: [Why do peoples age? the mechanisms of organismal aging and longevity]\n6892: Predicting whether dietary restriction would increase longevity in species not tested so far\n6893: Endogenous oxidative stress: relationship to aging, longevity and caloric restriction\n6894: Biorhythms as a possible regulator of longevity\n6895: Maintaining your immune system--one method for enhanced longevity\n6896: Longevity and GAPDH Stability in Bivalves and Mammals: A Convenient Marker for Comparative Gerontology and Proteostasis\n6897: Longevity and lifetime reproductive success of barn swallow offspring are predicted by their hatching date and phenotypic quality\n6898: [Physiological requirements for longevity]\n6899: Reactive oxygen species, isotope effect, essential nutrients, and enhanced longevity\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug169_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Nonapeptide-1\" (also known as \"nonapeptide-1\"), here are the article headings along with their IDs:\n6871: Enhanced skin benefits of EGCG loaded in nonapeptide-1-conjugated mesoporous silica nanoparticles to reverse skin photoaging\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug170_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Ovagen\" (also known as \"ovagen\"), here are the article headings along with their IDs:\n6880: Superovulation and embryo recovery in goats treated with Ovagen and Folltropin\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug173_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Pancragen\" (also known as \"pancragen\"), here are the article headings along with their IDs:\n6900: Effects of pancragen on the differentiation of pancreatic cells during their ageing\n6901: Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus\n6902: Prospects of using pancragen for correction of metabolic disorders in elderly people\n6903: [Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys]\n6904: [Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug175_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Pinealon\" (also known as \"pinealon\"), here are the article headings along with their IDs:\n6905: Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes\n6906: Pinealon protects the rat offspring from prenatal hyperhomocysteinemia\n6907: [Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia]\n6908: [Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug176_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"PNC-27\" (also known as \"pnc-27\"), here are the article headings along with their IDs:\n6909: PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis\n6910: Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis:In vitrostudy\n6911: Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells\n6912: Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes\n6913: Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption\n6914: Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer\n6915: Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer\n6917: The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells\n6919: The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug177_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Prostamax\" (also known as \"prostamax\"), here are the article headings along with their IDs:\n6916: Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax\n6918: [The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug178_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Rigin\" (also known as \"rigin\"), here are the article headings along with their IDs:\n6920: Rigin, another phagocytosis-stimulating tetrapeptide isolated from human IgG. Confirmations of a hypothesis\n6921: Immunomodulatory potential of hydrophobic analogs of Rigin and their role in providing protection against Plasmodium berghei infection in mice\n6922: Synthesis and biological activity of tuftsin and rigin derivatives containing monosaccharides or monosaccharide derivatives\n6923: Folded conformation of an immunostimulating tetrapeptide rigin: high temperature molecular dynamics simulation study\n6924: Characterization of a novel type VII beta-turn conformation for a bio-active tetrapeptide rigin A synergy between theoretical and experimental results\n6925: [On the rigin of life. Report on the Third International Conference on the Origin of Life at Pont-\u00e0-ousson]\n6926: Determination of an unusual secondary structural element in the immunostimulating tetrapeptide rigin in aqueous environments: insights via MD simulations, (1)H NMR and CD spectroscopic studies\n6927: Evaluating the Biological Role of Lassa Viral Z Protein-Mediated RIG-I Inhibition Using a Replication-Competent Trisegmented Pichinde Virus System in an Inducible RIG-IN Expression Cell Line\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug186_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Protirelin\" (also known as \"protirelin\"), here are the article headings along with their IDs:\n6928: Protirelin (thyrotropin-releasing hormone) in amyotrophic lateral sclerosis. The role of androgens\n6929: Protirelin (TRH) in depression\n6930: Protirelin (TRH): a potent neuromodulator with therapeutic potential\n6931: Dose-response studies with protirelin\n6932: [Pharmacologic profile of protirelin tartrate]\n6933: Protirelin (thyrotropin-releasing hormone) in thyroid gland: possible involvement in regulation of thyroid status\n6934: TRH (protirelin) in depressed alcoholic men. Behavioral changes and endocrine responses\n6935: Thyroid failure and protirelin (thyrotropin-releasing hormone) test abnormalities in depressed outpatients\n6936: Diagnostic dosages of protirelin (TRH) elevate BP by noncatecholamine mechanisms\n6937: Oral protirelin (T.R.H.) in depression\n6938: Endocrine, cardiovascular, and behavioral effects of intravenous protirelin in patients with panic disorder\n6939: [Protirelin tartrate. Evaluation of its effects on pyramidal-extrapyramidal rigidity in the aged during protracted treatment]\n6940: Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients\n6941: Amelioration of subacute camptocormia in multiple system atrophy by protirelin tartrate\n6942: [Protirelin in the treatment of cerebrovascular disorders]\n6943: Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro\n6944: Behavioral effects of protirelin in schizophrenia\n6945: [Changes in blood levels of the pituitary-thyroid axis observed during therapy with protirelin ++ in hospitalized euthyroid patients with cerebrovascular disease]\n6946: Hyperthermia induced by thyrotropin-releasing hormone (TRH, protirelin) in the rat\n6947: [Neuropsychologic and clinical effects of protirelin tartrate in patients with stroke sequelae]\n6948: [Blood prolactin under the effect of protirelin in spondylarthropathies. Treatment trial of 4 cases of reactive arthritis and 2 cases of psoriatic arthritis with bromocriptine]\n6949: [Evaluation of the efficacy and tolerability of protirelin. Results of a multicenter study in Italy]\n6950: Thyrotropin and prolactin responses to protirelin (TRH) prior to and during chronic imipramine treatment in patients with panic disorder\n6951: [Pharmacokinetics and pharmacodynamics of protirelin (TRH) in man]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug191_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"Vilon\" (also known as \"vilon\"), here are the article headings along with their IDs:\n6952: ViLoN-a multi-layer network approach to data integration demonstrated for patient stratification\n6953: Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people\n6954: Effect of vilon on biological age and lifespan in mice\n6955: [Vilon effect on consequences of repeated radioactive and mercuric impact in small doses]\n6956: Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells\n6957: Effect of peptide Vilon on the content of transforming growth factor-beta and permeability of microvessels during experimental chronic renal failure\n6959: Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats\n6961: [Effect of vilon on neuroendocrine status and sexual function of old male rats]\n6963: [Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus]\n6965: [Effect of \"vilon\" on cirrhotically changed rat liver. Liver regeneration, and status of glycogen-forming function of hepatocytes]\n6967: [Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age]\n6969: [Effect of dipeptide vilon on emotional stress resistance in rats]\n6970: [Effect of Epitalon and Vilon treatment on mammary carcinogenesis in transgenic erbB-2/NEU mice]\n6972: [The effect of vilon (Lys-Glu) on 1.2-dimethylhydrazine-induced neoplasia]\n6974: [Reciprocal relation of proliferative activity in central and peripheral zones of splenic organ culture exposed to vilon in rats of various ages]\n6976: Effect of the dipeptide vilon on activity of digestive enzyme in rats of various ages\n6978: A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice\n6979: [Characteristics of effect of ultralow doses of vilon in organotypic culture of spleens from rats of various ages]\n6981: [Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age]\n6983: [Functional morphology of organotypic culture of spleens from rats of various ages exposed to vilon]\n6985: [The effect of vilon on the thymus and spleen in a radiation model of premature aging]\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
{"custom_id": "drug192_order", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4o", "messages": [{"role": "user", "content": "For the research chemical \"VIP\" (also known as \"vip\"), here are the article headings along with their IDs:\n6958: VIP as a trophic factor in the CNS and cancer cells\n6960: VIP: molecular biology and neurobiological function\n6962: Vegetative Insecticidal Protein (Vip): A Potential Contender FromBacillus thuringiensisfor Efficient Management of Various Detrimental Agricultural Pests\n6964: VIP Modulation of Hippocampal Synaptic Plasticity: A Role for VIP Receptors as Therapeutic Targets in Cognitive Decline and Mesial Temporal Lobe Epilepsy\n6966: VIP regulation of embryonic growth\n6968: Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases\n6971: Cortical VIP+Interneurons in the Upper and Deeper Layers Are Transcriptionally Distinct\n6973: Study effect of MAPA-VIP on control of allergic asthma pathophysiology\n6975: [Role of VIP-neurons in the hypothalamic suprachiasmatic nucleus in the control of blood glucose]\n6977: Role of VIP in the regulation of LH secretion in the female rat\n6980: Reduced VIP Expression Affects Circadian Clock Function in VIP-IRES-CRE Mice (JAX 010908)\n6982: Distinct VIP and PACAP Functions in the Distal Nerve Stump During Peripheral Nerve Regeneration\n6984: Intercellular communication mediated by VIP in the cerebral cortex\n6986: The vasoactive intestinal peptide (VIP) receptor: recent data and hypothesis\n6987: The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation\n6988: The spike-timing-dependent plasticity of VIP interneurons in motor cortex\n6989: Ablation of microRNAs in VIP+interneurons impairs olfactory discrimination and decreases neural activity in the olfactory bulb\n6990: Characterizing VIP Neurons in the Barrel Cortex of VIPcre/tdTomato Mice Reveals Layer-Specific Differences\n6991: Cell Type-Specific Genetic Manipulation and Impaired Circadian Rhythms inViptTAKnock-In Mice\n6992: VIP- and PHI-immunoreactivity in olfactory centers of the adult cat\n6993: Neuronal VIP in salivary glands: distribution and release\n6994: Salivary VIP concentrations are elevated in humans after acute stress\n6995: The short-term plasticity of VIP interneurons in motor cortex\n6996: VIP gene deletion in mice causes cardiomyopathy associated with upregulation of heart failure genes\n6997: Cortical Control of Spatial Resolution by VIP+ Interneurons\n6998: VIP innervation of the gallbladder\n6999: Ovarian premature aging: VIP as key regulator of fibro-inflammation and foamy macrophages generation\n7000: Effects of Locomotion in Auditory Cortex Are Not Mediated by the VIP Network\n7001: Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study\n7002: VIP terminals, axons, and neurons: distribution throughout the length of monkey and cat spinal cord\n7003: VIP receptor-effector system in rat harderian gland and its coupling to activation of type II thyroxine 5'-deiodinase\n7004: VIP-immunoreactivity in the skin of various mammals: immunohistochemical, radioimmunological and experimental evidence for a dual localization in cutaneous nerves and merkel cells\n7005: VIP innervation of the tongue in vertebrates\n7006: Heme and Cu2+-induced vasoactive intestinal peptide (VIP) tyrosine nitration: A possible molecular mechanism for the attenuated anti-inflammatory effect of VIP in inflammatory diseases\n7007: VIP stimulates ACTH release and adenylate cyclase in human ACTH-secreting pituitary adenomas\n7008: VIP-targeted Cytotoxic Nanomedicine for Breast Cancer\n7009: Growth impairment, increased placental glucose uptake and altered transplacental transport in VIP deficient pregnancies: Maternal vs. placental contributions\n7010: A chimeric VIP-PACAP analogue but not VIP pseudopeptides function as VIP receptor antagonists\n7011: Vasoactive intestinal peptide (VIP) localization in the epididymis of two vertebrate species\n7012: Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability\n7013: VIP Regulates the Development & Proliferation of Treg in vivo in spleen\n7014: VIP-to-SST cell circuit motif shows differential short-term plasticity across sensory areas of mouse cortex\n7015: Virtual interprofessional (VIP) education, a family medicine-occupational therapy-physiotherapy collaborative experience: the perspectives of patients, learners and providers on the opportunities and challenges\n7016: Innervation of VIP-immunoreactive neurons by the ventroposteromedial thalamic nucleus in the barrel cortex of the rat\n7017: VIP and PHI in the pig pancreas: coexistence, corelease, and cooperative effects\n7018: Vasoactive Intestinal Peptide (VIP) and its Receptors in Adipose Tissue: Implications for Cold Stress Adaptation\n7019: VIP receptors in pig liver cells: binding characteristics and role in degradation\n7020: Visible Immunoprecipitation (VIP) Assay: a Simple and Versatile Method forVisual Detection of Protein-protein Interactions\n7021: VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways\n7022: VIP antagonist demonstrates differences in VIP- and PHI-mediated stimulation and inhibition of ACTH and corticosterone secretion in rats\n7023: Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors\n7024: [Liposome modified with VIP-lipopeptide as a new drug delivery system]\n7025: Experimental study on vasoactive intestinal peptide (VIP) and its diaminopropane bound (VIP-DAP) analog in solution\n7026: Gene Deletion of VIP Leads to Increased Mortality Associated with Progressive Right Ventricular Hypertrophy\n7027: VIP-, galanin-, and neuropeptide-Y-immunoreactive fibers in the chicken carotid bodies after various types of denervation\n7028: Activation of VIP signaling enhances immunosuppressive effect of MDSCs on CMV-induced adaptive immunity\n7029: [Expression and identification of an antimicrobial peptide VIP in Pichia pastoris]\n7030: Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo\n7031: Adenylate cyclase stimulation by VIP in rat and human parotid membranes\n7032: Regardless of genotype, offspring of VIP-deficient female mice exhibit developmental delays and deficits in social behavior\n7033: Inhibitory effect of vasoactive intestinal peptide (VIP) on phagocytosis in mouse peritoneal macrophages\n7034: Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting\n7035: VIP and secretin augment cardiac L-type calcium channel currents in isolated adult rat ventricular myocytes\n7036: In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera\n7037: VIP binding sites on synaptosomes from rat cerebral cortex: structure-binding relationship\n7038: Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS)-induced colitis in mice\n7039: Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes\n7040: Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat\n7041: A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 2. Effect of VIP on cAMP production and on cell-surface VIP-binding sites\n7042: Functional vasoactive intestinal polypeptide (VIP) receptors in human neuroblastoma subclones that contain VIP precursor mRNA and release VIP-like substances\n7043: Characterization of the vasoactive intestinal peptide (VIP) binding sites: a biochemical and an immunological approach\n7044: Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain\n7045: Development of vasoactive intestinal polypeptide (VIP) containing neurones in the rat brain\n7046: Inhibition of human neuroblastoma growth by a specific VIP antagonist\n7047: Developmental expression of the VIP-gene in brain and intestine\n7048: A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes\n7049: Sex differences in vasoactive intestinal peptide (VIP) concentrations in the anterior pituitary and hypothalamus of rats\n7050: Effect of VIP infusion in water and ion transport in the human jejunum\n7051: VIP and hormone secretion from thyroidal follicular and C-cells\n7052: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the circulation after sumatriptan\n7053: Vasoactive intestinal polypeptide carboxy-terminal fragment, VIP(22-28), and other fragments of VIP, in the central nervous system of the rat\n7054: Concentrations and distribution of vasoactive intestinal peptide (VIP), peptide histidine isoleucine (PHI) and peptide histidine valine (PHV) in the cerebral cortex and the suprachiasmatic nucleus of the mouse\n7055: Involvement of VIP on BDNF-induced somatostatin gene expression in cultured fetal rat cerebral cortical cells\n7056: Deficits in social behavior and reversal learning are more prevalent in male offspring of VIP deficient female mice\n7057: VIP stimulation of beta-naphthylamidase activity in guinea-pig thyroid sections\n7058: Simultaneous solubilization of high-affinity receptors for VIP and glucagon and of a low-affinity binding protein for VIP, shown to be identical to calmodulin\n7059: VIP and PHI in cat neurons: co-localization but variable tissue content possible due to differential processing\n7060: Rat and guinea pig pancreatic acini possess both VIP(1) and VIP(2) receptors, which mediate enzyme secretion\n7061: Content and distribution of vasoactive intestinal polypeptide (VIP) in cavernous tissue of human penis\n7062: Urinary bladder function and somatic sensitivity in vasoactive intestinal polypeptide (VIP)-/- mice\n7063: Neuropeptides in skin disease: increased VIP in eczema and psoriasis but not axillary hyperhidrosis\n7064: Human adrenocortical NCI-H295 cells express VIP receptors. Steroidogenic effect of vasoactive intestinal peptide (VIP)\n7065: The interaction of vasoactive intestinal polypeptide (VIP), glucose and arginine on the secretion of insulin, glucagon and somatostatin in the perfused rat pancreas\n7066: Vasoactive intestinal peptide (VIP) as transmitter of inhibitory motor neurons of the gut: evidence from the use of selective VIP antagonists and VIP antiserum\n7067: Pharmacological characterization of VIP receptors in human lung membranes\n7068: Ontogeny of the VIP system in the gastro-intestinal tract of the Axolotl, Ambystoma mexicanum: successive appearance of co-existing PACAP and NOS\n\nRank these articles in order of relevance for a customer seeking to understand the drug's effects on people or animals. \nRelevance criteria:\n  - A ranking of 1 means the article is most vital (e.g. clinical trials or in vivo studies).\n  - Higher numbers indicate lower relevance.\nReturn a JSON object where each key is an article id (as a number) and the corresponding value is its rank order (as an integer, starting at 1 for the most relevant).\nDo not include any extra text.\nOutput:"}], "max_tokens": 300, "temperature": 0.0}}
